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ABSTRACT 
ASSESSMENT OF NANOCOMPOSITES VS. AMORPHOUS SOLID 
DISPERSIONS FOR DISSOLUTION ENHANCEMENT OF BCS CLASS II 
DRUGS 
 
by 
Meng Li 
Nanoparticle-based formulations (nanocomposites) and amorphous solid dispersions, 
shortly ASDs, are two major pharmaceutical formulation platforms used for the 
bioavailability enhancement of poorly water-soluble drugs. While they both have several 
advantages–disadvantages, a scientific comparative assessment of their drug release 
performance and dissolution mechanisms at different drug doses is not available. With 
the goal of addressing this issue, the dissertation aims to achieve three major objectives: 
(1) develop a processing–formulation understanding of wet media milling process for 
fast–efficient production of drug nanoparticles in stable nanosuspension form, (2) 
elucidate the impact of various classes dispersants on drug release rate and mechanisms 
during the redispersion–dissolution of nanocomposites prepared via dying of the drug 
nanosuspensions, and (3) assess the dissolution enhancement imparted by drug 
nanocomposites vs. ASDs prepared via drying of drug nanosuspensions by a novel 
nanoextrusion process, which allows for a scientific, head-to-head assessment of the two 
formulation platforms at various drug doses.  
In achieving the first objective, this dissertation work firstly establishes a general 
stabilization strategy for ensuring the physical stability of five different wet-milled drug 
nanosuspensions via combined use of a polymer (HPC: hydroxypropyl cellulose)–anionic 
surfactant (SDS: sodium dodecyl sulfate). A microhydrodynamic model is used for 
enhanced process understanding of the wet media milling process and rational selection 
ii 
 
of bead sizes. Then, the media milling process is intensified with the guidance of the 
microhydrodynamic model for fast production of sub-100 nm drug particles with reduced 
specific energy consumption and low bead wear. In achieving the aforementioned second 
objective, drug nanosuspensions prepared by the media milling are processed into 
nanocomposite microparticles with various classes of dispersants via either fluidized bed 
coating/drying or spray drying process. The drug nanosuspensions stabilized by HPC–
SDS or HPC alone are coated on Pharmatose® carrier particles, which allows us to 
elucidate the impact of the physical stability of drug nanosuspensions and different 
dispersants on drug dissolution from the nanocomposites. It is found that good physical 
stability of a drug nanosuspension is a necessary condition for fast nanoparticle recovery 
and drug dissolution, but it is insufficient; dispersant concentration/type plays a critical 
role for fast drug release. Fast drug dissolution from the nanocomposites is also attained 
by high drug-loaded, surfactant-free nanocomposites with a co-milled superdisintegrant–
HPC prepared via spray drying. The drug release rate is found to correlate positively with 
the dispersant concentration and the swelling capacity of the superdisintegrant. In 
achieving the last objective, drug nanosuspensions are dried in an identical nanoextrusion 
process with two polymers, which enables to produce both a nanocomposite (poor 
polymer–drug miscibility) and an ASD of the same drug (good polymer–drug miscibility). 
Nanocomposites outperforms the ASDs at low drug dose, whereas ASDs exhibits much 
higher supersaturation, outperforming the nanocomposites at high dose. Overall, this 
dissertation has established a platform approach (nanoextrusion) for a scientific 
comparison of drug nanocomposites vs. ASDs and the prerequisite processing–materials 
knowledge and methodology needed for such scientific comparison. 
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lubrication force stops increasing and becomes a constant, – 
εtot

total energy dissipation rate, W/m
3 
εvisc energy dissipation rate due to both the liquid–beads viscous 
friction and lubrication, W/m
3
 
 Poisson’s ratio, – 


material-dependent factor, kg/m
1.6s0.4 
µL

apparent shear viscosity of the equivalent fluid, Pa·s 
ν

frequency of single-bead oscillations, Hz
 
Π energy dissipation rate attributed to the deformation of drug 
particles per unit volume, W/m
3
 
 granular temperature, m
2
/s
2 
ρ

density, kg/m
3 
 xxxii 
 
b
max maximum bead contact pressure at the center of the contact 
circle, Pa 
y contact pressure in a drug particle when the fully plastic 
condition is obtained, Pa 
τp characteristic time constant of the milling process, s 
ω stirrer (rotational) speed, rpm 
Indices  
b beads 
L equivalent liquid (milled drug suspension) 
p drug particle 
y yield 
T total 
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CHAPTER 1 
INTRODUCTION 
 
1.1  Motivation 
It is estimated that between 40% and 70% of all new chemical entities identified in 
drug discovery programs have very low solubility in aqueous media (Kipp, 2004; 
Lipinski, 2002). Such drugs are difficult to formulate due to their low bioavailability, 
which can be improved, in general, by either increasing the drug surface area via size 
reduction or increasing the saturation solubility of the drug through the formation of 
an amorphous solid dispersion. 
Size reduction of drug crystals increases the specific surface area, which can 
improve their dissolution rate (Singh et al., 2011; Tanaka et al., 2012) according to 
the Noyes–Whitney equation (Noyes and Whitney, 1897). Nanoparticles have larger 
surface area; they may exhibit higher saturation solubility owing to their increased 
curvature especially when their size is in the sub-100 nm domain (Müller and Peters, 
1998), and therefore dissolve faster than micron-sized particles (Hall, 2010). In 
pharmaceutics literature, particles of sizes up to 1000 nm have been referred to as 
“nanoparticles” and used for enhancing the bioavailability of BCS Class II (poorly 
water-soluble) drugs (Keck and Müller, 2006).  
Among various methods used for the production of drug nanoparticles, wet 
stirred media milling (WSMM) has been commonly used in the pharmaceutical 
industry as it is continuous, scalable, solvent-free and environmentally benign 
(Afolabi et al., 2014; Kesisoglou et al., 2007; Merisko-Liversidge and Liversidge, 
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2008; Monteiro et al., 2013). Moreover, nanosuspensions prepared via wet media 
milling have the distinct advantages of high drug loading, low excipient side effects, 
and can be generally formulated for most drug candidates (Müller et al., 2001), while 
also offering the advantage of higher mass packing (and thus higher dose) per 
injection volume and improved physical stability through the use of stabilizers such 
as polymers and/or surfactants (Müller and Peters, 1998; Rabinow, 2004). Several 
marketed products such as Rapamune® (Pfizer (Wyeth), New York City, NY, USA), 
Emend® (Merck, Kenilworth, NJ, USA), Tricor® (AbbVie, North Chicago, IL, USA), 
Megace® ES (PAR Pharmaceuticals, Woodcliff Lake, NJ, USA), and Invega® 
SustennaTM (Janssen, Beerse, Belgium) made use of wet media milling.  
In wet stirred media milling, micron-sized drug particles in an aqueous 
solution of stabilizers, usually polymers and/or surfactants, pass through a milling 
chamber, while the milling media (beads) are retained inside the milling chamber by 
a screen. High-speed rotation of the mill stirrer induces turbulent motion in the 
suspension, which leads to frequent bead–bead collisions (Eskin et al., 2005b). The 
particles captured by the colliding beads are subjected to stress and broken down to 
smaller particles, eventually forming nanoparticles. Since the particle size reduction 
via wet media milling increases the surface energy of particles and there are 
significant interparticle interactions via Van der Waals forces and hydrophobic 
interactions among the particles, adequate stabilization is required by various 
stabilizers (Cerdeira et al., 2010; Wu et al., 2011), also known as dispersants. The 
selection of proper type and concentration of stabilizers plays a major role in 
formulating drug nanosuspensions. Although wet media milling has been used for 
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about two decades to produce drug nanoparticles (see e.g., Elan’s Nanocrystal 
Technology (Bruno et al., 1996)), it is still not possible to predict, based solely on 
first principles and mechanistic understanding, the optimal stabilizer type and 
concentration for a given drug to ensure a feasible wet media milling process and 
adequate short- and long-term physical stability. In addition, while polymers and 
surfactants alone can be effective for some drugs, there is a great need for (i) new 
combinative use of polymer–surfactant pairs, (ii) development of a general 
stabilization strategy for multitude of drug nanosuspensions, and (iii) development of 
novel stabilizers/dispersants besides polymers–surfactants. 
Another major issue in production of drug nanoparticles via media milling is 
that most wet media milling studies have focused mainly on optimization of various 
stabilizers and physical stability of the milled drug suspensions via trial-and-error 
approach (Kesisoglou et al., 2007; Peltonen and Hirvonen, 2010; Van Eerdenbrugh et 
al., 2008b), largely ignoring process development and optimization. Furthermore, 
WSMM process is considered time-consuming, costly, and energy-intensive 
(Kawatra, 2006; Li et al., 2016a), which limits its potential use as a platform 
technology in the pharmaceutical industry for bioavailability enhancement of BCS 
Class II drugs. Process parameters such as stirrer speed, bead loading, and suspension 
flow rate can significantly affect the breakage kinetics and milling time required for 
desired product fineness (Afolabi et al., 2014; Ghosh et al., 2012). In addition, proper 
selection of bead size along with processing conditions can reduce the energy 
consumption, cycle time, and operational costs for a desired drug particle size 
(Kawatra, 2006; Li et al., 2015b). To the author's best knowledge, there is no 
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fundamental, scientific rationale that guides the selection of bead sizes as a function 
of specific energy consumption or fundamental microhydrodynamic parameters. 
Wet media milling was typically used to prepare 150‒300 nm particles (Sinha 
et al., 2013) or larger in the pharmaceutical industry. The preparation of “true drug 
nanoparticles,” i.e., particles with sub-100 nm sizes, has been another great challenge 
in pharmaceutical literature. Drug particles with sub-100 nm sizes offer improved 
permeation through various biological barriers and rapid onset of therapeutic action 
(Merisko-Liversidge and Liversidge, 2011; Shegokar and Müller, 2010). Moreover, 
sub-100 nm particles could render sterile filtration of drug suspensions feasible and 
allow higher drug loading for reduced injection volume in parenteral dosage forms 
(Baert et al., 2009; Xiong et al., 2008). Lack of mechanistic, first-principle-based 
understanding of the impact of process parameters and/or heavy reliance on purely 
empirical approaches has been a barrier to process improvement (Afolabi et al., 2014) 
for effective production of sub-100 nm drug particles.  
As solid dosage forms are preferred over suspensions due to convenience and 
easiness of their use, nanosuspensions prepared via wet stirred media milling are 
usually converted via drying into nanocomposite microparticles, which will be 
synonymously referred to as the drug nanocomposites (or simply nanocomposites) 
throughout the dissertation, and incorporated into standard solid dosage forms such as 
capsules, tablets, and sachets (Basa et al., 2008; Bhakay et al., 2014a; Van 
Eerdenbrugh et al., 2008a). Drying of nanosuspensions can be achieved via spray 
drying (Azad et al., 2014a; Lee, 2003), spray-freeze drying (Cheow et al., 2011; 
Wang et al., 2012), freeze drying (de Waard et al., 2008; Layre et al., 2006), vacuum 
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drying (Choi et al., 2008; Kim and Lee, 2010), as well as granulation with, or coating 
onto, inert excipient particles (Basa et al., 2008; Bhakay et al., 2014b). Unfortunately, 
drug nanoparticles tend to form aggregates during both milling and drying of the drug 
suspensions (Bhakay et al., 2013; Lee, 2003), leading to the loss of their large surface 
area. Soluble polymers and surfactants can be used as dispersants to impart physical 
stability and retain the large surface area of the nanoparticles during the redispersion 
and dissolution (Bhakay et al., 2011; Bilgili and Afolabi, 2012; Kesisoglou et al., 
2007). However, depending on the formulation, drug nanoparticles may not be fully 
recovered from the dried composites during redispersion and dissolution, which will 
cause unexpectedly low dissolution rate and poor bioavailability from such 
nanoparticle-based formulations (Bhakay et al., 2013; Chaubal and Popescu, 2008). 
Hence, elucidation of the roles and impact of type/concentration of various classes of 
both traditional dispersants such as polymers and surfactants as well as relatively 
novel dispersants such as superdisintegrants on drug release from drug 
nanocomposites is warranted. 
Despite their effectiveness as dispersants, surfactants may pose several 
challenges such as aggregation of the drug nanoparticles in suspensions during 
milling/storage (Cerdeira et al., 2010; Knieke et al., 2013), micellar solubilization of 
the drug (Yalkowsky, 1981) and particle growth via Ostwald ripening during milling 
and/or storage (Ghosh et al., 2011; Knieke et al., 2013; Verma et al., 2011). 
Additional challenges associated with the use of anionic surfactants include 
incompatibilities with other ionic molecules, sensitivity to pH, salt or temperature 
changes, GIT irritation (Gupta and Kompella, 2006; Liversidge and Cundy, 1995), 
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and even toxicity when used in excess (Liversidge and Cundy, 1995), especially for 
inhalation applications (Lebhardt et al., 2011; Suzuki et al., 2000). In view of all the 
aforementioned issues, surfactant usage should be minimized to mitigate all potential 
negative impact during formulation development. Alternative surfactant-free 
formulations with novel dispersants that allow for high drug loading should be 
developed in comparison to conventional dispersants used in nanoformulations. 
Enhanced dissolution rate, improved bioavailability, safe dose escalation, 
elimination of food effects, and enhanced safety, efficacy and tolerability profiles are 
some of the numerous advantages of crystalline drug nanoparticles (Junghanns and 
Müller, 2008). However, with all the above-mentioned nanoparticle delivery 
techniques and advantages, the limitation is still the limited improvement on drug 
solubility. Often for drugs with very low aqueous solubility, the achieved increase in 
dissolution rate via size reduction is limited and insufficient to provide significant 
enhancement of bioavailability (Müller et al., 2001). Another platform approach is to 
produce amorphous solid dispersion (ASD) of poorly water-soluble drugs. ASDs tend 
to exhibit high levels of supersaturation in aqueous media relative to the crystal, and 
thus higher apparent solubility (Newman et al., 2012). The strategy is to combine a 
drug with a water-soluble polymer to produce a single-phase amorphous mixture of 
the drug and the polymer. It is well-known that utilizing the amorphous form of a 
drug can be a useful approach to improve the dissolution performance and 
bioavailability of poorly water-soluble drugs, as a result of supersaturation (Chiou 
and Riegelman, 1970; Goldberg et al., 1966; Hancock and Parks, 2000). Overall, both 
nanoparticle-based formulations (nanocomposites) and ASDs are two major 
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pharmaceutical formulation platforms used for the bioavailability enhancement of 
poorly water-soluble drugs. While they both have several advantages–disadvantages, 
a scientific comparative assessment of their drug release performance and dissolution 
mechanisms at different drug doses is not available. A major challenge is to develop a 
common processing approach which allows for production of both nanocomposites 
and ASDs and thus their scientific, head-to-head comparison. Recently, a novel 
nanoextrusion process has been developed to disperse drug nanoparticles in a 
polymeric matrix using a modified version of the standard hot melt extrusion process 
(Baumgartner et al., 2014; Khinast et al., 2013), which produced solid nanoparticle-
based formulations (nanocomposites), thereby improving the dissolution rate and thus 
the bioavailability of the drug as well as enhancing patient compliance. However, 
nanoextrusion has not been used for producing ASDs despite the fact that it poses a 
great potential to produce both forms of a drug, thus allowing a comparative 
assessment of the dissolution performance from both nanoparticle-based formulations 
and ASDs. 
In the rest of Chapter 1, the current state-of-art regarding stabilization of 
nanosuspensions, process intensification/optimization of wet media milling with the 
guidance of microhydrodynamic model, and production of nanocomposites and ASDs 
for drug dissolution enhancement via fluidized bed coating/drying, spray drying, and 
nanoextrusion will be discussed in greater detail. Also, how each chapter of this 
dissertation will address the existing gaps, issues, and challenges will be indicated. 
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1.2  Background  
1.2.1  Stabilization of Drug Nanosuspensions 
Drug nanosuspensions produced by wet media milling must be physically stable 
during milling and storage for proper downstream processing or adequate shelf-life 
depending on the intended final dosage form (Kesisoglou et al., 2007). Moreover, the 
dissolution performance of dried nanocomposites may be affected by the 
presence/absence of drug aggregates, i.e., clusters of primary nanoparticles. In this 
dissertation, physical stability of the suspensions is broadly defined in terms of the 
extent of particle aggregation in the milled suspensions and prevention of size 
increase during short-term storage following wet media milling. Particle size 
reduction via wet media milling increases the surface energy of particles and there are 
significant interparticle interactions via Van der Waals forces and hydrophobic 
interactions among the particles. Therefore, nanoparticles tend to aggregate (Cerdeira 
et al., 2010; Wu et al., 2011). Polymers and surfactants are generally used to protect 
drug particles against aggregation via electrostatic, steric, and electrosteric 
interactions (Napper, 1970; Wu et al., 2011). In electrostatic stabilization, the surfaces 
of the particles are charged so that repulsion forces are created, which can overcome 
the attractive Van der Waals forces between the particles. However, particles of most 
drugs are not inherently charged (Meng et al., 2012); hence, surface charges typically 
originate from adsorbed anionic surfactants and/or ionic polymers (Figure 1.1). Steric 
stabilization results from the adsorption of polymers onto the surface of the particles. 
If either the adsorbed polymer contains charged functional groups or non-ionic 
polymers and anionic surfactants are used in combination, steric and electrostatic 
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mechanisms act simultaneously, which is typically described as electrosteric 
stabilization. 
 
 
Figure 1.1  Schematic of physical stabilization mechanisms in drug nanosuspensions: 
(a) steric stabilization imparted by nonionic polymers or nonionic surfactants, (b) 
electrostatic stabilization imparted by anionic surfactants, and (c) electrosteric 
stabilization imparted by both nonionic polymers and anionic surfactants. The 
schematic assumes near neutral surface charge of drug nanoparticles before 
adsorption of the stabilizers. Figure is not drawn to scale. 
 
The selection of proper type and concentration of stabilizers plays a major role 
in formulating drug nanosuspensions. If used at insufficiently low concentrations, 
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stabilizers in drug nanosuspensions usually cannot prevent aggregation, while their 
excessive use, especially for surfactants, can promote Ostwald ripening (Knieke et al., 
2013; Verma et al., 2011) or raise the viscosity so much that downstream processing 
may be negatively affected. The first systematic investigations of the stabilizing 
capability of adsorbed polymers were carried out by Lee and Choi (Lee et al., 2008; 
Lee et al., 2005). A connection between the hydrophobicity of the polymer and the 
ability to stabilize drug nanocrystals was indicated (Lee et al., 2005). In addition, 
differences in the surface energy between the particle and the polymer were found to 
play a role in the stabilization process (Lee et al., 2008). Choi et al. (2005) concluded 
that not only the surface energy, but also the specific interaction between the 
stabilizer and the drug appears to play important role. George and Ghosh (2013) 
investigated the correlation between drug–stabilizer properties and critical quality 
attributes (CQAs) of drug nanosuspension formulations. Their study suggested that 
logP and fusion enthalpy of the drugs had direct impact on the feasibility of a stable 
nanosuspension and that the most likely candidate for wet media milling was a drug 
with high enthalpy and hydrophobicity. In contrast, a more comprehensive study 
(Van Eerdenbrugh et al., 2009) using 13 stabilizers at three different concentrations to 
stabilize nine drug compounds concluded that no correlation between 
physicochemical drug properties (molecular weight, melting point, logP, solubility, 
and density) and stable nanosuspension formation exists. In view of the contradictory 
results from the aforementioned studies, it is fair to assert that although WSMM has 
been used for about two decades to produce drug nanoparticles (see e.g., Elan’s 
Nanocrystal Technology (Bruno et al., 1996)), it is still not possible to predict, based 
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solely on first principles and mechanistic understanding, the optimal stabilizer type 
and concentration for a given drug to ensure a feasible WSMM process and adequate 
short- and long-term physical stability. Other researchers have focused on 
development of complementary characterization methods that help to screen 
stabilizer(s) and determine their optimal concentrations in a streamlined fashion. 
Verma et al. (2009) demonstrated that the use of atomic force microscopy (AFM) in 
visualizing the morphology of various adsorbed polymers/surfactants on ibuprofen to 
gain surface coverage and adhesion information, and used this information as a means 
of selecting suitable stabilizers for the production of a stable drug nanosuspension. 
Knieke et al. (2013) developed a streamlined stabilizer optimization method based on 
step-wise addition of stabilizers at the end of milling (Bhakay et al., 2011) and the 
concept of dynamic equilibrium (Opoczky and Farnady, 1984). Lee (2003), Bilgili 
and Afolabi (2012), Knieke et al. (2013), and Panmai and Deshpande (2003) 
constructed polymer adsorption isotherms to help the selection of polymer type and 
concentration. 
Recent modeling and experimental investigations (Bhakay et al., 2014b; 
Bhakay et al., 2013; Bilgili and Afolabi, 2012; Gupta and Kompella, 2006; Knieke et 
al., 2013; Ryde and Ruddy, 2002; Zhu et al., 2012) have suggested that the combined 
use of non-ionic cellulosic polymers such as hydroxypropyl cellulose (HPC), 
hydroxypropyl methyl cellulose (HPMC), etc. and surfactants, especially anionic 
surfactants such as sodium dodecyl sulfate (SDS), dioctyl sodium sulfosuccinate 
(DOSS), etc., can have synergistic stabilization effects on some drug 
nanosuspensions. However, whether such a strategy is general enough to be applied 
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to multiple drugs is unknown and its advantages and disadvantages have not been 
thoroughly investigated in a comparative study. Moreover, whether the interactions 
between non-ionic cellulosic polymers and anionic surfactants significantly affect 
apparent breakage kinetics, zeta potential and/or polymer adsorption for multiple drug 
suspensions needs exploration. Thus, the combined use of a non-ionic cellulosic 
polymer, HPC and an anionic surfactant, SDS, as a general strategy to stabilize 
nanosuspensions of multiple drugs with different physicochemical properties is 
investigated in Chapter 2. 
1.2.2  Rationale for Selection of Bead Size in Wet Stirred Media Milling 
Wet stirred media milling (WSMM) process is considered time-consuming, costly, 
and energy-intensive, which limits its potential use as a platform technology in 
pharmaceutical industry for bioavailability enhancement of BCS Class II drugs. 
Proper selection of bead size along with processing conditions can reduce the energy 
consumption, cycle time, and operational costs for a desired drug particle size 
(Kawatra, 2006; Li et al., 2015b). Although selection of bead size is of utmost 
importance in wet media milling (Li et al., 2016d), this has been largely performed as 
an empirical exercise throughout the literature, based on trial-and-error, which is 
usually costly and labor/material intensive. A cursory review of recent literature, 
which is not intended to be comprehensive, on bead sizes used in pharmaceutical wet 
media milling is presented in Table 1.1. For each study in Table 1.1, the optimal bead 
size, among several bead sizes used, was indicated based on the smallest final particle 
size after the same duration of milling (fastest overall breakage). Table 1.1 illustrates 
that zirconium dioxide beads with wide range of sizes (e.g., 50‒15,000 µm) have 
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been used for the production of drug nanoparticles. The investigations cited were 
mostly empirical, providing little to no first-principle mechanistic understanding of 
the impact of bead size. Moreover, they did not provide any fundamental rationale 
behind the selection of specific bead sizes. Another important consideration is that 
wet media mills of different energetic levels (specific energy consumption), ranging 
from low-energy mills such as ball mills to high-energy mills such as WSMM, were 
used from small-scale to large-scale manufacture of drug nanosuspensions. 
Unfortunately, the studies in Table 1.1 did not offer any fundamental, scientific 
rationale that guides the selection of bead sizes as a function of specific energy 
consumption or fundamental microhydrodynamic parameters. Overall assessment of 
the studies in Table 1.1 also reveals that large beads in the range of 400‒15,000 µm 
appear to be used at low stirrer speeds or in low-energy mills (Ain-Ai and Gupta, 
2008; Bitterlich et al., 2015; Branham et al., 2012; Choi et al., 2008; Ghosh et al., 
2012; Sarnes et al., 2014; Tuomela et al., 2015), whereas small beads in the range of 
50‒400 µm appear to be preferably used at high stirrer speeds or in high-energy mills 
(Cerdeira et al., 2011; Ghosh et al., 2011; Ghosh et al., 2012; Juhnke et al., 2012; 
Konnerth et al., 2016; Li et al., 2015a; Niwa et al., 2011; Shah et al., 2014; Singare et 
al., 2010). When relatively small beads (e.g., 200 and 400 µm) were used in 
medium/low-energy ball mills, the production of fine drug nanoparticles took days 
(Salazar et al., 2014; Sepassi et al., 2007), which was inefficient. It is obvious that the 
selection of bead size could significantly affect the cycle time, operational efficiency, 
and/or final drug particle size during wet media milling, which are important to 
process economics as well as the dissolution enhancement provided by the drug 
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nanoparticles. Hence, a fundamental understanding of the impact of bead size on 
breakage kinetics and particle size could help one to develop guidance and rationale 
for optimal bead size selection for wet media milling processes. 
  
Table 1.1  Recent Literature on Bead Sizes used in Pharmaceutical Wet Media Milling 
References (Year) Mill Type 
Stirrer/ 
Circumference 
Speed 
(rpm) 
Nominal Bead 
Size Investigated
a
 
(µm) 
Optimal Bead 
Size
b
 
(µm) 
Drug Particle Size
 
Produced
d
 (µm) 
Konnerth et al. (2016) Wet stirred media mill 2.9–6.4c 100–2,000 100 0.179e 
Bitterlich et al. (2015) Planetary ball mill 6.3
c
 100–500 500 ~0.100f 
Li et al. (2015) Wet stirred media mill 11.7–14.7c 50–800 50 0.088f 
Tuomela et al. (2015) Planetary ball mill 600 5,000 5,000 0.550, 0.970
f
 
Sarnes et al. (2014) Planetary ball mill 1100 1,000 1,000 0.315
f
 
Shah et al. (2014) Wet media mill 400–1100 100 and 1,000 100 0.329f 
Branham et al. (2012) Planetary ball mill 200 15,000 15,000 0.355
g
 
Ghosh et al. (2012) 
Planetary ball mill 
150 100–500 500 ~0.600f 
400 100–500 100 ~0.250f 
Juhnke et al. (2012) Wet stirred media mill 6–12c 100 and 200 100 ~0.150e 
Cerdeira et al. (2011) Agitator media mill 2400–3600 400–800 400 ~0.130e 
Ghosh et al. (2011) Wet stirred media mill 2500 100–500 200 0.230f 
Niwa et al. (2011) 
Oscillating beads-
milling apparatus 
2700 100–1,000 300 ~0.250e 
Singare et al. (2010) Wet stirred media mill 2500–3400 200 200 0.211i 
Ain-Ai and Gupta 
(2008) 
Centrifugal ball mill 400 800 800 0.536
h
 
Choi et al. (2008) Ball mill 100 1,000 1,000 0.100
h
 
a
Bead made up of zirconium dioxide; 
b
Bead size which led to the smallest final drug particle size or the only bead size chosen for the particular study; 
c
 m/s; 
d
The smallest drug particle size produced using the optimal bead size; 
e
d50; 
f 
Z-average; 
g
Sauter mean diameter; 
h
Mean size; 
i
d90 
1
4
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Only very recently, various microhydrodynamic models (Eskin et al., 2005a, 
b) have been adopted by Afolabi et al. (2014) to describe the fluctuating motion of the 
beads during WSMM and elucidate the impact of process parameters with the goal of 
developing a fundamental understanding of the WSMM process. The important 
findings can be summarized as follows: upon an increase in stirrer speed, more 
mechanical energy was imparted and all microhydrodynamic parameters increased 
monotonically. This suggests that more frequent and energetic/forceful bead–bead 
collisions and more frequent drug particle compressions occurred during WSMM, 
thus explaining the faster drug particle breakage at higher stirred speed. An increase 
in volumetric bead concentration led to more bead–bead collisions and drug particle 
compressions, which favored faster breakage; yet, such collisions were less 
energetic/forceful, which could slow down the breakage. Overall, despite these two 
counteracting effects of bead concentration, the overall impact was favorable in terms 
of enhanced breakage kinetics. An increase in drug loading led to a slight, almost 
linear decrease in all microhydrodynamic parameters, thus explaining the reduced 
breakage rate. However, a comprehensive study has not been conducted to determine 
the impact of bead size at different stirrer speeds and elucidate any optimal bead size, 
with the ultimate goal of developing a fundamental rationale for bead size selection.  
Proper stabilizer formulation is selected based on the investigation presented 
in Chapter 2. Chapter 3 in this dissertation aims to elucidate the impact of bead size 
on the breakage kinetics at different stirrer speeds and rationalize the selection of 
bead size for the optimal performance of WSMM. The experimental observations 
were explained within the context of a microhydrodynamic model. Furthermore, the 
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implications of the findings were indicated so as to develop a rationale for bead size 
selection in WSMM process and offer an overarching explanation about the typical 
bead sizes used for all wet media milling processes with low–medium vs. high-energy 
levels. 
 
1.2.3  Preparation of Sub-100 nm Drug Particles  
Preparation of “true drug nanoparticles,” i.e., particles with sub-100 nm sizes, has 
been a great challenge in pharmaceutical literature. Despite the use of various top-
down and bottom-up approaches in the last few decades, only a few examples of 
nanosized drugs having a median particle size below 100 nm are available in the 
literature (refer to Sinha et al. (2013)). Among the bottom-up approaches such as 
liquid anti-solvent precipitation, melt emulsification, precipitation using supercritical 
fluids, evaporative precipitation, and micro-emulsions, only the micro-emulsion 
approach appears to be capable of producing sub-100 nm particles for multiple drugs. 
For example, about 85 nm griseofulvin particles were prepared with use of lecithin 
and water–butyl lactate/1,2-propanediol system (Trotta et al., 2003), and simvastatin 
particles of 50–70 nm were prepared with use of lecithin/polysorbate 80 and water–
ethanol/butylacetate system (Margulis-Goshen and Magdassi, 2009). Although this 
technique demonstrates the feasibility of preparing sub-100 nm particles, like other 
bottom-up approaches, it suffers from various limitations such as low drug loading, 
the presence of organic solvents, and thermodynamically unstable particles. Contrary 
to bottom-up approaches, WSMM, a top-down approach, is considered more 
universal and promising for the large-scale production of poorly water-soluble drug 
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nanoparticles as mentioned before. A cursory review of recent literature, which is not 
intended to be comprehensive, on finely milled BCS Class II drugs via WSMM is 
presented in Table 1.2. The data support the commonly held notion that preparation 
of drug suspensions with a sub-100 nm particle size via WSMM is extremely 
challenging. Since the use of sub-100 nm drug nanoparticles can have a positive 
impact on bioavailability enhancement through solid and parenteral dosage forms 
while potentially enabling sterile filtration, development of an improved WSMM 
process with sub-100 nm particle formation capability is highly desirable. 
 
  
 
Table 1.2  Recent Literature on Drug Nanosuspensions with Median Particle Size < 200 nm Prepared via Wet Stirred Media 
Milling 
Drug Initial Median 
Size (µm) 
Drug Loading 
(% w/w) 
Batch Size Milling Time       
(min) 
Final Median 
Size (nm) 
Reference 
Arsenic sulfide NR
a
 ~1.7 300
b 
120 115 (Bujňáková et al., 2015) 
Bifendate 8 20 NR
a
 45 120 (Yao et al., 2014) 
Etravirine 11 20 NR
a
 60  140 (Cerdeira et al., 2011) 
Fenofibrate 16 10 200
b 
120 150 (Knieke et al., 2013) 
Griseofulvin 20 10 200
b 
96 132 (Afolabi et al., 2014) 
Itraconazole 20 20 300
c
 60  136 (Cerdeira et al., 2013a) 
Miconazole 20 20 300
c
 60 140 (Cerdeira et al., 2013a) 
Naproxen NR
a
 1 NR
a
 240 196 (Kumar and Burgess, 2014) 
Undisclosed 15–20 5 NRa 360 200 (Bose et al., 2012) 
a
Not reported. 
b
Volume of water used in the suspension. 
c
Mass (g) of the suspension. 
 
1
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It is arguable that one can prepare sub-100 nm drug particles with the 
currently existing WSMM processes by simply prolonging the milling. WSMM 
process is generally regarded as time-consuming, costly, and energy-intensive 
(Kawatra, 2006). Contamination of the milled product due to bead wear and possible 
changes in the crystalline state of the drugs are some other concerns (Kesisoglou et 
al., 2007). Although drug product contamination introduced by typical ceramic and 
polymeric milling beads are mostly not regulated by health authorities, they should be 
quantified in the lower ppm range, according to the current regulatory concepts and 
permitted daily exposures for oral, parenteral, pulmonary and topical administration 
(Juhnke et al., 2012). Besides these issues and concerns, most suspensions approach a 
well-known grinding limit or dynamic equilibrium after a certain milling time 
(Knieke et al., 2009; 2013). Hence, simply prolonging the milling process would 
make the aforementioned issues worse without necessarily reducing the particle size 
below 100 nm. 
A more feasible approach for the preparation of sub-100 nm particles can be 
process improvement/optimization that ensures faster particle breakage. However, 
lack of mechanistic, first-principle-based understanding of the impact of process 
parameters and/or heavy reliance on purely empirical approaches has been a barrier to 
process improvement (Afolabi et al., 2014). In fact, most wet media milling studies 
have focused mainly on optimization of various stabilizers and physical stability of 
the milled drug suspensions (Kesisoglou et al., 2007; Peltonen and Hirvonen, 2010; 
Van Eerdenbrugh et al., 2008b). While ensuring the physical stability of the 
nanosuspensions is important, so are other aspects such as breakage kinetics, energy 
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consumption, and bead wear; however, such aspects have not been thoroughly 
examined in a holistic approach, especially with the ultimate goal of preparing sub-
100 nm particles. Enhanced breakage kinetics can reduce milling time required, 
energy consumption, and even bead wear, which can be achieved by proper selection 
of the milling parameters such as bead size, bead loading, drug loading, rotor speed, 
and suspension flow rate. Influence of these parameters on the final drug particle size 
has been studied previously through experiments (Afolabi et al., 2014; Cerdeira et al., 
2011; Ghosh et al., 2011; Ghosh et al., 2013; Ghosh et al., 2012; Monteiro et al., 
2013; Singare et al., 2010; Singh et al., 2011). However, the influence of these 
parameters on breakage kinetics leading to sub-100 nm drug particles with reduced 
energy consumption and low bead wear has not been addressed. Moreover, no first-
principle mechanistic understanding of the breakage kinetics has emerged, except that 
presented in Afolabi et al. (2014), and conflicting results about the optimal bead size 
have been reported. Moreover, Cerdeira et al. (2011), Ghosh et al. (2011; 2012; 
2013), and Juhnke et al. (2012) used only two-three different bead sizes while 
investigating the impact of bead size without considering the microhydrodynamics 
inside the mills. Nonetheless, the studies above overall suggest that sub-100 nm drug 
nanoparticles may be produced by increasing rotor speed, bead loading, and 
suspension flow rate. On the other hand, the ever-present concerns about bead 
contamination along with high energy consumption and the need for selecting an 
optimal bead size may have prevented or delayed such attempts. In addition, some 
drugs can be so hard that it may not be feasible to produce sub-100 nm drug particles 
with low bead contamination in a reasonable time. While developing a particle-scale 
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understanding of breakage in view of the mechanical properties of drug particles is 
important, this aspect is beyond the scope of the current work. 
A brute-force approach that uses a more energetic milling process without any 
consideration of the impact of bead size could actually lead to excessively high bead 
wear and high energy consumption. Hence, fast preparation of sub-100 nm drug 
particles with reduced energy consumption and acceptable media contamination 
entails a thorough mechanistic understanding of the impact of the bead size and 
process parameters. This objective can be achieved by analyzing the fluctuating 
motion of beads in sheared suspensions, i.e., microhydrodynamics of beads and 
capture/deformation of the drug particles. To this end, Eskin et al. (2005a, b) 
developed a microhydrodynamic model for a dense slurry flow of beads and particles. 
Bilgili and Afolabi (2012) applied it to WSMM of drugs in order to elucidate the 
viscous dampening caused by various stabilizers. Recently, Afolabi et al. (2014) has 
elucidated the impact of stirrer speed and bead–drug loading on the breakage kinetics 
using this microhydrodynamic model; however, preparation of sub-100 nm particles, 
the impact of bead size, and reduction of wear and energy consumption have not been 
addressed. 
Chapter 4 presents an intensified WSMM process for the faster production of 
sub-100 nm BCS Class II drug particles with reduced specific energy consumption 
and low bead wear. Since stabilization plays a significant role in preparing drug 
nanosuspensions, an aggressive baseline WSMM process along with proper stabilizer 
formulation was selected based on the investigations presented in Chapters 2 and 3. In 
Chapter 4, the impact of bead size on the drug particle size, breakage kinetics, energy 
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consumption, and bead wear was investigated for griseofulvin and indomethacin, two 
poorly water-soluble drugs, under highly energetic milling conditions in the turbulent 
flow regime. The microhydrodynamic model of the process was used to gain insight 
into the impact of bead size. Then, the baseline process with the optimal beads was 
intensified stepwise by increasing the rotor tip speed, bead loading, and suspension 
flow rate, as guided by the microhydrodynamic model. In pursuit of the goal of 
preparing sub-100 nm drug particles fast, this study contributes to a fundamental 
understanding of the impact of bead size and process intensification while addressing 
all major issues associated with the WSMM process, i.e., excessively long processing 
time, high energy consumption, and potentially high media contamination in a 
holistic, model-guided approach. 
 
1.2.4  Impact of Polymer–Surfactant on Dissolution Performance of Drug 
Nanocomposites 
The studies in Chapters 2‒4 enable to develop fundamental process–formulation 
understanding for the effective production and stabilization of drug nanosuspensions. 
Interestingly, except for parenteral formulations, drug nanosuspensions were not 
directly applied to patients. Depending on the route of administration intended, drug 
nanosuspensions are usually converted via drying into drug composites, and 
incorporated into standard solid dosage forms such as capsules, tablets, and sachets 
(Basa et al., 2008; Bhakay et al., 2014a; Van Eerdenbrugh et al., 2008a) to meet the 
high patient/clinical demand for solid dosage forms. Drying of nanosuspensions can 
be achieved via spray drying (Azad et al., 2014a; Lee, 2003), spray-freeze drying 
(Cheow et al., 2011; Wang et al., 2012), freeze drying (de Waard et al., 2008; Layre 
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et al., 2006), vacuum drying (Choi et al., 2008; Kim and Lee, 2010), as well as 
granulation with, or coating onto, inert excipient particles (Basa et al., 2008; Bhakay 
et al., 2014b). 
Unfortunately, drug nanoparticles tend to form aggregates during both milling 
and drying of the drug suspensions (Bhakay et al., 2013; Lee, 2003), leading to the 
loss of their large surface area. Soluble polymers and surfactants can be used to 
impart physical stability and retain the large surface area of the nanoparticles (Bhakay 
et al., 2011; Bilgili and Afolabi, 2012; Kesisoglou et al., 2007). However, depending 
on the formulation, drug nanoparticles may not be fully recovered from the dried 
composites during redispersion and dissolution, which will slow down the drug 
dissolution and reduce the bioavailability (Bhakay et al., 2013; Chaubal and Popescu, 
2008). Here, redispersion testing entails dispersing the drug composites in various 
physiologically relevant fluids like water, and comparing the particle size of the 
resulting suspension with that of the precursor suspension used in drying. Various 
redispersion methods were studied extensively by Bhakay et al. (2013). 
Slow/incomplete recovery of drug nanoparticles from the composites was observed 
when a steric stabilizer or ionic stabilizer was used alone in the precursor drug 
suspension (e.g., (Bhakay et al., 2013; Lee, 2003). Drug nanoparticles were fully 
recovered only when steric stabilizer and ionic stabilizer were used in combination 
(e.g., (Basa et al., 2008; Bhakay et al., 2013) or when swellable dispersants were co-
milled along with the drug (Azad et al., 2014a; Bhakay et al., 2014b). However, in all 
these studies, either single grade (molecular weight) of polymer and/or single 
polymer concentration was investigated. Molecular weight (MW), a critical property 
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of the polymer, determines both the solution properties of polymer chains and the 
capability for steric stabilization (Adamson and Gast, 1997; Ploehn and Russel, 1990), 
mechanical properties of films (Rowe, 1986), and the release of drug particles for oral 
administration (Mittal et al., 2007). Therefore, MW of polymers may be tailored to 
achieve the best stabilization performance in milling and fast drug release from the 
composites. Choi et al. (2008) investigated the impact of hydroxypropyl cellulose 
(HPC) MW on itraconazole nanoparticle production and their recovery from the drug 
composites. In that paper, HPC was used as a sole stabilizer at a single concentration, 
and dissolution performance was not investigated. Sepassi et al. (2007) investigated 
the impact of hydroxypropylmethyl cellulose (HPMC) and polyvinylpyrrolidone 
(PVP) MW on the particle size of milled nabumetone and halofantrine suspensions; 
however, drying, redispersion, and drug dissolution were not studied. In addition, in 
the previous works mentioned above, an optimal polymer concentration that ensures 
full recovery of drug nanoparticles from the composites with minimal usage has not 
been identified.  
The literature review suggests that there is no systematical and comprehensive 
study about the impact of polymer concentration and molecular weight in the 
presence/absence of an ionic surfactant on the redispersion and drug dissolution from 
the nanoparticle-laden composites. Chapter 5 aims to fill this gap and develop an 
understanding of the relationships between the physical stability of drug 
nanosuspension, redispersion, and drug dissolution from the composites prepared via 
fluidized bed coating/drying. The role of nanoparticle stabilization and drug particle 
size in drug dissolution performance was also investigated. Moreover, Chapter 5 also 
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attempts to test the validity of the commonly-held notion that the use of stable wet-
milled drug nanosuspensions ensures fast redispersion and drug dissolution from the 
dried composites. 
 
1.2.5  Impact of Various Dispersants on the Dissolution Performance of 
Nanocomposites  
Among various dispersants used in nanocomposite formulations, a soluble polymer, 
typically cellulosic ones, and an anionic surfactant in combination has been shown to 
be very effective in stabilizing drug nanosuspensions (Bilgili and Afolabi, 2012; 
Bilgili et al., 2016d; Cerdeira et al., 2010) and allowed for complete recovery of drug 
nanoparticles from the nanocomposites during redispersion/dissolutions tests, thus, 
enabling enhanced drug dissolution performance (Basa et al., 2008; Li et al., 2016c; 
Niwa et al., 2011). However, despite their effectiveness as dispersants, surfactants 
may pose several challenges such as aggregation of the drug nanoparticles in 
suspensions during milling/storage (Cerdeira et al., 2010; Knieke et al., 2013), 
micellar solubilization of the drug (Yalkowsky, 1981) and particle growth via 
Ostwald ripening during milling and/or storage (Ghosh et al., 2011; Knieke et al., 
2013; Verma et al., 2011). Additional challenges associated with the use of anionic 
surfactants include incompatibilities with other ionic molecules, sensitivity to pH, salt 
or temperature changes, GIT irritation (Gupta and Kompella, 2006; Liversidge and 
Cundy, 1995), and even toxicity when used in excess (Liversidge and Cundy, 1995), 
especially for inhalation applications (Lebhardt et al., 2011; Suzuki et al., 2000).  
In view of all the aforementioned issues, surfactant usage should be 
minimized to mitigate all potential negative impact during formulation development. 
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Sugars (e.g., Sucrose, Lactose), sugar alcohols (e.g., Mannitol, Sorbitol), and water-
soluble polymers (e.g., HPC, HPMC, PVP, and PEG) are commonly used in 
nanocomposite formulations as dispersants. However, in the absence of surfactants, 
sugars and sugar alcohols must be added in high concentrations up to 1000% w/w 
w.r.t. (with respect to) the drug nanoparticles to ensure fast nanoparticle release from 
the nanocomposites (Hu et al., 2011; Kho and Hadinoto, 2010; Kim and Lee, 2010). 
Such high dispersant concentrations render drug concentration in the composite 
particles relatively low, minimizing the drug carrying capacity of the nanocomposites. 
Besides, when used alone, water-soluble polymers may not guarantee fast drug 
dissolution from drug nanocomposites (Choi et al., 2008; Li et al., 2016c), and their 
overuse may potentially slow down dissolution (Jagtap et al., 2012; Knieke et al., 
2015a; Möckel and Lippold, 1993; Shah and Sheth, 1976). Alternative surfactant-free 
formulations with novel dispersants that allow for high drug loading should be 
developed in comparison to conventional dispersants used in nanoformulations. 
Bilgili et al. (2016b) and Azad et al. (2015a) wet co-milled superdisintegrants 
and BCS Class II drugs in the presence of an adsorbing neutral polymer, thus, 
providing a novel method for formulating surfactant-free drug nanosuspensions. 
While large superdisintegrant particles with high swelling capacities are typically 
used for fast disintegration of tablets in the pharmaceutical industry (Omidian and 
Park, 2008), the use of colloidal or wet-milled superdisintegrants for enhancing drug 
nanoparticle release/dissolution from nanocomposites is relatively novel. A recent 
study by Bhakay et al. (2014b) explored the use of wet-milled superdisintegrants as a 
novel class of dispersants that improve the recovery/dissolution of drug nanoparticles 
27 
 
from nanocomposites in the absence of surfactants. Bhakay et al. (2014b) coated wet 
co-milled griseofulvin (GF)–croscarmellose sodium (CCS) suspensions on 
Pharmatose® via a fluidized bed processor, which yielded core–shell type GF 
nanocomposites with a relatively low drug loading: <13% w/w. The major focus there 
was to optimize the co-milling time of the superdisintegrant for the best dissolution 
improvement. In a separate study, Azad et al. (2015b) demonstrated the positive 
impact of CCS and SSG on the dissolution performance of GF nanocomposites and 
the feasibility of spray drying to prepare high-loaded, surfactant-free GF 
nanocomposites. GF was used as the model drug in both studies (Azad et al., 2015b; 
Bhakay et al., 2014b) and superdisintegrants were used at one concentration. While 
the aforementioned studies provided the proof-of-concept for surfactant-free 
nanocomposites with colloidal superdisintegrants in dissolution enhancement, the 
positive correlation with their swelling capacity was not established. Besides, no 
head-to-head comparison between colloidal superdisintegrants and conventionally 
used dispersants, e.g., sugar, sugar alcohol, and soluble polymers, at various 
concentrations has been conducted previously. More importantly, the mechanisms 
associated with the dissolution enhancement provided by wet-milled 
superdisintegrants have not been fully elucidated. 
In Chapter 6, nanocomposites of itraconazole (a BCS Class II drug) was 
prepared by spray-drying precursor wet media milled drug suspensions with various 
classes of dispersants with the goal of elucidating their roles in drug release from the 
nanocomposites during dissolution. Itraconazole (ITZ) is an antifungal drug for the 
treatment of local and systemic mycoses, which belongs to BCS Class II, having high 
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permeability, but a very poor water solubility (< 1 ng/mL) (Peeters et al., 2002). The 
impact of Sucrose vs. microcrystalline cellulose (MCC) on the dissolution of freeze-
dried ITZ nanocomposites was assessed by Bernard et al. (2008) in the presence of D-
α-tocopherol polyethylene glycol 1000 succinate (TPGS), where Sucrose and MCC as 
extra dispersants had to be used at 50% and 200%, respectively, w.r.t ITZ to achieve 
80% ITZ dissolution in 20 min. Similarly, Mannitol and MCC were studied as extra 
dispersants in the presence of HPC and SDS by Cerdeira et al. (2013b), where 
Mannitol and MCC were used at 100% w.r.t ITZ for effective dissolution 
improvement of spray-dried ITZ nanocomposites. Other literature on ITZ 
nanocomposite did not investigate different dispersants on ITZ dissolution. For 
example, Parmaentier et al. (2017) and Azad et al. (2016) used the HPMC‒SDS 
combination to achieve fast dissolution of ITZ nanocomposites produced by fluid bed 
coating; Sarnes et al. (2014) produced fast-dissolving ITZ nanocomposite with 
Poloxamer P407 via freeze drying; De Smet et al. (2014) spray-dried ITZ 
nanocomposite in the presence of adipic acid and Tween 80. Interestingly, all of the 
work mentioned above relied upon the use of certain surfactant, e.g., TPGS, sodium 
dodecyl sulfate (SDS), Tween, Poloxamer, etc., and thus none of them produced fast 
dissolving surfactant-free ITZ nanocomposites. More importantly, wet co-milled 
superdisintegrants and polymer alone at high concentration were not considered for 
the dissolution improvement of ITZ nanocomposites. The comparison between co-
milled superdisintegrants and conventionally used dispersants was completely 
missing. All these gaps and issues will be addressed in Chapter 6.  
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1.2.6  Comparative Assessment of the Dissolution Performance of 
Nanocomposites and Amorphous Solid Dispersions: Matrix Size Effect 
Chapters 2–6 deal with the production, stabilization, and dissolution of the drug 
nanoparticle-based formulations, i.e., drug nanosuspensions and nanocomposite 
microparticles. Nanoparticle delivery relies on reduced particle size for increased 
dissolution rate (Möschwitzer et al., 2011),
 
according to the Noyes–Whitney equation 
(Noyes and Whitney, 1897). Enhanced dissolution rate, improved bioavailability, safe 
dose escalation, elimination of food effects, and enhanced safety, efficacy and 
tolerability profiles are some of the numerous advantages of crystalline drug 
nanoparticles (Junghanns and Müller, 2008). Despite all the above-mentioned 
advantages, nanoparticle formulations have a serious drawback: the limited 
improvement on drug solubility. Often for drugs with very low aqueous solubility, the 
achieved increase in dissolution rate via size reduction is limited and insufficient to 
provide significant enhancement of bioavailability (Müller et al., 2001). 
Another approach to enhance the bioavailability of poorly water-soluble drugs 
is to produce amorphous solid dispersions (ASDs). ASDs tend to exhibit high levels 
of supersaturation in aqueous media relative to the crystal form of the drug, and thus 
higher apparent solubility (Newman et al., 2012). The preparation involves 
combining a drug with a water-soluble polymer to produce a single-phase amorphous 
mixture of the drug and the polymer. Once the solid dispersion encounters dissolution 
media, supersaturation in solution must be maintained over a period of time that will 
ensure complete dissolution and potential enhancement in bioavailability (Alonzo et 
al., 2010; Brouwers et al., 2009). Processes for the preparation of amorphous solid 
dispersions can be categorized into two general types: solvent methods and fusion–
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melting methods (Brough and Williams III, 2013). With solvent methods, solid 
dispersions are obtained by evaporating solvent from a drug and carrier solution. 
Practical applications of the solvent method are spray drying (Langham et al., 2012; 
Paradkar et al., 2004) and freeze drying (Kagotani et al., 2013; Schersch et al., 2010). 
On the other hand, pharmaceutical hot-melt extrusion (HME), is an evolving, solvent-
less fusion technique, currently being investigated by both industry and academia as a 
means to produce amorphous solid oral dosages, with improved bioavailability of the 
poorly water-soluble drugs (Gogos et al., 2012).  
It is well known that utilizing the amorphous form of a drug can be a useful 
approach to improve the dissolution behavior and bioavailability of poorly water-
soluble drugs, as a result of supersaturation (Chiou and Riegelman, 1970; Goldberg et 
al., 1966; Hancock and Parks, 2000). However, the dissolution advantage of 
amorphous solids can be negated either by crystallization of the amorphous solid on 
contact with the dissolution medium or through rapid crystallization of the 
supersaturated solution (Alonzo et al., 2010). The majority of research work on 
amorphous dispersions focused on the drugs at a relatively high dose, which led to 
supersaturation in the dissolution media (Konno et al., 2008; Langham et al., 2012; 
Yang et al., 2010), where the major research focus was to retard the recrystallization 
and maintain the highest level of supersaturation during dissolution (Konno et al., 
2008). It is interesting to note that a head-to-head comparison of the dissolution 
performance between nanoparticle-based formulations and amorphous solid 
dispersion of poorly water-soluble drugs is not available in the open literature. Yang 
et al. (2010) investigated the bioavailability enhancement induced by amorphous 
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versus crystalline itraconazole nanoparticles. It was found that amorphous 
itraconazole had higher supersaturation that increased the permeation, but dissolution 
performance was not investigated. Six et al. (2004) investigated the relative 
dissolution improvement achieved by ASD with respect to as-received itraconazole 
microparticles. It was found that the dissolution of itraconazole was significantly 
improved by producing ASD compared to the microparticles. However, it is still 
unknown if nanoparticles of itraconazole can also achieve similar or better dissolution 
improvement. Similar to Six et al. (2004), Jung et al. (1999) conducted a comparison 
between amorphous solid dispersion of itraconazole to commercial products as well 
as as-received itraconazole microparticles in tablet form. By changing different 
polymers during spray drying process, fast dissolution of itraconazole amorphous 
solid dispersion can be achieved. A comparison of the dissolution performance of 
nanoparticles vs. ASD does not exist. Furthermore, the drug doses in the above-
mentioned dissolution studies were all above 100 mg up to 200 mg. For drugs with 
high potency, low dose (typically <<10 mg), is preferred to mitigate the potential side 
effects (Branchey et al., 1978; Law et al., 2003). Hence, a direct comparison of the 
dissolution enhancement imparted by nanocomposites versus ASDs for low drug dose 
can be of special interest for formulating high potency drugs.  A commonly-held 
notion in pharmaceutical literature is that nanocrystals of a drug formulated in 
nanocomposites are not as effective as the amorphous form of the drug formulated in 
the form of ASDs because the latter offers significant supersaturation advantage. 
Chapters 7 and 8 of this dissertation will challenge this commonly-held notion and 
test its limits in terms of drug dose and particle size of the nanocomposites vs. ASDs.  
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Recently, a nanoextrusion process has been developed to disperse drug 
nanoparticles in a polymeric matrix using a modified version of the standard hot melt 
extrusion process (Baumgartner et al., 2014; Khinast et al., 2013). Nanoextrusion 
appears to be a new promising platform technology to make solid nanoparticle-based 
formulations (nanocomposites), thereby improving the dissolution rate and thus the 
bioavailability of the drug as well as enhancing patient compliance. This technique 
was first presented by Khinast et al. (2013) as a one-step process for drying a 
stabilized nanosuspension of crystalline titanium oxide. In a followed-up study by 
Baumgartner et al. (2014), drug nanoparticles were used to demonstrate applicability 
to pharmaceutical products. However, the dissolution rate of the produced 
nanocomposite was very low, which casts doubt about the use of the technology for 
immediate-release drug products. In a separate study conducted by Park et al. (2013), 
the same technique was explored with an emphasis on the preparation of content-wise 
uniform solid dosage forms with very low dose drugs. In that study, the dissolution 
performance of the produced nanocomposites was not studied. Ye et al. (2015) 
combined the use of high-pressure homogenization and extrusion for the production 
of nanocomposites with low drug concentration, i.e., 1‒2%. Throughout the literature, 
no study has been conducted on the dissolution performance comparison between 
drug nanocomposites and ASDs that are prepared via the same nanoextrusion process.  
Extrusion processes of manufacturing drug solid dosages, including traditional 
hot melt extrusion and nanoextrusion, usually involve downstream processes such as 
milling of the extrudates, sieving, compression, and coating. Milling of extrudates 
into various particle (matrix) sizes opens the possibility of manipulating the drug 
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dissolution performance. The majority of the literature on extrusion process ignored 
the matrix size effect of the milled extrudates on the dissolution performance. For 
examples, Fule et al. (2016) used hot melt extrusion process to produce ASD of 
artesunate in the matrices of Soluplus® and Kollidon® VA64. The produced 
extrudates were milled and passed through a 200 µm for various characterizations. 
Similar to Fule et al. (2016), most literature simply passed the milled extrudate 
powder through a sieve without reporting the actual particle sizes and their 
distribution, e.g., (Ghebremeskel et al., 2006; Juluri et al., 2016; Perissutti et al., 
2002; Pudlas et al., 2015). Most importantly, all the reported literature focused on 
only one particle size of the extrudates. Even when nanocomposites were produced 
by an extrusion process, i.e., nanoextrusion (Baumgartner et al., 2014; Ye et al., 
2015), the impact of matrix size was not thoroughly investigated. Hence, it is not 
unfair to assert that the impact of particle (matrix) size of the milled extrudate 
powders on drug dissolution has been extensively studied neither for nanocomposites 
nor for ASDs produced by an extrusion process. 
To address the aforementioned issues and challenges, Chapter 7 presents a 
first attempt to prepare both a drug nanocomposite and a drug ASD using the same 
nanoextrusion process by using two different extrusion polymers with different 
polymer–drug miscibility. As the nanoextrusion process is a newly developed process 
to create a dispersion of drug nanoparticles while drying the drug nanosuspensions, 
its comparison to conventionally used drying processes, e.g., spray drying, was also 
carried out for the first time in literature. As a continuation, Chapter 8 uses the 
nanoextrusion process as a platform enabling the systematical assessment of extrudate 
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particle (matrix) size impact on the drug dissolution performance under both non-
supersaturating and supersaturating conditions for nanocomposites as well as ASDs at 
two drug loading levels.  
 
1.3  Objectives and Major Research Tasks 
In view of the above mentioned issues, the goal of this dissertation is to enhance the 
dissolution performance of poorly water-soluble drugs using nanoparticle-based 
formulations and ASDs, compare their dissolution performance, and elucidate the 
mechanisms. To achieve this goal, three major objectives are targeted. The first major 
objective is to develop a processing–formulation understanding of wet stirred media 
milling process for fast–efficient production of drug nanoparticles in a stable 
nanosuspension form. To this end, combination of an adsorbing polymer–anionic 
surfactant was assessed for five poorly water-soluble drugs as a general stabilizing 
strategy; a microhydrodynamic model-based rationale was developed for optimal 
bead size selection that achieves the fastest production of drug nanoparticles; and a 
process intensification methodology for production of sub-100 nm stable drug 
nanoparticles with minimal product contamination was developed in view of the 
microhydrodynamic model. The second major objective is to elucidate the impact of 
various classes dispersants on drug release rate and mechanisms during the 
redispersion–dissolution of nanocomposites prepared via dying of the drug 
nanosuspensions. To this end, drug nanosuspensions were used as precursor materials 
for the production of nanocomposite microparticle powders (nanocomposites) via 
various drying techniques. Several classes of dispersants/stabilizers such as polymer, 
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surfactants, sugars, sugar-alcohols, and superdisintegrants (SDIs) were used at 
various concentration to modulate the drug nanoparticle release and dissolution rate. 
The role of drug nanoparticle stabilization and drug particle size in dissolution 
performance of the nanocomposites was also investigated as well as the roles/impact 
of dispersant type and concentration. Finally, the third major objective is to assess the 
dissolution enhancement imparted by drug nanocomposites vs. ASDs prepared via 
drying of drug nanosuspensions by a novel nanoextrusion process. To attain a 
scientific, head-to-head assessment of the two formulation platforms, nanocomposites 
and ASDs of the same drug were prepared using the nanoextrusion process, and the 
dissolution performance of drug nanocomposites vs. ASDs was evaluated at two drug 
loadings, three different matrix size, and two doses. 
 
1.4  Dissertation Outline 
This dissertation has been organized into various chapters as follows:  
1) Chapter 2 assesses the combined use of non-ionic cellulosic polymers and anionic 
surfactants in stabilizing multiple drug nanosuspensions prepared via wet media 
milling. The aim is to provide a generally applicable stabilization strategy for 
multiple drug nanosuspensions. 
2) With the established stabilization strategy for drug nanosuspensions in Chapter 2, 
Chapter 3 studies the impact of bead size on the drug breakage kinetics at 
different stirrer speeds and rationalizes the selection of bead size in view of a 
microhydrodynamic model for the optimal performance of wet stirred media 
milling. 
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3) Combining the knowledge generated in Chapter 2 on formulating stable drug 
nanosuspensions and Chapter 3 on bead size optimization, Chapter 4 presents an 
intensified wet media milling process with the objective of preparing sub-100 nm 
drug nanosuspensions with reduced energy consumption and low contamination 
under the guidance of a microhydrodynamic model. 
4) Chapters 2‒4 established fundamental understanding on the fast production of 
drug nanoparticles in the form of aqueous suspensions with desired drug particle 
size and minimal aggregation. In Chapter 5, the drug suspensions stabilized by 
polymer/surfactant are dried‒coated on the Pharmatose® carriers in a fluidized 
bed processor, and the impact of the physical stability of drug nanosuspension and 
roles of polymer/surfactant in drug dissolution from the nanocomposites are 
elucidated.  
5) Chapter 6 presents spray drying of the drug suspensions into nanocomposite 
microparticles to produce high drug-loaded, matrix-type nanocomposites. The 
impact of various classes of dispersants is investigated for the preparation of fast-
dissolving, high drug-loaded, and surfactant-free nanocomposites. Further, the 
mechanisms for the enhanced dissolution of nanocomposites is elucidated. 
6) With all the established knowledge on nanoparticle-based formulations in 
previous chapters, Chapter 7 aims to develop a nanoextrusion process, which 
allows for preparing nanocomposites vs. ASDs of the same drug and enables 
comparative assessment of their capability for drug dissolution enhancement. 
Depending on the selection of polymeric matrix, the same nanoextrusion process 
can produce extrudates with crystalline (nanocomposites) and amorphous (ASD) 
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forms of the same drug. 
7) As a continuation of Chapter 7, Chapter 8 investigates the impact of polymeric 
matrix size on the dissolution performance of nanocomposites vs. ASDs at both 
low dose and high dose conditions.   
8) Finally, Chapter 9 provides the conclusions and recommendations for future work 
that originate from interesting research questions/issues identified during the 
course of this investigation.  
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CHAPTER 2 
A GENERAL STRATEGY FOR ENSURING PHYSICAL STABILITY OF 
BCS CLASS II DRUG NANOSUSPENSIONS 
 
Ensuring the physical stability of drug nanosuspensions prepared via wet media 
milling has been a challenge for pharmaceutical scientists. The aim of this study is to 
assess the feasibility of combined use of nonionic cellulosic polymers and anionic 
surfactants in stabilizing multiple drug nanosuspensions as a general stabilization 
strategy. The particle size of five drugs, i.e., azodicarbonamide (AZD), fenofibrate 
(FNB), griseofulvin (GF), ibuprofen (IBU), and phenylbutazone (PB) was reduced 
separately in an aqueous solution of hydroxypropyl cellulose (HPC) with/without 
sodium dodecyl sulfate (SDS) via a stirred media mill. Laser diffraction, scanning 
electron microscopy, thermal analysis, rheometry, and electrophoresis were used to 
evaluate the breakage kinetics, storage stability, electrostatic repulsion, and stabilizer 
adsorption.  
 
2.1  Materials and Methods 
2.1.1  Materials 
Azodicarbonamide (AZD; Pfaltz & Bauer, Waterbury, CT), fenofibrate (FNB; BP 
grade, Jai Radhe Sales, Ahmedabad, India), griseofulvin (GF; BP/EP grade, Letco 
Medical, Decatur, AL), ibuprofen (IBU; PH.EUR/USP/JP/IP grade, Alfa Chem, 
Kings Point, NY), and phenylbutazone (PB; USP grade, Medisca, Plattsburgh, NY) 
were used as-received in the wet media milling experiments. These drugs were 
selected as they belong to BCS Class II and have different physicochemical properties 
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(Table 2.1). 
 
Table 2.1  Physicochemical Properties of the Drugs 
Drug 
Solubility in 
Water at 4°C 
(mg/l) 
Molecular 
Weight (g/mol) 
Melting Point 
(°C) 
LogP 
AZD 35 116.1 225 -1.7 
FNB 0.7 360.8 80.5 5.3 
GF 8.6 352.8 220 2.2 
IBU 21 206.3 76 3.6 
PB 32 308.4 105 3.2 
 
Hydroxypropyl cellulose (HPC, SL grade) donated by Nisso America Inc. 
(New York, NY, USA) was used as model non-ionic cellulosic polymer and steric 
stabilizer. SDS purchased from Sigma-Aldrich (Milwaukee, WI, USA) was used as a 
model anionic surfactant that acts as a wetting agent and electrostatic stabilizer. Its 
critical micelle concentration (CMC) in water is 8.2 mM (0.24% w/w) at ambient 
temperature. Wear-resistant yttrium stabilized zirconia beads (Zirmil Y, Saint Gobain 
ZirPro, Mountainside, NJ), with a median size of 430 µm, were used as milling 
media. 
 
2.1.2  Preparation of Suspensions via Wet Media Milling 
Feed suspensions to be milled were prepared in a DLM 1638X1 shear mixer (Cat#. 
14-503 Fisher Scientific Pittsburgh, PA, USA). The drug and HPC concentrations 
were kept at 10 and 2.5%, respectively, in all suspensions, with or without 0.5% SDS. 
Hence, HPC was present in all suspensions as the baseline stabilizer, whereas SDS 
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was used along with HPC in some additional suspensions prepared. All 
concentrations reported here are with respect to deionized water (250 g) unless 
otherwise specified. SDS, where applicable, was added to deionized water in a beaker 
gradually for 15 min while the mixer ran at a fixed speed of 300 rpm. Then, HPC was 
added to the SDS solution gradually for 30 min. The final HPC–SDS solution or HPC 
solution was further mixed for 15 min to ensure proper dissolution. The desired 
amount of drug powder was weighed and added to this solution gradually for 30 min 
while mixing continued. 
The wet stirred media mill (Figure 2.1) used in this study was manufactured 
by Netzsch Fine Particle Technology, LLC. (Model: Microcer, Exton, PA). The 
milling chamber has a volume of 80 ml and is lined with zirconia. During milling, a 
peristaltic pump recirculated the suspension between the holding tank and the milling 
chamber, while a 200 µm screen kept the zirconia beads in the milling chamber, but 
allowing the passage of the drug suspension. The feed suspensions prepared using the 
shear mixer were poured into the holding tank and milled under the following 
conditions: bead loading of 50 ml (bulk), suspension flow rate of 126 ml/min and 
stirrer (rotor) speed of 3200 rpm corresponding to a tip speed of 11.7 m/s. Both the 
milling chamber and the holding tank were equipped with a cooling system (model 
number M1-.25A-11HFX, Advantage Engineering, Greenwood, IN) to keep the 
suspension below 35 °C. The procedure and the aforementioned processing 
parameters were selected based on Bhakay et al. (2013) and Bilgili and Afolabi 
(2012).  
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At pre-determined intervals, samples were taken at the outlet of the milling 
chamber for particle size analysis. The final suspensions (after 120 min milling) for 
all formulations were tested for apparent shear viscosity, zeta potential, and 
refrigerated at 8 °C for a period of 7 days. Particle size results obtained immediately 
after milling and after 7-day storage were compared for all suspensions to assess the 
short-term physical stability of the suspensions. In general, this study assumed the 
milled suspensions were intended to be dried shortly after milling, justifying the 7-
day stability. On the other hand, particle sizes for GF suspension samples were also 
measured after 6-month storage at 8 °C to assess the long-term physical stability as 
GF suspensions exhibit severe aggregation in the absence of surfactants (Afolabi et 
al., 2014). 
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Mixer
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inlet
Inlet
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Pressure 
sensor
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Particles
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Coolant 
flow
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Figure 2.1  Schematic of a wet stirred media mill with recirculation mode of 
operation. Figure is not drawn to scale. 
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2.1.3  Particle Size Determination 
Particle size distributions were measured using laser diffraction (LD) (LS 13 320, 
Coulter Beckman, Brea, CA, USA). A polarized intensity differential scattering 
(PIDS) obscuration water optical model was employed. The PIDS was maintained 
between 40% and 50% while the obscuration was maintained below 8% for all 
particle size measurements. Particle size distribution was computed by the 
equipment’s software using the Mie scattering theory. Refractive index (RI) values 
are 1.68, 1.45, 1.65, 1.44, and 1.61, respectively, for AZD, FNB, GF, IBU, and PB 
particles, and 1.33 for the measurement medium (de-ionized water). Prior to the size 
measurement, ~2 ml samples of the milled suspensions were diluted with 8 ml 
solution of HPC or HPC–SDS depending on the stabilizer(s) used in the milling 
experiment. The refrigerated suspension samples after 7 days (all suspensions) and 6 
months (GF only) of storage were mixed with the shear mixer running at 300 rpm for 
5 min. Then, ~2 ml samples were taken and diluted for particle size measurement 
using the pertinent stabilizer solution. 
 
2.1.4  Scanning Electron Microscopy 
SEM imaging was used to examine the morphology of particles after milling and 
after 7-day storage and determine the primary particle sizes of various drugs. An 
aliquot of 1 ml drug suspension sample was diluted into 30 ml de-ionized water, 
vortex-mixed for 30 s and mounted on a silicon chip (Ted Pella, Inc., Redding, CA, 
USA), placed on top of carbon specimen holders, and dried in a desiccator. The 
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samples were then sputter coated with carbon and examined under a LEO 1530 
SVMP (Carl Zeiss, Inc., Peabody, MA, USA). 
 
2.1.5  Apparent Shear Viscosity of Stabilizer Solution and Milled Suspensions 
The apparent shear viscosity of the milled suspensions and the stabilizer solutions 
was measured using an R/S Plus Rheometer (Brookfield Engineering, Middleboro, 
MA, USA) with a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, 
NJ, USA). A coaxial cylinder (CC40) was used to provide a controlled shear rate on 
the samples from 0 to 1000 1/s for 60 s. The temperature of the jacket was kept 
constant at 25±0.5 °C. The raw data were analyzed using the Rheo 3000 software 
(Brookfield Engineering, Middleboro, MA, USA) of the equipment to obtain the 
apparent shear viscosity as a function of the shear rate. 
 
2.1.6  Determination of the Polymer Adsorption on Milled Drug Particles 
Polymer adsorption onto the drug particles was studied using a thermo-gravimetric 
technique. Fresh drug suspensions were prepared by wet stirred media milling under 
similar conditions to those described above, except for the milling time. The drugs 
were wet-milled for about 10 min, which yielded particles with Sauter mean diameter 
(D32) values of 0.7000.225 m. Such colloidal sizes allowed for easier separation of 
the drug particles from the suspensions during the subsequent centrifugation step
22
. 
Each suspension was centrifuged (Sorvall RS-28S, DuPont Company, Wilmington, 
DE, USA) at 20,000 rpm for about 6 h. The polymer content in the supernatant 
solution was determined using a thermogravimetric analyzer (TGA): Mettler-Toledo 
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TGA/DSC1/SF, Stare system (Mettler Toledo, Inc., Columbus, OH, USA). A sample 
taken from the supernatant solution was heated to 200 °C under nitrogen at 10 °C/min 
to evaporate the water and determine the residual weight. The polymer concentration 
in the supernatant solution was determined using the initial weight and the residual 
weight. The amount of polymer adsorbed was back-calculated by subtracting the 
polymer concentration in the supernatant solution from the initial nominal polymer 
concentration in the suspension sample. Assuming sphericity of the drug particles, the 
external specific surface area (S) was calculated approximately from S = 6/(ρpD32), 
where ρp is the true density of drug particles (i.e., AZD: 1.87 g/cm
3
, FNB: 1.18 g/cm
3
, 
GF: 1.45 g/cm
3
, IBU: 1.12 g/cm
3
, and PB: 1.54 g/cm
3
), and D32 is the Sauter mean 
diameter of the milled particles, which was obtained from the LD measurement. The 
amount of polymer amount adsorbed divided by S was used to calculate the amount 
of polymer adsorbed per drug surface area. 
 
2.1.7  Zeta Potential Measurement 
The zeta potential of milled suspensions with and without SDS was measured using a 
zeta potential analyzer (Delsa Nano C, BeckmanCoulter, USA). The Delsa Nano C 
uses electrophoretic light scattering (ELS) for zeta potential determination; 
electrophoretic movement of charged particles was determined from the Doppler shift 
of scattered light under an applied electric field. 
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2.2  Results and Discussion 
2.2.1  Apparent Breakage Kinetics 
The time-wise variation of the 50% cumulative passing size or median size (d50) and 
90% cumulative passing size (d90) is shown in Figure 2.2 for each of the five drugs 
wet-milled in the stirred media mill. While the apparent breakage kinetics of various 
drugs would be expected to be different due to their different mechanical and 
physico-chemical properties, Figure 2.2 illustrates some general trends that merit 
discussion first. Considering the relatively large micron-sized crystals initially present 
(at time t = 0 min), the data presented in Figure 2.2 suggest fast breakage of particles 
within the first 4 min for all drugs as the coarser particles were easier to break (Bilgili 
et al., 2004, 2006). In general, as milling continued, the apparent breakage rate 
decreased upon formation of smaller colloidal particles and nanoparticles, which can 
be explained by the difficulty to capture such small particles and their inherent high 
strength as compared to the coarser particles (Afolabi et al., 2014; Knieke et al., 
2013). As a consequence, particle size approached or attained an equilibrium particle 
size. Another reason for the observed approach to such dynamic equilibrium is the 
competition between the particle breakage and aggregation (Bhakay et al., 2011; 
Bilgili et al., 2004; Sommer et al., 2006). The latter mechanism emerges to be 
significant as finer particles with large surface area and high surface energy were 
formed. Moreover, as the drug particle size decreased, particle number concentration 
in the suspension increased and the interparticle distance decreased, leading to more 
frequent collisions and potentially higher aggregation rate (Sommer et al., 2006). 
During prolonged milling of all drugs considered, the evolution of d50 and d90 in the 
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presence of SDS exhibited a monotonic decrease and approached a smaller plateau 
size compared to the absence of SDS. It must be noted that the presence of SDS shifts 
the dynamic equilibrium toward finer sizes through its positive impact on the 
prevention of aggregate formation. This effect was most pronounced for GF and FNB 
with relatively low solubility compared with the other drugs. Hence, the combined 
use of HPC and SDS appears to be beneficial in reducing the particle size during 
milling. However, the particle size of the suspensions may change during the storage, 
which will be explored below. 
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Figure 2.2  Temporal evolution of azodicarbonamide (AZD), fenofibrate (FNB), griseofulvin (GF), ibuprofen (IBU), and 
phenylbutazone (PB) particle sizes during wet media milling. All suspensions had 2.5% HPC with/without 0.5% SDS. The 
abscissa starts at t = 4 min for proper scaling of the curves. Initially, at t = 0 min, the AZD particles had d50 = 6.398 µm and d90 = 
17.99 µm; the FNB particles had d50 = 17.32 µm and d90 = 40.88 µm; the GF particles had d50 = 27.74 µm and d90 = 58.00 µm; the 
IBU particles had d50 = 92.59 µm and d90 = 188.0 µm; and the PB particles had d50 = 71.82 µm and d90 = 445.5 µm. 
4
7
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2.2.2  Physical Stability of the Suspensions after Milling and Stabilization 
Mechanisms 
The GF suspension with HPC as the sole stabilizer, reached an early median size 
plateau at 16 min (Figure 2.2 (c)). The final particle sizes (both d50 and d90) for GF 
were greater than 1.3 µm (Table 2.2). Since the primary GF nanoparticles observed 
via SEM (Figure 2.3 (c)) had sizes in the range of 0.05–0.40 µm, the laser diffraction 
(LD) results suggest the significant extent of nanoparticle aggregation in the 
insufficiently stabilized GF suspension. Unlike the evolution of d50 and d90 in the 
absence of SDS, the evolution of both d50 and d90 exhibited a fast monotonic decrease 
in the presence of SDS and the particle size approached a plateau at about d50 = 0.160 
µm and d90 = 0.208 µm. In view of the 0.05‒0.25 µm primary particles produced (see 
Figure 2.3(d)) and the above information, the author can assert that the extent of 
aggregation in the 120 min milled suspension with SDS was low, and the breakage 
was the dominant mechanism, not the aggregation. This finding can be explained by 
the synergistic stabilizing action of HPC–SDS combination, as observed earlier by 
Bilgili and Afolabi (2012), where even 15% HPC alone was not able to stabilize a 
10% GF suspension. In addition, Bhakay et al. (2011) reported that 0.1% SDS alone 
could not stabilize a 2% GF suspension either. However, a combination of HPC and 
SDS (2.5% HPC and 0.5% SDS) led to the narrowest particle size distribution and 
smallest d50 and d90 values of 10% GF suspension (Bilgili and Afolabi, 2012), which 
is due to synergistic effects of the HPC–SDS combination (Basa et al., 2008; Lee et 
al., 2008; Ryde and Ruddy, 2002). Similarly, HPC alone was not able to fully 
stabilize the FNB suspension. The apparent breakage rate of FNB was lower in the 
presence of HPC than in the presence of HPC–SDS (Figure 2.2(b) and Table 2.2) 
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because aggregation was still a significantly competing mechanism in the former 
case. For the FNB suspension milled with HPC–SDS, the sizes of the small primary 
nanoparticles shown in Figure 2.3(e) confirmed the LD size statistics in Table 2.2, 
which suggests that the HPC–SDS combination properly stabilized the milled FNB 
suspension. 
 
Table 2.2  Effects of HPC and SDS on the Median Size (d50) and 90% Passing Size 
(d90) of Drug Suspensions after Milling and after 7-day Storage 
Drug 
With 2.5% HPC Only With 2.5% HPC and 0.5% SDS 
After Milling After 7 Days After Milling After 7 Days 
d50, d90 (µm) d50, d90 (µm) d50, d90 (µm) d50, d90 (µm) 
AZD 0.339, 1.641 0.388, 1.909 0.340, 1.522 0.358, 1.682 
FNB 0.264, 0.487 0.266, 0.472 0.148, 0.232 0.340, 1.190 
GF 1.343, 2.183 1.546, 2.178 0.160, 0.208 0.164, 0.214 
IBU 0.311, 0.477 0.346, 0.495 0.301, 0.445 0.386, 0.610 
PB 0.182, 0.278 0.187, 0.305 0.177, 0.249 0.177, 0.253 
 
AZD appears to have a relatively slow breakage after 4 min as shown in 
Figure 2.2(a). After 2 h milling, the d90 was still in the micron-range in the presence 
or absence of SDS. Unlike the case for GF and FNB with HPC, most of the coarse 
AZD particles were not aggregates of small primary nanoparticles; instead, they were 
large primary plate-like particles in the range of 0.80–2.40 µm as shown by the SEM 
images (Figure 2.3(a) and (b)). While the presence of SDS led to a smaller d90, it did 
not eliminate the coarse micron-sized particles. These results imply that an AZD 
suspension with d90 less than 1 µm can only be produced if milling is carried out for 
more than 2 h and/or under more intense milling conditions.  
 50 
 
 
Figure 2.3  SEM images of drug particles: (a) the AZD particles milled for 120 min 
with HPC (marker size: 200 nm, 20k magnification), (b) the AZD particles milled 
for 120 min with HPC–SDS (marker size: 200 nm, 20k magnification), (c) the GF 
particles milled for 120 min with HPC (marker size: 200 nm, 30k magnification), 
(d) the GF particles milled for 120 min with HPC–SDS (marker size: 200 nm, 131k 
magnification), (e) the FNB particles milled for 120 min with HPC–SDS (marker 
size: 200 nm, 18k magnification), (f) the milled FNB particles in the presence of 
HPC–SDS after 7-day storage at 8 °C (marker size: 2 µm, 15k magnification). 
 
Figure 2.2(d) and (e) show that the IBU and PB particles monotonically 
decreased in size and approached their equilibrium sizes, which were not significantly 
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affected by the presence of SDS, unlike the case for GF and FNB. Interestingly, the 
apparent breakage rate within the first 16 min of milling was lower in the presence of 
SDS, which is counterintuitive at first glance considering that SDS is an anionic 
surfactant which decreases surface tension, enhances wettability of hydrophobic drug 
particle surfaces, and minimizes aggregation through electrostatic forces (Kissa, 
1999) (see Figure 1.1(b)). For IBU and PB, initially, micron-sized coarse particles 
present had a relatively low strength and a small surface area; hence, they were easier 
to break and stabilize; implying particle breakage mechanism to be the controlling 
mechanism during the first 16 min of milling. In view of this, the observed initial 
slower breakage of the drug particles in the presence of HPC–SDS vs. HPC alone can 
be explained by the higher viscosity of the HPC–SDS based drug suspension vs. HPC 
based drug suspension (see Figure 2.4). The higher the apparent shear viscosity of a 
suspension is, the higher the viscous dampening of the milling media or the beads, 
which leads to slower drug particle breakage (Bilgili and Afolabi, 2012). After the 
IBU and PB particles were broken into smaller particles following 16 min milling, the 
aggregation rate increased and the viscous dampening effect became weaker. In this 
regime, formulations with SDS exhibited higher apparent breakage rate. Interestingly, 
the higher viscosity and ensuing viscous dampening due to the use of SDS was not a 
significant factor for GF and FNB because particle aggregation was the controlling 
mechanism during milling, and the main effect of SDS was through stabilization. 
Despite the higher viscous dampening resulting from the use of HPC–SDS, the use of 
SDS in addition to HPC was generally beneficial due to the mitigation of the 
aggregation. 
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Figure 2.4  The apparent shear viscosity of 120 min milled drug suspensions in the 
presence of HPC alone and HPC–SDS: (a) AZD, (b) FNB, (c) GF, (d) IBU, and (e) 
PB. 
 
2.2.3  Storage Stability of the Milled Suspensions 
Milled drug suspensions were refrigerated at 8 °C for a period of 7 days to examine 
the aging effects. Note that all suspensions had 2.5% HPC as baseline stabilizer. All 
milled suspensions had smaller particles in the presence of SDS in addition to HPC 
(Table 2.2), which indicates that SDS helped to suppress the particle aggregation for 
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all drugs during the milling. After storage, the characteristic sizes of GF and PB 
suspensions with SDS remained unchanged within experimental accuracy, and AZD 
exhibited a slight increase in d90. On the other hand, FNB and IBU suspensions with 
SDS exhibited significant size increase, whereas the suspensions of the same drugs 
without SDS (having HPC as the sole stabilizer) did not exhibit such a high size 
increase during the storage. While SDS helped to suppress aggregation of FNB and 
IBU particles during wet media milling, it unfortunately caused the growth of 
particles over 7 days, thus pointing to a need to optimize the SDS concentration.  
The increase in particle size during storage can be attributed to two 
mechanisms: Brownian aggregation of the particles caused by insufficient 
stabilization and/or particle growth due to Ostwald ripening (Knieke et al., 2013; 
Verma et al., 2011). 2.5% HPC alone was not sufficient to stabilize FNB and GF 
suspensions via steric stabilization alone; hence, FNB and GF suspensions were 
already aggregated during the milling and interestingly GF showed no increase and 
FNB showed about 15% increase in the median size after 7-day storage (Table 2.2). 
The median size increase was less than 15% for all drugs in the absence of SDS. In 
the presence of 0.5% SDS, FNB and IBU showed a significant increase in both d50 
and d90 after 7-day storage. The SEM image of FNB suspension after 7-day storage 
shows approximately 12 µm rhombohedral primary particles (Figure 2.3(f)) that did 
not exist in the milled suspension (Figure 2.3(e)). The presence of such rhombohedral 
crystals implies that the observed size increase was governed more by the Ostwald 
ripening than the aggregation. The water-solubility of FNB increases significantly 
with an increase in surfactant concentration especially above the critical micelle 
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concentration (CMC) of SDS, which in turn facilitates the ripening process (Ng et al., 
1996). A similar effect with SDS was observed by Gosh et al. (2011) and Verma et al. 
(2011) for several drugs.  
To mitigate Ostwald ripening and possible size increase during storage, while 
maintaining the positive effects imparted by combined HPC–SDS during the milling, 
the SDS concentration should be optimized. Knieke et al. (2013) constructed dynamic 
equilibrium curves to optimize surfactant concentration at constant HPMC loading 
with several SDS concentrations in a single milling experiment, and the particle sizes 
obtained after milling and after 7-day storage were compared to find the optimal SDS 
loading. In the current study, such a method was not used; but, an attempt was made 
to prove that optimization of the SDS concentration can mitigate the Ostwald ripening 
significantly. When 0.05% of SDS (below CMC), instead of 0.5% SDS (above 
CMC), was used in the presence of 2.5% HPC, FNB particles with d50 and d90 of 
0.157 µm and 0.248 µm, respectively, were obtained after 120 min milling, and the 
d50 and d90 values were 0.171 µm and 0.342 µm, respectively, after 7-day storage. At 
0.05% SDS, the positive impact of SDS on the suppression of particle aggregation 
was still maintained, while the negative impact via Ostwald ripening was significantly 
reduced, but not eliminated completely. Moreover, the FNB suspensions with HPC 
and 0.05% SDS had smaller sizes than those with HPC alone both after milling and 
after storage, again confirming the success of the HPC–SDS combination strategy. A 
similar reduction in SDS concentration could be applied to IBU case; however, this 
was not explored here because the beneficial effect of even 0.5% SDS was not 
pronounced for the milled IBU suspension as compared with the milled FNB 
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suspension, which can be inferred from the relatively small difference between 
particle sizes right after milling in the absence/presence of SDS (see Table 2.2). 
Additionally, the size increase during storage was much less pronounced for IBU than 
for FNB; hence, the benefit of using a smaller SDS concentration would be negligibly 
small. In a future study, the relative extent of Ostwald ripening could be investigated 
for different storage times and conditions, and SDS concentration could be optimized 
using the approach proposed by Knieke et al. (2013). 
Since the milled suspensions are intended for immediate drying for eventual 
solid dosage manufacture, long-term stability of the suspensions was not a major 
focus of this work; it was studied only for one of the drugs, i.e., GF, which exhibited 
pronounced difference in the aggregation state depending on the presence/absence of 
SDS. When HPC was the sole stabilizer, not only did the GF particles aggregated 
extensively (refer to Table 2.2), but also they phase-segregated or settled after long-
term storage due to the presence of coarse micron-sized aggregates (Figure 2.5(a) and 
(b)). The GF suspension with 2.5% HPC–0.5% SDS exhibited good long-term 
stability even without necessitating further formulation optimization. It did not show 
phase-segregation even after 6 months because all particles were colloidal and 90% of 
particles were smaller than ~300 nm (Figure 2.5(c) and (d)).  
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Figure 2.5  Images showing GF suspensions (a) after 120 milling in the presence of 
HPC alone (d50 = 1.343 µm and d90 = 2.183 µm), (b) after 6-month storage in the 
presence of HPC alone (d50 = 1.949 µm and d90 = 2.374 µm),  (c) after 120 milling in 
the presence of HPC–SDS (d50 = 0.160 µm and d90 = 0.208 µm), (d) after 6-month 
storage in the presence of HPC–SDS (d50 = 0.186 µm and d90 = 0.301 µm). 
 
2.2.4  HPC–SDS Synergistic Stabilization  
The data presented in Table 2.2 have shown that the HPC–SDS combination gave 
finer milled particle sizes for five drugs as compared to the case with HPC alone as 
the sole stabilizer. Various researchers have pointed out the potential synergistic 
stabilization effects ensuing from the use of cellulosic polymers–anionic surfactant 
combinations (Basa et al., 2008; Bilgili and Afolabi, 2012; Knieke et al., 2013; Lee et 
al., 2008; Ryde and Ruddy, 2002). A manifestation of HPC–SDS interactions above 
the CMC of SDS is illustrated in Figure 2.4. The HPC–SDS solution had a much 
higher viscosity than the HPC solution, which can be attributed to the formation of 
HPC–SDS aggregates or micelle-like SDS clusters bound to the polymer (Berglund et 
al., 2003; Evertsson and Nilsson, 1997; Winnik and Winnik, 1990). It is expected that 
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such interactions could lead to enhanced electrosteric stabilization (see Figure 1.1(c)), 
i.e., the steric stabilization from the HPC and electrostatic repulsion from the 
negatively charged SDS.  
To further elucidate the stabilization mechanisms, zeta potential and the extent 
of polymer adsorption on the drug nanoparticles were investigated. The value of the 
zeta potential indicates the strength of the electrostatic repulsive forces between 
particles at their surfaces, which is the basis for the physical stability imparted by the 
electrostatic mechanism besides the steric hindrance provided by the adsorbed 
polymer (Bilgili and Afolabi, 2012). For a physically stable nanosuspension stabilized 
by combined electrostatic and steric stabilization, a zeta potential value of ±20 mV 
may be sufficient (Müller et al., 2001). In general, the use of SDS led to higher 
(absolute) zeta potential in all drug nanosuspensions (Figure 2.6). The absolute values 
of the zeta potentials for FNB, GF, and PB in the presence of HPC–SDS were above 
17 mV, which suggests a relatively stable suspension. However, the zeta potential of 
AZD suspension in the presence of HPC–SDS did not suggest a stable system even 
though the particle sizes from LD (Table 2.2) and SEM (Figure 2.3(b)) were very 
close. In addition, all suspensions had zeta potentials (absolute) less than 20 mV 
when HPC was used alone; yet, PB and IBU suspensions did not show significant 
aggregation. In fact, earlier work (Mishra et al., 2009) suggested that the adsorbed 
polymer layer can reduce the surface charge, and suspensions even with less than 20 
mV (absolute) zeta potential could be stable via steric mechanism (Cerdeira et al., 
2013a; Mishra et al., 2009). Thus, zeta potential alone may not adequately 
characterize the stability of all drug nanosuspensions stabilized with combined 
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stabilizers (Cerdeira et al., 2013a; Van Eerdenbrugh et al., 2009) and such results 
must be interpreted with caution (Cerdeira et al., 2013a). 
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Figure 2.6  The zeta potential of drug suspensions after 120 min milling in the 
presence of HPC alone and HPC–SDS. 
 
Polymer adsorption on drug particles in the absence–presence of SDS was 
explored following the same procedure of Bilgili and Afolabi (2012), where full 
adsorption isotherms for GF–HPC–SDS system suggested that the stabilizer 
adsorption was mainly due to HPC and, to a much smaller extent, by SDS at 0.5% 
concentration. In general, a thicker layer of the adsorbed polymer and strong 
adsorption are desirable for good steric stability (Bilgili and Afolabi, 2012; Knieke et 
al., 2013; Lee, 2003). Figure 2.7 shows that the amount of HPC adsorbed was much 
higher in the presence of SDS for all drugs potentially due to the co-adsorption of 
SDS with HPC and the facilitation of HPC adsorption by SDS (Bilgili and Afolabi, 
2012; Cerdeira et al., 2010). The co-adsorbed layers can impart electrosteric 
stabilization to the GF particles (see Figure 1.1(c)); a sufficiently thick stabilizer layer 
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on drug particle surfaces provides a sufficiently high steric barrier to mitigate 
aggregation along with electrostatic charges (Knieke et al., 2013; Meng et al., 2012). 
Despite such possible advantages of higher amount of adsorption and associated 
lower d90 and improved stability for AZD, the AZD suspensions had d90 values 
greater than 1 µm because the coarse particles in the suspensions were mostly plate-
like crystals (coarsely broken crystals), not solely aggregates of smaller primary 
particles. It should also be noted that while GF particles had higher amount of 
polymer adsorbed compared to other drugs (except AZD), its suspension was not 
stable in the absence of SDS whereas that of IBU with lower adsorption was 
relatively more stable. Hence, it appears that polymer adsorption alone does not 
predict the physical stability of all drugs with/without SDS. However, the presence of 
SDS led to both higher zeta potential and adsorption, which overall could explain the 
better physical stability of the milled suspensions with SDS. The storage stability, on 
the other hand, was affected by the Ostwald ripening, especially for FNB and IBU, 
thus necessitating the optimization of the SDS concentration.  
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Figure 2.7  Amount of HPC adsorbed on milled drug particles in the absence and 
presence of SDS.  
 
Finally, it is worth-mentioning a concern during milling, i.e., the formation of 
amorphous material from an initially crystalline drug. While such a concern needs 
further exploration and warrants in-depth study of crystallinity, the available literature 
suggests that wet milling does not significantly alter the crystallinity of most BCS 
Class II drugs including GF (Monteiro et al., 2013; Sievens-Figueroa et al., 2012), 
FNB (Sievens-Figueroa et al., 2012), IBU (Plakkot et al., 2011), naproxen (NPX) 
(Monteiro et al., 2013; Sievens-Figueroa et al., 2012), and indomethacin (IND) 
(Sharma et al., 2009). This is not surprising as water plays a major role in inhibiting 
the amorphization during wet milling of crystalline drugs (Sharma et al., 2009). 
Besides acting as a plasticizer, water present in the milling medium or suspension 
provides fast and effective cooling during particle breakage, which can minimize 
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formation of local hot spots on particle surfaces and thus reduce the extent of surface 
amorphization and oxidation (Monteiro et al., 2013). 
 
2.2.5  On Correlations between Size Reduction/Physical Stability and Physico-
Chemical Drug Properties 
Mathematical correlations between measures of size reduction or drug suspension 
stability and physico-chemical drug properties, if exist, would benefit the formulators 
in developing drug nanoparticle formulations in a streamlined fashion. To 
quantitatively describe the extent of size reduction during milling, a size reduction 
ratio (SRR) (Bhakay et al., 2011; Verheezen et al., 2004) was defined for both d50 and 
d90: 
mil,90
ini,90
90
mil,50
ini,50
50 and
d
d
SRR
d
d
SRR   (2.1) 
where the subscripts ini and mil refer to the initial (unmilled) drug particles and the 
final milled drug suspension, respectively. Similarly, a size growth ratio (SGR) was 
defined for both d50 and d90 in order to quantify the size increase during the 7-day 
storage: 
mil,90
sto,90
90
mil,50
sto,50
50 and
d
d
SGR
d
d
SGR   (2.2) 
In Eq. (2.2), the subscripts sto and mil refer to the 7-day stored suspension and the 
final milled drug suspension, respectively. Similar SGR definitions have been used to 
describe size enlargement during granulation (Sahoo, 2012). As opposed to more 
elaborate measures like agglomeration ratio (Knieke et al., 2015b), SGR defined in 
Eq. (2.2) was used due to its simplicity in describing size increase during the storage 
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of the milled suspensions. In general, a higher value of SRR suggests the greater 
extent of particle breakage, whereas the higher value of SGR suggests the greater 
extent of size increase during the storage and thus poorer physical stability. The SRR 
and SGR values for both d50 and d90 were calculated using the experimentally 
measured particle sizes of the drug suspensions with HPC as the sole stabilizer and 
the drug suspensions with HPC–SDS as the binary stabilizer system in two separate 
analyses. Then, an attempt was made to correlate the SRR and SGR with each one of 
the physico-chemical drug properties, i.e., molecular weight, melting point, logP, and 
solubility, via linear and nonlinear regression models in the comprehensive model 
library of SigmaPlot® (Version 11). In this study, a correlation is regarded as good if 
it has R
2
 > 0.95 with statistical significance (p < 0.05 for both the model and each and 
every model parameter). In general, neither SRR nor SGR had good correlations with 
the physico-chemical drug properties when HPC was used as the sole stabilizer. 
There were only few good fits when HPC–SDS was used in the formulations (fits not 
shown). However, these few fits were so dependent upon one drug out of five (PB for 
SRR correlation with either molecular weight or logP and FNB for SGR correlation 
with either solubility or logP) that the removal of the respective drug from the fitting 
led to completely different and poor fits, signifying the low reliability of these 
correlations. Overall, our results from the statistical analysis appear to coincide with 
the findings from a more comprehensive study (Van Eerdenbrugh et al., 2009) using 
13 stabilizers at 3 different concentrations to stabilize 9 drug compounds, which 
concluded that no correlation between physicochemical drug properties and stable 
nanosuspension formation exists.  
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The lack of any statistically significant and reliable correlation is mainly due 
to the complexity of the particle change mechanisms, i.e., particle breakage–
aggregation–Ostwald ripening and the influence of multiple mechanical–physico-
chemical properties of the drugs as well as the stabilizers during milling–storage. 
Empirically, one can use multiple non-linear regression, which requires a dense data 
set, to describe the effects of the multiple parameters. However, in this study, it was 
not even possible to fit a quadratic regression model with only two regressors due to 
the small number of drugs investigated. Another issue is that even if some statistically 
significant and reliable correlations were found, they would not imply causation. For 
example, the model fits of SRR to the physico-chemical drug properties alone cannot 
lead to correlations with causation because particle breakage is largely controlled by 
the mechanical properties including the strength parameters of the drug crystals, 
which are relatively hard to measure. Hence, elucidation of the impact of physico-
chemical drug properties is elusive and warrants further investigation.  
 
2.3  Conclusions 
As a top-down approach, wet media milling has been investigated for the production 
of nanoparticles of five BCS Class II drugs to increase their total surface area, with 
the ultimate goal of increasing the dissolution rate and thus enhancing the 
bioavailability. The author assessed a recently suggested synergistic stabilization 
strategy with the use of a nonionic cellulosic polymer (HPC) and an anionic 
surfactant (SDS) to stabilize drug nanoparticles having different physico-chemical 
properties. Generally, using SDS, in addition to HPC, gave smaller particle sizes after 
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milling than in the absence of SDS, especially for GF and FNB. The combination of 
HPC and SDS led to the electrosteric stabilization of the drug nanosuspensions due to 
higher electrostatic repulsive forces (higher zeta potential) between the particles as 
well as enhanced steric hindrance from the adsorbed polymer, which was facilitated 
by the presence of SDS. However, after 7-day storage, FNB and IBU showed notable 
growth in the presence of SDS most likely due to Ostwald ripening. This negative 
effect was shown to be curtailed to a large extent by the use of smaller concentration 
of SDS for the FNB nanosuspension. In this study with five drugs, no correlation was 
found between the size reduction ratio for milling or the size growth ratio for storage 
stability and the physico-chemical drug properties. 
Overall, this study suggests that the combination of nonionic cellulosic 
polymers and anionic surfactants generally provides physical stability for wet-milled 
drug suspensions provided that the surfactant concentration is optimized to mitigate 
the Ostwald ripening. Cellulosic polymers alone may still impart sufficient stability 
for some drug suspensions.  
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CHAPTER 3 
A MICROHYDRODYNAMIC RATIONALE FOR SELECTION OF BEAD 
SIZE IN PREPARATION OF DRUG NANOSUSPENSIONS VIA WET 
STIRRED MEDIA MILLING 
 
As has been indicated in Chapter 1, although wet stirred media milling has proven to 
be a robust process for producing nanoparticle suspensions of poorly water-soluble 
drugs and thereby enhancing their dissolution rate–bioavailability, selection of bead 
size, which is the most important design parameter in media milling, has been largely 
empirical, lacking any fundamental rationale. Chapter 3 aims to establish such 
rationale by investigating the impact of bead size at various stirrer speeds on the drug 
breakage kinetics via a microhydrodynamic model. A proper stabilizer formulation 
was selected based on Chapter 2 for the preparation of stable griseofulvin 
suspensions. The drug suspensions were milled at four different stirrer speeds (1000–
4000 rpm) using various sizes (50–1500 m) of the yttrium-stabilized zirconia beads. 
Laser diffraction, scanning electron microscopy (SEM), and X-ray powder diffraction 
(XRPD) were used for characterization. In order to elucidate the impact of bead size 
at different stirred speeds on characteristic process times, time-wise evolution of 
median particle size d50 and 90% passing cumulative particle size d90 in time was 
analyzed using piecewise cubic Hermite interpolation and an exponential model fit. 
The characteristic times reveal the existence of optimal bead sizes at different stirrer 
speeds. Then, the experimental observations were explained within the context of a 
microhydrodynamic model. Furthermore, the implications of our findings were 
indicated so as to develop a rationale for bead size selection in WSMM process and 
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offer an overarching explanation about the typical bead sizes used for all wet media 
milling processes with low–medium vs. high-energy levels. 
 
3.1  Materials and Methods 
3.1.1  Materials 
EP/BP grade griseofulvin (GF) was purchased from Letco Medical (Decatur, AL, 
USA). GF is a BCS Class II drugs with an aqueous solubility of 8.9 g/ml at 25 ˚C. 
Two stabilizers were used: a non-ionic cellulosic polymer, hydroxypropyl cellulose 
(HPC, SL grade, Nisso America Inc, New York, NY, USA) and an anionic surfactant, 
sodium dodecyl sulfate (SDS, 99% ACS reagent, Sigma Aldrich, Bellefonte, PA, 
USA). Zirmil Y grade yttrium-stabilized zirconia (YSZ) beads with nominal sizes of 
50, 100, 200, 400, 800, and 1500 µm were purchased from Saint Gobain ZirPro 
(Mountainside, NJ, USA) as such media have been commonly used in many wet 
media milling studies (see Table 4.1) besides crosslinked polystyrene media. In this 
dissertation, the beads were labeled with their nominal sizes, while their actual 
median sizes are 54, 127, 215, 430, 798, and 1458 µm, respectively, as measured in 
dry dispersion mode via a laser diffraction particle size analyzer (Helos/Rodos, 
Sympatec, NJ, USA). The actual median sizes were used in the microhydrodynamic 
model. De-ionized water was used in all experiments.  
 
  
 
Table 3.1  Recent Literature on Bead Sizes used in Pharmaceutical Wet Media Milling 
References (Year) Mill Type 
Stirrer/ 
Circumference Speed 
(rpm) 
Nominal Bead Size 
Investigated
a
 
(µm) 
Optimal Bead 
Size
b
  
 (µm) 
Drug Particle 
Size
 
Produced
d
 
(µm) 
Konnerth et al. 
(2016) 
Wet stirred media mill 2.9–6.4c 100–2,000 100 
0.179
e
 
Bitterlich et al. 
(2015) 
Planetary ball mill 6.3
c
 100–500 500 
~0.100
f
 
Li et al. (2015) Wet stirred media mill 11.7–14.7c 50–800 50 0.088f 
Tuomela et al. (2015) Planetary ball mill 600  5,000 5,000 0.550, 0.970
f
 
Sarnes et al. (2014) Planetary ball mill 1100  1,000 1,000 0.315
f
 
Shah et al. (2014) Wet media mill 400–1100  100 and 1,000 100 0.329f 
Branham et al. (2012) Planetary ball mill 200  15,000 15,000 0.355
g
 
Ghosh et al. (2012) Planetary ball mill 
150 100–500 500 ~0.600f 
400 100–500 100 ~0.250f 
Juhnke et al. (2012) Wet stirred media mill 6–12c 100 and 200 100 ~0.150e 
Cerdeira et al. (2011) Agitator media mill 2400–3600 400–800 400 ~0.130e 
Ghosh et al. (2011) Wet stirred media mill 2500 100–500 200 0.230f 
Niwa et al. (2011) 
Oscillating beads-
milling apparatus 
2700 100–1,000 300 ~0.250e 
Singare et al. (2010) Wet stirred media mill 2500–3400 200 200 0.211i 
Ain-Ai and Gupta 
(2008) 
Centrifugal ball mill 400 800 800 0.536
h
 
Choi et al. (2008) Ball mill 100 1,000 1,000 0.100
h
 
a
Bead made up of zirconium dioxide; 
b
Bead size which led to the smallest final drug particle size or the only bead size chosen for the particular study; 
c
 m/s; 
d
The smallest drug particle size produced using the optimal bead size; 
e
d50; 
f 
Z-average; 
g
Sauter mean diameter; 
h
Mean size; 
i
d90 
6
7
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3.1.2  Preparation of Suspensions via Wet Media Milling 
The stabilizer types/concentrations and milling conditions were selected based on our 
recent investigations (Afolabi et al., 2014; Li et al., 2015b). First, about 225 g pre-
suspensions were prepared by dispersing 10% drug particles in an aqueous solution of 
2.5% HPC and 0.2% SDS under constant stirring at 300 rpm (Cat#. 14-503, Fisher 
Scientific, Pittsburgh, PA, USA) for a total of 90 min. Here, all percentages are w/w 
with respect to de-ionized water (200 g). The pre-suspensions were then milled for 
256 min at the conditions presented in Table 3.2. A chiller (Model M1-.25A-11HFX, 
Advantage Engineering, Greenwood, IN, USA) provided cooling for both the milling 
chamber and the holding tank and kept the suspension temperature in the holding tank 
below 34 
o
C, as a maximum. The impact of bead size was studied at the stirrer speeds 
 of 1000, 1600, 2800, and 4000 rpm. The highest speed was selected upon 
considering the maximum speed allowed by design, i.e., 4200 rpm. Speeds lower than 
1000 rpm were not considered because they would cause extremely slow breakage 
and many practical processing issues (erratic flow, pressure build-up, etc.). Pre-
suspensions were milled in a Microcer stirred media mill (Netzsch Fine Particle Size 
Technology, LLC, Exton, PA, USA) with a chamber volume Vm of 80 ml, lined with 
zirconia, and a zirconia shaft. The pre-suspension was added to the holding tank and 
recirculated between the holding tank and the milling chamber at a volumetric flow 
rate Q of 126 ml/min by a peristaltic pump (Cole-Parmer, Master Flex
®
, USA), based 
on previous work (Afolabi et al., 2014). Stainless steel screens with different opening 
sizes, which are approximately half of the nominal size of the beads, were used to 
keep the beads inside the milling chamber. The mass of beads was set constant in all 
 69 
 
runs, i.e., 196 g, which corresponded to a fractional bead volume fraction c of 0.408 
(40.8%) and was selected based on previous work (Afolabi et al., 2014). The Netzsch 
Microcer mill is limited to 50 µm beads in the recirculation mode by its design, which 
requires the use of a screen with an opening size of 25 µm. The bead sizes above 
1500 µm are not desirable in this mill due to significant heat generation and inability 
to keep the temperature below 34 
o
C. In fact, even the use of 1500 m beads at high 
speeds (2800 and 4000 rpm) caused excessive heat generation; hence, these runs were 
not considered in the analysis. Finally, 200 µm beads were used as the smallest beads 
at 1000 rpm and 100 µm beads at 1600 and 2800 rpm. Smaller beads than these 
resulted in clogging of the mill screen, erratic suspension flow, and sharp pressure 
rise at the indicated speeds, which all point to a practical processing limit; hence, 
these runs were not analyzed.  
Suspension samples at several milling time points were collected from the 
outlet of milling chamber and used for particle size analysis. The sampling points 
were selected based on a geometric progression of 2 min (2
s
, s = 0, 1, 2,...8). 
However, the author used additional time points (24 min, 48 min, and 96 min) so that 
there are sufficient data points available, without prolonging the total milling time, for 
reliable fitting and interpolation in the study of breakage kinetics. The final milled 
suspensions were stored in a refrigerator at 8 
o
C for 7 days and then their particle 
sizes were measured again to assess the physical stability. 
The stirrer power per unit volume of the slurry (beads and drug suspension) in 
the milling chamber, shortly will be referred to as the stirrer power, i.e., Pw = P/Vm, 
was calculated as a time-averaged value. The stirrer power P was directly recorded 
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from the mill control panel. In the absence of the milling beads, the power input per 
unit volume of the suspension, i.e., εht, was also measured at each stirrer speed. The 
specific energy consumption, i.e., E* = PtT/msus, is the energy spent per unit mass of 
drug suspension, where tT is the total milling time and msus is the total mass of the 
drug suspension. In all cases, the no-load power value obtained from a dry run of the 
mill rotor was subtracted from the power values used in the calculation of Pw, εht, and 
E*. 
 
3.1.3  Particle Size Determination  
Particle size distribution (PSD) of the GF suspensions at various milling times was 
determined by laser diffraction using LS 13-320 Beckman Coulter instrument (Brea, 
CA, USA). A refractive index of 1.65 and 1.33 was used for GF and water 
(measurement medium), respectively. In all measurements, the polarized intensity 
differential scattering (PIDS) was maintained between 40% and 50% while the 
obscuration was maintained below 8%. PSD was computed by the software using the 
Mie scattering theory. Prior to the size measurement, milled suspension samples (~ 2 
ml) were diluted in a vial with 10 ml of HPC‒SDS solution by using a vortex mixer 
(Fisher Scientific Digital vortex mixer, Model No: 945415, NH, USA), which rotates 
at 1500 rpm for 1 min. The particle size was measured four times (n = 4) and the 
average value was calculated together with the standard deviation (SD).  
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3.1.4  Scanning Electron Microscopy  
Particle size and morphology of the as-received and milled drug particles were 
examined via SEM with a LEO 1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA). 
About 0.1 ml of the milled suspension was diluted with 30 ml de-ionized water, and a 
drop was placed on a silicon chip (Ted Pella, Inc., Redding, CA, USA), vacuum-dried, 
sputter coated, and observed in SEM. 
 
3.1.5  X-ray Powder Diffraction 
The crystallinity of the as-received drug, unmilled physical mixture of 
GF‒HPC‒SDS, and overnight dried, milled suspensions (Runs 4 and 14) was 
analyzed using XRPD (PANalytical, Westborough, MA, USA), provided with Cu 
Kradiation ( = 1.5406 Å). The samples were scanned for 2θ ranging from 5
o
 to 40
o
 
at a scan rate of 0.165 s
–1
.  
 
3.1.6  Apparent Shear Viscosity of Milled Suspensions 
The apparent shear viscosities L of the milled suspensions were measured at 25 ± 0.5 
o
C using R/S plus Brookfield Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) with a coaxial cylinder (CC40). The suspension was sheared from 0 to 1000 1/s 
in 60 s and the apparent shear viscosity at the maximum shear rate was taken 
(Bernhardt et al., 1999).  
 
3.1.7  Density Measurement of Milled Suspensions 
The density of the milled suspension was measured by weighing 25 ml of the milled 
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suspension. The weight of the suspension divided by its volume was used to calculate 
the suspension density.  
  
 
Table 3.2  Operating Parameters Varied in the Wet Stirred Media Milling Experiments and Particle Size Statistics of the 
Suspensions after 256 min Milling and after 7-day Storage 
Run 
No.
a 
Stirrer Speed, , 
Stirrer Tip Speed, 
u (rpm, m/s) 
Bead 
Size, db 
(µm) 
Particle Sizes After Milling 
(µm) 
Particle Sizes After 7-Day Storage 
(µm) 
d10 ± SD d50 ± SD d90 ± SD d10 ± SD d50 ± SD d90 ± SD 
1 1000, 3.67 200 0.122 ± 0.006 0.250 ± 0.005 0.456 ± 0.012 0.156 ± 0.008 0.276 ± 0.005 0.480 ± 0.004 
2 1000, 3.67 400 0.100 ± 0.001 0.218 ± 0.003 0.405 ± 0.005 0.134 ± 0.008 0.232 ± 0.007 0.434 ± 0.006 
3 1000, 3.67 800 0.161 ± 0.002 0.308 ± 0.006 0.607 ± 0.032 0.174 ± 0.005 0.325 ± 0.004 0.667 ± 0.033 
4 1000, 3.67 1500 0.201 ± 0.007 0.422 ± 0.007 1.341 ± 0.016 0.210 ± 0.008 0.442 ± 0.009 1.373 ± 0.003 
5 1600, 5.86 100 0.118 ± 0.000 0.160 ± 0.001 0.220 ± 0.001 0.117 ± 0.000 0.161 ± 0.000 0.227 ± 0.000 
6 1600, 5.86 200 0.109 ± 0.000 0.160 ± 0.000 0.203 ± 0.001 0.124 ± 0.000 0.158 ± 0.001 0.208 ± 0.001 
7 1600, 5.86 400 0.115 ± 0.001 0.161 ± 0.001 0.230 ± 0.001 0.112 ± 0.000 0.161 ± 0.000 0.234 ± 0.001 
8 1600, 5.86 800 0.109 ± 0.000 0.171 ± 0.002 0.291 ± 0.010 0.093 ± 0.007  0.185 ± 0.001 0.332 ± 0.007 
9 1600, 5.86 1500 0.144 ± 0.004 0.285 ± 0.002 0.537 ± 0.012 0.154 ± 0.007 0.293 ± 0.005 0.544 ± 0.004 
10 2800, 10.3 100 0.093 ± 0.000 0.115 ± 0.000 0.143 ± 0.000 0.101 ± 0.000 0.125 ± 0.001 0.154 ± 0.001 
11 2800, 10.3 200 0.119 ± 0.000 0.146 ± 0.001 0.178 ± 0.001 0.127 ± 0.002 0.157 ± 0.001 0.189 ± 0.001 
12 2800, 10.3 400 0.129 ± 0.000 0.160 ± 0.001 0.199 ± 0.001 0.125 ± 0.001 0.159 ± 0.001 0.208 ± 0.001 
13 2800, 10.3 800 0.110 ± 0.003 0.157 ± 0.001 0.232 ± 0.001 0.110 ± 0.000 0.160 ± 0.001 0.235 ± 0.000 
14 4000, 14.7 50 0.095 ± 0.001 0.118 ± 0.001 0.145 ± 0.001 0.107 ± 0.001 0.129 ± 0.001 0.158 ± 0.001 
15 4000, 14.7 100 0.097 ± 0.000 0.120 ± 0.001 0.146 ± 0.001 0.109 ± 0.001 0.135 ± 0.001 0.168 ± 0.001 
16 4000, 14.7 200 0.107 ± 0.000 0.132 ± 0.001 0.162 ± 0.001 0.114 ± 0.000 0.141 ± 0.001 0.174 ± 0.001 
17 4000, 14.7 400 0.124 ± 0.001 0.154 ± 0.001 0.195 ± 0.001 0.119 ± 0.002 0.153 ± 0.001 0.206 ± 0.002 
18 4000, 14.7 800 0.109 ± 0.001 0.152 ± 0.001 0.223 ± 0.001 0.107 ± 0.000 0.151 ± 0.001 0.226 ± 0.000 
a
Drug (GF) loading of 10%, HPC/SDS concentration of 2.5%/0.2%, beads loading of c = 0.408, and suspension volumetric flow rate of Q = 126 
ml/min were kept constant in all runs. 
7
3
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3.2  Theoretical 
3.2.1  Analysis of Breakage Kinetics 
Breakage kinetics during wet media milling can be studied by analyzing the time-
wise evolution of the median particle size d50, which usually decreases in time t and 
approaches a limiting value, provided that milling is continued for a prolonged time 
and particle aggregation is suppressed by a properly chosen stabilizer system (Bilgili 
et al., 2016a). The time-wise evolution of the median size can be described by a first-
order exponential decay function as follows (Stražišar and Runovc, 1996; Varinot et 
al., 1999):  
  )/exp()0()( lim50lim50 ptdddtd   (3.1) 
where d50(0) and dlim are the initial median size and the limiting median size, 
respectively, while τp is a characteristic time constant of the WSMM process. A lower 
τp value corresponds to faster breakage of the particles and a higher overall apparent 
breakage rate, which will be referred as the breakage rate in the rest of the dissertation 
for brevity. For the estimation of dlim and τp, Eq. (3.1) was fitted to the measured d50 
data via the Marquardt-Levenberg algorithm. Our preliminary analysis indicated that 
large particles with a d50 = 16.08 ± 0.05 µm broke faster initially (within the first 
minute) than the particles produced after one minute. Therefore, Eq. (3.1) with a 
single time constant τp was not able to fit the whole experimental data governed by 
two or potentially more characteristic time constants (Cho et al., 1996). Hence, the 
initial median particle size at 0 min was discarded, thus making the first-minute 
median size the initial size for better fitting capability. This approach was justifiably 
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adopted from earlier studies (Bilgili and Afolabi, 2012; Stražišar and Runovc, 1996; 
Varinot et al., 1999). 
 
3.2.2 Microhydrodynamic Analysis 
The dynamics of the inter-particle collisions in a dense slurry flow is referred to as 
microhydrodynamics. Eskin et al. (2005a, b) developed a model to calculate the mean 
velocity of bead oscillations in well-mixed slurries using the kinetic theory of 
granular flows and fundamental granular energy balance (Gidaspow, 1994). Salient 
features of this microhydrodynamic model with slight modification (Afolabi et al., 
2014) in view of Eskin and Miller (2008) are presented here, and readers are referred 
to aforementioned literature for the assumptions and derivations. The power applied 
per unit volume of slurry Pw inside a stirred mill dissipates through several 
mechanisms, which are mathematically expressed as follows:  
htcollviscw  P  (3.2) 
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where εvisc is the energy dissipation rate due to both the liquid–beads viscous friction 
and lubrication,  εcoll  
is the energy dissipation rate due to partially inelastic bead–bead 
collisions, and εht is the power spent on shearing the equivalent liquid (milled drug 
suspension). In Eq. (3.3), L is the apparent shear viscosity of the equivalent liquid, c 
is the bead volumetric concentration (volume fraction),   is the granular temperature 
defined as the bead–equivalent liquid relative mean-square velocity, Rdiss is the 
effective drag (dissipation) coefficient, db 
is the median size of the beads, k is the 
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restitution coefficient for the bead–bead collisions (0.76 from Tatsumi et al. (2009)), 
and b is the density of the zirconia beads (6000 kg/m
3
). 
The equivalent liquid properties µL and L as well as the power applied per 
unit volume in the presence of the beads Pw were measured. The energy dissipation 
rate for shearing the equivalent liquid εht was found to be negligibly small (much 
smaller than Pw) due to the low viscosity of the suspensions. MATLAB’s fsolve 
function was used to solve Eq. (3.3) for the granular temperature  using Pw measured 
and Rdiss values calculated (refer to Eqs. (A.1)–(A.5) in Appendix A). From the 
calculated  the frequency of single-bead oscillations  and the average oscillation 
velocity of the beads ub were determined as follows: 
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Eskin et al. (2005a) advanced the microhydrodynamic model (Eskin et al., 2005b) by 
considering the elastic contact deformation of the beads along with the elastic–
perfectly plastic deformation of the particles caught between the beads. While the 
beads frequently collide due to their fluctuating motions in a slurry, which are 
characterized by , ub, and , the beads capture and compress the drug particles to be 
milled. The maximum contact pressure at the center of the contact circle σb
max
 of the 
two colliding beads is given by 
2
b
bmax
b
2
3


nF
  (3.6) 
where Fb
n
 and αb are the average maximum normal force during the collision of two 
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elastic beads and the radius of the contact circle formed at the contact of two beads 
respectively (refer to Eqs. (A.6) and (A.7), respectively). The average frequency of 
drug particle compressions a equals the product of probability p of a single particle 
caught between beads (refer to Eq. (A.8)) and the frequency of single-bead 
oscillations  as follows: 
pa   (3.7) 
It must be noted that only a small fraction of energy consumption is actually 
used for deforming the drug particles, which is explained by the energy dissipation 
rate resulting from the deformation of the particles per unit volume Π and expressed 
as (Eskin et al., 2005a): 
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where ε, Y*, Yp, b, σy, Rp, and Rb are the volume fraction of the drug particles in the 
suspension, reduced elastic modulus of the bead–drug particle contact, elastic 
modulus of the drug particles, Poisson’s ratio of the beads, contact pressure in a drug 
particle captured when the fully plastic condition is reached, radius of the drug 
particle, and radius of the bead, respectively. To calculate Π, the mechanical 
properties of the drug particles (Yp, p, σy) have to be known, and only scant 
information for drugs is available in the literature and they are also difficult to 
measure. Since the objective here is to rationalize the selection of bead size, the 
author decomposed Π multiplicatively into a material-dependent factor  and a 
milling intensity factor F, similar to Afolabi et al. (2014), as follows:  
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3.3  Results and Discussion 
3.3.1  Effects of Wet Media Milling on the Drug Particle Size and Morphology 
Two concerns during WSMM of BCS Class II drugs are physical instability of the 
milled drug suspensions and possible solid-state changes (Kesisoglou et al., 2007; 
Kumar and Burgess, 2014). To this end, Runs 4 and 14 suspensions were selected for 
SEM imaging and XRPD diffractograms because they led to the coarsest (slowest, 
least intense breakage) and finest (fastest, most intense breakage) drug particles after 
256 min milling, respectively, among all different stirrer speed‒bead size 
combinations (see Table 3.2). Figure 3.1 shows the SEM images of GF particles 
before and after 256 min milling. The SEM images show that as-received, coarse GF 
particles (Figure 3.1a) were broken into primary particles in the range of 0.20‒2.00 
µm for Run 4 (Figure 3.1b) and in the range of 0.05‒0.20 µm for Run 14 (Figure 
3.1c), which qualitatively agree with the particle sizes obtained from laser diffraction 
(Table 3.2). Results from laser diffraction and SEM images suggest that the drug 
suspension even with the smallest nanoparticles (Run 14) did not exhibit severe 
aggregation at the time scale of the milling process, and the electrosteric stabilization 
mechanism imparted by the HPC–SDS combination (Bilgili and Afolabi, 2012; 
Bilgili et al., 2016d) was effective. Hence, the presence of coarser primary particles in 
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Run 4 suspension can be attributed to the slower breakage in Run 4, which will be 
further elucidated.  
  
 
 
Figure 3.1.  SEM images showing GF particle size and morphology: (a) before 
milling and after 256 min milling at (b)  = 1000 rpm with db = 1500 µm beads (Run 
4) and (c) 4000 rpm with db = 50 µm beads (Run 14). Before milling, the GF particles 
had d50 = 16.08 ± 0.05 m and d90 = 35.47 ± 0.55 m. 
 
Short-term physical stability of the suspensions was studied for a storage 
period of 7 days at 8 °C (Table 3.2). The suspensions were physically stable and 
remained colloidal owing to the synergistic stabilizing action of the HPC–SDS 
combination. The slight size increase observed in most samples could have resulted 
from the temperature cycle during the sample preparation following the milling 
process, i.e., initial cooling to 8 °C and equilibration to room temperature after 7-day 
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storage, and associated particle aggregation. These observations are in line with our 
recent work (Bilgili et al., 2016d; Li et al., 2016b), where nanoparticles of GF and 
other poorly water-soluble drugs such as azodicarbonamide, phenylbutazone, and 
indomethacin were adequately stabilized by HPC–SDS. Long-term physical stability 
of the suspensions was not investigated in the present study. Reproducibility was 
established by repeating Run 4 (the slowest, least intense breakage among all runs) 
and Run 14 (fastest, most intense breakage among all runs), which essentially 
captures the full range of breakage dynamics observed in all milling experiments. For 
both runs, the time-wise evolution of PSD was almost identical in the repeated runs, 
with slight deviations within experimental accuracy of the size measurements (see 
Figure B2 in Appendix B). Hence, the milling process is considered reproducible, 
which is in line with some previous investigations on WSMM (see Li et al., (2016a), 
and the references cited therein). 
Another potential concern with wet media milling is potential solid-state 
changes to the drugs. Figure 3.2 presents the XRPD diffractograms of as-received GF, 
unmilled physical mixture of GF‒HPC‒SDS, as well as 256 min milled GF 
suspensions (Runs 4 and 14) after overnight drying. The characteristic peaks of GF 
appeared in all diffractograms without a broad halo after milling, despite the 
contribution of amorphous HPC in the samples. As compared to the as-received GF 
pattern, a slight reduction in the GF peak intensities in the unmilled physical mixture 
is observed due to dilution and surface coverage of GF particles by HPC (Hecq et al., 
2005). On comparing Runs 4 and 14 patterns with the unmilled physical mixture, it is 
noted that the peak positions remained the same despite a slight reduction in peak 
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heights after milling, which can be attributed to defect formation–accumulation 
during milling (Monteiro et al., 2013) besides more effective coverage of GF particles 
by HPC in dried Runs 4 and 14 samples than that in the physical mixture. While 
XRPD cannot detect minor amount of amorphous phase due to indirect inference and 
crystal orientation effects, the aforementioned XRPD results overall suffice to show 
that the crystalline state of GF was largely preserved after 256 min milling. 
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Figure 3.2  XRPD diffractograms of as-received GF, HPC, unmilled physical mixture 
of GF‒HPC‒SDS, and dried, milled suspensions of Runs 4 and 14.  Run 4 refers to 
the drug suspension milled at  = 1000 rpm with db = 1500 µm beads and Run 14 
refers to the drug suspension milled at  = 4000 rpm with db = 50 µm beads.  
 
3.3.2  Effects of Bead Size at different Stirrer Speeds 
A comprehensive investigation of the impact of bead size at various energetic 
conditions, i.e., different specific energy consumptions, was conducted by milling the 
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as-received GF particles using 50, 100, 200, 400, 800, and 1500 µm zirconia beads at 
a range of stirrer speeds from 1000 rpm to 4000 rpm. While Table 3.2 presents the 
particle size statistics of the suspensions after 256 min milling and 7-day storage only, 
Figure. B1 (Appendix B) illustrates the time-wise evolution of cumulative PSD during 
the wet stirred media milling in all 18 runs.  
Temporal evolution of the median size d50 and 90% passing size d90 of the GF 
particles during the wet media milling was first analyzed to identify “general trends” 
(see Figure 3.3). In most runs, the characteristic particle sizes decreased 
monotonically in time and approached or tended to approach a limiting/plateau size, 
known as apparent grinding limit (Knieke et al., 2013; Knieke et al., 2009), except for 
1000 rpm for which breakage was too slow, hence, it must be prolonged significantly 
to approach such plateau size. For a given bead size, an increase in stirrer speed led to 
faster breakage and smaller final milled particle sizes (see also Table 3.2); however, 
this effect got saturated at higher speeds and was less notable for 100 m beads. The 
monotonic decrease of the drug particle size again suggests that particle breakage was 
the dominant mechanism. While Bhakay et al. (2011) noted severe aggregation and 
drastic increase in d50 of GF particles stabilized with HPMC (hydroxypropyl 
methylcellulose) alone, the author did not see such behavior here because aggregation 
of the particles was largely suppressed due to the synergistic action of HPC–SDS 
combination, as discussed in Section 3.3.1. Finally, a delay in the reduction of d90 
along with some fluctuation/increase was noted for Runs 1 and 5 with the smallest 
beads used at 1000 rpm and 1600 rpm, respectively. For these runs only, coarse GF 
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particles were difficult to capture/break between the smallest beads used, leading to 
slower GF breakage initially and slightly irregular flow at the outlet of the mill.  
In order to analyze the impact of bead size at different stirrer speeds on the 
apparent, overall breakage rate, shortly referred to as the breakage rate in the rest of 
this dissertation, various quantitative measures were used. A characteristic time 
constant τp, which considers all data points for each milling run, was obtained by 
fitting Eq. (3.1) to the evolution of the GF median size in Figure 3.3. The drug 
breakage rate can be calculated by 1/τp (not reported). Most R
2
 values from the fits 
were greater than 0.95 (all above 0.87), and the parameters were all statistically 
significant with p-value ˂ 0.05 (details in Table B1 of Supplementary Material). 
Moreover, motivated by earlier work (Afolabi et al., 2014), two practical 
characteristic time constants were introduced: the milling time required to attain a 
median drug particle size d50 of 0.5 m, td50 and the milling time required to attain a 
90% passing size d90 of 1 m, td90. These measures mathematically represent the 
particle sizes of a nanosuspension with the majority of particles less than 1 µm, which 
is required for effective improvement of drug dissolution rate (Kumar et al., 2014; 
Muller and Keck, 2004). A piecewise cubic Hermite interpolating polynomials 
(MATLAB's pchip function) was used to calculate both td50 and td90. 
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Figure 3.3  Effects of bead size db on the temporal evolution of GF particle sizes 
during wet stirred media milling at various stirrer speeds: (a)  = 1000 rpm, (b)  = 
1600 rpm, (c)  = 2800 rpm, and (d)  = 4000 rpm. At t = 0 min, the GF particles 
had d50 = 16.08 ± 0.05 m and d90 = 35.47 ± 0.55 m. 
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Figure 3.4 presents all calculated characteristics time constants td50, td90, and τp 
for various bead sizes at different stirrer speeds. A quick comparison of all data 
presented in Figures 3.4a,b,c, and d reveals that they all decreased upon an increase in 
stirred speed, suggesting enhanced breakage kinetics at higher stirrer speeds observed 
by many researchers (e.g., (Afolabi et al., 2014; Hennart et al., 2010; Singh et al., 
2011)), which gives credence to the use of these measures for the assessment of the 
impact of bead sizes as well. Moreover, all three characteristic time constants td50, td90, 
and τp exhibited clear minima (highest breakage rate) for the same bead size: 400 µm 
beads at 1000 rpm (Figure 3.4a). The use of either smaller or larger beads than 400 
µm caused slower breakage (higher values of td50, td90, and τp). When 1500 µm beads 
were used at 1000 rpm, d90 = 1 µm was not even attained during 256 min milling 
(hence, td90 not shown in Figure 3.4a). Similarly, Figure 3.4b indicates 200 µm beads 
being the optimal bead size at 1600 rpm. Hence, an interesting phenomenon emerges: 
an increase in stirrer speed shifted the optimal bead size to a smaller value. This trend 
continued when the stirrer speed was further increased to 2800 rpm and 4000 rpm for 
which 100 µm and 50 µm beads exhibited the lowest td50, td90, and τp (Figures 3.4c 
and d). However, at these higher speeds, td50, td90, and τp tended to decrease 
monotonically with a decrease in bead size; the minima occurred at the lower 
boundary of the experimentally feasible bead size domain unlike the clear minima 
that occurred within the bead size domain at 1000 rpm and 1600 rpm. It must also be 
noted that at 2800 and 4000 rpm, 100 µm and 50 µm were the smallest feasible sizes 
of the beads, respectively, due to the practical processing issues (Section 3.2.1) and 
the restriction imposed by the current mill design. Thus, they were regarded as the 
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practically attainable optimal size, leading to the fastest drug breakage at the 
corresponding speeds. 
 
 
 
Figure 3.4  Effects of bead size db on the characteristic milling times td50, td90, and τp 
at various stirrer speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and 
(d)  = 4000 rpm.  Note that d90 = 1 µm was not reached during 256 min milling 
when 1500 µm beads were used at  = 1000 rpm (Run 4). (Continued) 
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Figure 3.4  (Continued) Effects of bead size db on the characteristic milling times td50, 
td90, and τp at various stirrer speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 
2800 rpm, and (d)  = 4000 rpm.  Note that d90 = 1 µm was not reached during 256 
min milling when 1500 µm beads were used at  = 1000 rpm (Run 4). 
 
While the final milled particle sizes after 256 min milling (refer to Table 3.2) 
could be conveniently used to describe breakage kinetics, i.e., smaller d50 and d90 
values corresponding to faster breakage, this approach may not be very reliable for 
several reasons. It only considers one time point (256 min) and that point corresponds 
to prolonged milling, at which differences that stem from different bead size–stirrer 
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speed might be reduced upon approach to the apparent grinding limit. Interestingly, 
the author notes from Table 3.2 that the smallest d50 and d90 values of the suspensions 
after 256 min milling, i.e., the fastest breakage, correspond to the same optimal bead 
sizes at the respective speeds as those revealed by td50, td90, and τp values, which were 
mentioned above. Hence, the calculated τp, td50, and td90 as well as d50 and d90 for the 
256 min milled suspensions all show (1) the significant impact of bead size on the 
drug breakage kinetics and milled particle sizes, (2) the existence of a different 
optimal bead size at each stirrer speed, and (3) the shift of the optimal bead size to 
smaller sizes at the higher stirrer speeds.  
 
3.3.3  Microhydrodynamic Analysis of the Impact of Bead Size at Different 
Stirrer Speeds 
Figure 3.5 shows the specific energy consumption E* and the average power applied 
per unit volume of slurry Pw during 256 min milling of GF particles at different stirrer 
speeds when various bead sizes were used. At the same stirrer speed, higher 
mechanical energy was expended to stir a slurry with larger beads; hence, the higher 
E* and Pw for larger beads. Similarly, higher mechanical energy was expended to stir 
a slurry with the same bead size at higher speeds; hence, higher E* and Pw. The 
specific energy consumption E* is known to correlate positively with the breakage 
rate and extent of size reduction (Kawatra, 2006). Hence, it is no surprise to see faster 
breakage at the higher stirrer speeds that also resulted in higher E* and Pw. On the 
other hand, the optimal bead sizes were found to be 400 µm at 1000 rpm, 200 µm at 
1600 rpm, 100 µm at 2800 rpm, and 50 µm at 4000 rpm (Section 3.3.2), which cannot 
be explained by E* and/or Pw because E* and Pw for the respective beads were either 
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too low or the lowest among all beads used at the respective speeds (refer to Figure 
3.5 or Table B2 in Appendix B). This finding implies that the specific energy 
consumption E* is not the sole factor that determines the breakage rate and that the 
impact of bead size at a given stirrer speed cannot be explained by E* alone. 
Considering that only a small fraction of E* or Pw is actually spent on 
deforming/breaking the (drug) particles to be ground (Eskin et al., 2005a), a 
microhydrodynamic analysis of the bead–bead collisions is required to explain the 
bead size impact on fundamental grounds.  
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Figure 3.5  Effects of bead size db on the specific energy consumption E* and the 
power applied by the stirrer per unit volume Pw for 256 min milling at various stirrer 
speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and (d)  = 4000 rpm.  
(Continued) 
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Figure 3.5  Effects of bead size db on the specific energy consumption E* and the 
power applied by the stirrer per unit volume Pw for 256 min milling at various stirrer 
speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and (d)  = 4000 rpm.  
(Continued) 
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Figure 3.5  (Continued) Effects of bead size db on the specific energy consumption 
E* and the power applied by the stirrer per unit volume Pw for 256 min milling at 
various stirrer speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and (d) 
 = 4000 rpm.  
 
To develop a fundamental understanding of the aforementioned dependency 
of optimal bead size on the stirrer speed, a microhydrodynamic analysis was 
performed and several microhydrodynamic parameters were calculated as a function 
of bead size at various stirrer speeds (see Figures 3.6 and 3.7). In general, at a given 
stirrer speed or tip speed u, bead loading c, and suspension flow rate Q, the 
microhydrodynamic parameters in Figures 3.6 and 3.7 show two major counteracting 
effects of the bead size. Smaller beads have a higher number concentration, which 
equals 6c/db
3
, than larger beads for a given loading of the beads. On one hand, the 
fluctuating motion of the beads became less vigorous with a decrease in bead size as 
signified by the lower granular temperature  (Figure 3.6). This decrease resulted 
from the decrease in the applied power Pw (Figure 3.5) and the increase in the bead 
number concentration. The slower fluctuating motion of the smaller beads was also 
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reflected in the lower average bead oscillation velocity ub (Figure 3.6), which led to 
development of a lower maximum contact pressure b
max 
(Figure 3.7), i.e., lower 
stress intensity. Up to this point, one may argue that the drug particle breakage would 
be slower with the use of smaller beads as the aforementioned changes in the 
microhydrodynamic parameters do not seem to favor particle breakage. On the other 
hand, the frequency of bead oscillations  (Figure 3.6) and the average frequency of 
drug particle compression a (Figure 3.7) increased with a decrease in bead size due to 
the higher number concentration of the smaller beads. Figures 3.6 and 3.7 also show 
that   and a approached a plateau or slightly decreased at the lowest bead size 
depending on the stirrer speed, which resulted from a secondary effect of reduced Pw. 
The overall increasing trend in   and a with smaller beads correlates to higher 
number of stressing events and favors the drug particle breakage. In summary, upon a 
decrease in bead size, ub, and b
max
 decreased, whereas   and a increased up to a 
certain point, signifying more bead number of collisions yet with less energy/force. 
Hence, these two effects could counteract each other for a specific bead size, which 
can, in principle, explain the observed optimal bead size at a given stirrer speed.  
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Figure 3.6  Effect of bead size db on the granular temperature, the average bead 
oscillation velocity ub, and the frequency of single bead oscillations at various stirrer 
speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and (d)  = 4000 rpm.  
(Continued) 
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Figure 3.6  (Continued) Effect of bead size db on the granular temperature, the 
average bead oscillation velocity ub, and the frequency of single bead oscillations at 
various stirrer speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and (d) 
 = 4000 rpm.  
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Figure 3.7  Effect of bead size db on the maximum contact pressure b
max
, the 
average frequency of drug particle compressions a, and the milling intensity factor F 
at various stirrer speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  = 2800 rpm, and 
(d)  = 4000 rpm. (Continued) 
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Figure 3.7  (Continued) Effect of bead size db on the maximum contact pressure 
b
max
, the average frequency of drug particle compressions a, and the milling 
intensity factor F at various stirrer speeds: (a)  = 1000 rpm, (b)  = 1600 rpm, (c)  
= 2800 rpm, and (d)  = 4000 rpm.  
 
While none of the microhydrodynamic parameters alone predicts the optimal 
bead sizes for different stirrer speeds perfectly (refer to Figure 3.4), it appears that the 
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experimentally observed optimal bead size corresponds to either the highest   
(except for 4000 rpm, Figure 3.6) or highest a (except for 1000 rpm, Figure 3.7) for 
each stirrer speed, i.e., highest frequency of bead oscillations or drug particle 
compressions. The parameters that relate to stress intensity and impact energies, i.e., 
ub, and b
max
, when considered alone, indicate the largest beads as optimal bead 
sizes, which contradicts the experimental findings. The above observations can be 
explained as follows: first, as mentioned earlier, the bead size has two major 
counteracting effects, which can only be characterized thoroughly by all 
microhydrodynamic parameters calculated. Second, a possible explanation for the 
dominant effect associated with  and a on the breakage kinetics emerges from a 
damage mechanism called contact fatigue for the drug particles when they are 
captured multiple times by the colliding beads: multiple, frequent compressions of the 
particles with low stress intensity can cause nucleation of permanent structural 
defects that lead to crack initiation; the growth of cracks eventually results in particle 
fracture (Bilgili et al., 2006; Eskin et al., 2005a). Thus, it is likely that GF particles 
may break at lower stresses than their static fracture strength values, thus making 
their breakage rate more sensitive to the average frequency of drug particle 
compressions a than the maximum bead contact pressure b
max
 under the specific 
milling conditions explored here. Further investigation is needed to elucidate these 
mechanisms, which is beyond the scope of this dissertation. Finally, the milling 
intensity factor F, which was originally developed by Afolabi et al. (2014) to explain 
the impact of milling process parameters using a single microhydrodynamic 
parameter, exhibited a maximum at the optimal bead sizes for the lower stirrer speeds 
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(1000 and 1600 rpm) (Figure 3.7). However, the maximum F occurred for larger 
beads at the higher speeds, i.e., 200 m and 100 m at 2800 and 4000 rpm, than for 
the experimentally found optimal beads, i.e., 100 m and 50 m, respectively. Since 
bead size is usually regarded as an equipment parameter in media milling (Kawatra, 
2006), F alone cannot capture the bead size effects well; however, it explains the 
impact of stirrer speed (a process parameter) well, as will be mentioned below.  
The impact of stirrer speed was analyzed here within the context of 
microhydrodynamics in order to elucidate why the optimal bead size shifted to lower 
values at higher speeds. Upon an increase of stirrer speed, both E* and Pw increased 
(refer to Figure 3.5), all microhydrodynamic parameters increased monotonically for 
a given size of beads (refer to Figures 3.6 and 3.7 and Table B2 in Appendix B). Upon 
an increase in the stirrer speed, the fluctuating motion of the beads became more 
vigorous (higher θ). There were more frequent bead oscillations (higher ν), which led 
to a more frequent compression of the drug particles (higher a). The beads had higher 
fluctuating velocity (higher ub), which led to more impactful bead collisions and 
development of higher compressive stress (higher σb
max
). An increase in stirrer speed 
significantly increased F, which indicates a more intensified milling process. These 
combined effects led to the aforementioned enhanced breakage kinetics with 
increasing stirrer speed for a given bead size. In view of the above, upon an increase 
in stirrer speed, even the smallest beads undergo more vigorous/energetic collisions. 
With the added advantage of having a higher number concentration leading to more 
frequent collisions, smaller beads become more advantageous at higher speeds. Hence, 
considering the counteracting effects of bead size, i.e., more bead–bead collisions yet 
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with less energy/force upon the use of smaller beads, small beads are favored more 
than larger beads at the higher stirrer speeds in terms of the balancing action of the 
two effects. This could explain the shift of the optimal bead size to smaller values at 
the higher stirrer speeds.  
 
3.3.4  A Rationale for Bead Size Selection for WSMM with Implications for All 
Wet Media Mills 
It is important to develop a rationale for the selection of optimal bead size as a 
function of stirrer speed on the basis of specific energy consumption E* and the 
microhydrodynamic parameters. The optimal bead sizes at different stirrer tip speeds, 
determined in Section 3.3.2 experimentally, exhibited a negative power-law 
correlation with E* and the microhydrodynamic parameters (Figure 3.8). The R
2
 
values for the fittings of optimal bead size vs. stirrer speed and microhydrodynamic 
parameters were above 0.997, and the fitted parameters were all statistically 
significant with p-values < 0.0015. Some deviation occurred at higher energy 
consumption E*, which resulted in an R
2
 of 0.947 and p-value of 0.0266 for the 
optimal bead size–E* correlation. Overall, these correlations suggest that smaller 
beads are more effective at higher stirrer tip speeds or when wet media milling was 
conducted under more energetic (higher E*)/more intensified (higher F) conditions. 
These correlations between optimal bead sizes and the microhydrodynamic 
parameters describe the experimentally observed shift of the optimal bead size, i.e., 
smaller optimal bead sizes at higher stirrer speeds. This fundamental finding also 
rationalizes the global trend in the preparation of drug nanosuspensions: mills that 
typically impart lower power consumption/energy such as ball mills, planetary ball 
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mills, etc. usually use coarser beads than the highly energetic wet stirred media mills 
(refer to Table 3.1).  
 
 
Figure 3.8  Scatter plots and power-law scaling for the dependence of optimal bead 
size on the stirrer tip speed u, the specific energy consumption E*, the frequency of 
singe-bead oscillations ν, the average frequency of drug particle compression a, and 
the milling intensity factor F.  
 
3.4  Conclusions  
This study has been driven by the importance of stable nanoparticle suspensions for 
bioavailability enhancement of poorly water-soluble drugs and the lack of 
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fundamental understanding of bead size effects and a scientific rationale for bead size 
selection in their preparation by wet media milling. To this end, the author has studied 
the milling of griseofulvin suspensions and elucidated the dependency of optimal 
bead size on the stirrer speed via combined breakage kinetic‒microhydrodynamic 
models. Drug breakage kinetics, Hermite interpolation, and empirical model fitting 
indicated the existence of optimal bead size at each stirrer speed. More importantly, 
the optimal bead size decreased upon an increase in the stirrer speed. While all 
microhydrodynamic parameters provided significant physical insight, the existence of 
optimal bead size was overall explained by the two counteracting effects of bead size: 
more bead‒bead collisions (more stressing events) with less energy/force (lower 
stress intensity) upon a decrease in bead size. The optimal bead size exhibited a 
negative power-law correlation with either the specific energy consumption or any of 
the microhydrodynamic parameters. Overall, this study has rationalized the use of 
smaller beads for more energetic wet media milling and provided an overarching 
explanation as to the use of smaller beads in wet stirred media mills than in low-
energy mills such as ball mills and planetary ball mills. This study is expected to 
guide the design and optimization of wet media milling processes in terms of proper 
choice of bead size for optimal performance.  
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CHAPTER 4 
SUB-100 NM DRUG PARTICLE SUSPENSIONS PREPARED VIA WET 
MILLING WITH LOW BEAD CONTAMINATION THROUGH NOVEL 
PROCESS INTENSIFICATION 
 
As discussed in Chapter 1, there is sustained interest in sub-100 nm particles of 
poorly water-soluble drugs as such small particles offer improved permeation through 
various biological barriers and result in rapid onset of therapeutic action. Chapter 3 
rationalized the selection of bead size at different stirrer speeds for the efficient 
production of drug nanosuspensions via the wet stirred media milling (WSMM) 
process. Not only the bead size, but also the other process parameters, such as stirrer 
speed, bead loading, and suspension flow rate, can affect the drug breakage. Chapter 
4 aims to develop an intensified WSMM process to produce sub-100 nm BCS Class II 
drug particles. To this end, the impact of bead size on the drug particle size, breakage 
kinetics, energy consumption, and bead wear were investigated for griseofulvin, a 
poorly water-soluble drug, under highly energetic milling conditions in the turbulent 
flow regime. Laser diffraction, dynamic light scattering, scanning electron 
microscopy, and XRD were used to characterize the milled suspensions. Yttrium-
stabilized zirconia beads with a nominal size ranging from 50 µm to 800 µm were 
used in the baseline process, which was subsequently intensified with the optimal 
bead size by increasing rotor tip speed, bead loading, and suspension flow rate 
stepwise, as guided by a microhydrodynamic model. After examining the breakage 
kinetics under the intensified conditions, shorter milling experiments, which targeted 
approximately 100 nm particle size, were performed to examine the energy 
consumption and bead wear along with the microhydrodynamics. The novel 
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intensification method, i.e., the use of optimal (50 m) beads with the intensified 
process conditions as guided by the microhydrodynamic model, was also applied to 
wet-milling of indomethacin, another poorly water-soluble drug, confirming the 
generality of the novel model-guided process intensification method. In pursuit of the 
goal of preparing sub-100 nm drug particles fast, this study contributes to a 
fundamental understanding of the impact of bead size and process intensification 
while addressing all major issues associated with the WSMM process, i.e., 
excessively long processing time, high energy consumption, and potentially high 
media contamination in a holistic, model-guided approach. 
 
4.1  Materials and Methods 
4.1.1  Materials 
EP/BP grade griseofulvin (GF) and USP grade indomethacin (IND) were purchased 
from Letco Medical (Decatur, AL, USA). GF and IND are two BCS Class II drugs 
with an aqueous solubility of 7.7 and 16 g/ml, respectively (Merisko-Liversidge and 
Liversidge, 2011). Methocel E3 grade hydroxypropyl methyl cellulose (HPMC), 
which is commonly used as a neutral polymeric stabilizer, was a donation from Dow 
Chemical (Midland, MI, USA). Sodium dodecyl sulfate (SDS), which is an anionic 
surfactant, was purchased from Sigma Aldrich (Bellefonte, PA, USA), and nitric acid 
(65 wt%) was purchased from Fisher Scientific Inc. (Pittsburgh, PA, USA). Zirmil Y 
grade yttrium-stabilized zirconia (YSZ) beads with nominal sizes of 800, 400, 200, 
100, and 50 µm were purchased from Saint Gobain ZirPro (Mountainside, NJ, USA) 
and used as the milling media. Throughout the dissertation, the beads were labeled 
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with their nominal sizes, while their actual median sizes, i.e., 802, 396, 214, 107, and 
54 µm, respectively, measured in dry dispersion mode via a laser diffraction particle 
size analyzer (Helos/Rodos, Sympatec, NJ, USA) were used in the 
microhydrodynamic model. De-ionized water was used in all milling and particle 
sizing experiments. Fresh beads were rinsed with de-ionized water and sonicated for 
40 min followed by a final rinse. 
 
4.1.2  Preparation of Suspensions via Wet Media Milling 
The stabilizer concentrations, milling procedure, and baseline process conditions 
were selected based on our recent investigations (Afolabi et al., 2014; Knieke et al., 
2013). First, about 225 g pre-suspensions were prepared by dispersing 10% drug 
particles in an aqueous solution of 2.5% HPMC-E3 and 0.2% SDS under constant 
stirring at 300 rpm (Cat#. 14-503, Fisher Scientific, Pittsburgh, PA, USA) for a total 
of 90 min. Here, all percentages are w/w with respect to de-ionized water (200 g). 
The pre-suspensions were then milled at the conditions presented in Table 4.1. The 
impact of bead size db was studied through Runs 1–5, followed by process 
intensification experiments (Runs 6–8) guided by the microhydrodynamic model. 
Runs 9 and 10 were performed to establish the applicability of the intensification 
method to IND.  
Wet milling was carried out in a Microcer stirred media mill (Netzsch Fine 
Particle Size Technology, LLC, Exton, PA, USA) with an 80 ml (Vm) milling 
chamber lined with zirconia and a zirconia shaft with a diameter D of 7 cm (Figure 
2.1). The pre-suspension was added to the holding tank (500 ml) and recirculated 
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between the holding tank and the milling chamber at a controlled flow rate Q by a 
peristaltic pump (Cole-Parmer, Master Flex
®
, USA). Stainless steel screens with 
different opening sizes, which are approximately half of the nominal size of the 
beads, were used to keep the beads inside the milling chamber. The Netzsch Microcer 
mill is limited to ~50 µm beads in the recirculation mode by its design, which 
requires the use of a screen with an opening size of 25 µm. When 50 µm beads were 
used as the smallest beads, the presence of large GF particles and IND particles 
initially resulted in clogging of the screen and the pressure rose. This practical issue 
was resolved by using a higher rotor tip speed (14.7 m/s) and lower suspension flow 
rate (80 ml/min) shortly in Run 5, which were then restored back to the set values in 
Table 4.1. Similarly, in Runs 6–8 and 10, the milling with a lower flow rate (80 
ml/min) was carried out; then the flow rate was restored back to the target value and 
milling continued up to the long duration presented in Table 4.1. A chiller (Model 
M1-.25A-11HFX, Advantage Engineering, Greenwood, IN, USA) provided cooling 
for both the milling chamber and the holding tank, which allowed for keeping the 
suspension temperature in the holding tank below 34 
o
C, as a maximum. Due to the 
low cooling capacity of this specific chiller, a cooling strategy similar to that in 
Afolabi et al. (2014) was adopted here: the mill was stopped for few minutes of 
additional, intermittent cooling after 3 h during Runs 1–5 and Run 9 and about every 
8 min during Runs 6–8 and Run 10. The suspensions at several milling time points 
were collected from the outlet of milling chamber and used for particle size and 
morphology analysis. The final milled suspensions were also characterized and 
remaining suspensions were stored in a refrigerator at 8 
o
C for 7 days.  
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To study the impact of bead size on wear, additional 6 h milling experiments 
were performed under the same conditions of Runs 1–5 mentioned above using 800, 
400, 200, 100, and 50 m beads, respectively. These beads had already been used in 
the previous milling experiments as described above; hence, they are regarded as 
conditioned or pre-treated for the purpose of the wear study. Additional experiments 
were also performed with pre-treated 50 m beads under Runs 6–10 conditions, 
including shorter milling times that allow for preparation of 100 nm drug particles. 
Bead wear was characterized on suspension samples following the procedure detailed 
in Section 4.1.3. The wet beads were oven-dried overnight at 40 °C following 40 min 
sonication–rinsing in de-ionized water before a new milling experiment. 
The total energy consumption E was directly recorded from the mill control 
panel. Using this information, the average stirrer power applied per unit volume of 
the slurry (beads, drug, stabilizers, and water) Pw was calculated using  
 Tmw tVEP   (4.1) 
where tT is the total milling time. The specific energy consumption E*, which is the 
energy spent per unit mass of drug suspension, was also calculated as follows: 
sus
* mEE   (4.2) 
where msus is the total mass of the drug suspension. 
  
 
Table 4.1  Parameters Varied in the Wet Milling Experiments. Fixed Parameters: Drug Loading of 10%, 200 g
 
De-ionized Water, 
and HPMC/SDS Concentration of 2.5%/0.2% (Weight Percent with Respect to De-ionized Water) 
Run No. 
Drug 
 
Nominal 
Bead Size 
db (µm) 
Rotor Tip 
Speed u 
(rpm, m/s)
 
Bead Mass, 
Volume Fraction c 
(g), (–) 
Suspension 
Flow Rate Q 
(ml/min) 
Milling 
Time t 
(min) 
1 GF 800 3200, 11.7 196, 0.408 126 360 
2 GF
 
400 3200, 11.7 196, 0.408 126 360 
3 GF
 
200 3200, 11.7 196, 0.408 126 360 
4 GF
 
100 3200, 11.7 196, 0.408 126 360 
5 GF 50 3200, 11.7 196, 0.408 126 360 
6 GF
 
50 4000, 14.7 196, 0.408 126 120 
7 GF
 
50 4000, 14.7 261, 0.543 126 120 
8 GF
 
50 4000, 14.7 261, 0.543 343 120 
9 IND 50 3200, 11.7 196, 0.408 126 360 
10 IND 50 4000, 14.7 261, 0.543 343 120 
 
1
0
7
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4.1.3  Particle Size Determination 
Particle size distribution (PSD) of the drug suspensions was determined using a 
combination of laser diffraction (LD) and dynamic light scattering (DLS) (see e.g., 
Schubert et al., 2006; Knieke et al., 2009 for a similar approach). LD was used to 
determine the PSD of all milled suspension samples. The measurements were 
performed in LS 13-320 Beckman Coulter instrument (Brea, CA, USA). A refractive 
index of 1.65, 1.50, and 1.33 were used for GF, IND, and water (measurement 
medium), respectively. For the particles with median particle size d50 above 200 nm, 
median particle sizes from LD were reported. The particle size was measured at least 
thrice and the average value was calculated together with standard deviation (SD). As 
DLS is more sensitive and accurate when the majority of particle sizes are less than 
200 nm, the PSD of the milled suspension samples with d50 less than ~200 nm were 
determined by DLS using Delsa Nano C Particle analyzer (Beckman Coulter, Brea, 
CA, USA). About 0.5 ml of the milled suspension was diluted with 4 ml de-ionized 
water prior to measurement at 25 °C. The median size from LD and the Z-average 
(cumulant) size from DLS are referred to as the particle size.  
 
4.1.4  Scanning Electron Microscopy 
Particle size and morphology of the as-received and milled drug particles were 
examined via scanning electron microscopy (SEM) with a LEO 1530 SVMP (Carl 
Zeiss, Inc., Peabody, MA, USA). About 0.1 ml of the milled suspension was diluted 
with 30 ml de-ionized water, and a drop was placed on a silicon chip (Ted Pella, Inc., 
Redding, CA, USA), dried, sputter coated, and observed in SEM. Image J software 
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was used to analyze about 1500 particles and determine the average particle size 
based on equivalent projected-area diameters of the particles from the SEM images. 
 
4.1.5  X-ray Powder Diffraction 
The crystallinity of the as-received drug, unmilled physical mixture (overnight dried 
aqueous suspension with as-received drug, HPMC, and SDS), and overnight 
dried‒milled suspensions was analyzed using X-ray Powder Diffraction (XRD, 
PANalytical, Westborough, MA), provided with Cu Kradiation ( = 1.5406 Å). The 
samples were scanned for 2θ ranging from 5o to 40o at a scan rate of 0.165 s–1. 
 
4.1.6  Apparent Shear Viscosity of Milled Suspensions 
The apparent shear viscosities L of the milled suspensions were measured at 25 ± 0.5 
o
C using R/S plus Brookfield Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) with a coaxial cylinder (CC40). The suspension was sheared from 0 to 1000 1/s 
in 60 s and the apparent shear viscosity at the maximum shear rate was taken 
(Bernhardt et al., 1999). 
 
4.1.7  Density Measurement of Milled Suspensions 
The density of the milled suspension was measured by weighing 25 ml of the milled 
suspension. The weight of the suspension divided by its volume was used to calculate 
the suspension density.  
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4.1.8  Determination of Contamination in the Milled Suspensions 
The elemental zirconium (Zr), the most abundant heavy metal in the beads and the 
main contaminant in the milled suspensions due mostly to bead wear, was measured 
by inductively coupled plasma mass spectrometry (ICP-MS) via an Agilent 7500i 
Bench-top ICP-MS System (Santa Clara, CA, USA) according to European 
Pharmacopeia 6.0 §2.2.58. The suspension samples were dried at 40 °C for 24 h in a 
convective drier (Gallenkamp, Netherlands), and the dried powder was finely ground 
by a mortar and pestle. Then, 1 g of ground powder was added to 40 ml of 
membrane-filtered de-ionized water, followed by addition of 40 ml of 65% nitric 
acid. The mixture was heated to 90 °C, and maintained at this temperature until a 
clear solution was observed. Finally, the resultant clear solution was cooled down to 
room temperature, diluted to 50 ml with the membrane-filtered deionized water, and 
subjected to ICP-MS analysis. The measurements were performed thrice, and an 
average value along with SD was reported. 
 
4.2  Theoretical 
The dynamics of the inter-particle collisions in a dense slurry flow is referred to as 
microhydrodynamics. Eskin et al. (2005a, b) developed a model to calculate the mean 
velocity of bead oscillations in well-mixed slurries using the kinetic theory of 
granular flows and fundamental granular energy balance (Gidaspow, 1994). Salient 
features of this microhydrodynamic model with slight modification (Afolabi et al., 
2014) in view of Eskin and Miller (2008) are presented here, and readers are referred 
to aforementioned literature for the assumptions and derivations. The power applied 
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per unit volume of slurry Pw inside a stirred mill dissipates through several 
mechanisms, which are mathematically expressed as follows:  
htcollviscw  P  (4.3) 
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where εvisc is the energy dissipation rate due to both the liquid–beads viscous friction 
and lubrication,  εcoll  
is the energy dissipation rate due to partially inelastic bead–bead 
collisions, and εht is the power spent on shearing the equivalent liquid (milled drug 
suspension). In Eq. (4.4), L is the apparent shear viscosity of the equivalent liquid, c 
is the bead volumetric concentration (volume fraction),   is the granular temperature 
defined as the bead–equivalent liquid relative mean-square velocity, Rdiss is the 
effective drag (dissipation) coefficient, db 
is the median size of the beads, k is the 
restitution coefficient for the bead–bead collisions (0.76 from Tatsumi et al., 2009), 
and b is the density of the zirconia beads (6000 kg/m
3
). 
The equivalent liquid properties µL and L as well as the power applied per 
unit volume in the presence of the beads Pw were measured. The energy dissipation 
rate for shearing the equivalent liquid εht was negligibly small (much smaller than Pw) 
due to the low viscosity of the suspensions. MATLAB’s fsolve function was used to 
solve Eq. (4.4) for the granular temperature  using Pw measured and Rdiss values 
calculated (refer to Eqs. (A.1)–(A.5)). From the calculated  the frequency of single-
bead oscillations  and the average oscillation velocity of the beads ub were 
determined as follows: 
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Eskin et al. (2005b) advanced the earlier microhydrodynamic model (Eskin et 
al., 2005a) by considering the elastic contact deformation of the beads along with the 
elastic–perfectly plastic deformation of the particles caught between the beads. While 
the beads frequently collide due to their fluctuating motions in a slurry, which are 
characterized by , ub, and , the beads capture and compress the drug particles to be 
milled. The maximum contact pressure at the center of the contact circle σb
max
 of the 
two colliding beads is given by 
2
b
bmax
b
2
3


nF

 
(4.7)
 
where Fb
n
 and αb are the average maximum normal force during the collision of two 
elastic beads and the radius of the contact circle formed at the contact of two beads 
respectively (refer to Eqs. (A.6) and (A.7), respectively). The average frequency of 
drug particle compressions a equals the product of probability p of a single particle 
caught between beads (refer to Eq. (A.8)) and the frequency of single-bead 
oscillations  as follows: 
pa   (4.8) 
It must be noted that only a small fraction of energy consumption is actually 
used for deforming the drug particles, which is explained by the energy dissipation 
rate resulting from the deformation of the particles per unit volume Π and expressed 
as (refer to Eskin et al., 2005b): 
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where ε, Y*, Yp, b, σy, Rp, and Rb are the volume fraction of the drug particles in the 
suspension, reduced elastic modulus of the bead–drug particle contact, elastic 
modulus of the drug particles, Poisson’s ratio of the beads, contact pressure in a drug 
particle captured when the fully plastic condition is obtained, radius of the drug 
particle, and radius of the bead, respectively. To calculate Π, the mechanical 
properties of the drug particles (Yp, p, σy) have to be known, and only scant 
information for drugs is available in the literature and they are also difficult to 
measure. Since the objective here is to gain insight and guide process intensification, 
similar to Afolabi et al. (2014), the author decomposed Π multiplicatively into a 
material-dependent factor λ and a milling intensity factor F as follows:  
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4.3  Results and Discussion 
4.3.1  Impact of Bead Size and Selection of Optimal Bead Size for Intensification 
Proper selection of bead size can have a significant impact on the breakage kinetics, 
final milled particle size, energy consumption, and bead wear. A comprehensive 
analysis of the impact of bead size is presented in this section. 
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4.3.1.1  Effects of Bead Size on the Breakage Kinetics and Milled Particle Size.         
GF particles were wet-milled using beads with different nominal sizes: 800, 400, 200, 
100, and 50 µm at the baseline process conditions (Table 4.1, Runs 1–5). Figure 4.1 
shows the temporal evolution of GF particle size during milling. For all bead sizes, 
the GF particle size decreased monotonically with a decreasing rate and slowly 
approached a limiting (plateau) size, also known as the grinding limit. Table 4.2 
presents the particle sizes and their standard deviation (SD) as well as the 
polydispersity index (PDI) for 360 min milled suspensions. Sub-100 nm GF particles 
were only produced when 50 or 100 µm beads were used; these two bead sizes led to 
similar breakage profiles after 8 min (Figure 4.1). Reproducibility was established by 
repeat milling experiments on Runs 1 and 5. The particle sizes from the repeat 
experiments were 167 and 97 nm, respectively. The deviations of the repeat particle 
size values were less than or equal to 2%. In light of the low variability of the size 
measurements presented in Figure 4.1, the milling process is considered to be 
reproducible, which is consistent with our earlier investigations on the reproducibility 
of the wet milling process (e.g., Afolabi et al., 2014; Bilgili and Afolabi, 2012). 
 
 
 
 
 
 
 
 
 115 
 
Table 4.2  Z-average Particle Size and its Standard Deviation (SD) as well as 
Polydispersity Index (PDI) Obtained from Dynamic Light Scattering (DLS) for Runs 
1–10 Suspensions after Milling and 7 Days Storage. 
Run 
No. 
Milling Time 
(min) 
After Milling 7 Days Storage 
Particle Size (nm), 
SD 
PDI 
Particle Size (nm), 
SD 
PDI 
1 360 169, 1.1 0.158 174, 7.3 0.155 
2 360 137, 4.8 0.144 148, 3.2 0.114 
3 360 120, 4.4 0.246 124, 5.1 0.239 
4 360 97, 1.0 0.272 115, 0.6 0.279 
5 360 95, 2.0 0.241 108, 2.8 0.270 
6 120 94, 3.9 0.228 104, 3.0 0.314 
7 120 93, 3.3 0.250 104, 3.3 0.237 
8 120 88, 2.7 0.269 97, 2.2 0.281 
9 360 77, 2.7 0.272 85, 2.3 0.212 
10 120 72, 2.1 0.338 87, 1.7 0.237 
 
Reynolds number Re, which equals ND
2L/L, was calculated to be 47,300  
1,600 for all different sizes of the beads (Runs 1–5), which is greater than 35,000 
(Kawatra, 2006), suggesting a fully turbulent motion in the mill. The use of low 
viscosity HPMC (E3 grade) and SDS as stabilizers in the suspensions helped to 
achieve these high Re values while mitigating viscous dampening. Having a fully 
turbulent motion, the baseline process is sufficiently aggressive for fast breakage, as 
seen from the attainment of a particle size less than 400 nm within 8 min (see Runs 
3–5 in Figure 4.1). This proves that the baseline conditions were chosen rationally 
based on our earlier investigations (Afolabi et al., 2014; Knieke et al., 2013), setting 
the stage for the fast production of sub-100 nm particles via process intensification. 
Figure 4.1 and Table 4.2 overall suggest that the use of 100 and 50 µm beads can be 
advantageous for the fast production of finer GF particles. 
 
 116 
 
Time, t (min)
10 100
P
a
rt
ic
le
 S
iz
e
 (
n
m
)
100
1000
Run 1 (800 µm)
Run 2 (400 µm)
Run 3 (200 µm)
Run 4 (100 µm)
Run 5 (50 µm)
 
Figure 4.1  Temporal evolution of GF particle sizes during Runs 1–5. Runs 1, 2, 3, 4, 
and 5 refer to milling of GF with 800, 400, 200, 100, and 50 µm YSZ beads 
respectively at the baseline process conditions (u = 11.7 m/s, c = 0.408, and Q = 126 
ml/min). At t = 0 min, the GF particles have d50 = 21.85 ± 1.25 µm and d90 = 57.77 ± 
4.35 µm. 
 
It is important to establish the aggregation state and physical stability of the 
milled suspensions. Figure 4.2 shows the SEM images of 4, 32, 120, 240, and 360 
min milled GF particles with 50 µm beads (Run 5), capturing the evolution of the 
particle size and morphology. GF particles became smaller and more rounded as 
milling progressed. The average size of the 360 min milled particles (Figure 4.2(f)) 
calculated using the SEM images was 90 nm, which is slightly smaller than the Z-
average particle size obtained from DLS (Table 4.2). These findings suggest that even 
the suspension with the smallest particles at the baseline conditions is not 
significantly aggregated at the time scale of the milling process, and the electro-steric 
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stabilization mechanism imparted by the HPMC–SDS combination was quite 
effective. Short-term physical stability of the suspensions was studied for a storage 
period of 7 days at 8 °C. Table 4.2 shows that the particle size did not change 
significantly after 7 days storage; hence, the suspensions were physically stable and 
remained colloidal mainly due to the synergistic stabilizing action of the HPMC–SDS 
combination. These observations are in line with our recent work (Bhakay et al., 
2013; Knieke et al., 2013; Sievens-Figueroa et al., 2012), where nanoparticles of 
other poorly water-soluble drugs such as fenofibrate, naproxen, and phenylbutazone 
were properly stabilized in the presence of SDS with either HPC (hydroxypropyl 
cellulose) or HPMC. Long-term physical stability of the suspensions was not 
investigated in the present study as the milled suspensions are mainly intended for 
immediate drying with the ultimate goal of preparing solid dosage forms (similar to 
e.g., Bhakay et al., 2014; Kesisoglou et al., 2007). 
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Figure 4.2  SEM images showing the evolution of GF particle size and morphology 
during Run 5: (a) particles before milling and after milling for (b) 4 min, (c) 32 min, 
(d) 120 min, (e) 240 min, and (f) 360 min. Run 5 refers to the use of 50 µm YSZ 
beads at the baseline process conditions (u = 11.7 m/s, c = 0.408, and Q = 126 
ml/min). Initially, the GF particles have d50 = 21.85 ± 1.25 m and d90 = 57.77 ± 4.35 
m. 
 
Monotonic decrease of the particle size in Figure 4.1 as well as the similarity 
of the primary particle sizes from the SEM image and the particle size measured by 
(e) 240 min (f) 360 min 
milling 
(c) 32 min  (d) 120 min  
(a) 0 min (b) 4 min 
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DLS suggest that particle breakage was the dominant mechanism and aggregation of 
the particles occurred at a smaller rate than the breakage in the presence of HPMC–
SDS during most of the milling process. Hence, the commonly observed slow-down 
in Figure 4.1 is mainly attributed to the generation of smaller particles, which have a 
lower specific breakage rate (Bilgili et al., 2004, 2006), as milling continued. In 
addition, smaller particles especially nanoparticles are harder to capture by beads, and 
the intensity/number of stressing events due to compressions by the colliding beads 
may not be sufficiently high. Hence, the limiting size and the time to reach the 
limiting size are functions of both the material properties of the bead and the drug as 
well as the process parameters. Since 360 min was already too long, the author has 
not prolonged the milling to find the exact grinding limit in this study.  
 
4.3.1.2  Effects of Bead Size on Wear and Product Contamination.     Wear of the 
YSZ beads during milling can lead to undesirable contamination of the milled drug 
product with zirconium (Zr), the most abundant element in the beads. The toxicity of 
Zr is moderately low, as confirmed by both histological and cytological studies, and 
the average daily human uptake has been known to be as high as about 125 mg 
(Ghosh et al., 1992). However, its consumption has to be considerably reduced as Zr 
is prone to cross the blood brain-barrier and results in accumulation in the brain 
(Ghosh et al., 1992). GF suspensions milled for 360 min with the use of 800, 400, 
200, 100, and 50 m beads (Runs 1–5, respectively) were analyzed for elemental 
zirconium (Zr) level using ICP-MS. The elemental Zr levels, quantified as the mass 
ratio of Zr to milled drug in µg/g, were listed in Table 4.3. Juhnke et al. (2012) found 
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contamination with 100–500 µg/g Zr from three different grades of 100 µm YSZ 
beads when an undisclosed drug was wet-milled to 140 nm particles (unspecified 
time and batch size). In our study, Zr contamination was similar in order of 
magnitude, but reduced by a factor of 21.4 to 47  1.2 µg/g when 50 µm beads were 
used as opposed to 800 µm beads, which accords well with the general trends in the 
previous bead wear studies in terms of the impact of bead size (Breitung-Faes and 
Kwade, 2008; Hennart et al., 2010). 
 
Table 4.3  Power Applied per unit Volume of Slurry Pw, Specific Energy 
Consumption per unit Mass of Drug Suspension E*, Zr Concentration in Milled 
Suspension per unit Mass of Drug for Runs 1–10 
Run 
No. 
Drug 
Milling 
Time 
(min) 
Pw 
(W/m
3
) 
E* 
(MJ/kg) 
Zr Level (µg Zr/g drug) 
Average SD 
1 GF 360 3.13105 2.40 1004 18.1 
2 GF 360 2.92105 2.24 832 5.9 
3 GF 360 2.71105 2.08 453 1.0 
4 GF 360 2.29105 1.76 307 5.8 
5 GF 360 1.88105 1.44 47 1.2 
6 GF 120 2.32105 0.59 36 0.4 
7 GF 120 4.38105 1.12 70 1.3 
8 GF 120 5.00105 1.28 83 3.8 
9 IND 360 1.75105 1.34 24 0.2 
10 IND 120 5.00105 1.28 56 2.6 
 
4.3.1.3  Effects of Bead Size on Specific Energy Consumption and Applied 
Power.     Figure 4.3 shows the specific energy consumption E* and the average 
power applied per unit volume of slurry Pw for 360 min milling with various bead 
sizes. Both E* and Pw were the lowest for 50 µm beads and they increased when 
larger beads were used. For a fixed rotor tip speed, more power is required to stir the 
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larger beads. It is well-known that at fixed milling conditions, the particle size 
decreases with an increase in the specific energy consumption or milling time 
(Kawatra, 2006). Interestingly, despite the resultant lower specific energy 
consumption at 360 min, 50 µm beads led to finer drug particles than the larger beads 
used (Figure 4.1). This finding implies that the specific energy consumption is not the 
sole or direct measure of particle fineness during wet media milling because only a 
small fraction of the specific energy is actually spent on deforming/breaking the drug 
particles, which is largely controlled by the microhydrodynamics of the bead–bead 
collisions, which is explored in Section 4.3.1.4.  
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Figure 4.3  Specific energy consumption E* and power applied by the mill stirrer per 
unit volume Pw for various bead sizes (Runs 1–5) during 360 min of milling at the 
baseline process conditions (u = 11.7 m/s, c = 0.408, and Q = 126 ml/min). 
 
4.3.1.4  Microhydrodynamic Analysis of the Impact of Bead Size.     To develop a 
fundamental understanding of the aforementioned bead size effects on the GF particle 
size, energy consumption, and bead wear, the microhydrodynamic parameters were 
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calculated and plotted as a function of bead size (Figure 4.4(a) and (b)). In general, 
smaller beads have a higher number concentration, which equals 6c/db
3
, than larger 
beads for a given loading of the beads (constant c), and there are two major 
counteracting effects of the bead size. On one hand, the fluctuating motion of the 
smaller beads was less vigorous as indicated by the lower granular temperature . 
This effect can be explained by the decrease in the applied power Pw (see Table 4.4) 
and the increase in the bead number concentration. The slower fluctuating motion of 
the smaller beads was also reflected in the lower average bead oscillation velocity ub, 
which led to development of a lower maximum contact pressure b
max
, i.e., lower 
stress intensity. Up to this point, one may argue that the drug particle breakage would 
be slower with the use of smaller beads as the aforementioned changes in the 
microhydrodynamic parameters do not favor particle breakage. On the other hand, the 
frequency of bead oscillations  increased when smaller beads were used and tended 
to plateau below 200 m bead size while the average frequency of drug particle 
compressions a increased dramatically and monotonically with a decrease in bead 
size due to the higher number concentration associated with the smaller beads. 
Obviously, this effect of the smaller beads, especially on a, favors faster breakage. 
The overall impact of the bead size is expected to be dependent upon which one of 
the two counteracting effects above is more pronounced and how they relate to the 
mechanical properties of the specific drug. This is why a universal explanation for the 
impact of bead size on all drugs appears to be elusive in terms of size on the breakage 
kinetics and final milled particle size. For example, due to the aforementioned 
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competing effects, an optimum bead size for maximum breakage rate can be found 
for a given set of milling conditions (e.g., Bilgili et al., 2004; Ghosh et al., 2011).  
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Figure 4.4  Effects of bead size on the microhydrodynamic parameters (Runs 1–5): 
(a) granular temperature, average bead oscillation velocity ub, and frequency of 
single bead oscillations and (b) maximum contact pressure b
max
 and average 
frequency of drug particle compressions a. Baseline process conditions: u = 11.7 m/s, 
c = 0.408, and Q = 126 ml/min. 
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In view of the above discussion, it may be difficult to predict the impact of 
bead size using a single microhydrodynamic parameter. Afolabi et al. (2014) 
successfully established a unified process correlation between the breakage kinetics 
and the milling intensity factor F for a given drug–bead pair in that an increase in F 
led to faster breakage of the drug particles; however, they did not investigate the 
impact of bead size. Table 4.4 shows that F exhibited a maximum with 200 m beads 
while its value for 100 m beads was slightly smaller. On the other hand,  exhibited 
a maximum with 100 m beads and a had the maximum with 50 m beads. 
Considering that the size evolution for 50 and 100 m beads were similar and faster 
than those of the coarser beads (refer to Figure 4.1),   and a seems to explain the 
bead size impact better than F. This may also partly be due to the fact that while F 
can successfully explain the impact of process parameters (Afolabi et al., 2014), it 
may be inadequate to explain the impact of bead size, usually regarded as an 
equipment parameter in media milling. In summary, a holistic analysis of the results 
presented in Figures 4.1 and 4.4 and Table 4.4 suggests that an increased frequency of 
bead–bead collisions and drug particle compressions (the favorable effect of the 
smaller beads) dominates over the decreased stress intensity (the unfavorable effect of 
the smaller beads) in terms of their overall impact on the GF particle breakage rate. A 
possible explanation for the dominant effect associated with   and a on the breakage 
kinetics emerges from a damage mechanism called contact fatigue for the drug 
particles when they are captured multiple times by the colliding beads: multiple, 
frequent compressions of the particles with low stress intensity can cause nucleation 
of permanent structural defects that lead to crack initiation; the growth of cracks 
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eventually results in particle fracture (Bilgili et al., 2006; Eskin et al., 2005b). Thus, it 
is likely that GF particles may break at lower stresses than their static fracture 
strength values, thus making their breakage rate more sensitive to the average 
frequency of drug particle compressions a than the maximum bead contact pressure 
b
max
 under the specific milling conditions explored here. Further investigation is 
needed to elucidate these mechanisms, which is beyond the scope of this dissertation. 
The observed reduction in Zr contamination with the use of smallest beads (50 
µm) may be partly explained by the lower b
max
 despite higher a. Smaller beads 
underwent less impactful collisions (lower b
max
) that resulted in less bead wear. On 
comparing b
max
 for 800 µm (Run 1) and 50 µm (Run 5) beads (Table 5), b
max
 was 
reduced by a factor of 2.3 upon the use of 50 µm beads, which could account for the 
reduced Zr contamination. Another possible explanation is that smaller beads may be 
more wear-resistant with a smaller number of inherently present surface/bulk defects. 
  
 
Table 4.4  Power Applied per unit Volume of Slurry Pw, Measured Viscosity L and Density L of the Milled Drug Suspensions, 
and the Microhydrodynamic Parameters (, ub, , b
max
, a, and F) Calculated for Runs 1–10 
Run 
No. 
Milling Time 
(min) 
Pw 
(W/m
3
) 
µL 
(mPa·s) 
ρL 
(kg/m
3
) 
 (m2/s2) 
ub 
(m/s) 
ν (KHz) 
b
max 
(GPa) 
a (Hz) F (m
0.6
/s
2.6
) 
1 360 3.13105 5.97 1034 2.2510–2 2.4010–1 3.98 2.19 1.5410–2 8.37105 
2 360 2.92105 5.73 1026 1.2410–2 1.7810–1 5.47 1.95 3.0910–2 1.33106 
3 360 2.71105 5.51 1028 5.3010–3 1.1610–1 7.17 1.64 5.7710–2 1.76106 
4 360 2.29105 5.63 1040 2.1010–3 7.2410–2 7.58 1.36 7.1410–2 1.52106 
5 360 1.88105 5.64 1029 3.6810–4 3.0610–2 7.48 0.96 8.2010–2 8.62105 
6 120 2.32105 5.84 1033 4.3910–4 3.3410–2 8.17 1.00 9.6010–2 1.08106 
7 120 4.38105 5.64 1050 3.0910–4 2.8110–2 18.2 0.93 3.2110–1 2.43106 
8 120 5.00105 5.56 1057 3.5710–4 3.0110–2 19.5 0.96 3.6510–1 2.92106 
9 360 1.75105 5.64 1065 3.4410–4 2.9610–2 7.22 0.95 1.9910–1 7.44105 
10 120 5.00105 5.74 1053 3.4610–4 2.9710–2 19.3 0.95 9.2010–1 2.66106 
 
1
2
6
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4.3.2  Process Intensification 
Developing an intensified milling process is important as it can increase the breakage 
rate, thereby achieving faster production of nanoparticles; however, such 
intensification can also cause a dramatic and unacceptable increase in bead wear and 
specific energy consumption, if not performed rationally. The results in Section 4.3.1 
suggest that the use of 50 m beads led to the fastest GF breakage (similar to 100 m 
beads) when an aggressive milling process with fully turbulent motion was carried 
out and that 50 m beads were superior to 100 m beads because the former led to 
lower bead contamination along with reduced specific energy consumption. The 
microhydrodynamic analysis and contamination results have elucidated the impact of 
the bead size and rationalized the use of 50 µm beads. Notwithstanding all the 
relatively favorable outcomes originated from the use of 50 µm beads, it took 240 
min to obtain GF particles with a particle size of 100 nm at the baseline milling 
conditions (see Run 5 in Figure 4.1). Obviously, process intensification is required to 
reduce milling time to achieve sub-100 nm particle size. At this juncture, the question 
as to whether the intensification could cause a dramatic increase in bead wear and 
specific energy consumption must be answered.  
 
4.3.2.1  Process Intensification Guided by the Microhydrodynamic Model.     
Although milling intensity factor F may not be the best predictor of bead size impact 
(Section 4.3.1.4), it can successfully explain the impact of other milling parameters as 
established by Afolabi et al. (2014): an increase in F led to faster drug particle 
breakage for a given drug–bead pair (GF–YSZ beads), signifying a more intense 
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process. In view of this, the use of F in guiding the process intensification is deemed 
appropriate since the bead size was taken fixed (50 m) based on the analysis in 
Section 4.3.1. As seen from Eq. (4.11), F strongly depends on bead volume fraction c, 
bead size db or radius Rb, and drug loading  explicitly as well as all other process 
parameters including the rotor tip speed implicitly through the granular temperature 
, which is a monotone increasing function of the power consumption Pw (refer to Eq. 
(4.4)). A detailed analysis of Eqs. (4.4) and (4.11) suggests that a higher rotor tip 
speed leading to a higher Pw and/or higher bead loading may increase F, which 
accords well with the findings in Afolabi et al. (2014). In addition, it has been 
reported that an increase in suspension flow rate may lead to faster breakage 
(Monteiro et al., 2013; Stehr, 1984). Hence, the combination of higher rotor tip speed, 
higher bead loading, and higher suspension flow rate may allow for the development 
of the most intensified process.  
In the preliminary intensifications experiments (Runs 6–8, Table 4.1), the 
baseline process (Run 5) was intensified by increasing the rotor tip speed, the bead 
loading, and the suspension flow rate sequentially one at a time while keeping all the 
other conditions the same. To avoid unnecessarily high damage to the beads, the 
study of breakage kinetics in Runs 6–8 was carried out with 120 min milling, as 
opposed to 360 min milling in the baseline process (Run 5). It should be noted that 
the maximum rotor tip speed allowed per our mill design is 4200 rpm (15.4 m/s); 
hence; a rotor tip speed of 14.7 m/s was used as the maximum to avoid stressing the 
mill close to the design limit. Similarly, a bead loading above 90% v/v of the milling 
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chamber (c = 0.543) results in pressure build-up and excessive heat generation; hence, 
0.543 was taken as the maximum c value.  
4.3.2.2  Impact of Process Intensification on the Breakage Kinetics.     Figure 
4.5(a) shows the temporal evolution of GF particles during 120 min milling in Runs 
5–8. Compared to Run 5, the higher rotor tip speed in Run 6 led to faster particle 
breakage and consequently smaller particles, which is in line with previous studies 
(Afolabi et al., 2014; Ghosh et al., 2012). Unlike Run 5, sub-100 nm particle size (94 
nm) was attained after 120 min in Run 6. Therefore, the high rotor tip speed of 14.7 
m/s was used in the subsequent experiment (Run 7), where the bead volume fraction 
c was increased to 0.543. Due to the increase in bead loading, Run 7 exhibited faster 
breakage than Run 6, and 93 nm particle size was attained within 90 min of milling, 
which remained the same even after 120 min. Similar positive impact of the bead 
loading was reported previously (Afolabi et al., 2014; Sadler III et al., 1975). As 
compared with Run 7, the higher suspension flow rate (Run 8) resulted in faster 
breakage initially, but the difference diminished during prolonged milling, leading to 
particle sizes of 91 and 88 nm after 90 and 120 min (Figure 4.5(a)). Hence, the 
suspension flow rate had the smallest overall impact among all three parameters. As a 
most intensified process, Run 8 was close to the design limits of the milling 
equipment. Therefore, it is argued that a grind limit was attained for GF about ~90 
nm particle size. Reproducibility was established by repeat milling experiments on 
Run 8. A particle size of 90 nm was attained after 120 min in the repeat experiment. 
Hence, the milling process was considered reproducible. SEM of the GF particles 
prepared in Run 8 (Figure 4.5(b)) shows the primary GF particles with an average 
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particle size of 74 nm. The small difference between the particles sizes measured via 
SEM and DLS could be due to the different basis for particle size distributions by the 
respective methods, i.e., number and intensity, different equivalent sphere size 
definitions, and the smaller sample size used in SEM. 
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Figure 4.5  (a) Temporal evolution of GF particle sizes for Runs 5–8 with the use of 
50 µm YSZ beads and (b) SEM images of the GF nanoparticles formed after 64 min 
milling at the intensified process conditions (Run 8: u = 14.7 m/s, c = 0.543, and Q = 
343 ml/min). Inset SEM image shows magnified view of the GF nanoparticles. At t = 
0 min, the GF particles have d50 = 21.85 ± 1.25 m and d90 = 57.77 ± 4.35 m.   
(b) 
(a) 
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4.3.2.3  Shorter Milling Experiments for the Preparation of ~100 nm Particles.     
An overall analysis of the results for Runs 5–8 (Figure 4.5(a) and Table 4.3) suggests 
that a more intense milling process with 50 m beads, signified by higher milling 
intensity factor F (Table 4.4), had also higher power consumption Pw and led to faster 
breakage. Although Pw was significantly higher in the intensified Runs 6–8 than in 
Run 5, the specific energy consumption E
*
, which determines the electric utility cost, 
was lower because Runs 6–8 were carried out for a shorter time (120 min as opposed 
to 360 min). On the other hand, the intensification led to higher Zr contamination, 
which is still well below the 100–500 g/g reported for YSZ beads in Juhnke et al. 
(2012). Hence, overall, the process intensification did not lead to a dramatic increase 
in the energy consumption and bead contamination although the GF breakage kinetics 
was enhanced and smaller GF particles were produced for a given milling time.  
As compared with the aforementioned performance comparison, a more 
exacting comparison of the baseline and intensified processes would result if these 
processes were run so as to produce the same desired product particle size (e.g., 100 
nm in the spirit of this dissertation). The milling time required to produce a GF 
particle size of 100 nm for Runs 5 and 8 was taken from the experimental data 
presented in Figures 4.1 and 4.5(a): 240 and 64 min, respectively. The milling time 
required to achieve ~100 nm was about 4 times lower when the intensified process 
(Run 8) was used as opposed to the baseline process (Run 5), which is attributed to 
the enhanced breakage kinetics upon intensification (see also Figure 4.5(a)). Hence, 
the intensified process (Run 8) can be run shorter to minimize specific energy 
consumption and media contamination for a desired product particle size. To prove 
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this point further, new milling experiments were performed under the same 
conditions of Runs 5 and 8, but at the shorter milling times that correspond to the 
attainment of a particle size of ~100 nm from Figure 4.5(a), i.e., 240 and 64 min, 
respectively. As would be expected from reproducible milling processes, these two 
additional experiments indeed led to final particle sizes of 101 nm (Run 5 at 240 min) 
and 100 nm (Run 8 at 64 min). The specific energy consumption E* and the 
elemental Zr level were also determined for these shorter milling experiments. 
Although Pw was higher in Run 8 (5.00×10
5
 W/m
3
) than in Run 5 (1.88×10
5
 W/m
3
), 
E* was lower in Run 8 (0.69 MJ/kg) than in Run 5 (0.96 MJ/kg) at the indicated 
times. The reduced energy consumption was explained by the shorter milling in Run 
8. Second, the Zr levels for both Runs 5 and 8 at the indicated milling times were 
relatively low: 17 ± 0.3 µg/g, and 27 ± 1.2 µg/g, respectively. If the milling was 
carried out under Run 8 conditions for 120 min, then the Zr level would be higher, 
i.e., 83 ± 3.8 µg/g (Table 3.3). Hence, it is concluded that the enhanced breakage 
kinetics owing to process intensification allows for 4 times reduction in milling time 
and 28% reduction in the specific energy consumption when 100 nm particle size was 
desired with the relatively low media contamination (much lower than 100 µg/g).  
Another potential concern with process intensification is that a more energetic 
milling process may lead to significant changes in the crystalline state of drugs. 
Figure 4.6 presents the XRD diffractograms of as-received GF, unmilled physical 
mixture (dried aqueous suspension with GF, HPMC, and SDS), as well as 240 min 
milled (baseline process, Run 5) and 64 min milled (intensified process, Run 8) GF 
suspensions after overnight drying. The characteristic peaks of GF appeared in all 
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diffractograms without a broad halo after milling, despite the contribution of 
amorphous HPMC in the samples. As compared to the as-received GF pattern, a 
slight reduction in the GF peak intensities in the unmilled physical mixture is seen, 
which is due to dilution and surface coverage of GF particles by HPMC (Hecq et al., 
2005). On comparing Run 5 and Run 8 patterns with those of the physical mixture, 
the author notes that the peak positions remained the same despite a slight reduction 
in peak heights after milling, which can be attributed to defect formation and 
accumulation during milling (Monteiro et al., 2013). While XRD cannot detect minor 
amount of amorphous phase due to indirect inference, crystal orientation effects, and 
instrument-related intensity variations (Venkatesh et al., 2001), the aforementioned 
XRD results overall suffice to show that the crystalline state of GF was largely 
preserved after milling. Most importantly, the intensified process and the baseline 
process led to identical diffractograms, which demonstrates that the crystalline state 
of GF was not severely altered when the process intensification was carried for a 
shorter duration. 
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Figure 4.6  XRD diffractograms of as-received GF, unmilled physical mixture (dried 
aqueous suspension with GF, HPMC, and SDS), and dried, milled suspensions 
prepared with 50 µm YSZ beads. Run 5 refers to 240 min milling at the baseline 
process conditions (u = 11.7 m/s, c = 0.408, and Q = 126 ml/min), and Run 8 refers to 
64 min milling at the intensified process conditions (u = 14.7 m/s, c = 0.543, and Q = 
343 ml/min). 
 
4.3.2.4  A Microhydrodynamic Analysis of the Intensified Process.     Table 4.4 
shows the calculated microhydrodynamic parameters for the baseline process (Run 5) 
and intensified process conditions (Runs 6–8). Here, the milling intensity factor F 
expressed in Eq. (4.11) was used to quantify the process intensification. At the higher 
rotor tip speed (Run 6), all microhydrodynamic parameters (, ub, , b
max
, a, and F) 
increased as compared with those in Run 5, and F increased 1.3 times. These 
combined effects led to the aforementioned enhanced breakage kinetics, which allows 
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for shorter milling time required for a desired fineness of the drug particles. At the 
higher bead volume fraction c (Run 7), a counteracting effect was observed: , ub, 
and b
max
 were smaller, whereas , a, and F were greater as compared to Run 6 
values (Table 4.4). In other words, the stress intensity decreased while the number of 
stressing events dramatically increased. The number concentration of the beads 
increased and the clearance between the beads decreased at higher c, both causing a 
dramatic increase in the bead–bead collisions and the average number of drug particle 
compressions per unit time (higher  and a). On the other hand, despite the increase 
in the stirrer power Pw, higher number of inelastic bead–bead collisions and liquid-
film squeezing events coupled with an increase in the effective drag coefficient Rdiss 
led to greater energy dissipation, which explains smaller values of , ub, and b
max
. 
Apparently, the extent of  decrease was not sufficiently great to compensate for the 
significant positive impact of an increase in bead number concentration on  and a, 
which was explained overall by higher F alone (see Afolabi et al., 2014), resulting in 
enhancement of the breakage kinetics presented in Figure 4.5(a). Finally, when a 
higher suspension flow rate was used in the most intensified process (Run 8), the 
initial breakage rate was further increased due to tighter residence time of the 
suspension in the mill chamber (Monteiro et al., 2013; Stehr, 1984) as well as the 
slight increase in Pw and all microhydrodynamic parameters. Overall, 3.4 times 
increase in F can be achieved with the most intensified conditions (Run 8) compared 
to the baseline conditions (Run 5), which in turn led to enhanced breakage kinetics, 
thus enabling shorter milling time (64 min) to attain ~100 nm particles with energy 
savings up to 28%, and low Zr contamination (27 µg/g).  
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4.3.3  Applicability of the Novel Process Intensification Method to Other Drugs 
It is important to demonstrate the general applicability of the process intensification 
method on another drug. To this end, indomethacin (IND), another poorly water-
soluble drug, was milled at the baseline process conditions (Run 9, 360 min) and the 
most intensified process conditions (Run 10, 120 min). The formulation was kept the 
same as that of GF. The breakage kinetics was first studied using the long milling 
times indicated above. Figure 4.7 shows the temporal evolution of IND particle sizes 
at both sets of conditions. Similar to the GF case, to produce 78 nm particles, the 
baseline process (Run 9) took almost 300 min, whereas the intensified process (Run 
10) took only 48 min, which again proves that the process intensification can prepare 
sub-100 nm particle size much faster. The Zr contamination increased upon 
intensification, but still remained well below 100 g/g (Table 3.3), and E* slightly 
decreased despite a much higher Pw in the intensified process (Run 10). Table 4.4 
shows the calculated microhydrodynamic parameters for Runs 9 and 10. The 
intensified process (Run 10) had a 3.6 times higher F than the baseline process 
condition (Run 9), and  and a dramatically increased while other parameters did not 
change significantly upon intensification. Overall, the general trends and results were 
similar for both GF and IND, signifying the generality of the process intensification. 
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Figure 4.7  Temporal evolution of IND particle sizes milled with the use of 50 µm 
YSZ beads at the baseline process conditions (Run 9) and the intensified process 
conditions (Run 10). At t = 0 min, the IND particles have d50 = 56.56 ± 0.20 m and 
d90 = 143.10 ± 1.28 m.  
 
To perform a more exacting comparison, additional milling experiments were 
also carried out to attain ~100 nm size under Runs 9 and 10 conditions. The milling 
time to achieve a 100 nm particle size was first estimated from the data in Figure 4.7 
to be 201 min and 28 min for Runs 9 and 10, respectively, via piecewise cubic 
Hermite interpolating polynomials (MATLAB's pchip function). These values are 
only approximate as there are errors involved with any interpolation used, especially 
in the absence of a dense temporal data set. The particle sizes obtained from the 
additional milling experiments, after 201 min (Run 9) and 28 min (Run 10), were 106 
and 105 nm, respectively, which confirms the success of the interpolation. XRD 
analysis of the dried suspensions also confirmed that crystalline state of milled IND 
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was not significantly altered (Figure 4.8). Zr level and specific energy consumption 
E* were also determined after performing additional milling experiments with these 
shorter milling times. The E* values were determined to be 0.75 MJ/kg and 0.30 
MJ/kg, respectively, and the elemental Zr levels were 15 ± 1.1 µg/g and 18 ± 0.6 µg/g 
for Runs 9 and 10, respectively. Overall, a significant reduction in the milling time (7 
times) was achieved upon intensifying the process, which allowed for about 60% 
energy savings while keeping the Zr contamination low. These trends appear to be 
similar to those for the milling of GF particles as discussed in Section 4.3.2.3, thus 
proving the general applicability of the process intensification method to multiple 
drugs.  
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Figure 4.8  XRD diffractograms of as-received IND, unmilled physical mixture 
(dried aqueous suspension of IND, HPMC, and SDS), 201 min milled IND 
suspensions (Run 9) and 28 min milled IND suspension (Run 10) after drying. Run 9 
refers to the use of 50 µm YSZ beads at the standard conditions: u = 11.7 m/s, c = 
0.408, and Q = 126 ml/min. Run 10 refers to the use of 50 µm YSZ beads at 
intensified conditions: u = 14.7 m/s, c = 0.543, and Q = 343 ml/min. 
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4.4  Conclusions  
This study has demonstrated, for the first time, the use of small beads in an intensified 
wet stirred media milling (WSMM) process for the faster production of sub-100 nm 
particles of two BCS Class II drugs while achieving reduced energy consumption and 
keeping Zr contamination low. A novel process intensification method based on 
microhydrodynamics has been used as opposed to ad-hoc trial-error. The grinding 
limit for two drugs has been proven to be in the sub-100 nm size domain. Provided 
that the WSMM process is sufficiently energetic with turbulent fluid motion in the 
mill, small (50 m) beads can be very effective owing to their high number 
concentration for the same beads loading and small inter-bead distances despite 
generating relatively low bead contact pressures upon bead–bead collisions. This 
leads to a high number of drug particle compressions at lower specific energy 
consumption without causing significantly elevated wear, thus rendering process 
intensification feasible. The intensification can be realized by a simultaneous or 
sequential increase in rotor tip speed, bead loading, and suspension flow rate. Process 
intensification with small beads increases the breakage rate, thus allowing for 
reduction in milling time required for a desired product particle size. A shorter 
milling with the intensified process leads to reduced energy consumption and 
relatively low bead wear/contamination despite the higher mechanical power applied.  
The model-guided intensification method empowers the WSMM for fast 
production of dense (>1% drug-loaded) suspensions of sub-100 nm drug particles, 
which can be incorporated into various solid and parenteral dosage forms upon drying 
and sterile filtration respectively with the ultimate goal of bioavailability 
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enhancement. Moreover, by following this general method, engineers can improve 
the existing WSMM processes in industry, which can lead to significant cycle time, 
energy, and cost savings, whether these processes are intended for sub-100 nm 
particles or not.  
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CHAPTER 5 
A STUDY OF THE IMPACT OF POLYMER–SURFACTANT IN DRUG 
NANOPARTICLE COATED PHARMATOSE COMPOSITES ON 
DISSOLUTION PERFORMANCE 
 
The preceding chapters have addressed the challenges associated with producing drug 
nanosuspensions with good physical stability (Chapter 2) and microhydrodynamic 
model-guided development of an intensified WSMM process with optimal bead size 
(Chapters 3 and 4). In order to preserve the nanosuspension stability over a long period 
of time and from a patient compliance perspective, these suspensions are usually dried 
into powders (nanocomposites), which are ultimately incorporated into final solid 
dosage forms such as tablets, capsules, sachets, etc. As discussed in Chapter 1, without 
a proper stabilizer formulation, drug nanoparticles can aggregate during the formation 
of nanosuspensions and their drying into nanocomposite powders, which in turn can 
cause inadequate bioavailability enhancement from nanoparticles and ensuing lack of 
therapeutic efficacy. No systematic and comprehensive study has been conducted to 
elucidate the impact of polymer concentration and molecular weight in the 
presence/absence of an ionic surfactant on the redispersion and drug dissolution from 
the nanoparticle-laden composites. The study presented in this chapter aims to fill this 
gap and develop an understanding of the relationships between the physical stability of 
drug nanosuspension, redispersion, and drug dissolution from the composites. 
Griseofulvin (GF) suspensions were wet-milled in a stirred media mill and then 
fluidized-bed dried–coated onto Pharmatose® carrier particles. Three grades of 
hydroxypropyl cellulose (HPC) having different molecular weights and sodium dodecyl 
sulfate (SDS) were used as non-ionic, adsorbing polymer and anionic surfactant, 
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respectively. HPC concentrations varied from 0.25% to 7.5% (w/w) for each polymer 
molecular weight/grade in the absence/presence of SDS. Laser diffraction, SEM, and 
UV spectroscopy were used to characterize the drug suspensions and the composites. 
Particle sizes of the redispersion samples were compared with those of the milled 
suspensions to assess drug nanoparticle recovery from the composites. Drug dissolution 
from the composites was measured using a USP II paddle apparatus. Besides 
elucidating the impact of HPC–SDS, this study also attempts to assess the validity of 
the commonly-held notion that the use of stable wet-milled drug nanosuspensions 
ensures fast redispersion and drug dissolution from the dried composites. 
 
5.1  Materials and Methods 
5.1.1  Materials 
GF (BP/EP grade), a poorly water-soluble drug which belongs to Biopharmaceutics 
Classification System (BCS) Class II, was purchased from Letco Medical (Decatur, 
AL, USA) and used as-received in the wet media milling experiments. Three grades 
(SSL, SL, and L) of hydroxypropyl cellulose (HPC) with ~40, ~100, and ~140 kDa 
molecular weight, respectively, were donated by Nisso America Inc. (New York, NY, 
USA) and used as model non-ionic, cellulosic polymer which serves as a steric 
stabilizer during the milling and a film-former during the drying. SDS purchased 
from Sigma-Aldrich (Milwaukee, WI, USA) was used as a model anionic surfactant 
that acts as a wetting agent and electrostatic stabilizer. Its critical micelle 
concentration (CMC) in water is 8.2 mM (0.24% w/w) at ambient temperature 
(Kagotani et al., 2013). Pharmatose® DCL 11, a grade of lactose monohydrate 
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produced by DMV International (Netherlands), was used as the water-soluble carrier 
for fluidized bed drying–coating. Wear-resistant yttrium stabilized zirconia beads 
(Zirmil Y, Saint Gobain ZirPro, Mountainside, NJ, USA), with a median size of 430 
µm, were used as the milling media. 
 
5.1.2  Preparation of Suspensions via Wet Media Milling 
The preparation of initial (feed) drug suspensions followed the same procedure used 
in Afolabi et al. (2014). The formulation of the suspensions is listed in Table 5.1. 
Drug concentration was kept at 10%. All concentrations reported here are with 
respect to deionized water (300 g). In the absence of SDS, only HPC SSL and L 
grades were investigated in the 0.25–7.5% (w/w) concentration range. At SDS 
loading of 0.05% (w/w), HPC concentrations varied from 0.25% to 7.5% (w/w) for 
all three grades. SDS concentration was purposefully selected well below the CMC so 
as to suppress the Ostwald ripening during the storage (Bilgili et al., 2016c; Knieke et 
al., 2013) because the aqueous solubility of GF is order of magnitude smaller below 
the CMC than that above the CMC (Rao et al., 1997). 
A Microcer wet stirred media mill (Netzsch Fine Particle Technology, LLC, 
Exton, PA, USA) with 80 ml chamber was used to prepare the drug nanosuspensions. 
A peristaltic pump (Masterflex L/S Cole-Parmer Company, USA) recirculated the 
suspension between the holding tank and the milling chamber, while a screen with a 
200 µm opening kept the zirconia beads in the milling chamber, but allowing the 
passage of the suspension. The feed suspensions prepared using a shear mixer (Fisher 
Scientific Laboratory Stirrer, Catalog no. 14-503, Pittsburgh, PA) were poured into 
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the holding tank and milled under the following conditions: bead loading of 50 ml 
(bulk), suspension flow rate of 126 ml/min, and rotor speed of 3200 rpm 
corresponding to a tip speed of 11.7 m/s. Both the milling chamber and the holding 
tank were equipped with a chiller (Advantage Engineering, Greenwood, IN, USA) to 
keep the suspension below 35 °C. The aforementioned processing parameters were 
selected based on Bilgili and Afolabi (2012). The particle sizes of the final 
suspensions (after 80 min milling) were determined, and the suspensions were 
refrigerated at 8 °C for one day before coating onto Pharmatose®.  
 
5.1.3  Fluidized Bed Drying–Coating of Drug Suspensions onto Pharmatose® 
The suspensions prepared by wet media milling, also referred to as precursor 
suspensions, were sprayed onto Pharmatose® carrier particles in a conventional 
bench-top fluidized bed processor (Mini-Glatt 5, Glatt Air, Ramsey, NJ, USA) with 
the top spray configuration. The operating conditions were selected based on Bhakay 
et al. (2013). 100 g Pharmatose® powder with d50 and d90 values of 123.6 μm and 
195.2 μm was charged in the product bowl and fluidized at an inlet air pressure of 
0.4–0.5 bar. After the powder was fluidized, the heater and suspension spray were 
turned on. About 200 g milled drug suspension was pumped through a peristaltic 
pump (Masterflex L/S Cole-Parmer Company, USA) at a constant rate of 0.6 ml/min. 
Sedimentation of the particles was prevented by constant stirring of the suspension 
during the spraying process. The suspensions were atomized through a bi-fluid nozzle 
with 0.5 mm tip diameter at an atomization air pressure of 1 bar. The fluidizing air 
temperature was set at 70 °C. The coated powder continued to fluidize and dried for 
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10 min after all suspension was sprayed. The coated powders (composites) were then 
tested for particle size and morphology, and used in redispersion–dissolution tests.  
 
5.1.4  Particle Size Determination 
Particle size distributions (PSDs) were measured using laser diffraction (LS 13 320, 
Coulter Beckman, Brea, CA, USA). A polarized intensity differential scattering 
obscuration water optical model was employed. It was maintained between 40% and 
50% while the obscuration was maintained below 8% for all measurements. PSD was 
computed by the software using the Mie scattering theory. Refractive index values are 
1.65 for GF and 1.33 for the measurement medium (deionized water). Prior to the size 
measurement, ~2 ml samples of the milled suspensions were taken from the outlet of 
mill chamber and diluted with 8 ml solution of water, HPC, SDS, or HPC–SDS 
depending on the stabilizer(s) used in the milling experiment. The particle size of the 
suspensions was also measured at the end of the drying process (about 30 h after 
milling) to assess aggregation in the suspensions during the storage–coating period, 
and this size was referred to as the size of the milled suspension before redispersion.  
The particle size of the composite particles produced by the fluidized bed 
drying was measured by a Rodos/Helos laser diffraction system (Sympatec, NJ, USA) 
based on Fraunhofer theory. Approximately 1 g of the composites was placed on the 
sample chute of the Rodos dispersing system. As the sample chute was vibrated to 
feed the sample at a 50% setting, a dispersion pressure of 0.1 bar was imposed to suck 
in falling powder through the sample cell of the Rodos. 
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5.1.5  Determination of Drug Content in the Composite Powders 
Maximum theoretical amount of GF in 100 mg composites is estimated to be 15.4 mg 
disregarding losses during the coating (Run 1). GF solubility in methanol is 3 mg/ml 
(Bhakay et al., 2013). 100 mg of the nanocomposite particles was dissolved in 20 ml 
of methanol and sonicated for 30 min to ensure that all GF had dissolved in methanol. 
The Pharmatose® particles do not dissolve in methanol and remain suspended. After 
sonication, they were allowed to sediment overnight, and an aliquot of 100 μl was 
taken from the supernatant. This aliquot was diluted to 10 ml methanol. The 
absorbance of all the samples was measured at the wavelength of 292 nm by 
Ultraviolet (UV) spectroscopy in a UV Spectrophotometer (Agilent, Santa Clara, CA, 
USA). Six replicates from each composite formulation were used to calculate the 
mean drug content along with the percent relative standard deviation (RSD). 
 
5.1.6  Redispersion of the Drug Composites  
The redispersion method was selected based on previous work (Bhakay et al., 2014a; 
Bhakay et al., 2013). 1 g of the composites was weighed and dispersed in 30 ml 
deionized water for 2 min. This early time point was purposefully selected because of 
its good discriminatory power for different formulations. The samples were paddle-
stirred with a laboratory stirrer (CAT R18, Scientific Instrument Center Limited, 
Winchester, UK) at 200 rpm for 2 min to determine if the GF drug particles are 
redispersed from the composites fast. The maximum amount of drug that can dissolve 
in water during the redispersion test is very small (e.g., about 0.2% of GF particles for 
Run 1). Approximately, 0.5 ml aliquot of redispersed sample was taken while stirring 
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and its particle size was measured. HPC, SDS, and Pharmatose® are all water-
soluble. Hence, unless otherwise indicated, the particle sizes obtained from the laser 
diffraction were mainly the sizes of GF particles and their clusters. The redispersion 
response in an aqueous solution of SDS at 0.05% was also studied for formulations 
with HPC alone. All redispersion tests were done thrice for each formulation and the 
average with standard deviation was reported. 
 
5.1.7  Dissolution Test 
Drug dissolution from the composites was determined via a Distek 2100C dissolution 
tester (North Brunswick, NJ, USA) according to the USP II paddle method. The 
dissolution medium was 1000 ml deionized water that was maintained at 37 °C, and a 
paddle speed of 50 rpm was used for all runs. Deionized water allowed for good 
discrimination of different formulations under non-sink conditions. The composites 
were weighed equivalent to a dose of 8.9 mg of GF. They were poured into the 
dissolution medium and 4 ml samples were taken out manually at 1, 2, 5, 10, 20, 30, 
and 60 min. These aliquots were filtered with a 0.1 µm PVDF membrane type syringe 
filter before UV spectroscopy measurements to minimize any confounding effect of 
the undissolved drug aggregates. The amount of GF dissolved was measured by UV 
spectroscopy at a wavelength of 296 nm. Deionized water was used as the blank. 
 
5.1.8  Scanning Electron Microscopy (SEM) 
SEM images of the milled drug particles, Pharmatose® particles, composite particles, 
and the dried sample after redispersion were taken with LEO 1530 SVMP (Carl 
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Zeiss, Inc., Peabody, MA, USA). For Pharmatose® particles and the composite 
particles, a carbon tape was placed on an SEM stub, the particles were then placed on 
the carbon tape. An aliquot of 1 ml drug suspension sample was diluted to 30 ml de-
ionized water, vortex-mixed for 30 s, and mounted on a silicon chip (Ted Pella, Inc., 
Redding, CA, USA). For redispersed samples, after 2 min paddle stirring, a drop 
sample was mounted on a silicon chip. The stubs with liquid sample were put in a 
desiccator and allowed to dry overnight under vacuum. All samples were then sputter 
coated with carbon using BAL-TEC MED 020 (BAL-TEC AG, Balzers, Switzerland) 
prior to imaging. 
 
5.2  Results and Discussion 
5.2.1  Formation of Drug Nanoparticles via Wet Stirred Media Milling 
Table 5.1 presents the formulations of the milled drug (GF) suspensions. The 
formation of GF nanoparticles was first explored in the absence of any stabilizers 
(Run 1) and in the presence of an anionic surfactant, SDS (Run 2). These two 
formulations were used as baseline to assess the impact of various stabilizers and 
physical stability of the resulting suspensions. The impact of HPC concentration was 
then studied in the absence (Runs 3–12) and presence of 0.05% SDS (Runs 13‒27) 
using SSL, SL, and L grades of HPC with MW of ~40, ~100, and ~140 kDa, 
respectively.  
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Table 5.1  Formulations of the Milled Drug Suspensions and Drug Content of the 
Composites 
Run No. 
HPC 
Grade 
Suspension Composite 
HPC 
(% w/w)
a
 
SDS 
(% w/w)
a
 
Average, RSD 
(%w/w, %)
b
 
1 - - - 15.2, 5.95 
2 - - 0.05 13.8, 7.28 
3 SSL 0.25 0 15.0, 8.08 
4 SSL 1 0 14.9, 3.36 
5 SSL 2.5 0 12.5, 5.74 
6 SSL 5 0 14.0, 4.61 
7 SSL 7.5 0 12.5, 5.19 
8 L 0.25 0 11.3, 1.72 
9 L 1 0 12.3, 2.16 
10 L 2.5 0 13.7, 1.12 
11 L 5 0 11.7, 2.09 
12 L 7.5 0 10.3, 4.67 
13 SSL 0.25 0.05 12.1, 3.17 
14 SSL 1 0.05 13.2, 0.16 
15 SSL 2.5 0.05 13.5, 6.21 
16 SSL 5 0.05 12.8, 1.31 
17 SSL 7.5 0.05 11.6, 5.02 
18 SL 0.25 0.05 13.5, 5.64 
19 SL 1 0.05 11.5, 5.71 
20 SL 2.5 0.05 11.3, 5.95 
21 SL 5 0.05 10.6, 3.21 
22 SL 7.5 0.05 11.2, 6.30 
23 L 0.25 0.05 12.1, 4.08 
24 L 1 0.05 14.3, 0.69 
25 L 2.5 0.05 11.9, 2.88 
26 L 5 0.05 12.0, 2.29 
27 L 7.5 0.05 9.30, 6.43 
a w/w with respect to deionized water in the suspension. 
b w/w with respect to dried composite. 
 
Figure 5.1 presents the PSD of the milled suspensions for Runs 1 and 3‒12, 
where HPC was the sole stabilizer and its concentration varied from 0 to 7.5% for 
both SSL and L grades. When no stabilizer was used (Run 1), a coarse suspension 
with particles in the size range of 1‒60 µm was formed (Figure 5.1), as measured by 
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laser diffraction. On the other hand, SEM images show that the as-received GF 
particles (Figure 5.2(a)) were broken into 50‒400 nm primary nanoparticles (Figure 
5.2(b)) upon milling in Run 1. Clearly, Figures 5.1 and 5.2 suggest that the 
nanoparticles formed upon breakage of the micron-sized GF particles severely 
aggregated due to high attractive inter-particle forces (van der Waals, hydrophobic 
forces, etc.). Similar observations were reported by Bilgili et al. (2016c) and Ain-Ai 
and Gupta (2008) for several wet-milled, poorly water-soluble drugs.  
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Figure 5.1  Volume frequency distributions of various milled drug suspensions 
containing HPC with different molecular weights: (a) 40 kDa (SSL grade, Runs 3‒7) 
and (b) 140 kDa (L grade, Runs 8‒12). Run 1 had no stabilizers. 
 
 151 
 
 
Figure 5.2  SEM images of drug (GF) particles: (a) before milling and (b) after 
milling (Run 1, without HPC/SDS). 
 
When HPC (SSL and L grades) was used as the sole stabilizer especially at a 
higher concentration, the PSDs shifted to the finer particles, while showing bi-
modality due to presence of aggregates (Figure 5.1). Although smaller aggregates 
were formed upon use of lower MW HPC (SSL grade) as compared with L grade, 
even 7.5% HPC SSL was insufficient to stabilize GF nanoparticles. Figure 5.3 shows 
PSDs for all formulations with 0.05% SDS (below the CMC of SDS). When SDS was 
used alone at this low concentration (0.05%, Run 2), a tri-modal PSD was observed. 
This indicates that 0.05% SDS alone was not able to stabilize the GF nanoparticles. A 
fine, uni-modal PSD was attained when HPC and SDS were used in combination. The 
use of HPC–SDS has synergistic stabilizing effects, as demonstrated on multiple 
drugs (Bilgili et al., 2016c). An increase in HPC concentration led to finer particles 
and narrower PSDs for the SL and L grades, whereas the PSD was less sensitive to 
the concentration for the SSL grade. SDS acts as a wetting agent, allowing for 
effective deaggregation of the milled particles and it may also impart some 
electrostatic stabilization, whereas non-ionic HPC adsorbs on GF particles and 
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sterically stabilize the nanoparticles (Bilgili and Afolabi, 2012). An increase in 
cellulosic polymer concentration is known to increase adsorption onto drug particles, 
thus offering enhanced steric stability via thicker adsorbed polymer layer (Knieke et 
al., 2013; Sepassi et al., 2007).  
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Figure 5.3  Volume frequency distributions of various milled drug suspensions 
containing 0.05% SDS and HPC with different molecular weights: (a) 40 kDa (SSL 
grade, Runs 13‒17), (b) 100 kDa (SL grade, Runs 18‒22), and (c) 140 kDa (L grade, 
Runs 23‒27). Run 2 had only 0.05% SDS. 
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The reproducibility of wet stirred media milling of GF and other BCS Class II 
drugs has been established in several studies (Bilgili and Afolabi, 2012; Li et al., 
2015b). In this study, the d50 and d90 values for the repeat of Run 20 were 0.236 ± 
0.001 and 0.435 ± 0.002 µm, respectively. Compared to d50 = 0.230 ± 0.001 and d90 = 
0.443 ± 0.001 µm in Run 20, the deviations in the repeated milling experiment were 
less than 3%. Also, as will be shown below, for most formulations, the suspensions 
did not exhibit a drastic shift in particle sizes after 30 h storage (before redispersion 
samples vs. after milling samples), and any variations could be partly attributed to the 
handling–sampling of the aggregated suspensions following refrigerated storage. 
 
5.2.2  Formation of Drug Composites via Fluidized Bed Drying of the Precursor 
Drug Suspensions 
The GF suspensions produced by milling were sprayed onto Pharmatose® carrier 
particles (see Figure 5.4(a)), which form the core of the composite particles, in a 
fluidized bed drier. Throughout the rest of the dissertation, all composites are labeled 
based on the formulation of the respective precursor drug suspension that was used as 
the feed during the drying. The mean drug content was in the range of 9.3‒15.2% due 
to different stabilizer concentrations in the milled suspensions and variable 
drug/Pharmatose® losses to the filters and side walls of the drier (Table 5.1). Most 
importantly, the composite powders exhibited pharmaceutically acceptable content 
uniformity: RSD was less than 6% for most formulations. Upon atomization, droplets 
of the milled suspensions impinged on Pharmatose® carrier particles and dried, 
leading to the formation of a single coated composite particle (Figure 5.4(b)), which 
embeds GF nanoparticles on its shell (Figure 5.4(c)). Some SEM images (not shown 
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for brevity) indicated presence of granules, i.e., doublets, triplets, etc. at higher HPC 
L concentration, which is quantified by the presence of much coarser composite 
particles (see Table 5.2) than the uncoated Pharmatose® particles with d50: 
123.6±0.86 m, d90: 195.2±4.79 m. The larger composite particles prepared at 
higher HPC concentration, especially with the use of L grade, can be explained by 
higher viscosity of the respective drug suspensions and coarser droplets formed upon 
atomization as well as higher coalescence probability of wetted Pharmatose® 
particles (Bhakay et al., 2013; Bilgili et al., 2011). SEM images of the composite 
particle surfaces with different suspension formulations were shown in Figure 5.4(c)–
(g). Drug aggregates as well as primary nanoparticles encapsulated in the HPC film 
can be observed on the composite surface.  
 
  
Figure 5.4  SEM images of the surfaces of (a) as-received Pharmatose® particles as 
well as the composites prepared using (b) 1% HPC SSL, 0.05% SDS (Run 14), (c) 
1% HPC SSL, 0.05% SDS (Run 14, higher magnification), (d) 1% HPC SSL (Run 4), 
(e) 5% HPC SSL, 0.05% SDS (Run 16), (f) 1% HPC L, 0.05% SDS (Run 24), and (g) 
5% HPC L, 0.05% SDS (Run 26). (Continued) 
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Figure 5.4  (Continued) SEM images of the surfaces of (a) as-received Pharmatose® 
particles as well as the composites prepared using (b) 1% HPC SSL, 0.05% SDS (Run 
14), (c) 1% HPC SSL, 0.05% SDS (Run 14, higher magnification), (d) 1% HPC SSL 
(Run 4), (e) 5% HPC SSL, 0.05% SDS (Run 16), (f) 1% HPC L, 0.05% SDS (Run 
24), and (g) 5% HPC L, 0.05% SDS (Run 26). 
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Table 5.2  Particle Sizes of the Composites Prepared using Various Precursor 
Suspensions 
HPC Concentration Drug Composite Particle Size (µm) 
(% w/w), Grade 
Without SDS With 0.05% SDS 
d50±SD d90±SD d50±SD d90±SD 
0%, – 127.8±0.67 201.8±3.61 130.1±2.34 199.1±6.72 
0.25%, SSL 123.2±0.75 187.7±2.58 123.4±2.17 199.0±8.25 
1%, SSL 124.1±2.33 193.2±3.08 124.6±1.79 196.4±4.36 
2.5%, SSL 124.6±3.94 199.4±7.63 127.4±3.24 201.0±5.85 
5%, SSL 131.2±2.43 207.7±7.49 128.6±1.96 202.8±4.16 
7.5%, SSL 152.9±5.53 320.5±25.2 145.3±0.52 229.1±6.09 
0.25%, L 126.4±2.02 192.7±2.20 139.2±3.00 222.6±12.5 
1%,  L 137.7±0.96 212.5±1.93 154.3±3.45 236.4±7.93 
2.5%, L 163.0±0.29 249.8±6.17 187.2±7.21 381.5±24.6 
5%, L 238.4±2.71 436.0±26.5 251.1±6.55 428.8±18.4 
7.5%, L 289.8±24.1 442.7±18.5 260.7±0.61 502.2±22.3 
 
5.2.3.  Recovery of the Drug Nanoparticles from the Composite Particles in 
Deionized Water  
The composite particles produced via fluidized bed drying–coating of precursor GF 
suspensions onto Pharmatose® were redispersed in water to study the recovery of GF 
nanoparticles via gentle paddle stirring for 2 min. Figure 5.5 presents the particle size 
statistics of drug particles right after milling, before redispersion (30 h storage after 
milling), and after redispersion in deionized water for formulations without stabilizers 
and those with HPC alone having different MWs. Figure 5.5 shows that the particle 
sizes after the redispersion test were much greater than the drug particle sizes after 
milling and 30 h storage. Although there were some micron-sized particles in the 
milled suspensions (Figure 5.1), the clusters in the redispersed suspension samples 
had particle sizes above 10 µm (Figure 5.5), which are all larger than those in the 
milled suspensions, indicating poor redispersibility of the composites and potentially 
formation of large clusters during the drying. In fact, it is likely that the shell of some 
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composite particles did not break at all, keeping the core (Pharmatose®) intact for 
low HPC concentrations, and that coarse clusters might have appeared after 
redispersion. A higher polymer concentration (especially at and above 2.5%) led to 
smaller clusters after redispersion for both HPC grades.  
 
M
e
d
ia
n
 s
iz
e
, 
d
5
0
 (

m
)
0.1
1
10
100
after milling
before redispersion
after redispersion
HPC SSL concentration
9
0
%
 p
a
s
s
in
g
 s
iz
e
, 
d
9
0
 (

m
)
0.1
1
10
100
0.25% 1% 2.5% 5% 7.5%
HPC SSL,  No SDS
No HPC
a)
 
M
e
d
ia
n
 s
iz
e
, 
d
5
0
 (

m
)
0.1
1
10
100
after milling
before redispersion
after redispersion
HPC L concentration
9
0
%
 p
a
s
s
in
g
 s
iz
e
, 
d
9
0
 (

m
)
0.1
1
10
100
HPC L,  No SDS
0.25% 1% 2.5% 5% 7.5%No HPC
b)
 
Figure 5.5  Particle sizes of the composites prepared using various precursor 
suspensions with (a) HPC SSL (40 kDa, Runs 3‒7) and (b) HPC L (140 kDa, Runs 
8‒12) after 2 min redispersion in deionized water in comparison to the particle sizes 
of the suspensions after milling and after 30 h storage (before redispersion). Run 1 
had no stabilizers. 
 
A specific example of the poor redispersion is the composite particles with no 
stabilizer in the suspension (Run 1), which had the median size of 127.8 µm (Table 
5.2). After redispersion in deionized water, the median size was 105.5 µm, whereas 
the milled suspension had GF median size of 9.1 µm (Figure 5.5). SEM images of the 
redispersed suspension samples following drying are shown in Figure 5.6. Figure 
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5.6(a) confirmed the aforementioned poor redispersion: the Run 1 composite particles 
slightly shrunk upon partial dissolution of Pharmatose® and the coated layer (shell 
structure) broke into large pieces. The poor redispersion is most likely due to hard 
aggregates formed upon removal of water during the drying; solid bridges could have 
formed upon re-crystallization of the small amount of dissolved GF. The hard 
aggregates might not have allowed for proper shell breakage and or full dispersion 
into primary GF nanoparticles. Moreover, without having any stabilizers, Run 1 
composite particles are covered solely by hard aggregates of hydrophobic GF 
particles, which may have slowed down water penetration into the core. During the 
redispersion test, water penetrates through the pores in the shell of the composite 
particles and dissolves the Pharmatose® core, which is largely inhabited by the poor 
wettability of Run 1 composite, leading to the coarse clusters (Figure 5.6(a)).  
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Figure 5.6  SEM images of the drug composites prepared using various precursor 
suspensions (a) without stabilizers (Run 1) as well as with (b) 7.5% HPC SSL (Run 
7), (c) 0.25% HPC SSL, 0.05% SDS (Run 13), and (d) 5% HPC SSL, 0.05% SDS 
(Run 16) after 2 min redispersion in deionized water. 
 
For composites with HPC as the sole stabilizer, HPC acts as a film former and 
partially covers hydrophobic GF nanoparticles (e.g., Figure 5.4(d)). Due to the 
dissolution of HPC and the mechanical action of paddle stirring, the shell of the 
composite particles broke down to smaller clusters in water, especially at higher HPC 
concentration as compared with Run 1 case (Figures 5.5 and 5.6(b)). On the other 
hand, even with 7.5% HPC, the primary drug nanoparticles cannot be recovered for 
both HPC grades. This is partly due to the slow dissolution of HPC and its relatively 
low wetting capability (Dalvi and Dave, 2010; Rasenack et al., 2003), which limited 
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the water penetration. Moreover, the hydrophobic nature of GF led to poor wetting of 
the clusters, thus slowing down the release of drug nanoparticles. Finally, the 
precursor suspensions with HPC as the sole stabilizer exhibited severe aggregation 
(see Figure 5.5). Hence, the redispersion of these composites at best might have 
resulted in aggregates whose sizes would be similar to those in the precursor 
suspensions; however, much larger clusters formed due to the poor wettability and the 
formation of hard aggregates especially below 2.5% HPC. 
Figure 5.7 shows the particle size statistics for the composites with SDS and 
HPC of various MWs after redispersion and those of the corresponding precursor 
suspensions. As a baseline, Run 2 had only SDS in the precursor suspension. Drug 
nanoparticles in the milled suspension show significant particle size increase after 30 
h storage (before redispersion) and drug nanoparticles were not recovered from its 
dried composite. SDS can impart excellent wettability and thus effective 
deaggregation of clusters that formed during or after the breakdown of the shell under 
the action of gentle paddle stirring (Bhakay et al., 2013). However, SDS alone was 
not able to provide sufficient coverage of the drug nanoparticles and prevent the 
formation of hard aggregates during drying. This, coupled with the presence of 
aggregates formed during the storage, could explain the poor redispersibility of Run 2 
composite without any HPC. It appears that while wettability imparted by SDS and 
small aggregates formed during the milling upon use of SDS are both desirable, a 
minimum HPC concentration is still required.  
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Figure 5.7  Particle sizes of the composites prepared using precursor suspensions 
with 0.05% SDS and (a) HPC SSL (40 kDa, Runs 13‒17), (b) HPC SL (100 kDa, 
Runs 18‒22), and (c) HPC L (140 kDa, Runs 23‒27) after 2 min redispersion in 
deionized water in comparison to the particle sizes of the suspensions after milling 
and after 30 h storage (before redispersion).  
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The formulations with SDS (Figure 5.7) exhibited smaller drug particle sizes 
and lower extent of drug nanoparticle aggregation in the milled suspensions, 
enhanced wettability of the composites, and faster redispersion and recovery of the 
drug nanoparticles as compared with those without SDS (Figure 5.5), pointing out the 
criticality of SDS. Moreover, with 0.05% SDS, an increase in HPC concentration led 
to smaller milled particle sizes and faster/more complete recovery of the drug 
nanoparticles (Figure 5.7). Different from the formulations with HPC alone (Figure 
5.5), the formulations with SDS led to effective recovery of the drug nanoparticles at 
5% HPC SSL or 2.5% HPC SL or L. The SEM image (Figure 5.6(d)) qualitatively 
confirms the full recovery of nanoparticles from the composite with SDS. The 
excellent wettability and water penetration imparted by SDS led to the fast 
disintegration of the shell of the composites followed by fast dispersion of any 
clusters into drug nanoparticles. However, despite ensuring the formation of fine 
nanoparticles in the respective milled suspensions, the use of SDS did not allow for 
full nanoparticle recovery when HPC was below a threshold concentration (~1%) (see 
e.g., Figure 5.6(c)). This may be explained by the formation of hard aggregates during 
the drying process when HPC concentration was low. Considering that the respective 
milled suspensions with SDS had low extent of aggregation and were relatively stable, 
the existence of large clusters emanating from the redispersed composites (Figure 5.7) 
implies that a relatively stable nanosuspension did not guarantee full and fast 
recovery of nanoparticles from the composites. It is concluded that the presence of 
sufficient amount of HPC is critical for full recovery of drug nanoparticles, and a 
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lower HPC concentration may be needed for the higher molecular weight (SL or L 
grades). 
 
5.2.4  Recovery of Drug Nanoparticles from the Drug Composite Particles in 
0.05% SDS Solution 
To further elucidate the role of SDS and investigate the impact of wettability of the 
composites, the composites with HPC alone (without SDS) were redispersed in 
0.05% SDS solution (see Figure 5.8), in comparison to their redispersion in de-
ionized water (Figure 5.5). This medium has the same SDS concentration as in the 
milled suspensions containing SDS (Figure 5.7). It should be noted that GF solubility 
is only slightly increased by SDS below the CMC (Rao et al., 1997). Interestingly, 
drug nanoparticles were effectively recovered only from the composites with high 
HPC concentration, at or above 5%, for both SSL and L grades (Figure 5.8) because 
0.05% SDS in the redispersion medium enhanced the wetting and dispersed the drug 
aggregates, unlike the redispersion in de-ionized water (Figure 5.5). Drug 
nanoparticles could not be recovered from the composites with less than 5% HPC 
despite the presence of 0.05% SDS in the redispersion medium. Figures 5.5 and 5.8 
both illustrate coarse clusters (>10 m) at or below 1% HPC. These results can again 
be explained by the presence of significant fraction of aggregates in the composites 
without SDS (refer to Figure 5.1) and formation of hard aggregates during drying, 
which did not allow for fast shell breakage/disintegration even under paddle stirring 
with good wettability imparted by SDS. Similar results were obtained by de Villiers 
for aggregated drug powders (de Villiers, 1996).  
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A comparison of the redispersed particle sizes for the formulations with 
0.05% SDS in the respective precursor suspensions, which led to an estimated 
0.0026% SDS upon the redispersion of the respective composites in de-ionized water 
(see Figure 5.7(a), (c)), vs. those formulations with HPC/without SDS, redispersed in 
0.05% SDS solution (see Figure 5.8a,b) sheds further insight. Despite the attainment 
of 0.0026% SDS concentration in the redispersion medium, 0.05% SDS in the milled 
suspension/composite led to smaller redispersed particles, i.e., more effective 
recovery of the GF nanoparticles, notably at the intermediate HPC concentrations, i.e., 
1% and 2.5% HPC (Figure 5.7), as compared with 0.05% SDS added to the 
redispersion medium directly (Figure 5.8). A similar, albeit less pronounced 
difference occurred at 0 and 0.25% HPC because hard aggregate formation controlled 
the poor redispersibility observed at such low HPC concentration. These findings 
could be mainly explained by the presence of smaller aggregates in the precursor 
milled suspensions with SDS (refer to Figure 5.3) than without SDS (refer to Figure 
5.1) besides facilitated disintegration of the composite shell with enhanced wettability 
during the redispersion test. At 5% and 7.5% HPC, a similar pattern was observed for 
the L grade, whereas an anomaly occurred for the SSL grade for which the smaller 
redispersed particles were obtained when 0.05% SDS was added to the redispersion 
medium directly. It seems the much higher SDS concentration, i.e., 0.05% vs. 
0.0026%, in the redispersion medium affected the redispersion results differently at 
only for the high HPC SSL concentration. 
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Figure 5.8  Particle sizes of the composites prepared using various precursor 
suspensions with (a) HPC SSL (Runs 3‒7) and (b) HPC L (Runs 8‒12) after 2 min 
redispersion in 0.05% SDS solution in comparison to the particle sizes of the 
suspensions after milling and after 30 h storage (before redispersion). Run 1 had no 
stabilizers. 
 
Overall, the redispersion experiments with deionized water and 0.05% SDS 
solution as two separate media point out the need for preparing aggregate-free 
precursor (milled) drug suspensions upon use of HPC–SDS combination. Moreover, a 
minimum HPC concentration (within 0.25–1% in the precursor) is required to prevent 
hard-aggregate formation during drying and to give strength and proper film 
formation in the shell of the composite particles.  
 
5.2.5  Drug Dissolution from the Composites 
The composites produced via fluidized bed drying were dissolved in excess de-
ionized water to allow for full dissolution of the poorly water-soluble drug. 
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Dissolution profiles of the composites without SDS in the precursor suspensions are 
shown in Figure 4.9. For both HPC SSL and L, dissolution rates increased with 
higher polymer concentration, but immediate drug release (80% dissolved within 20 
min) was not realized for any formulation. These findings can overall be explained by 
the poor redispersibility of the composites without SDS and slow/incomplete 
nanoparticle recovery during the dissolution (see Figure 4.5). It is expected that GF 
nanoparticle recovery precedes GF dissolution from the composites considering the 
poorly water-soluble nature of this drug.  
For HPC SSL at the highest concentration (7.5%), the dissolution of drug 
particles only reached 50.2% at 60 min. Applying f1 and f2 tests and t-test (Azad et 
al., 2015a; Moore and Flanner, 1996), the author found that the dissolution profiles of 
the composite formulations with 1–7.5% HPC SSL presented in Figure 4.9 were not 
statistically different. For 7.5% HPC L having the highest polymer molecular weight, 
the drug dissolution reached 68.8%, which is higher than that for HPC SSL at the 
same concentration. This may be due to the better coverage of the hydrophobic drug 
surfaces with higher MW HPC, despite its slower diffusion/dissolution in water. It 
should be noted that, in the absence of SDS, HPC as a film former in composites can 
only provide limited wettability for dissolution, which is the limiting mechanism for 
their dissolution performance. 
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Figure 5.9  Drug dissolution profiles of the composites prepared using various 
precursor suspensions containing HPC with different molecular weights: (a) 40 kDa 
(SSL grade, Runs 3‒7) and (b) 140 kDa (L grade, Runs 8‒12). Run 1 had no 
stabilizers. 
 
Dissolution profiles of the composites with 0.05% SDS in the precursor 
suspensions are shown in Figure 5.10. A comparative analysis of the results in 
Figures 5.9 and 5.10 suggests that most composites with SDS exhibited immediate 
drug release and faster drug dissolution than those without SDS, which can be overall 
explained by the enhanced redispersibility/faster nanoparticle recovery (refer to 
Figure 5.7) stemming from the excellent wettability and electrosteric stabilization 
imparted by the use of HPC–SDS. An increase in HPC concentration led to faster 
dissolution for all three HPC grades. This positive effect of HPC appears to saturate 
when the HPC concentration was above 2.5% for SSL and SL grades and 5% for L 
grade. These observations can again be explained by enhanced nanoparticle recovery 
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(smaller redispersed particle sizes) at higher HPC concentration and the tendency of 
the redispersed particle sizes to minimum values above 2.5% HPC (refer to Figure 
5.7). At or below 5% HPC concentration, unlike the formulations without SDS, the 
formulations with HPC–SDS exhibited slower dissolution when a higher MW HPC 
was used. With SDS, the dissolution profiles are more sensitive to the dissolution–
diffusion rate of HPC with various MW. The slower dissolution for the composites 
with higher MW HPC may be explained by the slower dissolution and diffusion of 
the higher MW HPC. In addition, the relatively large granules formed during the 
drying process for the higher MW HPC (L grade in Table 5.2) may also partly explain 
the slower dissolution profiles. 
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Figure 5.10  Drug dissolution profiles of the composites prepared using various 
precursor suspensions with 0.05% SDS and HPC with different molecular weights: 
(a) 40 kDa (SSL grade, Runs 13‒17), (b) 100 kDa (SL grade, Runs 18‒22), and (c) 
140 kDa (L grade, Runs 23‒27). Run 2 had only 0.05% SDS. 
 
5.3  Conclusions 
Nanocomposite microparticles were produced by fluidized bed drying–coating of wet 
stirred media-milled GF nanosuspension onto Pharmatose® carrier particles. The 
drug composites were redispersed in water and aqueous solution of SDS. Three 
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different HPC polymer molecular weights at varied concentrations in the 
absence/presence of SDS were investigated for their ability to enhance the 
redispersion and dissolution of the drug nanoparticles. The results overall suggest that 
well-stabilized drug nanosuspensions with minimal amount of aggregates is necessary 
to produce drug composites with good redispersion and fast dissolution. However, 
good physical stability and prevention of aggregation in the milled suspensions is not 
sufficient. The presence of a soluble, adsorbing polymer above a minimum 
concentration is also needed so as to suppress formation of hard aggregates during 
drying. Hence, our study concludes that proper stabilization of drug suspensions is a 
necessary condition for fast drug nanoparticles recovery and fast drug dissolution 
from the composites, but not sufficient. Sufficiency originates from the use of SDS in 
combination with HPC above the threshold concentration, which results in almost 
aggregate-free drug nanosuspensions and mitigates hard-aggregate formation. 
Immediate drug release is achieved when a lower molecular weight (SSL grade) HPC 
at or above 1% concentration was used along with 0.05% SDS. Despite the use of 
0.05% SDS, the highest grade of HPC (L grade) entails relatively high concentrations 
to ensure immediate drug release from the composites.  
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CHAPTER 6 
ENHANCED DISSOLUTION OF ITRACONAZOLE FROM HIGH DRUG-
LOADED SURFACTANT-FREE NANOCOMPOSITE MICROPARTICLES 
 
The previous chapter has developed an understanding of the relationships between the 
physical stability of drug nanosuspension, redispersion, and drug dissolution from the 
nanocomposites based on HPC‒SDS formulations. The problem associated with the 
use of surfactant was discussed in detail in Chapter 1, which includes, for instance, 
Ostwald ripening of nanosuspensions during storage and irritation to the pulmonary 
epithelium. Thus, there is a need to find potential dispersants that can replace the 
surfactants to prepare surfactant-free formulations for certain pharmaceutical 
applications. The aim of Chapter 6 is to investigate the impact of various classes of 
dispersants, including the relatively novel class of swellable dispersants (e.g., 
superdisintegrants) on drug release from high drug-loaded, surfactant-free 
nanocomposites and elucidate the mechanisms for enhanced dissolution. To this end, 
precursor suspensions of itraconazole (ITZ) nanoparticles in the presence of various 
dispersants were prepared via wet stirred media milling and spray dried to form the 
nanocomposites. Hydroxypropyl cellulose (HPC, polymer) alone and sodium dodecyl 
sulfate (SDS, surfactant) alone as well as their combination were used as baseline 
stabilizers/soluble dispersants during milling and drying. Three commonly used 
superdisintegrants, which are insoluble swellable dispersants, i.e., sodium starch 
glycolate (SSG), crospovidone (CP), and croscarmellose sodium (CCS) were wet co-
milled along with ITZ in the presence of HPC. In addition, two conventional soluble 
matrix formers, Sucrose and Mannitol, were dissolved in milled ITZ suspensions with 
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HPC. Laser diffraction, viscometry, scanning electron microscopy (SEM), X-ray 
powder diffraction (XRD), differential scanning calorimetry (DSC), and ultraviolet 
spectroscopy were used for characterization. In addition, drug wettability 
enhancement by soluble dispersants was investigated using the Washburn method so 
as to elucidate the mechanisms. Dissolution performance of the nanocomposites was 
determined, and dissolution profiles of selected formulations were compared by 
calculating the difference and similarity factors (Costa and Lobo, 2001). These 
methods and analysis allows for elucidating the impact of dispersants on both wet-
milled particle size and drug dissolution. 
 
6.1  Materials and Methods 
6.1.1  Materials 
Sodium starch glycolate (SSG, Primojel), croscarmellose sodium (CCS, Ac-Di-Sol, 
type-SD711), and crospovidone (CP, Polyplasdone XL-10) were donated by DMV 
Fonterra Excipients LLC (Princeton, NJ), FMC Biopolymer (Newark, DE), and ISP 
Chemicals (Wayne, NJ), respectively. Hydroxypropyl cellulose (HPC, SL grade) was 
donated by Nisso America, Inc. (New York, NY). Sodium dodecyl sulfate (SDS), 
Mannitol, and Sucrose were purchased from Fisher Scientific (Pittsburgh, PA), Pure 
Bulk Inc. (Roseburg, OR), and GFC Chemicals, Inc. (Columbus, OH), respectively. 
Itraconazole (ITZ) was purchased from Jai Radhe Sales (Ahmedabad, India). 
Mannitol is classified as a sugar alcohol with a solubility of 180 g/L in water, whereas 
sucrose is a common, naturally occurring sugar with a solubility of 2000 g/L. 
Superdisintegrants (SSG, CP, and CCS) are insoluble and highly swellable in water. 
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The swelling capacities of SSG, CP, and CCS in water are 23.6, 5.4, and 13.5cm3/g, 
respectively (Quadir and Kolter, 2006). As-received SSG and CCS were dry-sieved in 
a sieve shaker (Octagon 2000, Endecotts Ltd., London, England) for 1 h using the US 
Standard Testing Sieves (ASTM E-11 specification), and < 38 µm particles were 
collected. This step is intended to prevent potential clogging of the mill screen by 
water-swollen, coarse SSG/CCS particles during wet media milling (Azad et al., 
2014b; Bhakay et al., 2014b). CP was used as is. The d50 and d90 values of the 
particles after sieving are 28.8 ± 0.1 µm and 41.0 ± 0.5 µm; 21.7 ± 0.3 µm and 49.0 ± 
2.0 µm; and 34.5 ± 0.3 µm and 56.4 ± 0.1 µm for SSG, CP, and CCS respectively, as 
measured via the Rodos/Helos system (Sympatec, Pennington, NJ). 
 
6.1.2  Preparation Methods 
Drug precursor suspensions were prepared via wet media milling, followed by their 
spray drying into nanocomposite powders. The formulations of the drug precursor 
suspensions are presented in Table 6.1. Selection of the milling conditions and 
formulations were guided by our prior work on wet media milling (Azad et al., 
2014b; Bilgili et al., 2016d). All percentages (%) refer to w/w with respect to total 
weight of deionized water (200 g). Unless otherwise indicated, suspensions and 
nanocomposites are labeled with the type‒concentration of the dispersants in the 
precursor suspensions, which all contain 10% ITZ. The rationale behind the 
experimental design is as follows: since HPC is the only film-forming polymer in this 
study, which is essential to the formation of the nanocomposite structure, a minimum 
of 2.5% HPC was used in all formulations, except F2 (with 0.2% SDS alone). 
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Formulations F1–F3 allow one to examine the impact of HPC–SDS combination, 
which is known to be effective for stabilizing multiple drug nanosuspensions (see 
e.g., (Bilgili et al., 2016d)), on milled ITZ particle size with the respective controls 
(no SDS or no HPC). In F4–F6 and F7–F9 formulations, Mannitol and Sucrose were 
respectively used as soluble dispersants at 1%, 2%, and 4% levels and added right 
after milling to prepare precursor suspensions. Besides these soluble dispersants, 
SSG, CP, and CCS were used as insoluble, swellable dispersants at 1% and 2% levels 
and co-milled with ITZ (see below) to prepare F11–F16 precursor suspensions. F10 
and F17 formulations had extra 4% and 2% HPC added before milling, without any 
additional dispersant, to enable comparative assessment of all dispersants at the same 
total dispersant concentrations of 6.5% and/or 4.5%. 
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Table 6.1  Formulations of the Precursor Suspensions used to Prepare 
Nanocomposites via Spray Drying and Drug Content of the Nanocomposites 
Formula 
ID 
HPC 
(% 
w/w)
a
 
SDS 
(% w/w)
a
 
Other 
Dispersants 
(% w/w)
a
 
Theoretical 
Drug 
Content 
(%) 
Drug Content 
(RSD) of the 
Nanocomposites 
(% w/w)
b
 
F1 2.5 0 – 80.0 78.9 (5.19) 
F2 0 0.2 – 98.0 N/M 
F3 2.5 0.2 – 78.7 78.3 (4.66) 
F4 2.5 0 1 (Mannitol)
c
 74.1 72.4 (5.59) 
F5 2.5 0 2 (Mannitol)
c
 69.0 64.9 (4.68) 
F6 2.5 0 4 (Mannitol)
c
 60.6 55.5 (5.76) 
F7 2.5 0 1 (Sucrose)
 c
 74.1 70.3 (4.20) 
F8 2.5 0 2 (Sucrose)
 c
 69.0 65.4 (5.94) 
F9 2.5 0 4 (Sucrose)
 c
 60.6 54.8 (5.03) 
F10 6.5 0 – 60.6 55.2 (4.64) 
F11 2.5 0 1 (SSG)
d
 74.1 74.0 (2.73) 
F12 2.5 0 2 (SSG)
d
 69.0 66.8 (3.12) 
F13 2.5 0 1 (CP)
d
 74.1 72.8 (4.30) 
F14 2.5 0 2 (CP)
d
 69.0 64.4 (6.48) 
F15 2.5 0 1 (CCS)
d
 74.1 74.0 (3.69) 
F16 2.5 0 2 (CCS)
d
 69.0 66.6 (6.27) 
F17 4.5 0 – 69.0 66.1 (3.81) 
a
Drug loading in all suspensions is 10%. % w/w is with respect to the weight of deionized water, 200 g.  
b
% w/w is the weight of ITZ with respect to the weight of NCMPs. 
c
Added to the suspension after milling. 
d
Co-milled along with ITZ for 15 min. 
 
6.1.3  Preparation of Precursor Suspensions 
For formulations, F1 and F3‒F17, HPC at the indicated concentrations was dissolved 
in water using a shear mixer (Fisher Scientific Laboratory Stirrer, Catalog no. 14–
503, Pittsburgh, PA). In Runs 2 and 3, 0.2% SDS was added in deionized water and 
2.5% HPC solution, respectively. ITZ (10%) was then added to these stabilizer 
solutions and dispersed for 30 min with the shear mixer. Following the dispersion of 
the drug, each suspension was poured into the holding tank of a Netzsch mill 
(Microcer, Fine Particle Technology LLC, Exton, PA), pumped through the milling 
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chamber at a flow rate of 126 ml/min, and milled for 65 min (total milling time) at 
4000 rpm stirrer speed (14.7 m/s tip speed). 196 g of yttria-stabilized zirconia beads 
with a nominal size of 400 µm were used as the milling media. A 200 µm screen was 
used to retain the beads in the milling chamber. The temperature inside the milling 
chamber was maintained below 34 ˚C with a chiller (Advantage Engineering, Inc., 
Greenwood, IN). 
In preparation of F4–F9 precursor suspensions, Mannitol or Sucrose was 
dissolved in an already milled 10% ITZ‒2.5% HPC suspension right after milling (65 
min) while the suspension was still being stirred in the holding tank and re-circulated 
in the mill by the peristaltic pump. In Runs 11‒16, superdisintegrants (SSG/CP/CCS) 
were added as additional dispersants after 50 min milling while the mill was 
operating and co-milled with ITZ for 15 min. This short milling time was selected 
based on the previous study (Azad et al., 2015b; Bhakay et al., 2014b), where short-
milled CCS with multimodal size distribution enabled fastest recovery/dissolution of 
drug nanocomposites. To avoid clogging of the mill screen and associated pressure 
build-up (Azad et al., 2014b), superdisintegrant (SSG/CCS/CP) was added slowly. 
The particle size of the precursor suspensions was measured at the end of wet milling 
of ITZ or wet co-milling of ITZ–superdisintegrant or following the addition of 
Mannitol/Sucrose after wet milling. The milled suspensions were stored in a 
refrigerator at 8 ˚C. Particle size was also measured on samples stored in the 
refrigerator for 7 days to assess the impact of storage. Long-term stability was not 
studied as the precursor suspensions are intended to be dried following the wet media 
milling. 
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6.1.4  Spray Drying of the Precursor Suspensions 
The precursor suspensions prepared via wet media milling were dried, within the 
same day of milling, using a spray dryer (4M8-Trix, Procept, Zelzate, Belgium) 
running in a co-current flow set-up. For each formulation, 150 g suspension was 
sprayed. The suspensions were atomized and spray-dried under identical conditions to 
those in Azad et al. (2015b). Drying air was fed co-currently at a temperature of 120 
°C and a volumetric flow rate of 0.39‒0.40 m3/min. The suspensions were pumped at 
a rate of 1.6 g/min using a peristaltic pump (Make-it-EZ, Creates, Zelzate, Belgium) 
and atomized through a bi-fluid nozzle with 0.6 mm tip diameter at an atomization air 
pressure of 2 bar. The dried nanocomposites were then tested for particle size and 
used in the dissolution test. 
 
6.1.5  Particle Size Analysis 
The particle size distributions (PSDs) of the precursor suspensions after milling and 
after 7-day refrigerated storage were measured by laser diffraction using Coulter LS 
13 320 (Beckman Coulter, Miami, FL) based on Mie scattering theory following the 
procedure in Bilgili et al. (2016d). The refractive index of ITZ is 1.64. The area-based 
PSDs were also obtained upon transformation of the volume-based PSDs via the 
instrument’s software. Unless otherwise indicated, all PSDs and their statistics 
reported throughout the dissertation are volume-based. The particle sizes of the spray-
dried nanocomposites were measured by a Rodos/Helos laser diffraction system 
(Sympatec, NJ, USA) based on Fraunhofer theory following the procedure in Li et al. 
(2016b). 
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6.1.6  Scanning Electron Microscopy (SEM) 
The morphology of as-received ITZ microparticles before milling, primary size of 
ITZ nanoparticles after milling (F1‒F3, and F12) and nanocomposites (F1‒F3, F5, 
F8, F12, F14, and F16) were examined via a scanning electron microscope (SEM) 
LEO 1530 SVMP (Carl Zeiss, Inc., Peabody, MA). Detailed sample preparation 
procedure can be found in Li et al. (2016b). The stub was coated with carbon using 
BAL-TEC MED 020 (BAL-TEC AG, Balzers, Switzerland) to reduce possible 
charging effects during the imaging. 
 
6.1.7  Apparent Shear Viscosity of the Precursor Suspensions 
The apparent shear viscosity of stabilizer solutions and the precursor suspensions was 
measured using an R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) with a water jacket assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, 
USA). A coaxial cylinder (CC40) was used to provide a controlled shear rate on the 
samples from 0 to 1000 1/s for 60 s. The temperature of the jacket was kept constant 
at 25 ± 0.5 °C. The raw data were analyzed using the Rheo 3000 software (Brookfield 
Engineering, Middleboro, MA, USA) of the equipment to obtain the apparent shear 
viscosity as a function of the shear rate.  
For selected stabilizer solutions (F1, F3, F6, F9, F10, F17) in the liquid 
penetration experiments, the viscosities at the lowest shear rate (i.e., 254 1/s) that are 
representative were reported. Due to the inaccuracy of the instrument at low viscosity 
region (< 5 cP), the viscosities of water and the F2 stabilizer solution were adopted 
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from Korson et al. (1969) and Kushner et al. (1952), respectively. For the stabilizer 
solutions of F9 and F10, 4% Mannitol/Sucrose was dissolved in 2.5% HPC solutions. 
 
6.1.8  Determination of Drug (ITZ) Content of Nanocomposites 
Nanocomposites (100 mg) were dispersed in 20 ml dichloromethane and then 
sonicated for 30 min to dissolve ITZ. The solubility of ITZ in dichloromethane is 239 
mg/ml at 25 ˚C (Garg et al., 2013). After sonication, the solution was stored overnight 
during which insoluble superdisintegrants or Mannitol or Sucrose particles, if present, 
were allowed to settle. An aliquot (100 µl) was taken from the supernatant, diluted to 
10 ml with dichloromethane, and the absorbance was measured at a wavelength of 
260 nm by an Ultraviolet (UV) spectrophotometer (Agilent, Santa Clara, CA). The 
absorbance was then converted into the drug concentration via pre-established 
calibration curve of absorbance vs. concentration. Six replicates from each 
nanocomposite formulation were used to determine the mean drug content and the 
relative standard deviation (RSD), which are presented in Table 6.1. 
 
6.1.9  X-ray Powder Diffraction (XRPD) 
The crystallinity of the as-received ITZ, physical mixtures corresponding to F12 and 
F17 formulations, and overnight-dried ITZ precursor suspensions of F2, F12, and F17 
was analyzed using XRPD (PANalytical, Westborough, MA, USA), provided with 
Cu Kα radiation (λ = 1.5406 Å). The samples were scanned for 2θ ranging from 5° to 
30° at a scan rate of 0.165 s
–1
. The precursor suspensions were centrifuged (Compact 
II centrifuge, Clay Adams® Brand, Sparks, MD, USA) at 3200 rpm for 90 min to 
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separate the solid and aqueous phase. The resulted solid phase was redispersed in 
deionized water followed by another centrifugation. The final solid phase was 
overnight-dried in a vacuum hood for XRD and differential scanning calorimetry 
(DSC) analysis. 
 
6.1.10  Differential Scanning Calorimetry (DSC) 
A Mettler‒Toledo polymer analyzer DSC (PolyDSC, Columbus, OH, USA) was used 
to obtain the peak melting temperature and melting enthalpy of as-received ITZ, 
physical mixtures corresponding to F12 and F17 formulations, and overnight-dried 
ITZ precursor suspensions of F2, F12, and F17. The ITZ precursor suspensions were 
centrifuged‒rinsed‒centrifuged following the procedures in Section 6.1.9. ~6‒7 mg 
powder sample was weighed before being placed in a sealed perforated aluminum pan 
and loaded into the DSC. All samples were heated from 25 to 220 ˚C at a rate of 10 
˚C/min. Nitrogen was used as the purge gas and protective gas at a flow rate of 50 
ml/min and 150 ml/min, respectively. Data analysis was performed using STARe 10 
software provided by Mettler‒Toledo. 
 
6.1.11  Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a TGA/DSC1/SF Stare 
system (Mettler Toledo, Inc., Columbus, OH) for the characterization of the residual 
water in the spray-dried nanocomposites. A 5 mg spray-dried nanocomposite powder 
(F1 and F12) was placed in a ceramic crucible and heated from 25 °C to 150 °C at a 
constant rate of 10 °C/min under nitrogen flow. 
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6.1.12  Liquid Penetration Study 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Hołownia et al., 2008; Washburn, 1921). Attension Sigma 700 (Biolin 
Scientific, Linthicum, MD, USA) set-up was used in this study. Experimental 
methods were presented in Li et al. (2017) and the details can be found in 
Supplementary Material. In this study, liquids and powder are deionized 
water/stabilizer solutions (HPC, SDS, HPC‒SDS/Mannitol/Sucrose) and ITZ, 
respectively. For the stabilizer solutions with Mannitol/Sucrose, 4% 
Mannitol/Sucrose was dissolved in 2.5% HPC solutions. The apparent shear viscosity 
and surface tension of the liquids were respectively measured using R/S Plus 
Rheometer (Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma 
700 (Biolin Scientific, Linthicum, MD, USA), as described in Section 6.1.7 and 
Appendix C.1.1, respectively. The ratio of the cosine of contact angles cosθss/cosθw 
was calculated using the Modified Washburn equation and used as a wetting 
effectiveness factor. Here, θss is the contact angle between ITZ and the stabilizer 
solutions and θw is the contact angle between ITZ and deionized water. The ratio 
quantifies the drug wettability enhancement upon the use of different stabilizers 
(HPC, SDS, HPC‒SDS/Mannitol/Sucrose) in water.  
 
6.1.13  Dissolution 
Dissolution experiments on nanocomposites were performed using a Distek 
Dissolution tester (North Brunswick, NJ) according to the USP II paddle method. 
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Nanocomposites containing an equivalent ITZ dose of 20 mg were weighed and 
added to 1000 ml dissolution medium (3 g/L SDS solution). The SDS solution was 
selected for quantification of the dissolution rate enhancement and also for providing 
the rank order/good discrimination between nanocomposite formulations, similar to 
Azad et al. (2016) and Cerdeira et al. (2013b). The dissolution medium was 
maintained at 37.0 ± 0.1 ˚C and a paddle speed of 50 rpm was used. After addition of 
the nanocomposites, 4 ml samples were taken manually at 1, 2, 5, 10, 20, 30, and 60 
min and passed through a PVDF membrane type syringe filter with a nominal pore 
opening size of 0.1 µm. The amount of ITZ dissolved was measured by UV 
spectroscopy at a wavelength of 260 nm. SDS solution was used as the blank for UV 
measurements. Dissolution results are reported as ITZ release as a function of time 
for an average of six samples from each nanocomposite formulation.  
To describe the drug release kinetics from different polymeric matrices and 
rank the dissolution rate from different nanocomposites, fitting of ITZ dissolution 
data to Korsmeyer‒Peppas model (Ritger and Peppas, 1987a, b), as shown in Eq. 
(6.1), was performed using SigmaPlot’s (Version 11) regression wizard.  
 (6.1) 
where k is a constant incorporating structural and geometric characteristics of the 
drug dosage form, n is the release exponent, indicative of the drug release 
mechanism, and  is the fractional release of the drug. An apparent release 
mechanism was suggested in this dissertation based on the fitted n value and the 
specific geometry of the samples in view of various assumptions behind Eq. (6.1) 
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(refer to Ritger and Peppas (1987a)). Fitting of  included data up to and including 
one point after attainment of  value of 0.60. As the drug release rate (d( )/dt) is 
proportional to kn (Peppas, 1985), in this study, kn is used to compare dissolution rate 
of different formulations.  
 
6.1.14  Statistical Analysis 
All calculations were performed using Microsoft Excel® (Microsoft Office 2010, 
USA). Results for dissolution profiles are expressed as mean ± SD (standard 
deviation) while content uniformity results are expressed as mean with RSD% 
(relative standard deviation). Dissolution profiles of F2, F4‒F17 were compared to F1 
and F3, respectively, and those with 4.5% total dispersants (F5, F8, F12, F14, and 
F16) were compared to F17, using difference (ƒ1) and similarity (ƒ2)  factors (Boateng 
et al., 2009; Costa and Lobo, 2001). Generally, ƒ1 values up to 15 (0‒15) and ƒ2 
values greater than 50 (50‒100) ensure similarity/sameness/equivalence of the two 
profiles. When ƒ1 is greater than 15 or ƒ2 is smaller than 50, the dissolution profiles 
were regarded as statistically different. 
 
6.2  Results and Discussion 
6.2.1  Particle Sizes of the Precursor Suspensions 
Particle size statistics of the milled drug (ITZ) suspensions are shown in Figure 6.1. 
Actual particle size data can be found in Supplementary Material. Unless otherwise 
indicated, all statistics refer to volume-based PSD. As-received ITZ particles has d10: 
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4.8 ± 0.0 µm, d50: 15.5 ± 0.0 µm, and d90: 45.8 ± 0.1 µm (see Figure 6.2a). When 
they were wet-milled in the presence of 2.5% HPC alone as a baseline steric stabilizer 
(F1), extensive breakage occurred and 200–600 nm primary ITZ particles with 
irregular shapes can be seen in the SEM image (Figure 6.2b). However, in the liquid 
medium, ITZ nanoparticles aggregated due to high attractive inter-particle forces (van 
der Waals, hydrophobic forces, etc) and d50 and d90 values of 289 nm and 1543 nm 
were measured by laser diffraction (Figure 6.1a). While HPC likely adsorbed on the 
ITZ particles, imparting some steric stability and enhancing the wettability (see Table 
6.2 for the higher wetting effectiveness factor cosθss/cosθw of 2.5% HPC solution 
with respect to pure water), 2.5% HPC was not sufficient to prevent ITZ nanoparticle 
aggregation fully. Smaller aggregates were formed at the higher HPC concentrations 
of 4.5% (F17) and 6.5% (F10) because of enhanced wettability (higher cosθss/cosθw, 
Table 6.2) and higher extent of ITZ adsorption as adsorption of cellulosic polymers 
like HPC and HPMC onto drug nanoparticles are known to follow Langmuir or 
Freundlich adsorption isotherms (Bilgili and Afolabi, 2012; Knieke et al., 2013). At 
higher HPC concentrations, a thicker layer of the adsorbed polymer and stronger 
adsorption could have occurred (Bilgili and Afolabi, 2012; Lee, 2003). 
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Figure 6.1  (a) Volume-based and (b) area-based particle size distributions of the ITZ 
precursor suspensions.  
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When 0.2% of the anionic surfactant (SDS) was used as the sole stabilizer in 
F2, a coarse suspension with d50 of 21.11 µm was formed (Figure 6.1a) and the large 
aggregate particle was observed in Figure 6.2c. It is likely that 0.2% SDS was not 
capable of imparting sufficient electrostatic stabilization and it imparted the lowest 
wettability enhancement among all dispersants studied (see Table 6.2). When 2.5% 
HPC–0.2% SDS combination was used, an ITZ nanosuspension with the smallest 
nanoparticles with d50 of 168 nm was obtained (Figure 6.1a). The sizes of the primary 
particles are in the range of 100‒500 nm (Figure 6.2d). The synergistic stabilization 
effect can be seen from the markedly higher wettability enhancement by the 
combination of HPC–SDS vs. HPC or SDS alone. Such synergistic stabilization 
action has been previously reported for various BCS Class II drugs (Basa et al., 2008; 
Bilgili and Afolabi, 2012; Bilgili et al., 2016d). 
In F4‒F9, Mannitol or Sucrose was added to the milled ITZ suspension with 
2.5% HPC as extra soluble dispersants with the ultimate objective of elucidating their 
impact on ITZ release from the nanocomposites. The addition of Mannitol or Sucrose 
in the presence of 2.5% HPC did not significantly affect ITZ particle sizes after 
milling (Figure 6.1a). 
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Table 6.2  Wetting Effectiveness Factor of Various Stabilizer Solutions Determined 
by the Modified Washburn Method 
Formulation of the 
Stabilizer 
Solution
a
 
η/(C ρ2 γcosθ) 
(s/g
2
) 
R
2
 
ηb 
(cP) 
ρ 
(g/ml) 
γ 
(mN/m) 
cosθss/cosθw 
Water 93217 0.996 0.89c 1.000 70.8 1 
2.5% HPC 2199 0.997 5.17 1.025 42.4 390 
0.2% SDS 1802 1.000 0.94d 1.002 28.5 135 
2.5% HPC, 0.2% 
SDS 
1075 0.999 20.64 1.027 33.8 3974 
4.5% HPC 466 0.992 16.44 1.045 42.3 5631 
6.5% HPC 658 1.000 35.71 1.065 42.1 8393 
2.5% HPC, 4% 
Mannitol 
2098 0.998 5.673 1.065 42.2 433 
2.5% HPC, 4% 
Sucrose 
2119 0.994 5.685 1.065 42.3 429 
a
% w/w is with respect to the weight of deionized water.  
b
the viscosities at 254 1/s shear rate. 
c
adopted from Korson et al. (1968). 
 
d
adopted from Kushner et al. (1952). 
 
 
In F11‒F16, superdisintegrants were wet co-milled along with ITZ particles in 
the stirred media mill for 15 min. The short co-milling time allowed a wide PSD of 
superdisintegrants, which is known to be the most effective in the enhancement of 
nanocomposite dissolution rate (Azad et al., 2015b; Bhakay et al., 2014b). The 
shortly co-milled ITZ‒superdisintegrants had a mixture of large swollen 
superdisintegrant particles and ITZ nanoparticles (Figure 6.2e), which was reflected 
by the high d90 values in Figure 6.1a. Note that the d50 and d90 of the SSG, CP, and 
CCS particles swollen in 2.5% HPC solution, without milling, are 113.7 ± 0.1 µm and 
171.4 ± 0.2 µm; 29.9 ± 0.0 µm and 65.8 ± 0.3 µm; and 137.5 ± 0.3 µm and 213.8 ± 
0.8 µm, respectively. Hence, albeit being short, the wet milling of the 
superdisintegrants seems to be effective for breakage of large swollen particles during 
the wet co-milling of ITZ–superdisintegrant.  
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Figure 6.2  SEM images of the ITZ particles: (a) as-received ITZ before milling and 
the ITZ precursor suspensions with (b) 2.5% HPC (F1), (c) 0.2% SDS (F2), (d) 2.5% 
HPC‒0.2% SDS (F3), (e) 2.5% HPC‒2% co-milled SSG (F12). 
 
As the volume-based PSD (Figure 6.1a) is much more heavily weighted by 
the large particles than smaller ones, the volume-based PSD of 
ITZ‒superdisintegrants particles in F11‒F16 suspensions is largely dominated by the 
large volume occupied by the swollen superdisintegrants. On the other hand, the area-
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based distribution (Figure 6.1b) provides evidence of the presence of colloidal ITZ 
particles, while masking the effects of coarse swollen superdisintegrant particles 
(Azad et al., 2015b; Bhakay et al., 2014b), because, mathematically, coarse 
superdisintegrants weigh much less in the area-based PSD than in the volume-based 
PSD. In fact, when a suspension did not have a significant amount of aggregates 
and/or large superdisintegrant particles, the area-based particle size statistics were 
similar to the volume-based particle size statistics (e.g., for F3, F10, and F17).  
Although the drug suspensions were spray dried into nanocomposite powders 
within the same day, a small portion of drug suspensions was kept at 8 ˚C for 7 days 
for the evaluation of short-term storage stability. For well-stabilized ITZ suspensions 
(F3, F10, and F17), little shift in particle sizes was observed (data can be found in 
Appendix C Table C1). However, for F1 suspension, wherein ITZ was stabilized by 
2.5% HPC alone, ITZ particles were aggregated during/after milling and significant 
particle size increase was observed during the storage. Other suspensions with co-
milled superdisintegrants, except 1% SSG (F11), also showed increased aggregation. 
While the presence of Mannitol or Sucrose did not change the ITZ size during 
milling, they seem to reduce the extent of aggregation during storage as compared to 
HPC alone (F1). These results support the need for a drying process like spray-drying 
to convert suspensions to nanocomposite powders for long-term storage. 
 
6.2.2  A Rheological Characterization of the Precursor Suspensions 
Laser diffraction involves a dilution step for particle sizing of the precursor 
suspensions, which affects the interpretation of the aggregation state of the drug. 
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Here, an orthogonal method, i.e., rheological characterization of the suspensions was 
carried out to further assess the aggregation state of the suspensions without dilution. 
The apparent shear viscosities of the stabilizer solutions (without the drug, 
corresponding to F1 and F3) and ITZ precursor suspensions of selected formulations 
(F1‒3, F6, F9‒17) were measured as a function of shear rate.  
Figure 6.3a shows the viscosity of the stabilizer solutions. As the shear rate 
was increased, the viscosity of the stabilizer solution decreased slightly (shear-
thinning behavior) and tend to an asymptotic value (Newtonian fluid behavior) above 
a shear rate of 200 1/s. Similar observation for stabilizer solutions was reported by 
Bilgili and Afolabi (2012). Besides, the addition of SDS in HPC solution significantly 
increased the viscosity due to the formation of HPC‒SDS aggregates or micelle-like 
SDS clusters bound to the polymer (Berglund et al., 2003; Evertsson and Nilsson, 
1997; Winnik and Winnik, 1990), which could be another manifestation of the 
synergistic action of HPC–SDS combination. Thus, for stabilizer solutions, 
HPC‒SDS had the highest viscosity followed by HPC alone. The viscosity of SDS 
solution was not reported due to the inaccuracy of the instrument at low viscosity 
region (< 5 cP). 
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Figure 6.3  Apparent shear viscosity of (a) various stabilizer solutions (no drug) with 
HPC/SDS (F1 and F3), (b) ITZ precursor suspensions with HPC/SDS (F1‒F3), (c) 
ITZ precursor suspensions with Mannitol (F6), Sucrose (F9), and wo/w extra HPC 
(F1/F10), (d) co-milled ITZ‒SSG precursor suspensions (F11 and F12) and ITZ 
precursor suspensions wo/w extra HPC (F1/F17), (e) co-milled ITZ‒CP precursor 
suspensions (F13 and F14) and ITZ precursor suspensions wo/w extra HPC (F1/F17), 
and (f) co-milled ITZ‒CCS precursor suspensions (F15 and F16) and ITZ precursor 
suspensions wo/w extra HPC (F1/F17). 
 
Drug precursor suspensions stabilized by 2.5% HPC (F1) or 0.2% SDS (F2) 
alone (Fig. 3b) show a high viscosity initially and exhibited strong shear-thinning 
behavior that was prevalent up to 700 1/s for F1 and 1000 1/s for F2. This finding 
accords well with other studies in literature and could be attributed to the higher 
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extent of aggregation breakage (deaggregation) at high shear rate (Barthelmes et al., 
2003; Bernhardt et al., 1999). Presence of aggregates, which can occlude liquid in 
their void space, increases the effective volume fraction of the solid in a suspension 
with fixed solids loading. Hence, in general, an aggregated suspension had a higher 
shear viscosity than an otherwise fully dispersed suspension consisting of discrete 
primary particles. Since the ITZ aggregates broke more extensively at the higher 
shear rates, the apparent shear viscosity decreased with an increase in the shear rate. 
The drug precursor suspension stabilized by HPC‒SDS (F3) had the lowest apparent 
shear viscosity with near Newtonian behavior (Figure 6.3b), which indicates the well-
dispersed nature of the drug suspension and the least amount of aggregates. Overall, 
these findings corroborate the aggregation state assessment based on laser diffraction 
and SEM imaging in Section 6.2.1. 
The apparent shear viscosity profiles of the precursor suspensions with 4% 
Mannitol or Sucrose or 4% extra HPC (6.5% HPC total) (F6, F9, and F10, 
respectively) are presented in Figure 6.3c. All formulations where additional 
dispersants were added have 2.5% HPC as a baseline in the precursor suspensions. 
The addition of even 4% Mannitol or Sucrose (the highest amount of extra 
dispersants added in this study) did not increase the shear viscosity of the precursor 
suspensions. Besides, they all show similar shear-thinning behavior, which indicates a 
significant amount of aggregates in the precursor suspensions. However, when extra 
4% HPC was used (6.5% HPC in total), the suspension exhibited higher shear 
viscosity and near Newtonian behavior. The near Newtonian behavior indicates the 
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well-dispersed discrete primary particles (i.e., good physical stability) in F10 
precursor suspension. 
Unlike the addition of Mannitol or Sucrose, co-milling 1% SSG (Figure 6.3d) 
or 1% CCS along with ITZ (Figure 6.3f) significantly raised the viscosity of the drug 
precursor suspensions because of the removal of free water in the suspension via 
absorption by highly swellable superdisintegrants. On the other hand, co-milling 1% 
CP (Figure 6.3e) did not seem to raise the shear viscosity as significantly, which is 
due to the low swelling capacity of CP (i.e., 5.4 cm
3
/g) as compared to 23.6 cm
3
/g for 
SSG and 13.5 cm
3
/g for CCS. The increase in superdisintegrant concentration led to 
the higher shear viscosity of the precursor suspensions. Moreover, all precursor 
suspensions with co-milled superdisintegrants exhibited shear-thinning behavior, 
which again indicates the existence of aggregates. When extra 2% HPC was added to 
the precursor suspension (4.5% HPC in total), the suspension shows very slight shear-
thinning initially followed by Newtonian behavior, which indicates slightly 
aggregated suspension. In sum, the viscosity measurements (Figure 6.3) 
independently confirmed the aggregation state of the milled ITZ suspensions, 
agreeing well with the laser diffraction data (see Figure 6.1).  
 
6.2.3  Crystallinity of the Drug Nanoparticles 
The crystalline state of the ITZ particles in the precursor suspensions (after milling) 
was investigated via the XRPD and DSC on the pure ITZ, physical mixtures 
corresponding to F12 and F17 formulations, and overnight-dried ITZ precursor 
suspensions of F2, F12, and F17 after rinsing‒centrifugation. ITZ showed distinct 
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crystalline peaks in the precursor suspensions as compared to as-received ITZ and its 
physical mixtures in XRPD diffractograms (Figure 6.4a). The peak positions for the 
precursor suspensions remained the same but with lower peak intensity, which could 
be attributed to defect formation and accumulation during milling (Azad et al., 2015b; 
Monteiro et al., 2013) and slight loss of crystallinity (Cerdeira et al., 2013b). Besides, 
the ITZ precursor suspensions also showed a more peak broadening compared to the 
physical mixture and the as-received ITZ, which might be due to the smaller drug 
particle sizes or stress and strain caused by the milling process (Bernard et al., 2008). 
Similar observation also reported by Van Eerdenbrugh et al. (2007) for loviride 
nanoparticles and by Cerdeira et al. (2013b) for ITZ nanoparticles. 
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Figure 6.4  (a) XRPD diffractograms and (b) DSC thermograms of as-received ITZ, 
physical mixtures corresponding to F12 and F17 formulations, and overnight-dried 
ITZ precursor suspensions with 0.2% SDS (F2), 2.5% HPC‒2% co-milled SSG 
(F12), and 4.5% HPC (F17). (Continued) 
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Figure 6.4  (Continued) (a) XRPD diffractograms and (b) DSC thermograms of as-
received ITZ, physical mixtures corresponding to F12 and F17 formulations, and 
overnight-dried ITZ precursor suspensions with 0.2% SDS (F2), 2.5% HPC‒2% co-
milled SSG (F12), and 4.5% HPC (F17).  
 
DSC thermograms of the physical mixtures and the precursor suspensions 
exhibited a notable endothermic event associated with the melting of crystalline ITZ 
(Figure 6.4b). The melting temperature of both as-received pure ITZ and its physical 
mixtures was detected at 168.4 ± 0.2 ˚C. A slight reduction of the peak melting 
temperature (Tm) in the precursor suspensions was observed (i.e., 5.5˚C and 5.0 ˚C for 
F12 and F17, respectively). Besides, there is a slight ΔHm reduction with the 
precursor suspension comparing with its corresponding physical mixture (i.e., 12.6% 
and 8.1% for F12 and F17, respectively). The observed melting point reduction and 
peak reduction may due to the aforementioned defect formation‒accumulation during 
milling‒drying as well as the more efficient heat transfer during the DSC analysis for 
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the ITZ nanoparticles in comparison to that for the physical mixtures (Bonda et al., 
2016; Liu et al., 2011; Shah et al., 2016). Besides, according to Gibbs‒Thomson 
equation (Wu and Nancollas, 1998), the melting temperature of a material is 
proportional to its cohesive energy, which indicates that nanoparticles with reduced 
cohesive energy require less energy for melting, thus, resulting in a reduction of 
melting temperature and heat of fusion as compared to as-received drug 
microparticles. Based on the XRPD and DSC results, it can be concluded that wet 
media milling may have brought minor amorphous/defect formation in ITZ, but the 
crystallinity nature of ITZ was largely preserved. 
 
6.2.4  Characterization of the Drug Nanocomposites 
The precursor suspensions were spray dried into nanocomposite powders. Throughout 
the dissertation, all nanocomposites are labeled based on the formulation of the 
respective drug precursor suspension that was used as the feed during drying. The 
theoretical and actual drug contents of the nanocomposites are presented in Table 6.1. 
Table 6.1 presents that high drug-loaded nanocomposites (~55–80%) were prepared 
by spray drying process. Most nanocomposite powders had RSDs less than 6%, 
suggesting pharmaceutically acceptable content uniformity. The slight variations of 
actual drug content from the theoretical one may be attributable to preferential drug 
loss to the spray drying chamber, poor separation of finer particles in the cyclone of 
the spray drier, and the potential presence of residual moisture in the nanocomposite 
(Azad et al., 2015b). The mean moisture contents of selected nanocomposite 
powders, i.e., F1 and F12, were determined by weight loss via TGA. F1 and F12 
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nanocomposite powders had a residual moisture content of 2.6 ± 0.3% and 2.8 ± 
0.4%, respectively, which demonstrates that most water in the drug precursor 
suspensions was removed during the spray drying process. Table 6.3 presents the 
particle sizes of the nanocomposites. For each dispersant class, an increase in the 
dispersant concentration led to slightly larger nanocomposites due to an increase in 
solids loading and viscosity. In general, spray drying produced small spherical and 
dimpled nanocomposite with drug nanoparticles embedded in the dispersant matrix 
(Figure 6.5). All formulations, except F2, contain HPC as a film–matrix former, 
which enables coverage and encapsulation of the drug nanoparticles. Note the 
irregular shapes of F2 nanocomposites (Figure 6.5b) and their smallest sizes among 
all nanocomposites indicate the criticality of HPC as a baseline dispersant. 
It is likely that some large superdisintegrant particles may not be embedded 
into the nanocomposite particles. SSG, CP, and CCS were milled separately in the 
presence of 2.5% HPC for proper stabilization without drug (Azad et al., 2014b). 
After 15 min short milling (including 12 min addition of superdisintegrants to the 
mill), the produced d50 and d90 of SSG, CP, and CCS are 30.7 µm and 72.1 µm; 7.3 
µm and 19.6 µm; and 39.3 µm and 91.2 µm, respectively, as measured by laser 
diffraction. Thus, the dried particle sizes of milled superdisintegrant particles were 
calculated based on their swelling ratio (refer to Section 6.1.1). The dried-milled d50 
and d90 of SSG, CP, and CCS are estimated 7.7 µm and 17.2 µm; 5.3 µm and 14.6 
µm; and 10.4 µm and 23.6 µm, respectively. Based on the study, there is also a 
possibility that drug nanoparticles were coated on the superdisintegrant particles and 
some superdisintegrant particles may be spray dried alone.  
  
 
Table 6.3  Particle Size Distributions of the Nanocomposites Produced by Spray Drying 
Formula 
ID 
HPC SDS 
Other 
Dispersants 
Particle Sizes of the Nanocomposites 
(% w/w)
a
 (% w/w)
a
 (% w/w)
a
 d10 (µm) SD (µm) d50 (µm) SD (µm) d90 (µm) SD (µm) 
F1 2.5 0 – 6.56 0.06 16.44 0.08 33.76 0.33 
F2 0 0.2 – 1.97 0.15 8.43 1.18 18.74 1.80 
F3 2.5 0.2 – 4.26 0.39 11.33 0.26 21.21 0.33 
F4 2.5 0 1 (Mannitol)
b
 2.73 0.02 9.95 0.23 25.56 8.09 
F5 2.5 0 2 (Mannitol)
b
 4.38 0.19 12.17 0.04 24.99 0.19 
F6 2.5 0 4 (Mannitol)
b
 5.13 0.58 14.00 0.30 29.72 0.42 
F7 2.5 0 1 (Sucrose)
b
 5.15 0.06 14.25 0.04 31.60 0.02 
F8 2.5 0 2 (Sucrose)
b
 5.23 0.06 14.73 0.02 32.90 0.06 
F9 2.5 0 4 (Sucrose)
b
 8.36 0.70 18.80 0.76 38.27 0.87 
F10 6.5 0 – 7.56 0.24 20.53 0.38 48.45 1.27 
F11 2.5 0 1 (SSG)
c
 7.97 0.08 16.30 0.13 31.75 0.62 
F12 2.5 0 2 (SSG)
c
 9.90 0.13 19.67 0.13 36.63 0.10 
F13 2.5 0 1 (CP)
c
 2.76 0.04 10.70 0.18 24.68 0.29 
F14 2.5 0 2 (CP)
c
 5.80 0.17 15.51 0.17 33.66 0.41 
F15 2.5 0 1 (CCS)
c
 6.67 0.03 13.73 0.18 25.93 1.21 
F16 2.5 0 2 (CCS)
c
 9.43 0.35 20.36 0.23 40.03 0.33 
F17 4.5 0 – 7.11 0.20 19.94 0.07 44.05 0.39 
a
Drug loading in all suspensions is 10%. % w/w is with respect to the weight of deionized water, 200 g.  
b
Added to the suspension after milling. 
c
Co-milled along with ITZ for 15 min. 
 
1
9
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Figure 6.5  SEM images of the nanocomposites produced by spray drying of the ITZ 
precursor suspensions with: (a) 2.5% HPC (F1), (b) 0.2% SDS (F2), (c) 2.5% 
HPC‒0.2% SDS (F3), (d) 2.5% HPC‒2% Mannitol (F5), (e) 2.5% HPC‒2% Sucrose 
(F8), (f) 2.5% HPC‒2% co-milled SSG (F12), (g) 2.5% HPC‒2% co-milled CP 
(F14), and (h) 2.5% HPC‒2% co-milled CCS (F16).  
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6.2.5  Impact of Dispersants on the Drug Dissolution from Nanocomposites 
The evolution of as-received (unmilled) ITZ and spray-dried nanocomposites was 
measured in 3 g/L SDS solution using a USP II apparatus. As discussed in Sections 
6.2.1 and 6.2.2, both the laser diffraction and rheological characterization results 
presented in Figures 6.1 and 6.3 overall suggest that all drug precursor suspensions 
with 2.5% HPC, even with additional Mannitol/Sucrose/co-milled superdisintegrants, 
exhibited similar extent of aggregation during milling and larger particle sizes (d50: 
~210–260 nm and d90: 400–470 nm, see Figure 6.1b) than the 2.5% HPC–0.2% SDS 
(F3), 6.5% HPC (F10), and 4.5% HPC (F17) suspensions, where aggregation was 
minimized. Hence, unless otherwise indicated below, for most dispersant 
formulations, the main impact of various dispersants on drug release during the 
dissolution is expected to be related to their capability to release drug nanoparticles 
from the nanocomposite particles, and much less related to the different drug particle 
sizes.  
The as-received ITZ particles with d50: 15.5 µm had extremely slow 
dissolution with only 7.3% of ITZ dissolved after 60 min, while the nanocomposites 
with wet-milled ITZ particles led to enhanced drug dissolution rate (Figure 6.6), 
regardless of the dispersants used. For nanocomposites with 2.5% HPC (F1) or 0.2% 
SDS (F2), the ITZ release was improved, i.e., 40.5% for F1 and 48.1% for F2 at 60 
min. However, the dissolution rates from F1 and F2 are still low. Fast, immediate 
release was achieved when HPC and SDS (F3) were used in combination, i.e., 86.6% 
drug release within 5 min. All of these results can be explained by (i) the larger 
surface area of wet-milled ITZ as compared with as-received ITZ, (ii) enhanced 
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wettability of ITZ owing to the presence of dispersants (2.5% HPC–0.2% SDS >> 
2.5% HPC > 0.2% SDS, refer to Table 6.2), which ensures the fast water penetration 
and dissolution-induced erosion/disintegration for F3, as well as (iii) the presence of 
smaller aggregates in precursor suspension of F3 as compared with those of F1 and 
F2 (Figure 6.2a). 
In this study, the author aims to prepare high drug loaded, surfactant-free 
nanocomposites that can achieve fast immediate ITZ release similar to that of the F3 
formulation by using additional soluble dispersants (Mannitol/Sucrose), swellable wet 
co-milled dispersants (SSG/CP/CCS) besides the baseline 2.5% HPC. Figure 6.6a and 
b also shows the impact of 1% dispersant. Upon addition of Mannitol (F4) or Sucrose 
(F7), the slight improvement on dissolutions was observed in Figure 6.6a, i.e., 48.9% 
for F4 and 50.8% for F7 at 60 min, but the dissolution profiles are still statistically 
similar to baseline nanocomposite (F1) according to similarity (f2) and difference (f1) 
factors (Table C3 in Appendix C). On the other hand, when 1% superdisintegrant, 
such as SSG (F11), CCS (F13), and CP (F15), were shortly co-milled with ITZ and 
thus incorporated into the nanocomposites, the dissolution performance of ITZ was 
significantly improved (Figure 6.6b). Quantitatively analysis of the dissolution data 
was carried out by using Korsmeyer‒Peppas model (Korsmeyer et al., 1983). The 
drug release rates of nanocomposites with various dispersants are captured by kn in 
Table 6.4. All R
2
 values are above 0.96, indicating a relatively good fitting by the 
Korsmeyer‒Peppas model. According to Peppas (1985), a higher kn corresponds a 
faster drug release. Hence, superdisintegrants are better dispersants than sugar alcohol 
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or sugar at the same concentration (1%). More interestingly, their desirable impact 
positively correlated with their swelling capacity (SSG > CCS > CP).  
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Figure 6.6  Evolution of ITZ dissolution from the nanocomposites prepared by spray 
drying of the ITZ precursor suspensions with 2.5% HPC‒1% (a) Mannitol (F4), 
Sucrose (F7) and (b) co-milled SSG (F11), CP (F13), and CCS (F15). The figure 
includes dissolution performance of as-received ITZ and nanocomposite formulations 
with HPC/SDS (F1‒F3) for comparison. 
 
In general, the additional dispersants besides baseline 2.5%  HPC led to a 
transition from diffusion controlled release to anomalous transport (Table 6.4). The 
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exceptions were F5 and F13. Conventional soluble dispersants such as HPC, 
Mannitol, and Sucrose, allows for drug release from the nanocomposite matrices via 
erosion/disintegration, which is initiated by their dissolution (Krull et al., 2016). On 
the other hand, the incorporation of shortly co-milled superdisintegrants along with 
soluble HPC facilitated erosion/disintegration of the nanocomposite matrix via both 
dissolution of HPC and swelling-induced degradation (Azad et al., 2015b; Bhakay et 
al., 2014b). The swellable superdisintegrant particles embedded in the 
nanocomposites tend to expand upon exposure to dissolution medium, but due to 
volumetric constraint within the matrix, mechanical stresses develop, facilitating the 
matrix erosion/disintegration. Apparently, simultaneous action of both mechanisms 
appears to be additive and more effective.  
 
6.2.6  Impact of Higher Dispersant Concentration at 2% and 4% Levels 
While dispersants at 1% level, besides 2.5% HPC, was shown to improve the ITZ 
release without SDS, even for the best performing superdisintegrant (1% SSG), the 
dissolution was still slower than/statistically different from 2.5% HPC‒0.2% SDS 
nanocomposite, suggesting a need to increase the dispersant concentration. Hence, 
nanocomposites were also prepared by spray-drying 2.5% HPC and 2% dispersants. 
Generally, higher dispersant concentration improved the drug release rate for all 
dispersants as dissolution profiles were compared (Figure 6.7a vs. Figure 6.6), which 
also corresponded to a higher kn (Table 6.4). Again, the co-milled superdisintegrants 
are all superior to Mannitol/Sucrose with the same trend (release rates: SSG > CCS > 
CP). Furthermore, similarity and difference test (f1–f2 test) was conducted to 
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statistically compare the dissolution performance of ITZ‒HPC‒SDS (F3) and 
ITZ‒HPC‒SSG (F12). Their dissolution profiles are statistically similar to each other: 
f1 = 7.2 < 15 and f2 = 62.3 > 50 (Table C4 in Appendix C).  
At 2% level, Mannitol/Sucrose in F5/F7 nanocomposites was not sufficient to 
improve the dissolution performance of ITZ to the extent that the F3 nanocomposite 
achieved. Thus, 4% Mannitol/Sucrose (F6/F9) was used as dispersants besides 2.5% 
HPC. These dispersants at 4% led to faster ITZ release from the nanocomposites 
(F6/F9) than at 2% level (F5/F7). Only when  Mannitol/Sucrose (F5/F7) were used at 
4% level, the dissolution profiles show a statistical difference from ITZ‒HPC (F3) 
(Table C3 in Appendix C), but F5 and F7 still led to inferior performance as compared 
to F3 nanocomposites HPC‒SDS (Figure 6.7b). While the use of higher than 4% 
Mannitol/Sucrose loading could further enhance the drug dissolution rate, this 
approach was not adopted here as it would cause a nanocomposite with much less 
than 50% drug loading. 
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Figure 6.7  Evolution of ITZ dissolution from the nanocomposites prepared by spray 
drying of the ITZ precursor suspensions with (a) 2.5% HPC‒2% Mannitol (F5), 
Sucrose (F8), co-milled SSG (F12), co-milled CP (F14), co-milled CCS (F16), and 
extra HPC (F17) and (b) 2.5% HPC‒4% Mannitol (F6), Sucrose (F9), and extra HPC 
(F10). The figures also include dissolution performance of nanocomposite 
formulations with HPC/SDS (F1 and F3) for comparison. 
 
  
 
Table 6.4  Statistical Analysis of the Fitting of the Drug Dissolution Profiles via Korsmeyer‒Peppas Model 
Formula 
ID 
HPC SDS Other Additives Korsmeyer‒Peppas Modeld kn 
(%min
-
n
) 
(% w/w)
a
 (% w/w)
a
 (% w/w)
a
 n
d
 
(-) 
k 
(%min
-n
) 
R
2
 
F1 2.5 0 – 0.360 9.155 0.998 3.30 
F2 0 0.2 – 0.468 7.667 0.963 3.59 
F3 2.5 0.2 – 0.998 34.95 1.000 34.86 
F4 2.5 0 1 (Mannitol)
b
 0.484 6.795 0.995 3.29 
F5 2.5 0 2 (Mannitol)
b
 0.414 12.33 0.985 5.10 
F6 2.5 0 4 (Mannitol)
b
 0.516 26.45 0.989 13.64 
F7 2.5 0 1 (Sucrose)
 b
 0.498 6.682 0.997 3.33 
F8 2.5 0 2 (Sucrose)
 b
 0.498 7.070 0.995 3.52 
F9 2.5 0 4 (Sucrose)
 b
 0.462 23.69 0.978 10.95 
F10 6.5 0 – 0.721 20.46 0.997 14.74 
F11 2.5 0 1 (SSG)
c
 0.674 21.73 0.979 14.65 
F12 2.5 0 2 (SSG)
c
 0.709 31.73 1.000 22.50 
F13 2.5 0 1 (CP)
c
 0.296 17.17 0.979 5.08 
F14 2.5 0 2 (CP)
c
 0.509 21.28 0.986 10.84 
F15 2.5 0 1 (CCS)
c
 0.474 23.21 0.993 11.00 
F16 2.5 0 2 (CCS)
c
 0.646 22.36 0.985 14.45 
F17 4.5 0 – 0.776 36.40 1.000 28.26 
a
Drug loading in all suspensions is 10%. % w/w is with respect to the weight of deionized water, 200 g.  
b
Added to the suspension after milling. 
c
Co-milled along with ITZ for 15 min. 
d
n ≈ 0.43 indicates diffusion-controlled release, 0.43 < n < 0.85 indicates anomalous transport, while n ≈ 0.85 indicates erosion-controlled release (Ritger and 
Peppas, 1987).  
 
2
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6.2.7  Additional Insight into the Dispersants 
Finally, the author would like to examine the impact of higher HPC concentration, 
i.e., 6.5% (F10) and 4.5% (F17) as opposed to the use of additional dispersants such 
as Mannitol/Sucrose or superdisintegrants. Comparing the drug release rates of the 
nanocomposites at the same total dispersant level allows us to assess the relative 
impact of the dispersants. The dissolution performance of the nanocomposite with 
4.5% HPC (F17) was compared to those with 2.5% HPC‒2% additional dispersant 
(F5, F8, F12, F14, and F16) (see Figure 6.7a). Note that different from the addition of 
Mannitol/Sucrose to the milled ITZ suspension, additional 2% HPC (4.5% HPC total) 
was performed during the preparation of presuspension before milling. As mentioned 
in Section 6.2.1, higher HPC concentration (4.5% vs. 2.5%) led to smaller drug 
nanoparticle aggregates in the precursor suspension (F17 vs. F1, F5, F8, F12, F14, 
and F16). Hence, F17 nanocomposite embedded smaller drug nanoparticles than F1, 
F5, F8, F12, F14, F16 nanocomposites (see Figure 6.2a and Tables C1 and C2 in 
Appendix C). F17 nanocomposite (4.5% HPC) released ITZ similar to F12 
nanocomposite (2.5% HPC‒2% SSG combination), according to f1–f2 statistics (Table 
C5 in Appendix C), and both released ITZ faster than the nanocomposites with 2.5% 
HPC‒2% Mannitol/Sucrose combination, with a 4.5% total dispersant concentration. 
Since the presence of extra HPC reduced ITZ drug nanoparticle aggregation in the 
precursor suspension (Figure 6.1), upon the erosion of F17 nanocomposite matrix, 
more discrete drug nanoparticles were released and dissolved in dissolution media as 
compared with the nanocomposites with HPC‒Mannitol/Sucrose. 
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Since Mannitol/Sucrose has been used at a higher concentration for the 
effective dissolution improvement, 6.5% HPC (F10) was compared to 2.5% HPC‒4% 
Mannitol/Sucrose (F6 and F9). Having more HPC than F17 precursor suspension 
(4.5%), F10 precursor suspension (6.5% HPC) exhibited the least aggregation and 
smallest particle sizes in the absence of SDS. The resultant F10 nanocomposite 
released ITZ faster than F6/F9 nanocomposite with HPC‒Mannitol/Sucrose at the 
same total dispersant concentration. Hence, better dissolution improvement imparted 
by HPC vs. Mannitol/Sucrose can be ascribed to (i) the smaller ITZ aggregates and 
the release of discrete fast-dissolving drug nanoparticles when 6.5% HPC alone was 
used and (ii) the significantly enhanced wettability of ITZ (6.5% HPC >> 2.5% 
HPC‒4% Mannitol > 2.5% HPC‒4% Sucrose, refer to Table 6.2), which ensures the 
fast water penetration and dissolution-induced erosion/disintegration for F10. 
Interestingly, a comparison of ITZ release profiles for the nanocomposites with 
higher HPC concentration, i.e., 2.5% (F1), 4.5% (F17), and 6.5% (F10) HPC in the 
respective precursor suspensions in Figure 6.7a and b, one notes an optimum HPC 
concentration leading to the fastest drug release, which is 4.5% HPC. Despite the 
enhanced wetting efficiency with higher HPC concentration (Table 6.2) and smaller 
ITZ nanoparticle aggregates in the respective precursor suspension, 6.5% HPC led to 
slower ITZ 4.5% HPC. This seemingly anomalous behavior could be due to gelling-
induced slow erosion/dissolution of the polymeric matrix, which has been commonly 
observed in the literature (Knieke et al., 2015a; Möckel and Lippold, 1993; Shah and 
Sheth, 1976). Overall, the use of higher HPC concentration can be another strategy 
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for producing fast-dissolving, surfactant-free, high drug-loaded nanocomposite, but 
its concentration should not be increased beyond an optimal level. 
 
6.3  Conclusions 
Nanocomposites of itraconazole (a BCS Class II drug) was prepared by spray-drying 
precursor wet media milled drug suspensions with various classes of dispersants with 
the goal of elucidating their roles in drug nanoparticle stabilization and drug release 
from the nanocomposites during dissolution. The highest dissolution enhancement 
was obtained via 2.5% HPC (soluble polymer)–0.2% SDS (anionic surfactant) 
combination due to enhanced ITZ wettability and presence of smallest drug 
nanoparticles in the precursor suspension. To achieve similar fast, immediate release 
without the surfactant, either wet co-milled superdisintegrants (SSG, CCS, CP)  at 2% 
level must be used along with 2.5% HPC or 4.5% HPC must be used. Wet co-milled 
superdisintegrants are much more effective dispersants than conventional, water-
soluble, low molecular weight dispersants like Mannitol/Sucrose. More importantly, 
the impact of superdisintegrants positively correlated with their swelling capacity 
(SSG>CCS>CP), signifying a swelling-induced erosion/disintegration mechanism for 
fast drug dissolution. The release and dissolution of drug nanoparticles from 
nanocomposites is governed by both the aggregates sizes of the drug and 
erosion/disintegration of the nanocomposite matrix. Dispersants affect and modulate 
the drug release through their impact on both. Erosion/disintegration of the 
nanocomposite is caused by the dissolution of the soluble polymer or sugar/sugar 
alcohol and/or the swelling-induced degradation induced by the wet co-milled 
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superdisintegrants. Overall, this study demonstrates that fast-dissolving, high drug-
loaded, surfactant-free nanocomposites could be prepared with either HPC‒co-milled 
superdisintegrant or optimal HPC concentration via spray drying. 
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CHAPTER 7 
A COMPARATIVE ASSESSMENT OF NANOCOMPOSITES VS. 
AMORPHOUS SOLID DISPERSIONS PREPARED VIA NANOEXTRUSION 
FOR DRUG DISSOLUTION ENHANCEMENT 
 
Previous chapters have demonstrated the impact of producing nanocrystals with large 
surface area on the dissolution enhancement of poorly water-soluble drugs. However, 
compared to amorphous form of the drug, the achieved increase in dissolution rate via 
nanoparticle-based formulations is limited and insufficient to provide significant 
enhancement of bioavailability for drugs with very low aqueous solubility. 
Interestingly, there is no head-to-head comparison established in literature to assess 
the dissolution enhancement of these drugs in both nanoparticles-based formulations 
as well as amorphous solid dispersions. In Chapter 7, the author proposes to use the 
nanoextrusion process as a platform enabling comparative assessment of 
nanocomposites vs. ASDs for drug dissolution enhancement. By using different 
polymers, the same nanoextrusion process can produce extrudates with crystalline 
and amorphous forms of the same drug, i.e., micro/nanocrystalline drug dispersed in 
the polymeric matrix (micro/nanocomposites) and amorphous drug molecularly 
dispersed within the polymer (ASD), respectively. To this end, hydroxypropyl 
cellulose (HPC) and Soluplus® were used to stabilize wet-milled griseofulvin (GF) 
suspensions and form the matrix of the extrudates during nanoextrusion. To assess the 
impact of drug particle size, GF suspensions with different GF particle sizes were 
prepared by wet stirred media milling using HPC and Soluplus® in the 
presence/absence of sodium dodecyl sulfate (SDS), an anionic surfactant. These 
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suspensions along with additional polymer (HPC/Soluplus®) were fed to a co-
rotating twin-screw extruder, which dried the suspensions and formed various 
extrudates. The extrudates were milled into powders via mortar–pestle and sieved for 
further analysis. As a comparison to nanoextrusion, nanocomposite particles were 
also prepared via spray drying of the GF nanosuspension. The suspensions were 
characterized via laser diffraction, while the extrudates and their milled powders were 
characterized by laser diffraction, BET nitrogen adsorption, SEM, and XRD. Digital 
microscopy was used to visualize the changes of different polymeric matrices when 
exposed to water. Drug wettability enhancement by HPC and Soluplus® solutions 
with SDS was studied using the modified Washburn method. In general, a relatively 
low drug dose, i.e., 8.9 mg, was used to investigate the dissolution response under 
non-supersaturating conditions. To gain additional insight, few experiments used 
extrudate powder samples with excess drug (100 mg dose) to allow for 
supersaturation in the bulk dissolution medium. It is hypothesized that drug 
nanocrystals in the nanocomposites can dissolve faster than the amorphous drug in 
ASDs when the drug dose is so low not to cause supersaturation in the bulk 
dissolution medium (low drug dose), depending on the polymeric matrix. The effects 
of drug particle size in the feed suspensions and polymeric matrix type–size of the 
milled extrudates were also examined. 
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7.1  Materials and Methods 
7.1.1  Materials 
BP/EP grade griseofulvin (GF) was purchased from Letco Medical (Decatur, AL, 
USA). GF is a Biopharmaceutical Classification System (BCS) Class II drug with an 
aqueous solubility of 8.9 mg/L at 25 °C and 14.5 mg/L at 37 °C, melting point of 220 
°C, and a glass transition temperature of 79 °C. Hydroxypropyl cellulose (HPC, SL 
grade, Nisso America Inc., New York, NY) and Soluplus® (BASF, Tarrytown, NY) 
were used as a polymeric stabilizer during wet media milling and polymeric matrix 
former during nanoextrusion and spray-drying processes. HPC is an amorphous 
polymer with two softening points at 68 and 178 °C, and has been commonly used to 
produce nanoparticle-laden nanocomposites of several BCS Class II drugs (Azad et 
al., 2015b; Bhakay et al., 2014a). Soluplus® is an amphiphilic polyvinyl 
caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer. It is amorphous 
with a single glass transition temperature of 73 ± 2 °C and is widely used to prepare 
ASDs of various poorly water-soluble drugs via traditional HME process (Hardung et 
al., 2010; Kyeremateng et al., 2014; Li et al., 2015a). Sodium dodecyl sulfate (SDS, 
GFS Chemicals, Inc., Columbus, OH) was used as an anionic surfactant to enhance 
the drug wettability and stabilize drug particles during milling. Its critical micelle 
concentration (CMC) in water is 0.23 wt.% at ambient temperature. Methanol (ACS 
reagent, ≥ 99.8%), purchased from Fisher Scientific (Suwanee, GA), was used as a 
solvent. Yttrium stabilized zirconia beads (Zirmil Y, Saint Gobain ZirPro, 
Mountainside, NJ, USA) with a median size of 430 µm were used as the milling 
media. 
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7.1.2  Preparation of Suspensions via Wet Media Milling 
Table 7.1 presents the formulations of the GF (drug) suspensions.  Drug concentration 
was kept at 22.4 wt.% in all suspensions. The concentrations reported for suspensions 
are with respect to the total suspension mass. Based on a previous milling study on 
GF (Bilgili and Afolabi, 2012), various GF suspensions were prepared to elucidate 
the potential impact of drug particle size on the dissolution. The F1 suspension had 
as-received, unmilled GF particles in HPC–SDS solution, whereas GF was milled for 
the preparation of F2, F4, and F5 suspensions in the presence of HPC or Soluplus® 
and SDS. SDS was avoided purposefully in F3 suspension in order to prepare a GF 
suspension with aggregated drug nanoparticles. A Microcer wet stirred media mill 
(Netzsch Fine Particle Technology, LLC, Exton, PA, USA) with 80 ml chamber was 
used to mill the drug suspensions. Feed suspensions were milled for 120 min under 
identical conditions to those reported in Bilgili and Afolabi (2012). The particle sizes 
of the suspensions after milling were determined using laser diffraction, and the 
suspensions were refrigerated at 8 °C for one day before nanoextrusion or spray 
drying.  
  
 
Table 7.1  Formulations of the Drug (GF) Suspensions Fed in Nanoextrusion and Spray-Drying Processes and Drug Content in the 
Produced Composites and Amorphous Solid Dispersion (ASD) 
Formula 
ID 
Drug Suspension
 
Composites/ASD Powder
a 
Polymer 
(% w/w)
b
 
SDS 
(% w/w)
b
 
Drug Particle Size 
(µm) 
Drug Content 
(RSD) 
(% w/w)
c
 
Particle (Matrix) Size 
(µm) 
D50, SD D90, SD D50, SD D90, SD 
F1 HPC, 1.9 0.2 15.28, 0.123 37.48, 0.973 22.7 (5.79) 127.9, 6.3 199.1, 13.6 
F2 HPC, 1.9 0.2 0.155, 0.001 0.225, 0.001 23.0 (0.33) 121.8, 2.4 214.3, 11.9 
F3 HPC, 1.9 0 3.763, 0.349 7.488, 1.114 23.7 (4.64) 113.0, 0.5 236.4, 1.2 
F4 
Soluplus®, 
1.9 
0.2 0.154, 0.000 0.205, 0.000 23.4 (5.81) 121.9, 9.0 202.7, 13.1 
F5
d
 HPC, 1.9 0.2 0.154, 0.000 0.220, 0.000 24.1 (5.59) 17.9, 2.6 39.0, 3.5 
a
Additional polymer was added to the drug suspension at 1:1.5 mass ratio during nanoextrusion and prior to spray drying.  
b
w/w with respect to total suspension mass. GF concentration in the suspension was 22.4% w/w for all formulations. 
c
w/w with respect to total composite/ASD mass. 
d
Suspension was spray-dried following the addition of extra HPC to form the nanocomposites.
 
 
2
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7.1.3  Nanoextrusion Process  
Nanoextrusion was performed with a Nano-16 co-rotating twin-screw extruder 
(Leistritz Extrusionstechnik GmbH, Nürnberg, Germany) with a die having a 0.8 mm 
hole. The extruder barrel has three temperature-controlled zones, which are 
individually heated with electric heaters and cooled with water. The temperatures of 
the individual heating zones and the die are shown in Figure 6.1. The screw-speed 
was kept at 50 rpm. Additional HPC and Soluplus®, which were used as polymeric 
matrix formers during nanoextrusion besides acting as stabilizers in wet media 
milling, were fed in feeding section before Zone 1 via an Accurate 102M volumetric 
feeder (Schenck Process, Whitewater, WI) at the rate of 0.8 g/min. Zone 1 with all 
conveying elements served to soften the polymer. Zone 2 had kneading elements with 
60° offset angle and served as a mixing zone. Each drug suspension was fed to Zone 
2, ahead of the kneading elements, by using a peristaltic pump (Masterflex L/S Cole-
Parmer Company, USA) at the constant rate of 1.2 g/min. Kneading elements 
provided intense mixing, which ensured homogeneous dispersion and distribution of 
the suspension within the molten polymeric matrix. After intense mixing via forward 
kneading elements in Zone 2, most of the water in the feed suspension evaporated in 
Zone 3, with conveying elements in place and 150 ºC barrel temperature. The 
extrudates that exit the die at 160 ºC were cooled to room temperature and milled into 
powders with D50 ranging 113–128 m (Table 7.1) with a mortar‒pestle to 
eliminate/minimize the potential confounding effect of matrix size on the dissolution 
rate among different formulations. Besides, a portion of F4 extrudate powder was 
passed through 90 µm sieve with the objective of studying the matrix size effect. 
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These powders will be generally referred to as extrudate powders throughout the 
dissertation, unless otherwise specified as micro/nanocomposites or ASDs, where 
more appropriate. 
 
 
Figure 7.1  Schematic illustration of the extruder setup, including the process 
temperature of the barrel zones, the screw configuration, and the throughput of the 
feeder before barrel 1 and the liquid side-feeding device in barrel 2. 
 
7.1.4  Spray Drying Process 
One nanosuspension (F5) prepared via wet media milling was also dried using a 
spray dryer (4M8-Trix, Procept, Zelzate, Belgium), which is a more common method 
to dry a wet-milled suspension. The spray dryer was run in a co-current flow setup. 
Additional HPC was added to the milled suspension (F5) to ensure that the dried 
nanocomposite powder would have the same drug–polymer concentration as the 
extrudates. The suspensions were atomized and spray-dried under identical conditions 
to those in Azad et al. (2015b). 
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7.1.5  Measurement of Particle Size, External Surface Area, and Specific Total 
Surface Area 
Drug particle sizes in suspensions were measured using laser diffraction (LS 13 320, 
Coulter Beckman, Brea, CA, USA) based on Mie scattering theory following the 
procedure in Bilgili et al. (2016d). The particle sizes of the extrudate powders and the 
spray-dried nanocomposites were measured by a Rodos/Helos laser diffraction 
system (Sympatec, NJ, USA) based on Fraunhofer theory following the procedure in 
Li et al. (2016b). Assuming that the GF particles in the GF suspensions are 
approximately spherical with smooth surfaces, the geometric (external) surface area 
(Sext) of the drug particles was calculated from the particle size distribution data using 
the relationship Sext = 6/D32 (Allen, 2003; Jelinek and sz. Kovats, 1994; Monteiro et 
al., 2013), where D32 is the surface-weighted diameter (Allen, 2003), also known as 
the Sauter mean diameter. 
F1–F4 extrudate powders, spray-dried nanocomposites (F5), sieved F4 
extrudate powder, and cylindrical threads of F2 and F4 extrudates were subjected to 
BET nitrogen adsorption with the objective of determining the specific surface area 
(Sv). The samples were degassed under vacuum at 45 
o
C for 4 h to remove 
atmospheric moisture bound to the particle surface prior to nitrogen adsorption. The 
specific surface area was determined from 11-point nitrogen adsorption isotherm 
using a Nova 3200 BET analyzer (Quantachrome Instruments, Boynton Beach, FL, 
USA). 
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7.1.6  Microscopy 
The presence of the drug particles in extrudate threads was explored via imaging of 
their cross-sections by a LEO 1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA) 
scanning electron microscope (SEM). The extrudates (F1–F4) in thread form were 
quenched in liquid nitrogen and manually broken to generate a relatively smooth 
cross-section. The cross-sections cut were placed on an aluminum stub using carbon 
tape. All samples were then sputter coated with carbon using BAL-TEC MED 020 
(BAL-TEC AG, Balzers, Switzerland) prior to imaging. Multiple images were taken 
to ensure consistent visualization from each sample. 
A VH-Z100 digital microscope (KEYENCE Corp., Osaka, Japan) was used to 
observe the morphological changes of a mortar‒pestle milled extrudate particle with 
different polymeric matrices, when exposed to deionized water. A milled particle 
with selected formulation (F2 and F4) was placed on a glass slide kept under VH-
Z100. A 3 l drop of deionized water was placed on the particle and images were 
captured at different times. Since the extrudate particle could not be fixed on the glass 
slide, more water droplets were not added, which would have allowed for full 
dissolution of the particles. 
 
7.1.7  X-ray Powder Diffraction (XRD) 
Drug dissolution from the nanocomposites/ASD was determined via a Distek 2100C 
dissolution tester (North Brunswick, NJ, USA) according to the USP II paddle 
method. The dissolution medium was 1000 ml deionized water that was maintained at 
37 °C, and a paddle speed of 50 rpm was used for all runs. Deionized water allowed 
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for good discrimination of different formulations under non-sink conditions. The 
nanocomposites/ASD were weighed equivalent to a dose of 8.9 mg of GF. Relatively 
low dose was selected purposefully in this study. The dose number calculated based 
on 8.9 mg GF was 0.36, which is much smaller than the most BCS Class drugs 
(Kasim et al., 2004). The nanocomposites/ASD were poured into the dissolution 
medium and 4 ml samples were taken out manually at 1, 2, 5, 10, 20, 30, and 60 min. 
These aliquots were filtered with a 0.1 µm PVDF membrane type syringe filter before 
UV spectroscopy measurements to minimize any confounding effect of the 
undissolved drug aggregates. The amount of GF dissolved was measured by UV 
spectroscopy at a wavelength of 296 nm. Deionized water was used as the blank. 
 
7.1.8  Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a TGA/DSC1/SF Stare 
system (Mettler Toledo, Inc., Columbus, OH) for the characterization of residual 
water. A 5 mg extruded composite powder (F1 and F2) or as-received HPC was 
placed in a ceramic crucible and heated from 25 °C to 150 °C at a constant rate of 10 
°C/min under nitrogen flow. 
 
7.1.9  Drug Wettability by HPC and Soluplus® Solutions with SDS 
Wettability was studied via liquid penetration into a (drug) powder bed, also known 
as the modified Washburn method (Hołownia et al., 2008; Washburn, 1921), using 
Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA), which measures the 
mass of liquid penetrated into the drug powder bed as a function of time. 
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Experimental details can be found in Appendix D. In this study, liquids and powder 
are deionized water/stabilizer solution (HPC/Soluplus® with SDS) and GF, 
respectively. The apparent shear viscosity and surface tension of the liquids were 
respectively measured using R/S Plus Rheometer (Brookfield Engineering, 
Middleboro, MA, USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, 
USA). The ratio of the cosine of contact angles cosθss/cosθw was calculated using the 
Modified Washburn equation and used as a wetting effectiveness factor. Here, θss is 
the contact angle between GF and the stabilizer solutions and θw is the contact angle 
between GF and deionized water. The ratio quantifies the drug wettability 
enhancement upon use of different stabilizers (polymers–surfactant) in water. 
 
7.1.10  Determination of Drug Content and Drug Release 
Maximum theoretical amount of GF in 100 mg extrudates was estimated to be 24.6 
mg (F3). GF solubility in methanol is 3 mg/ml (Bhakay et al., 2014b). Hence, 100 mg 
of the extrudate powders was dissolved in 20 ml of methanol and sonicated for 30 
min, followed by storage overnight to ensure that all GF had dissolved. An aliquot of 
100 μl was taken from the GF solution and diluted into 10 ml methanol. The 
absorbance of all samples was measured at the wavelength of 292 nm by Ultraviolet 
(UV) spectroscopy in a UV Spectrophotometer (Agilent, Santa Clara, CA, USA), and 
drug concentration was determined based on a pre-established calibration curve. Six 
replicates from each formulation were used to calculate the mean drug content along 
with the percent relative standard deviation (RSD). 
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Unless otherwise stated, all dissolution testing in this study was conducted 
with low drug dose (8.9 mg GF), which did not lead to supersaturation in the bulk 
dissolution medium. Drug release from the composites and ASD samples was 
determined via a Distek 2100C dissolution tester (North Brunswick, NJ, USA) 
according to the USP II paddle method. The dissolution medium was 1000 ml 
deionized water at 37 °C, and a paddle speed of 50 rpm was used. Deionized water 
allows for good discrimination of different GF formulations under non-sink 
conditions (Bhakay et al., 2014a; Li et al., 2016b). The composites and ASD were 
weighed equivalent to a dose of 8.9 mg of GF. This relatively low drug dose, which 
could emulate highly-potent drugs, was purposely selected in this study to ensure 
non-supersaturating conditions in the dissolution medium as the GF solubility in 
water at 37 
o
C is 14.5 mg/L. The composites/ASD powders were poured into the 
dissolution medium and 4 ml samples were taken out manually at 1, 2, 5, 10, 20, 30, 
and 60 min. These aliquots were filtered with a 0.1 µm PVDF membrane-type syringe 
filter before UV spectroscopy measurements to minimize any confounding effect of 
the undissolved coarse drug aggregates. The amount of GF dissolved was measured 
by UV spectroscopy at a wavelength of 296 nm and determined based on a pre-
established calibration curve. Deionized water was used as the blank. 
To describe the drug release kinetics from different polymeric matrices, fitting 
of GF dissolution data to Korsmeyer‒Peppas model (Ritger and Peppas, 1987a, b), as 
shown in Eq. (7.1), was performed using SigmaPlot’s (Version 11) regression wizard.  
 (7.1) 
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where k is a constant incorporating structural and geometric characteristics of the 
drug dosage form, n is the release exponent, indicative of the drug release 
mechanism, and is fractional release of drug. An apparent release mechanism was 
suggested in this dissertation based on the fitted n value and the specific geometry of 
the samples in view of various assumptions behind Eq. (7.1) (refer to Ritger and 
Peppas (1987b)). Fitting of  included data up to and including one point after 
attainment of  value of 0.85.  
To gain further insight into the dissolution mechanisms, additional dissolution 
experiments were conducted with excess drug (100 mg dose), which allowed for 
supersaturation in the bulk dissolution medium. In these experiments, as-received GF 
powder, F2 extrudate (nanocomposite powder), and F4 extrudate (ASD powder) were 
used in excess, with an equivalent dose of 100 mg GF under the same dissolution 
conditions, as described above. Dissolution testing was conducted for duration of 120 
min with additional sampling at 90 and 120 min. The filtered samples were diluted 
with 37 
o
C deionized water at a ratio of 1 to 7 before UV spectroscopy measurement. 
 
7.2  Results and Discussion 
7.2.1  Wet Stirred Media Milling of Drug Suspensions 
Table 6.1 presents the formulations of drug (GF) suspensions and their particle sizes 
as measured by laser diffraction. Several suspensions with different GF sizes were 
prepared to affect the drug dissolution rate from dried extrudates. F1–F3 and F5 
suspensions have the same polymer (HPC) and surfactant (SDS) with identical 
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concentrations. F1 has as-received unmilled GF microparticles (D50 = 15.3 m) in the 
suspension, whereas F2 and F5 have stabilized GF nanoparticles (D50 = 155 nm) 
obtained by wet media milling. HPC–SDS combination is known to stabilize GF 
nanosuspensions due to synergistic stabilizing action (Bilgili and Afolabi, 2012), 
which has been shown to work for multiple BCS Class II drugs (Bilgili et al., 2016d). 
HPC was also used as the sole stabilizer (F3), which lead to aggregated GF 
nanoparticles in the milled suspension (D50 = 3.76 m). Although primary GF 
nanoparticles can be produced upon wet media milling, as shown by previous work 
(Bilgili and Afolabi, 2012; Bilgili et al., 2016d), without sufficient amount of 
polymeric stabilizers or addition of SDS, the GF nanoparticles aggregated 
significantly due to high attractive inter-particle forces (van der Waals, hydrophobic 
forces, etc.). Essentially, for F3 suspension, laser diffraction measured the size 
distribution of soft aggregates, i.e., loose clusters of nanoparticles held together by the 
attractive forces. Soluplus®–SDS combination was used as stabilizers in F4, where a 
different polymeric stabilizer/matrix was investigated as a comparison to F2. The 
sizes of the milled drug particles produced by F4 were very close to those produced 
by F2 and F5 with HPC–SDS as stabilizers. Similarity of the particle sizes in F2 and 
F5 suspensions with identical formulations and processing variables signifies 
reproducibility of the wet media milling process as the deviations were less than 2%. 
All suspensions were stored in a refrigerator at 8 ºC for one day before drying. 
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7.2.2  Preparation and Characterization of Composites and Amorphous Solid 
Dispersion 
The nanoextrusion process used drug suspensions mentioned above and additional 
extrusion polymer as two separate feeds and continuously produced extrudates that 
contain the drug. The mean moisture content of as-received HPC and selected 
extrudates, i.e., F1 and F2 formulations, was determined by weight loss via TGA. As-
received HPC had moisture content of 2.35% and final extruded composites had a 
residual moisture content of 2.48 ± 0.18%, which demonstrates that most water in the 
drug suspensions was removed during the nanoextrusion process.  
It is hypothesized that depending on the polymer chosen and polymer‒drug 
miscibility (Qian et al., 2010; Thakral and Thakral, 2013), extrudates could be either 
in the form of ASD with amorphous form of the drug molecularly dispersed in the 
polymeric matrix or drug micro/nanocomposites embedding crystalline drug particles 
in the polymeric matrix, respectively. SEM images of the cross-section of various 
extrudates are presented in Figure 7.2 GF microparticles in the range of 2‒16 µm 
were embedded in the HPC matrix of F1 extrudate (Figure 7.2a and b). GF 
nanoparticles in the size range of 50‒400 nm were well-dispersed in the HPC matrix 
of F2 extrudate (Figure 7.2c and d). These observations accord well with the sizes of 
the drug particles in the feed suspensions, as measured by laser diffraction (refer to 
Table 7.1). Some aggregates of the drug nanoparticles were observed in the cross-
section of F3 extrudate (Figure 7.2e). SEM images overall show that F1, F2, and F3 
extrudates had drug particles dispersed throughout the HPC matrix; hence, these 
extrudates can be referred to as microcomposites (extrudate with drug microparticles 
embedded) (Figure 7.2a and b), nanocomposites (extrudate with drug nanoparticles 
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embedded) (Figure 7.2c and d), and nanocomposite with aggregated GF (extrudate 
with aggregated drug nanoparticles embedded) (Figure 7.2e), respectively. To 
confirm the crystalline state of the drug in the composites, F2 was selected for XRD 
analysis together with as-received GF microparticles, F1-physical mixture, and HPC 
(Figure 7.3). Theoretically, F1 and F2 had identical formulations with different drug 
particle sizes in the feed suspensions. As-received GF microparticles exhibited 
intense characteristic crystalline peaks (Figure 7.3), whereas the physical mixture of 
the as-received GF particles (F1 physical mixture) exhibited similar characteristic 
peaks with significantly reduced intensity, which is clearly attributable to dilution and 
surface coverage of the GF particles by HPC. Considering that F2 extrudate shows 
almost identical XRD diffractogram to that of the physical mixture, the author 
concludes that the GF nanoparticles in the HPC matrix (F2 extrudate) were largely 
crystalline. Besides the dilution effect of the polymer, reduction of drug particle size 
during milling could have resulted in some XRD peak broadening (Deng et al., 2008).  
Besides HPC, Soluplus® was used to produce extrudates (F4), for which 
Soluplus® was already used as steric stabilizer in combination with SDS producing 
well-stabilized feed nanosuspension (Table 7.1). No particle was observed in the 
cross-section in SEM images of F4 extrudate (Figure 7.2f). On comparing F4 
diffractogram with those of as-received GF microparticles and Soluplus®, no GF 
characteristic peak appeared for F4 (Figure 7.3). GF was molecularly dispersed 
within the Soluplus® matrix, forming a single-phase amorphous mixture also known 
as ASD. Similar observation was reported by Hardung et al. (2010) for 
GF‒Soluplus® obtained via traditional HME. Good miscibility between the drug and 
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the polymeric matrix is the fundamental requirement for the formation of ASD 
(Craig, 2002; Marsac et al., 2009). The difference between the drug‒polymer 
solubility parameters is widely used to estimate their miscibility. Namely, if the 
difference is < 7.0 MPa
1/2
, they are likely to be miscible and form an ASD; if > 10 
MPa
1/2
, they are likely to be immiscible and formation of an ASD is unlikely (Forster 
et al., 2001; Greenhalgh et al., 1999). The solubility parameters of GF, HPC, and 
Soluplus® are 12.2 (Thakral and Thakral, 2013), 24.0 (Choi et al., 1994), and 19.4 
(Kolter et al., 2012) MPa
1/2
, respectively. The solubility parameter differences 
between GF‒HPC and GF‒Soluplus® are calculated to be 11.8 and 7.2, respectively. 
Hence, the lower solubility parameter difference close to 7 could explain the 
formation of ASD when Soluplus® was used as the extrusion polymer as opposed to 
HPC.  
 
  
 
Figure 7.2 SEM images of the cross-sections of various extrudate threads: (a) and (b) 
F1 (microcomposite), (c) and (d) F2 (nanocomposite), (e) F3 (nanocomposite with 
aggregated GF), and (f) F4 (ASD). (Continued) 
 
 
(a) (b) 
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Figure 7.2 (Continued) SEM images of the cross-sections of various extrudate 
threads: (a) and (b) F1 (microcomposite), (c) and (d) F2 (nanocomposite), (e) F3 
(nanocomposite with aggregated GF), and (f) F4 (ASD). 
 
One milled suspension (F5) was also spray-dried to produce drug 
nanocomposites, in comparison to nanoextrusion (F2). F5 had the same formulation 
as F2, where HPC and SDS were used as the stabilizers in the milled suspension. 
Extra HPC, as a matrix former, was added to the milled GF suspension prior to spray 
drying. Spray-drying produced smaller nanocomposite particles than the 
nanoextrusion process (see F5 vs. mortar‒pestle processed F1–F4 extrudate powders 
in Table 7.1). XRD results confirm that F5 powder had crystalline GF dispersed in the 
HPC matrix (Figure 7.3). Since GF was largely present as nanoparticles in the HPC–
SDS solution (F5)/melt (F2) and GF–HPC miscibility is poor, drug nanocomposites 
(F5 and F2), with nanocrystals dispersed in the HPC matrix, were formed regardless 
of the drying method used.  
(c) (d) 
(e) (f) 
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Figure 7.3  XRD diffractograms of as-received GF microparticles, HPC, Soluplus®, 
F1-physical mixture, F2 extrudate (nanocomposite powder), F4 extrudate (ASD 
powder), and F5 spray-dried nanocomposite powder. 
 
The mean drug content was in the range of 22.7‒24.1% (Table 7.1) with F2 
showing the lowest RSD. Having the same formulation during milling and drying 
process, the F2 extruded nanocomposite had extremely low RSD, i.e., 0.33%, 
compared to the spray-dried nanocomposites (F5), which signifies the advantage of 
nanoextrusion process in preparing uniformly distributed and reproducible solid 
dosage forms. This finding is in line with a recent study which investigated the 
content uniformity of a low-dose drug using the nanoextrusion process (Park et al., 
2013). Note that the nanoparticles in the feed suspension (F2) were well-stabilized 
and the extent of aggregates was extremely low. The F1 extrudate (microcomposite) 
and the F3 extrudate (nanocomposite with aggregated GF) had higher RSD than the 
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F2 extrudate (nanocomposite), which may be explained by the presence of larger drug 
particles, i.e., unmilled drug microparticles in F1 and nanoparticle aggregates of 
several microns in F3. Slightly higher RSD in drug content was also observed for F4 
(ASD) and F5 (spray-dried nanocomposites).  
 
7.2.3  Dissolution Performance of Composites and Amorphous Solid Dispersion 
The evolution of GF dissolution was measured in de-ionized water using a USP II 
apparatus and presented in Figure 6.4. Milling of the extrudates via mortar‒pestle 
allowed for preparing F1–F4 extrudate powder samples with similar sizes: D50 ranged 
113–128 m (Table 7.1). The specific surface areas for F1–F4 extrudate powders 
were found to be identical (0.31 m
2
/g), as measured by BET nitrogen adsorption. The 
drug nanoparticles and microparticles (F1–F3) were covered and encapsulated by the 
polymer (HPC) well and their surface areas did not contribute to the specific surface 
area of the extrudate powders, resulting in F1–F3 surface areas identical to that of the 
F4 extrudate powder without drug particles (ASD). This finding suggests that the 
impact of polymeric matrix type and drug form/size on the dissolution can be 
investigated, with little to no confounding due to the matrix size (particle size of the 
extrudate) and extrudate surface area.  
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Figure 7.4  Evolution of GF dissolution from as-received GF microparticle powder, 
F1-physical mixture, F1 extrudate (microcomposite powder), F2 extrudate 
(nanocomposite powder), F3 extrudate (nanocomposite powder with aggregated GF), 
F4 extrudate (ASD powder), and F5 spray-dried nanocomposite powder in a USP II 
apparatus. Sample size equivalent to 8.9 mg GF dose. 
 
Let us first examine the impact of drug particle size by comparing the 
dissolution performance of as-received GF microparticle powder, F1-physical 
mixture, F1 extrudate (microcomposite powder), F2 extrudate (nanocomposite 
powder), and F3 extrudate (nanocomposite with aggregated GF). The geometric 
(external) surface area (Sext) of the drug particles is inversely proportional to the drug 
particle size, which was obtained from laser diffraction measurement. The respective 
XRD diffractograms in Figure 7.3 proved that GF particles were largely crystalline in 
these samples. A comparison of dissolution profiles of as-received GF and F1-
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physical mixture (Figure 7.4) shows that the GF dissolution was faster in the presence 
of HPC–SDS even without wet media milling‒nanoextrusion. This could be 
explained by the wetting enhancement of the hydrophobic drug (GF) particles in the 
presence of HPC–SDS dissolved in water. The wetting effectiveness factor for HPC–
SDS solution was 127 (see Appendix D for details), which suggests a significant 
enhancement in wettability due to presence of HPC–SDS in water as compared with 
deionized water.   
The dispersion of as-received GF microparticles in the HPC matrix (F1) via 
nanoextrusion process resulted in further improvement of the dissolution (Figure 7.4). 
This suggests that embedment of as-received drug microparticles into HPC matrix, 
even without milling, enhanced the drug dissolution as nanoextrusion achieves 
intimate and uniform mixing/dispersing of GF with HPC, as compared with simple 
blending (physical mixture). However, the dissolution rate was still low, i.e., 37.4% at 
20 min. When drug nanoparticles obtained from wet milling, as opposed to as-
received drug microparticles, were incorporated into HPC matrix during the 
nanoextrusion process (F2 vs. F1), a significant increase in dissolution rate was 
observed and 89.8% GF was released at 20 min. This finding is expected as GF 
nanoparticles with D50 = 155 nm (Sext = 38.46 m
2
/cm
3
) dissolved faster than GF 
microparticles with D50 = 15.28 m (Sext = 0.63 m
2
/cm
3
)
 
owing to larger surface area 
of the former. No significant difference in the dissolution profile was observed 
between F2 and F3, which indicates that aggregates of drug nanoparticles in F3 
suspension with reduced surface area (Sext = 5.31 m
2
/cm
3
)
 
did not seem to affect the 
drug dissolution performance. One possible explanation is that the extra HPC added 
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to the milled nanosuspension during the nanoextrusion could have redispersed some 
of the aggregates in the HPC matrix, thus reducing the sensitivity of the dissolution to 
the presence of drug aggregates. These results overall suggest that presence of drug 
nanoparticles in the composites enhanced the dissolution significantly and that the 
nanoextrusion is capable of continuously producing GF nanocomposites that provide 
immediate release of GF. Moreover, the nanoextrusion allows for proper dispersion 
of GF aggregates, mitigating any potential negative effect on the dissolution. 
A direct comparison of the dissolution performances of the nanocomposites 
(F2) and the ASD (F4) allows us to analyze the impact of the physical state of GF and 
the polymeric matrix. GF was nanocrystalline in F2 extrudate and amorphous in F4 
extrudate although both F2 and F4 extrudates were produced by the same 
nanoextrusion process, but in different polymeric matrices, i.e., HPC and Soluplus®, 
respectively. Note that both extrudates had similar milled particle (matrix) sizes and 
identical surface areas (Sv = 0.31 m
2
/g), which allows a head-to-head comparison. It is 
surprising that amorphous GF in ASD (F4) dissolved much slower than the crystalline 
GF nanoparticles in F2 composite (Figure 7.4). Previous in vivo animal studies and in 
vitro dissolution studies demonstrated that the amorphous form of a drug exhibited 
higher extent of drug dissolution and higher bioavailability than the nanocrystalline 
form of the drug (e.g., as in refs. (Fakes et al., 2009; Zhang et al., 2013; Zheng et al., 
2012)) when a high drug dose was used. In previous investigations on ASDs, a 
relatively high drug dose was used to achieve supersaturation in the dissolution 
medium (Knopp et al., 2016b; Konno et al., 2008; Langham et al., 2012).  However, 
here most dissolution experiments purposefully used a low drug dose (8.9 mg GF), 
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considering that the solubility of GF is 14.5 mg/L at 37 
o
C. Hence, the supersaturation 
in the bulk dissolution medium was not possible in these dissolution experiments. 
Under these non-supersaturating conditions in the bulk dissolution medium, 
nanocomposites allowed for faster GF dissolution than ASD. At this point, the author 
hypothesizes that the slower GF dissolution from ASD resulted from the slower drug 
release from the Soluplus® matrix than the HPC matrix under the non-
supersaturating dissolution conditions investigated here. While drug nanocrystals 
could provide some supersaturation locally (microenvironment around nanocrystals) 
and contribute to enhanced dissolution due to their high curvature, such 
supersaturation would be expected to be very pronounced for drug nanoparticles with 
sizes below 100 nm (Shegokar and Müller, 2010). The relative supersaturation 
capability of the amorphous drug (ASD) vs. nanocrystalline drug present in the 
nanocomposites will be elucidated in Section 7.2.4 via additional dissolution 
experiments by using excess extrudate powder samples with higher drug dose 
(equivalent of 100 mg GF). 
The author also compares the drug dissolution performance from F2 
nanocomposite powder prepared via nanoextrusion followed by mortar‒pestle milling 
to that from F5 nanocomposite powder prepared via spray-drying, which is a 
commonly used drying process to prepare nanocomposites. F2 and F5 have the same 
formulation in their suspensions and dried nanocomposites. Although the spray-dried 
nanocomposites have smaller particles with larger specific surface area (D50 = 17.9 
m, Sv = 0.85 m
2
/g) than the F2 extruded nanocomposites (D50 = 121.8 m, Sv = 0.31 
m
2
/g), both nanocomposites exhibited fast, immediate release similarly. This finding 
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suggests that (1) GF nanoparticles well-distributed in a hydrophilic polymeric (HPC) 
matrix were released in water fast regardless of the drying method and size of the 
polymeric matrix, and (2) nanoextrusion can be used for producing fast-dissolving 
drug nanocomposites continuously, similar to spray drying.  
 
7.2.4  On Dissolution Mechanisms with Different Polymeric Matrices 
The interaction of a milled nanocomposite particle (F2) and ASD particle (F4) with a 
water droplet was visualized using a digital microscope (Figure 7.5). The HPC matrix 
of F2 disappeared upon wetting and subsequent fast dissolution, thus releasing drug 
nanoparticles immediately when exposed to water (Figure 7.5a). Unlike HPC matrix, 
Soluplus® matrix of F4 particle swelled and its larger dimension increased by about 
60% in water while preserving the shape without significant erosion or disintegration 
(Figure 7.5b). Although this visualization is qualitative in nature and a water droplet 
was stationary during this experiment unlike voluminous water under stirring during 
the dissolution test, it is clear that HPC and Soluplus® matrices containing GF 
behaved differently in water, which could provide some evidence for the observed 
slower GF dissolution from Soluplus® matrix. To further elucidate the behavior of 
HPC and Soluplus® matrices in water, drug (GF) powder wetting by the respective 
polymer–SDS solutions was investigated. The calculated wetting effectiveness factor 
(i.e., cosθss/cosθw) for HPC–SDS and Soluplus®–SDS were 127 and 20, respectively. 
This finding suggests that while both polymer–SDS combinations enhanced the 
wettability of the hydrophobic drug significantly, a higher hydrophilicity and 
wettability enhancement to GF was provided by HPC–SDS in water than by 
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Soluplus®–SDS in water. The greater wettability enhancement of GF by HPC–SDS 
could be one reason for the fast redispersion and release of drug nanoparticles 
observed in Figure 7.5a and associated immediate drug release in the dissolution 
testing (F2). Similar slower release from Soluplus®-based extrudates, albeit prepared 
by traditional HME process, was observed by Pudlas et al. (2015), where it was 
shown that copovidone-based extrudates released ibuprofen faster than Soluplus®-
based extrudates. This was explained by the higher hydrophilicity and faster 
dissolution of copivodone in water as compared with Soluplus®; the latter aspect was 
clearly observed in their FTIR imaging. In other HME studies (Liu et al., 2012; 
Maniruzzaman et al., 2013; Song et al., 2015), Soluplus®-based extrudates exhibited 
a higher extent of drug release than extrudates with other polymers. These different 
observations in the above studies suggest that the aforementioned polymeric matrix 
effect was drug-specific, which could originate from specific drug–polymer 
interactions and differing wettability improvement of the hydrophobic drugs by 
various polymers (Knopp et al., 2016a; Konno et al., 2008).   
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Figure 7.5  Digital microscope images showing the evolution of polymeric matrix 
erosion of (a) F2 nanocomposite (ground particle) (b) F4 amorphous solid dispersion 
(ASD, ground particle) in 3 µl deionized water. 
  
(a) 
(b) 
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Quantitative analysis of the dissolution data was carried out by using the 
Korsmeyer‒Peppas model (Korsmeyer et al., 1983). As can be seen form Eq. (6.1), it 
relates the drug release to the elapsed time, and release exponent n could be used to 
characterize various release mechanisms (Peppas, 1985). This model is generally used 
to analyze the release of pharmaceutical polymeric dosage forms, when the release 
mechanism is not well-known or when more than one type of release phenomena 
could be involved (Costa and Sousa Lobo, 2001). The n values together with R
2 
values obtained for F2 and F4 are listed in Table 6.2. Both R
2 
values are above 0.96, 
indicating a relatively good fitting by the Korsmeyer‒Peppas model (Korsmeyer et 
al., 1983). The n values for F2 and F4 milled extrudate powders appear to suggest 
that drug nanocomposite with HPC as the matrix (F2) exhibits diffusion-controlled 
release (n  0.43) (Ritger and Peppas, 1987a), whereas Soluplus® matrix (F4) 
exhibits anomalous transport (0.43 < n < 0.85) (Ritger and Peppas, 1987a), for which 
swelling was observed under microscope in Figure 7.5b, and erosion might also have 
played a role.  
 
Table 7.2  Statistical Analysis of the Fitting of the Drug Dissolution Profiles via 
Korsmeyer‒Peppas Model 
Formulation, Matrix 
State of 
Extrudates 
Crystallinity of 
GF 
n R
2
 
F2, HPC 
Milled powders 
Crystalline 0.42 0.963 
F4, Soluplus® Amorphous 0.58 0.969 
F2, HPC 
Cylindrical thread 
Crystalline 0.72 0.981 
F4, Soluplus® Amorphous 0.84 0.999 
 
Another possible reason for the slower drug release from ASD (F4) may be 
due to the recrystallization of amorphous GF. It is known that amorphous drugs can 
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crystallize during dissolution, as they become hydrated and when they generate 
supersaturated solution (Alonzo et al., 2010; Hancock and Parks, 2000). Since a low 
dose of GF was selected below its crystalline solubility, recrystallization in the bulk 
dissolution medium is not very likely to happen. Moreover, GF was classified as an 
intermediate crystallizer, whose recrystallization tendency from amorphous solids 
could be observed only between 0.25‒1 h upon hydration (Van Eerdenbrugh et al., 
2014) without any polymeric matrix. Due to the presence of up to ~76% Soluplus® in 
the F4 matrix, the recrystallization tendency of GF is expected to be slow or retarded 
(Alonzo et al., 2010; Konno and Taylor, 2006). To support these theoretical 
considerations and to gain additional insight into the supersaturation capability of the 
ASD vs. drug nanocomposites, additional dissolution testing was conducted with 
excess extrudate powder (equivalent of 100 mg GF). Figure 7.6 presents the 
dissolution performance under such supersaturating conditions. When a powder 
sample with 100 mg GF was used in the dissolution medium, F2 nanocomposite 
containing GF nanocrystals supersaturated (22.1 ± 0.9 mg/L at 120 min) and 
dissolved faster than the as-received GF microparticles, which did not exhibit 
supersaturation (14.3 ± 0.3 mg/L at 120 min). Although F2 nanocomposite 
supersaturated and dissolved faster than the F4 ASD, the extent of supersaturation 
and drug dissolution achieved by the ASD was much greater than that of F2 
nanocomposite, i.e., 61.6 ± 4.5 mg/L vs. 22.1 ± 0.9 mg/L at 120 min. Within 2 h 
dissolution, no significant recrystallization of GF was seen for the ASD, providing 
evidence for the crystallization inhibiting action of Soluplus®. Hence, as expected 
from basic thermodynamic considerations and in line with previous literature (Zhang 
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et al., 2013), for high drug dose, the amorphous form of the drug attained higher 
supersaturation and exhibited higher extent/amount of drug dissolution than the 
nanocrystalline form of the drug in the nanocomposites. Overall, Figure 7.6 shows 
that the ASDs could indeed outperform drug nanocomposites in terms of higher 
extent of drug dissolution when a high drug dose is used to allow for supersaturation 
in the bulk dissolution medium. As shown in Figure 7.4, the reverse is true when the 
drug dose is low: the high supersaturating capability of the ASDs appears to have a 
smaller effect on dissolution, and dissolution enhancement is affected more by the 
relative wettability/ hydrophilicity, swelling–erosion, and size of the respective 
polymeric matrix (HPC vs. Soluplus®).  
In summary, the faster GF dissolution from F2 composite with HPC matrix 
than that from F4 ASD with Soluplus® matrix appears to mainly stem from the faster 
erosion/dissolution of the hydrophilic HPC matrix with its higher wettability 
enhancement to GF as compared with the amphiphilic Soluplus® matrix, under the 
non-supersaturating dissolution conditions (low drug dose). When a high drug dose 
was used in the dissolution medium, the extent of drug dissolution enhancement 
provided by the drug nanoparticles was lower than that provided by the amorphous 
form of the drug in the ASD because the latter provided a much higher 
supersaturation. Interestingly, even for the high drug dose case, as can be seen from 
Figure 7.6, the HPC-based nanocomposite released the drug faster than the 
Soluplus®-based ASD up to the occurrence of the plateau, which was set by the 
apparent solubility of the drug. 
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Figure 7.6  Evolution of GF dissolution from as-received GF microparticle powder, 
F2 extrudate (nanocomposite powder), and F4 extrudate (ASD powder) under 
supersaturating condition in a USP II apparatus. Sample size equivalent to 100 mg GF 
dose. 
 
7.2.5  Elucidating the Matrix Size Effect 
To elucidate the impact of matrix size on the drug dissolution rate, dissolution 
performances of a milled extrudate powder and a cylindrical thread were compared 
for F2 and F4 formulations. The milled matrix (particle) sizes of the extrudates are 
reported in Table 7.1. Single cylindrical threads of F2 and F4 extrudates (diameter  
length of 1 mm  31 mm) with the drug dose of 8.9 mg were used for the dissolution 
tests.  
Cylindrical threads of the extrudates exhibited slower drug dissolution than 
the milled extrudate powders (Figure 7.7a and 7.7b), especially for F4 (ASD), due to 
their larger matrix sizes and negligibly small surface areas, which were measured to 
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be zero by BET method, as compared with 0.31 m
2
/g for the F1–F4 extrudate 
powders. The release exponent values for the cylindrical threads in Table 7.2 could 
suggest anomalous transport (0.45 < n < 0.89) (Ritger and Peppas, 1987a), where 
matrix swelling/erosion plays a role, which is expected for these relatively coarse 
threads. For F2 extrudates, wherein drug nanoparticles were dispersed, the dissolution 
rate from the thread was slower than the milled extrudate powder initially but caught 
up quickly in 30 min (Figure 7.7a). 80% of the drug release was achieved within 20 
min in both nanocomposite powder and cylindrical nanocomposite thread for F2. In 
general, HPC matrix allowed for fast GF release with slight dependence on matrix 
size. This finding is in line with the earlier finding that F2 and F5 composites 
prepared via nanoextrusion/spray drying exhibited similar drug dissolution 
performance despite their differences in matrix size and specific surface areas (0.31 
m
2
/g vs. 0.85 m
2
/g, respectively). All these findings accord well with the fast release 
of drug nanoparticles from the hydrophilic HPC matrix, as shown in the microscopic 
visualization study (Figure 7.5a). In contrast, for F4 (ASD), the drug dissolution rate 
from the cylindrical ASD thread was remarkably slower than the ASD powder 
(Figure 7.7b). The dissolution of amorphous drug from the cylindrical threads in 
Soluplus® matrix was even slower than the as-received GF microparticles, 
suggesting Soluplus® matrix almost acted as a barrier to drug release. It is clear that 
the slower erosion/dissolution of the Soluplus® matrix appears to have a slowing-
down effect on drug dissolution, especially from larger matrices. 
In an attempt to achieve fast drug release from F4 extrudate (ASD), the milled 
extrudate powder was passed through a 90 µm sieve. The sieved F4 powder had D50 
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and D90 of 51.4 ± 4.3 µm and 107.7 ± 9.9 µm, respectively, and Sv = 0.45 m
2
/g. Upon 
further reduction in matrix/particle size of F4 (ASD) following sieving and resulting 
increase in the specific surface area from 0.31 m
2
/g (milled extrudate) to 0.45 m
2
/g 
(milled‒sieved extrudate), 76.8 ± 8.3% drug release was achieved in 20 min. Besides 
the increase in specific surface area, the significantly improved dissolution rate from 
F4 extrudate (ASD) following milling and sieving also resulted from the reduced 
diffusion length of the drug from the swollen Soluplus® matrix as the matrix size was 
smaller. A quick comparison of Figure 7.7a and Figure 7.7b suggests that although 
the amorphous drug in ASD dissolved slower than the drug nanocrystals in the 
nanocomposites with similar extrudate particle (matrix) sizes, faster drug dissolution 
from ASDs can be achieved by size reduction of the extrudate particles. 
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Figure 7.7  Evolution of GF dissolution from different polymeric matrices and matrix 
sizes: (a) F2 (nanocomposite) particles and (b) F4 (ASD) particles in a USP II 
apparatus. Sample size equivalent to 8.9 mg GF dose. (Continued) 
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Figure 7.7  (Continued) Evolution of GF dissolution from different polymeric 
matrices and matrix sizes: (a) F2 (nanocomposite) particles and (b) F4 (ASD) 
particles in a USP II apparatus. Sample size equivalent to 8.9 mg GF dose.  
 
7.3  Conclusions 
Extrudates with different forms of griseofulvin (GF) were prepared via nanoextrusion 
by making use of two extrusion polymers (HPC and Soluplus®) with different drug–
polymer miscibility: crystalline GF micro/nanoparticles dispersed in the HPC matrix 
(micro/ nanocomposites) and amorphous GF molecularly dispersed within Soluplus® 
(ASD). In the composites, GF particle size as modulated by wet media 
milling/formulation was the dominant factor that affected the GF dissolution 
performance, whereas the extrudate particle (polymeric matrix) size or even the 
drying method (nanoextrusion vs. spray drying) did not seem to have a significant 
impact. On the contrary, the matrix size appears to play a major role in GF dissolution 
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from ASD. A head-to-head comparison of the dissolution performance of the 
nanocomposites vs. ASD with the same drug loading and similar polymeric matrix 
sizes was made possible by using the same nanoextrusion process as a platform 
technology followed by dry milling. Under non-supersaturating conditions in the 
dissolution medium (low dose), drug nanocrystals in the nanocomposites with HPC 
matrix can dissolve faster than amorphous drug molecularly dispersed in Soluplus® 
matrix of the ASD. Fast release/dissolution of GF nanocrystals from fast 
eroding/dissolving, hydrophilic matrix of HPC as compared with the slower drug 
release from the slowly eroding/dissolving Soluplus® matrix was found to explain 
this observation. Microscopic examination and drug powder wettability testing 
provided significant insight into the fast nanoparticle redispersion from HPC matrix 
vs. swollen Soluplus® matrix and higher wettability enhancement to GF by HPC–
SDS than Soluplus®–SDS. When a high drug dose was used in the dissolution 
medium, the ASD formulation provided higher drug supersaturation than the 
nanocomposite. Overall, the findings in this study imply that drug nanocomposites 
with fast eroding/dissolving, hydrophilic polymers like HPC could be competitive to 
drug ASDs with Soluplus® in enhancing the dissolution rate of low dose (e.g., highly 
potent) BCS Class II drugs.  
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CHAPTER 8 
IMPACT OF PARTICLE (MATRIX) SIZE ON DISSOLUTION 
ENHANCEMENT FROM GRISEOFULVIN-LADEN EXTRUDATES 
PREPARED VIA NANOEXTRUSION 
 
In Chapter 7, a head-to-head comparison of the dissolution performance of the 
nanocomposites vs. ASD with the same drug loading and similar polymeric matrix 
sizes was made possible by using the same nanoextrusion process as a platform 
technology followed by dry milling. As a continuation, Chapter 8 systematically 
investigates the effects of particle (matrix) size and the form of the drug (crystalline 
vs. amorphous) on the drug release from extrudates at both non-supersaturating and 
supersaturating dissolution conditions. Soluplus® (Sol), Kolliphor® P407 (Kol), and 
Hydroxypropyl cellulose (HPC) were used to stabilize wet-milled drug suspensions 
and form matrices of the extrudates. The wet-milled suspensions along with 
additional polymer (Sol/Kol/HPC) were fed to a co-rotating twin-screw extruder, 
which dried the suspensions and formed various extrudates. The extrudates were dry-
milled and sieved into samples with various extrudate particle (matrix) sizes. Two 
forms of the drug were prepared: extrudates with nanocrystalline drug particles 
dispersed in the Kol or HPC matrices as a secondary phase (nanocomposites) and 
extrudates with amorphous drug molecularly dispersed within the Sol matrix (ASD) 
with two drug loadings in each polymeric matrix type. The produced extrudates with 
different polymeric matrix sizes, forms of drugs (crystalline vs. amorphous), and two 
different drug loadings were subjected to further characterization.  
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8.1  Materials and Methods 
8.1.1  Materials 
BP/EP grade griseofulvin (GF) was purchased from Letco Medical (Decatur, AL, 
USA). GF is a Biopharmaceutical Classification System (BCS) Class II drug with an 
aqueous solubility of 8.9 mg/L at 25 °C and 14.5 mg/L at 37 °C, melting point of 220 
°C, and a glass transition temperature of 79 °C. Soluplus® (Sol, BASF, Tarrytown, 
NY), Kolliphor® P407 (Kol, BASF, Tarrytown, NY), and Hydroxypropyl cellulose 
(HPC, SL grade, Nisso America Inc., New York, NY) and were used as the 
polymeric stabilizer during wet media milling and polymeric matrix former during 
nanoextrusion. HPC is an amorphous polymer with two softening points at 68 and 
178 °C. Kolliphor® P407 is a crystalline nonionic triblock copolymers composed of a 
central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by 
two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)) with a melting 
temperature at 57 °C. Soluplus® is an amphiphilic polyvinyl caprolactam–polyvinyl 
acetate–polyethylene glycol graft copolymer. It is amorphous with a single glass 
transition temperature of 73 ± 2 °C. Sodium dodecyl sulfate (SDS, GFS Chemicals, 
Inc., Columbus, OH) was used as an anionic surfactant to enhance the drug 
wettability and stabilize drug particles during milling. Its critical micelle 
concentration (CMC) in water is 0.23 wt.% at ambient temperature. Methanol (ACS 
reagent, ≥ 99.8%), purchased from Fisher Scientific (Suwanee, GA), was used as a 
solvent. Yttrium stabilized zirconia beads (Zirmil Y, Saint Gobain ZirPro, 
Mountainside, NJ, USA) with a median size of 430 µm were used as the milling 
media. 
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8.1.2  Wet Stirred Media Milling Process 
Table 8.1 presents the formulations of the GF (drug) suspensions. The suspensions 
consisted of 22.4% GF dispersed in a stabilizer solution of 1.9% polymer (i.e., 
Sol/Kol/HPC) and 0.15% SDS. All percentages (%) refer to w/w with respect to total 
suspension mass. Selection of the milling conditions and formulations were guided by 
our prior work on wet media milling (Azad et al., 2014b; Bilgili et al., 2016d). A 
Microcer wet stirred media mill (Netzsch Fine Particle Technology, LLC, Exton, PA, 
USA) with 80 ml chamber was used to mill the drug suspensions. Feed suspensions 
were milled for 120 min under identical conditions to those reported in Bilgili and 
Afolabi (2012). The particle sizes of the suspensions after milling were determined 
using laser diffraction, and the suspensions were refrigerated at 8 °C for one day 
before nanoextrusion. A single suspension was used for formulations with the same 
polymer as stabilizer/matrix former. 
  
 
Table 8.1  Formulations of the Drug (GF) Suspensions Fed in Nanoextrusion 
Formulation ID
a
  Polymer
b
  Drug Particle Size after Milling  (µm) 
D10, SD D50, SD D90, SD 
10% GF-Sol  Soluplus®  0.113, 0.000  0.156, 0.001  0.228, 0.001  
2% GF-Sol  Soluplus®  0.113, 0.000  0.156, 0.001  0.228, 0.001  
10% GF-Kol  Kolliphor® P407 0.100, 0.008  0.185, 0.004  0.358, 0.049  
2% GF-Kol  Kolliphor® P407 0.100, 0.008  0.185, 0.004  0.358, 0.049  
10% GF-HPC  HPC  0.121, 0.001  0.159, 0.000  0.215, 0.001  
2% GF-HPC  HPC  0.121, 0.001  0.159, 0.000  0.215, 0.001  
a
 all suspension formulations have 22.6% GF, 1.9% polymer, 0.15% SDS. w/w with respect to total suspension mass. 
b 
extrudates with the same polymer matrix used the same drug nanosuspension in the nanoextrusion process; hence, they had identical drug particle sizes. 
2
4
9
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8.1.3  Nanoextrusion Process 
Nanoextrusion was performed with a Process 11 co-rotating twin-screw extruder 
(Thermo Fisher Scientific, Waltham, MA) with a die having a 2.0 mm hole. Six 
temperature-controlled zones were used, which are individually heated with electric 
heaters and cooled with water. Polymer (i.e., Sol/Kol/HPC) and drug 
nanosuspensions were fed in Zone 1 and Zone 3, respectively, as two separate 
feedings (Figure 8.1), similar to Li et al. (2017). The temperatures of the individual 
heating zones and the die and the polymer and suspension feeding rates are shown in 
Table 8.2. Polymers were used polymeric matrix formers during nanoextrusion 
besides acting as stabilizers in wet media milling and were fed via a volumetric 
feeder (Thermo Fisher Scientific, Waltham, MA). The drug suspensions were fed 
ahead of the kneading elements, by using a peristaltic pump (Thermo Fisher 
Scientific, Waltham, MA). The ratio of polymer and suspension feeding rates 
determined the final drug loading of various extrudates. Two drug loadings were 
produced in each polymeric matrix. The produced extrudates were labeled with the 
expected drug content, the drug, and the polymeric matrix. For example, 10% GF-Sol 
has 10% GF in the polymeric matrix of Sol. The screw-speed was kept at 100 rpm. 
Zones 4 and 5 had kneading elements with 60° offset angle and served as a mixing 
zone. Kneading elements provided intense mixing, which ensured homogeneous 
dispersion and distribution of the suspension within the molten polymeric matrix. 
Most of the water in the feed suspension evaporated in Zones 4‒5, with conveying 
elements in place and elevated barrel temperature. The extrudates that exit the die 
were cooled to room temperature and stored in a desiccator for further 
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characterization. Due to the comparably low processing temperature and the resulting 
insufficient water evaporation, the Kol formulations were subjected to additional 
drying, i.e., 24 h storage in a desiccator. A higher processing time is not desirable for 
the production of Kol threads. 
 
Figure 8.1  Schematic illustration of the extruder setup, the screw configuration, and 
the locations of the volumetric feeder feeding polymer powders (zone 1) and the 
peristaltic pump at zone 3 feeding drug nanosuspensions. 
 
8.1.4  Microscopy 
The presence of the drug particles in extrudate threads was explored via imaging of 
their cross-sections by an LEO 1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA) 
scanning electron microscope (SEM). The extrudates in thread form were quenched 
in liquid nitrogen and manually broken to generate a relatively smooth cross-section. 
The cross-sections were placed on an aluminum stub using carbon tape. All samples 
were then sputter coated with carbon using BAL-TEC MED 020 (BAL-TEC AG, 
Balzers, Switzerland) prior to imaging. Multiple images were taken to ensure 
consistent visualization from each sample. 
An Axio Scope.A1 microscope (Carl Zeiss Microscopy, LLC, Thornwood, 
NY) was used to observe the morphological changes of a milled extrudate particle 
when exposed to deionized water. A milled particle with selected formulation (10 
GF-Sol, 10 GF-Kol, and 10 GF-HPC) in the size range of 125‒250 µm was placed on 
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a glass slide kept under the microscope. A 3 l drop of deionized water was placed on 
the particle and images were captured at different times. Since the extrudate particle 
could not be fixed on the glass slide, more water droplets were not added, which 
would have allowed for full dissolution of the particles. 
  
 
Table 8.2  Processing Temperature, Feeding Rate, and Residence Time for Each Formulation. The Extrusion is Run at 100 rpm 
Formulation 
ID 
Polymer 
Feeding Rate 
(g/min) 
Processing Temperature (°C) Residence 
Time (s) 
Polymer
a 
Suspension
b
 Zone 1 Zone 2 Zone 3 Zone 4 Zone 5 Zone 6 Die 
10% GF-Sol Soluplus® 2.9 1.4 70 70 100 100 165 165 165 120 
2% GF-Sol Soluplus® 2.7 0.25 70 70 90 100 165 165 165 115 
10% GF-Kol 
Kolliphor® 
P407 
2.9 1.4 10 25 100 100 110 110 90 120 
2% GF-Kol 
Kolliphor® 
P407 
2.8 0.28 10 25 95 100 110 110 85 110 
10% GF-HPC HPC 2.8 1.4 70 120 120 140 140 140 140 116 
2% GF-HPC HPC 2.8 0.27 70 120 120 140 140 140 140 120 
a
 Refers to the additional polymer mixed with the drug nanosuspension during the nanoextrusion process. 
b 
The drug nanosuspension has 22.6% w/w GF, 1.9% polymer, and 0.15% SDS for all formulations. w/w with respect to total suspension mass. 
2
5
3
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8.1.5  X-ray Powder Diffraction (XRD) 
The crystallinity of the as-received GF, as-received polymers, physical mixtures, and 
extrudate powders with various polymeric matrices were analyzed using XRD 
(PANalytical, Westborough, MA), provided with Cu Kα radiation (λ=1.5406 Å). The 
samples were scanned for 2θ ranging from 5° to 40° at a scan rate of 0.165 s–1. 
 
8.1.6  Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a TGA/DSC1/SF Stare 
system (Mettler Toledo, Inc., Columbus, OH) for the characterization of residual 
water. A ~8 mg as-received GF/Sol/Kol/HPC or extrudate powder was placed in a 
ceramic crucible and heated from 25 °C to 150 °C at a constant rate of 10 °C/min 
under nitrogen flow. 
 
8.1.7  Drug Wettability by Soluplus®, Kolliphor® P407, and HPC Solutions 
Wettability was studied via liquid penetration into a (drug) powder bed, also known 
as the modified Washburn method (Hołownia et al., 2008; Washburn, 1921), using 
Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA), which measures the 
mass of liquid penetrated into the drug powder bed as a function of time. 
Experimental methods were presented in Li et al. (2017) and the details can be found 
in Appendix E. In this study, liquids and powder are deionized water/stabilizer 
solution (Sol/Kol/HPC) and GF, respectively. The apparent shear viscosity and 
surface tension of the liquids were respectively measured using R/S Plus Rheometer 
(Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma 700 (Biolin 
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Scientific, Linthicum, MD, USA). The ratio of the cosine of contact angles 
cosθss/cosθw was calculated using the Modified Washburn equation and used as a 
wetting effectiveness factor. Here, θss is the contact angle between GF and the 
stabilizer solutions and θw is the contact angle between GF and deionized water. The 
ratio quantifies the drug wettability enhancement upon the use of different stabilizers 
(polymers) in water. 
 
8.1.8  Determination of Drug Content and Drug Release 
Maximum theoretical amount of GF in 100 mg extrudates was estimated to be 10 mg 
(10% GF-polymer). GF solubility in methanol is 3 mg/ml (Bhakay et al., 2014b). 
Hence, 100 mg of the extrudate powders was dissolved in 20 ml of methanol and 
sonicated for 30 min, followed by storage overnight to ensure that all GF had 
dissolved. An aliquot of 100 μl was taken from the GF solution and diluted into 10 ml 
methanol. The absorbance of all samples was measured at the wavelength of 292 nm 
by Ultraviolet (UV) spectroscopy in a UV Spectrophotometer (Agilent, Santa Clara, 
CA, USA), and drug concentration was determined based on a pre-established 
calibration curve. Six replicates from each formulation were used to calculate the 
mean drug content along with the percent relative standard deviation (RSD). 
Drug release from the extrudate samples was determined via a Distek 2100C 
dissolution tester (North Brunswick, NJ, USA) according to the USP II paddle 
method. The dissolution medium was 1000 ml deionized water at 37 °C, and a paddle 
speed of 50 rpm was used. Deionized water allows for good discrimination of 
different GF formulations under non-sink conditions (Bhakay et al., 2014a; Li et al., 
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2016b). Two doses (i.e., 8.9 mg and 100 mg) of GF were tested for the dissolution 
performance of the produced extrudate threads and milled powders. The relatively 
low drug dose (i.e., 8.9 mg), which could emulate highly-potent drugs, was selected 
to ensure non-supersaturating conditions in the dissolution medium as the GF 
solubility in water at 37 
o
C is 14.5 mg/L. The nanocomposites/ASD powders were 
poured into the dissolution medium and 4 ml samples were taken out manually at 1, 
2, 5, 10, 20, 30, and 60 min. These aliquots were filtered with a 0.1 µm PVDF 
membrane-type syringe filter before UV spectroscopy measurements to minimize any 
confounding effect of the undissolved coarse drug aggregates. Excess drug (i.e., 100 
mg) was selected to allow for supersaturation in the bulk dissolution medium. 
Dissolution was conducted for 210 min with additional sampling at 90, 120, 150, 180, 
and 210 min. The filtered samples were diluted with 37 
o
C deionized water at a ratio 
of 1 to 7 before UV spectroscopy measurement. The amount of GF dissolved was 
measured by UV spectroscopy at a wavelength of 296 nm and determined based on a 
pre-established calibration curve. Deionized water was used as the blank. 
To rank the drug dissolution rate from different polymeric matrices and matrix 
sizes, fitting of GF dissolution data to Korsmeyer‒Peppas model (Ritger and Peppas, 
1987a, b), as shown in Eq. (8.1), was performed using SigmaPlot’s (Version 11) 
regression wizard.  
 (8.1) 
where k is a constant incorporating structural and geometric characteristics of the 
drug dosage form, n is the release exponent, indicative of the drug release 
mechanism, and is the fractional release of the drug. An apparent release 
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mechanism was suggested in this dissertation based on the fitted n value and the 
specific geometry of the samples in view of various assumptions behind Eq. (8.1) 
(refer to Ritger and Peppas (1987a)). Fitting of  included data up to and including 
one point after attainment of  value of 0.60. As the drug release rate (d( )/dt) is 
proportional to kn (Peppas, 1985), in this study, kn is used to compare dissolution rate 
of different formulations. 
 
8.2  Results and Discussion 
8.2.1  Wet Stirred Media Milling of Drug Suspensions 
Table 8.1 presents the formulations of drug (GF) nanosuspensions and their particle 
sizes and standard deviation (SD) as measured by laser diffraction. All drug 
nanosuspensions have 1.9% polymer (Sol/Kol/HPC) and 0.15% surfactant (SDS) as 
steric and electrostatic stabilizers, respectively. Polymer–SDS combination is known 
to stabilize GF nanosuspensions due to synergistic stabilizing action (Bilgili and 
Afolabi, 2012), which minimizes the extent of drug nanoparticle aggregation during 
milling and storage. As-received unmilled GF microparticles have D10 = 4.67 ± 0.06 
m, D50 = 14.27 ± 0.25 m, and D90 = 37.46 ± 0.38 m. After milling, all the 
suspensions have D50 in the range of 0.156‒0.185 µm, indicating a similar drug 
particle size after milling despite the use of different polymeric stabilizers. The 
slightly higher particle size in the formulation of Kol‒SDS indicates presence of 
aggregates. All suspensions were stored in a refrigerator at 8 ºC for one day before 
nanoextrusion process. 
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8.2.2  Preparation and Characterization of Amorphous Solid Dispersion and 
Nanocomposites 
The nanoextrusion process used milled drug suspensions and additional extrusion 
polymer as two separate feeds and continuously produced extrudates by removing 
water via evaporation. Depending on the feeding rate ratio of polymer and 
nanosuspension, two drug loadings were produced in each polymeric matrix. The 
produced extrudates were labeled with the expected drug content, the drug, and the 
polymeric matrix, as introduced in Section 8.1.3. The produced extrudates were kept 
in a desiccator. The mean moisture content of the Sol and HPC formulations was 
measured immediately after the nanoextrusion process, while due to the comparably 
low processing temperature and the resulting insufficient water evaporation, the 
moisture content of the Kol formulations was measured after additional drying, i.e., 
24 h storage in a desiccator. The mean moisture content was reported in Table 8.3. 
Considering the moisture of the raw materials, it can be concluded that most water in 
the drug suspensions was removed. The extrudate threads were then subjected to 
other characterizations. The mean drug content was also reported in Table 8.3. All the 
produced extrudates had very low RSD, i.e., 0.95‒2.22%, which signifies the 
advantage of nanoextrusion process in preparing uniformly distributed and 
reproducible solid dosage forms even with low drug loading (~ 2%) formulations. 
This finding is in line with the previous research (Li et al., 2017) and a recent study 
which investigated the content uniformity of a low-dose drug using the nanoextrusion 
process (Park et al., 2013). 
 
  
 
Table 8.3  Drug Content and Moisture Content in the Produced Extrudates and Matrix Sizes of the Extrudate Powders after 
Grinding and Sieving 
Formulation ID 
Drug 
Content 
(RSD) 
(% w/w)
a
 
Moisture 
Content ± 
SD
b
 
(% w/w)
a
 
<63 µm 125‒250 µm 425‒710 µm 
D10, SD D50, SD D90, SD D10, SD D50, SD D90, SD D10, SD D50, SD D90, SD 
10% GF-Sol 9.8 (1.52) 3.6 ± 0.02 12.9, 0.1 51.7, 0.1 103.7, 0.2 103.5, 1.6 145.7, 0.8 194.7, 3.7 469.2, 16.5 716.1, 28.9 844.8, 3.5 
2% GF-Sol 1.9 (1.91) 3.2 ± 0.46 13.7, 0.3 42.8, 0.6 90.7, 0.5 103.6, 1.5 157.5, 3.5 230.1, 3.6 480.1, 19.5 726.4, 31.7 846.7, 4.3 
10% GF-Kol 9.7 (2.22) 0.8 ± 0.22 12.7, 3.4 40.0, 2.3 81.0, 9.9 123.0, 24.5 194.7, 9.9 277.8, 6.8 370.8, 7.7 497.0, 28.6 580.9, 14.0 
2% GF-Kol 2.1 (1.86) 0.7 ± 0.14 17.1, 0.9 39.6, 1.2 67.5, 6.7 137.8, 2.3 210.2, 8.7 279.5, 3.4 380.2, 4.7 492.3, 22.1 603.5, 13.9 
10% GF-HPC 
10.3 (0.95) 2.9 ± 0.24 16.9, 1.7 43.9, 12.9 114.6, 7.6 126.0, 3.3 194.9, 5.1 293.5, 16.1 464.3, 29.0 633.5, 24.0 811.7, 11.5 
2% GF-HPC 2.1 (1.36) 2.8 ± 0.18 21.3, 1.4 57.1, 0.6 122.5, 18.6 126.6, 2.4 185.1, 8.8 266.2, 22.6 446.2, 50.8 615.9, 46.1 798.5, 9.0 
a
w/w with respect to total nanocomposite/ASD mass. 
b
Moisture content of raw materials: GF 0.2%, Soluplus® 2.4%, Kolliphor® 0.3%, HPC 2.6%.
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Depending on polymer‒drug miscibility, extrudates could be either in the 
form of ASD with amorphous form of the drug molecularly dispersed in the 
polymeric matrix or drug nanocomposites embedding crystalline drug particles in the 
polymeric matrix, respectively (Li et al., 2017; Qian et al., 2010; Thakral and 
Thakral, 2013). SEM images of the cross-section of various extrudates are presented 
in Figure 8.2. GF nanoparticles in the range of 50‒300 nm are embedded in the Kol 
and HPC matrices, for which Kol/HPC was already used as a steric stabilizer in 
combination with SDS producing well-stabilized feed nanosuspensions (refer to 
Table 8.1). The drug particle sizes observed in the SEM images in Figure 8.2 accord 
well with the sizes of the drug particles in the feed suspensions, as measured by laser 
diffraction (Table 8.1). SEM images overall show that drug nanoparticles were 
dispersed throughout the Kol and HPC matrices; hence, these extrudates can be 
referred to as nanocomposites (extrudate with drug nanoparticles embedded). To 
confirm the crystalline state of the drug in the nanocomposites, XRD analysis was 
conducted for each extrudate together with as-received GF microparticles, polymer, 
and physical mixture (Figure 8.3). As-received GF microparticles exhibited intense 
characteristic crystalline peaks (Figure 8.3), whereas the physical mixture of the as-
received GF particles exhibited similar characteristic peaks with significantly reduced 
intensity, which is clearly attributable to dilution and surface coverage of the GF 
particles by the polymer. Considering that GF-Kol/HPC extrudate shows almost 
identical XRD diffractogram to that of their physical mixture, the author concludes 
that the GF nanoparticles in the HPC/Kol matrix were largely crystalline. Besides the 
dilution effect of the polymer, reduction of drug particle size during milling could 
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have resulted in some XRD peak broadening (Deng et al., 2008). It is noted that 2% 
drug crystal concentration for 2% GF-Kol/HPC is close to the detection limit of 
XRD; while the SEM images clearly showed drug nanocrystals forming a secondary 
phase. 
Besides Kol/HPC, Sol was used to produce extrudates, for which Sol was also 
used as a steric stabilizer in combination with SDS producing well-stabilized feed 
nanosuspension (Table 8.1). No particle was observed in the cross-section in SEM 
images of Sol extrudate (Figure 8.2a and b). On comparing GF-Sol extrudate 
diffractogram with those of as-received GF microparticles and Sol, no GF 
characteristic peak appeared (Figure 8.3a). GF was molecularly dispersed within the 
Sol matrix, forming a single-phase amorphous mixture also known as ASD. A similar 
observation was reported by Hardung et al. (2010) for GF‒Soluplus® obtained via 
traditional HME and Li et al. (2017) via nanoextrusion process.  
 
 
 
Figure 8.2  SEM images of the cross-sections of various extrudate threads: (a) 10% 
GF-Sol (ASD), (b) 2% GF-Sol (ASD), (c) 10% GF-Kol (nanocomposite), (d) 2% GF-
Kol (nanocomposite), (e) and (f) 10% GF-HPC (nanocomposite), and (g) and (h) 2% 
GF-HPC (nanocomposite). (Continued) 
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Figure 8.2  (Continued) SEM images of the cross-sections of various extrudate 
threads: (a) 10% GF-Sol (ASD), (b) 2% GF-Sol (ASD), (c) 10% GF-Kol 
(nanocomposite), (d) 2% GF-Kol (nanocomposite), (e) and (f) 10% GF-HPC 
(nanocomposite), and (g) and (h) 2% GF-HPC (nanocomposite). 
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Figure 8.3  XRD diffractograms of as-received GF microparticles, Soluplus®, 
Kolliphor® P407, HPC, physical mixtures and extrudate powders of (a) 10% GF-Sol 
and 2% GF-Sol, (b) 10% GF-Kol, (c) 2% GF-Kol, (d) 10% GF-HPC and 2% GF-
HPC. (Continued) 
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Figure 8.3  (Continued) XRD diffractograms of as-received GF microparticles, 
Soluplus®, Kolliphor® P407, HPC, physical mixtures and extrudate powders of (a) 
10% GF-Sol and 2% GF-Sol, (b) 10% GF-Kol, (c) 2% GF-Kol, (d) 10% GF-HPC and 
2% GF-HPC.  
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8.2.3  Effect of Polymeric Matrix Size at Non-supersaturating Condition 
The XRD diffractograms in Figure 8.3 proved that GF was amorphous in the Sol 
matrix and largely crystalline in the Kol and HPC matrices. The extrudates were 
milled into powders using a coffee grinder and sieved into three different sizes: < 63 
µm, 125‒250 µm, and 425‒710 µm. Their average sizes are reported in Table 8.3 
together with the standard deviation (SD). The evolution of GF dissolution was 
measured in de-ionized water using a USP II apparatus and presented in Figure 8.4. 
Under the non-supersaturating condition, drug dose of 8.9 mg was used for the 
dissolution tests, while the solubility of GF is 14.5 mg.  
A comparison of dissolution profiles of as-received GF and the physical 
mixtures with the corresponding extrudate formulations (Figure 8.4) shows that the 
GF dissolution was faster in the presence of polymer–SDS even without wet media 
milling‒nanoextrusion. This could be explained by the wetting enhancement of the 
hydrophobic drug (GF) particles in the presence of polymer dissolved in water, as 
shown by the wetting effectiveness factors (Table E1, Appendix E). However, by 
producing GF ASD in Sol matrix as a cylindrical thread, i.e., 10%/2% GF-Sol, the 
expected dissolution enhancement was not achieved under non-supersaturating 
condition (e.g., only 6.8 ± 0.31% drug dissolved in 60 min for 10% GF-Sol ASD 
thread, even lower for 2% GF-Sol). Surprisingly, the amorphous drug in the 
cylindrical thread of 10% GF-Sol dissolved slower than the as-received GF 
microparticle powder (Figure 8.4(a)), suggesting Sol matrix almost acted as a barrier 
for drug release. Although the amorphous drug in ASD dissolved very slow in the 
cylindrical threads, faster drug dissolution from ASDs was achieved by size reduction 
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of the GF-Sol extrudate matrices, indicating a negative correlation between matrix 
size and the dissolution rate. Immediate release (i.e., 80% drug release in less than 20 
min) was achieved when the matrix size of 10% GF-Sol was < 250 µm.  
The dissolution rate of the extrudate with various matrix sizes as well as as-
received GF microparticle powder and physical mixtures was quantitatively described 
by using Korsmeyer‒Peppas model (Korsmeyer et al., 1983). The drug release rates 
are captured by kn in Table 8.4. According to Peppas (1985), a higher kn corresponds 
a faster drug release. The fitted kn values in Table 8.4 suggest the following general 
trends: (i) smaller extrudate particles or smaller polymeric matrices led to faster drug 
release for all formulations; (ii) higher drug loading (10% vs. 2%) accompanied with 
a reduction of polymer loading led to faster release; and (iii) drug release from the 
ASDs with the Sol matrix exhibited markedly stronger dependence on matrix size 
than the nanocomposites (10%/2% GF-Kol and 10%/2% GF-HPC). Similarly, no 
significant matrix size was observed when the matrix size is < 250 µm for both Kol 
and HPC matrices at two drug loadings.  
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Figure 8.4  Evolution of GF dissolution from as-received GF microparticle powder, 
physical mixtures, and extrudates with various sizes of (a) 10% GF-Sol, (b) 2% GF-
Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 2% GF-HPC in a 
USP II apparatus. Sample size equivalent to 8.9 mg GF dose. (Continued) 
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Figure 8.4  Evolution of GF dissolution from as-received GF microparticle powder, 
physical mixtures, and extrudates with various sizes of (a) 10% GF-Sol, (b) 2% GF-
Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 2% GF-HPC in a 
USP II apparatus. Sample size equivalent to 8.9 mg GF dose. (Continued) 
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Figure 8.4  (Continued) Evolution of GF dissolution from as-received GF 
microparticle powder, physical mixtures, and extrudates with various sizes of (a) 10% 
GF-Sol, (b) 2% GF-Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 
2% GF-HPC in a USP II apparatus. Sample size equivalent to 8.9 mg GF dose. 
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Table 8.4  Statistical Analysis of the Fitting of the Drug Dissolution Profiles via 
Korsmeyer‒Peppas Model 
Formulation 
ID 
Matrix Size 
(µm) 
Korsmeyer‒Peppas Modela 
kn 
(%min
-n
) n (-) 
k (%min
-
n
) 
R
2
 
As-received 
GF 
‒ 0.746 0.785 0.992 0.58 
10% GF-Sol 
PM 0.530 4.720 0.965 2.50 
<63 1.297 10.14 0.991 13.15 
125‒250 1.101 6.187 0.953 6.81 
425‒710 0.932 1.46 0.963 1.36 
Thread 0.697 0.40 0.988 0.28 
2% GF-Sol 
PM 0.737 3.693 0.999 2.72 
<63 0.506 15.54 0.769 7.86 
125‒250 0.745 6.041 0.979 4.50 
425‒710 1.430 0.06 0.989 0.09 
Thread 0.628 0.11 0.948 0.07 
10% GF-Kol 
PM 0.492 9.060 0.976 4.46 
<63 0.389 43.07 0.981 16.76 
125‒250 0.527 30.952 0.939 16.32 
425‒710 1.271 8.66 0.990 11.01 
Thread 0.903 4.70 0.984 4.24 
2% GF-Kol 
PM 0.406 12.659 0.981 5.14 
<63 0.616 19.59 0.900 12.06 
125‒250 0.477 25.546 0.886 12.17 
425‒710 0.434 21.53 0.860 9.34 
Thread 0.824 3.01 0.981 2.48 
10% GF-
HPC 
PM 0.546 5.756 0.953 3.14 
<63 0.603 26.83 1.000 16.17 
125‒250 0.963 14.790 0.978 14.24 
425‒710 0.894 8.59 0.977 7.67 
Thread 0.826 2.80 0.991 2.31 
2% GF-HPC 
PM 0.528 6.105 0.981 3.23 
<63 0.521 21.77 0.995 11.34 
125‒250 0.641 15.759 0.997 10.10 
425‒710 0.795 6.95 0.997 5.52 
Thread 0.945 1.58 0.994 1.49 
a
n ≈ 0.43 indicates diffusion-controlled release, 0.43 < n < 0.85 indicates anomalous transport, 
while n ≈ 0.85 indicates erosion-controlled release (Ritger and Peppas, 1987). 
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8.2.4  Effect of Polymer Type at Non-supersaturating Condition 
A direct comparison of the dissolution performances of the ASD and nanocomposites 
allows us to analyze the impact of the GF physical state and the polymeric matrix 
type (refer to Figure 8.4). GF is amorphous in Sol extrudate and nanocrystalline in 
Kol and HPC extrudates although all the extrudates were produced by the same 
nanoextrusion process. All extrudates were milled‒sieved into same size ranges, 
which allows a head-to-head comparison on the physical state of GF and the 
polymeric matrix. Since ASDs allow for higher drug solubility than nanocomposites 
containing crystalline drug nanoparticles, one would expect that ASDs should 
outperform the nanocomposites. It is surprising that amorphous GF in ASD dissolved 
much slower than the crystalline GF nanoparticles at the non-supersaturating 
condition, except when the matrix size is < 63 µm for 10% GF-Sol/Kol/HPC (Figure 
8.4a, c, and e). Apparently, under these non-supersaturating conditions in the bulk 
dissolution medium, nanocomposites allowed for faster GF dissolution than ASD. 
The kn values also confirmed the rank order of the dissolution rate from different 
polymeric matrices, which is Kol > HPC > Sol at all matrix sizes and both drug 
loadings, except for 10% GF-Sol/Kol/HPC with the smallest matrix size, i.e., < 63 
µm. 
The observed polymeric matrix effect can be further elucidated by its 
interaction with water. A water droplet was added to a milled ASD particle (10% GF-
Sol) or a milled nanocomposite particle (10% GF-Kol and 10% GF-HPC), and the 
changes to the extrudate particles were visualized using a digital microscope (Figure 
8.5). The Kol and HPC matrices disappeared upon wetting and subsequent fast 
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dissolution, thus releasing drug nanoparticles immediately when exposed to water 
(Figure 8.5). Unlike Kol and HPC matrices, Sol matrix preserved the shape without 
significant erosion or disintegration. Although this visualization is qualitative in 
nature and a water droplet was stationary during this experiment unlike voluminous 
water under stirring during the dissolution test, it is clear that Sol, Kol, and HPC 
matrices containing GF behaved differently in water, which could shed light onto the 
observed slower GF dissolution from Sol matrix. Besides, the calculated wetting 
effectiveness factor (i.e., cosθss/cosθw) for each polymer solution (i.e., Sol, Kol, and 
HPC) were 5, 38, and 27, respectively. The wetting effectiveness factor suggests that 
while the presence of each polymer enhanced the wettability of the hydrophobic drug 
significantly, a higher hydrophilicity and wettability enhancement was imparted by 
Kol in water followed by HPC, and then Sol. The greater wettability enhancement by 
Kol and HPC could result in the fast redispersion and release of drug nanoparticles 
observed in Figure 8.5 and associated immediate drug release in the dissolution 
testing. Despite the high supersaturating capability of the ASD, under the non-
supersaturating condition/at low drug dose, the dissolution enhancement is perhaps 
affected more by the relative wettability/hydrophilicity, swelling‒erosion, and size of 
the respective polymeric matrix. 
 
  
 
 
Figure 8.5  Digital microscope images showing the morphological changes of 10% GF-Sol (ASD), 10% GF-Kol (nanocomposite), 
and 10% GF-HPC (nanocomposite) particle in 3 µl deionized water. 
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8.2.5  Effect of Polymeric Matrix and Polymer Matrix Size at Supersaturating 
Condition 
Additional dissolution testing was conducted with excess extrudate powder 
containing an equivalent of 100 mg GF. Figure 8.6 presents the dissolution 
performance under such supersaturating conditions. When a powder sample with 100 
mg GF was used in the dissolution medium, the presence of polymer in the physical 
mixture led to drug supersaturation for all drug–polymer pairs, as compared to the as-
received GF microparticles, which did not exhibit supersaturation (14.5 ± 0.3 mg/L at 
210 min). Presence of Sol in the physical mixture resulted in a higher supersaturation 
extent than Kol, followed by HPC. Besides, the extent of supersaturation is also 
positively correlated with the polymer concentration in the physical mixture. For 
example, the physical mixture of 10% GF-Sol has less polymer than 2% GF-Sol in 
the physical mixture so that 2% GF-Sol physical mixture led to a higher extent of 
drug supersaturation than 10% GF-Sol physical mixture. 
When dissolution was conducted on the extrudates, the nanocomposites 
containing GF nanocrystals supersaturated and dissolved faster than the as-received 
GF microparticles. Although nanocomposites also supersaturated, the extent of 
supersaturation and drug dissolution was much less than that of the ASDs, e.g., 98.8 ± 
3.5 mg/L, 16.5 ± 0.4 mg/L, and 16.3 ± 0.5 mg/L for Sol, Kol, and HPC matrices, 
respectively, containing 10% drug theoretically with the matrix size of < 63 µm at 
210 min. Hence, as expected from basic thermodynamic considerations and in line 
with previous literature (Zhang et al., 2013), for high drug dose, the amorphous form 
of the drug (Figures 8.6a and b) attained higher supersaturation and exhibited higher 
extent/amount of drug dissolution than the nanocrystalline form of the drug in the 
 275 
 
nanocomposites (Figures 8.6c–f). Overall, the ASDs did indeed outperform drug 
nanocomposites in terms of the higher extent of drug dissolution when a high drug 
dose was used to allow for supersaturation in the bulk dissolution medium. 
Under the supersaturating condition, smaller matrix size led to significantly 
faster dissolution for GF ASD in the matrix of Sol (Figure 8.6a and b). Also, it is very 
interesting that 10% GF-Sol dissolved faster than 10 GF-Sol when matrix size is < 63 
µm. Above 425µm, 2% GF-Sol dissolved faster than 10% GF-Sol. This observation 
indicated an optimal polymer‒matrix size combination. More polymer is needed to 
inhibit the drug recrystallization when the matrix size is large. On the other hand, for 
the nanocomposites considering the much lower extent of supersaturation, the matrix 
size impact does not seem to be significant (Figure 8.6c‒f). 
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Figure 8.6 Evolution of GF dissolution from as-received GF microparticle powder, 
physical mixtures, and extrudates with various sizes of (a) 10% GF-Sol, (b) 2% GF-
Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 2% GF-HPC in a 
USP II apparatus. Sample size equivalent to 100 mg GF dose. (Continued) 
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Figure 8.6 Evolution of GF dissolution from as-received GF microparticle powder, 
physical mixtures, and extrudates with various sizes of (a) 10% GF-Sol, (b) 2% GF-
Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 2% GF-HPC in a 
USP II apparatus. Sample size equivalent to 100 mg GF dose. (Continued) 
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Figure 8.6 Evolution of GF dissolution from as-received GF microparticle powder, 
physical mixtures, and extrudates with various sizes of (a) 10% GF-Sol, (b) 2% GF-
Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 2% GF-HPC in a 
USP II apparatus. Sample size equivalent to 100 mg GF dose. (Continued) 
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Figure 8.6 (Continued) Evolution of GF dissolution from as-received GF 
microparticle powder, physical mixtures, and extrudates with various sizes of (a) 10% 
GF-Sol, (b) 2% GF-Sol, (c) 10% GF-Kol, (d) 2% GF-Kol, (e) 10% GF-HPC, and (f) 
2% GF-HPC in a USP II apparatus. Sample size equivalent to 100 mg GF dose. 
 
8.3  Conclusions 
The nanoextrusion process enabled the systemic investigation on the extrudate matrix 
size effect on the dissolution performance of griseofulvin (GF) nanocomposite, i.e., 
crystalline GF nanoparticles dispersed in the Kol/HPC matrices, and amorphous solid 
dispersion (ASD), i.e., amorphous GF molecularly dispersed within Sol, under both 
non-supersaturating and supersaturating conditions.  
Under the non-supersaturating condition, nanocomposites dissolve faster than 
ASD when the matrix sizes are above 125 µm due to fast eroding/dissolving, 
hydrophilic matrix of Kol/HPC as compared with the slower drug release from the 
slowly eroding/dissolving Sol matrix. The drug ASDs outperformed the 
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nanocomposites in terms of the higher extent of drug dissolution under the 
supersaturation condition. The matrix size appears to play a major role in GF 
dissolution from ASD under both non-supersaturating and supersaturating conditions. 
The drug dissolution rate is negatively correlated with the matrix size. In the 
dissolution profiles of nanocomposites, the extrudate particle (polymeric matrix) size 
did not seem to have a significant impact under the non-supersaturating condition 
when the matrix size is below 250 µm. And the matrix size impact of nanocomposites 
is negligible considering their limited supersaturating capability. Formulations with 
more polymer dissolved slower, i.e., the drug in 10% GF-polymer always dissolved 
faster than 2% GF-polymer formulations, except when the matrix size is > 425 µm at 
the supersaturating condition for GF-Sol ASDs.  
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CHAPTER 9 
CONCLUSIONS AND FUTURE WORK 
 
9.1  Conclusions 
In summary, this dissertation has developed a processing–formulation understanding 
of wet media milling process for fast–efficient production of drug nanoparticles in 
stable nanosuspension form, elucidated the impact of various classes dispersants on 
drug release rate and mechanisms during the redispersion–dissolution of 
nanocomposites prepared via dying of the drug nanosuspensions, and assessed the 
dissolution enhancement imparted by drug nanocomposites vs. ASDs prepared via 
drying of drug nanosuspensions by a novel nanoextrusion process. 
The combination of cellulosic polymer and an anionic surfactant was proven 
to be a viable, general stabilization strategy for ensuring the physical stability of 
multiple wet-milled drug nanosuspensions, provided that the surfactant concentration 
is optimized to mitigate the Ostwald ripening. Further, with a well-stabilized 
suspension formulation, a microhydrodynamic rationale was developed for the 
selection of bead size in wet media milling process, which provides guidance on the 
wet media milling process design and optimization. Combining the knowledge 
obtained in both formulation and processing studies in drug nanosuspensions, wet 
stirred media milling process was intensified with the guidance of 
microhydrodynamic model for the fast production of sub-100 nm drug particles with 
reduced specific energy consumption and low bead wear. 
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The drug nanosuspensions were processed into nanocomposite 
microparticles/amorphous solid dispersions via various drying processes. Firstly, the 
drug nanosuspensions stabilized by polymer‒surfactant was coated on Pharmatose® 
carriers via fluid bed coating process, from which an understanding was developed on 
the relationship between the physical stability of drug nanosuspensions, drug 
redispersion, and dissolution from the nanocomposite. It was found that good 
physical stability of a drug nanosuspension is a necessary condition for fast 
nanoparticle recovery and drug dissolution, but it was insufficient; dispersant 
concentration/type plays a critical role for fast drug release. For best drug dissolution 
performance from the nanocomposites, the presence of SDS is critical; a minimum 
concentration of the polymer as a film former is also required to prevent the 
formation of hard aggregates during drying. Fast drug dissolution from the 
nanocomposites was also attained by high drug-loaded, surfactant-free 
nanocomposites with a co-milled superdisintegrant–HPC prepared via spray drying. 
The drug release rate was found to correlate positively with the dispersant 
concentration and the swelling capacity of the superdisintegrant.  
Finally, the dissolution profiles of nanoparticle-based formulations were also 
compared to those of the amorphous form of the same drug in ASDs prepared via the 
same nanoextrusion process for the first-time in literature. The findings imply that 
drug nanocomposites with fast eroding/dissolving, hydrophilic polymers like 
HPC/Kolliphor® could be competitive to drug ASDs with Soluplus® in enhancing 
the dissolution rate of low dose (e.g., highly potent) BCS Class II drugs. ASDs indeed 
outperform drug nanocomposites in terms of the higher extent of drug dissolution 
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when a high drug dose is used, generating high supersaturation in the bulk dissolution 
medium. 
While this dissertation has established a platform approach (nanoextrusion) 
for a scientific comparison of drug nanocomposites vs. ASDs and the prerequisite 
processing–materials knowledge and methodology needed for such scientific 
comparison, there are still various areas for further research and investigation, which 
are summarized below.  
 
9.2  Future Work 
9.2.1  Production of Nanocomposites and ASDs of Multiple Poorly Water-
Soluble Drugs via Nanoextrusion Process 
In current dissertation, a head-to-head comparison of the dissolution performance of 
nanocomposites vs. ASD of one drug, i.e., griseofulvin, was made possible by using 
the same nanoextrusion process as a platform technology followed by dry milling. To 
generalize the conclusions, multiple drugs with various polymers, having a wide 
range of polymer–drug miscibility, should be tested in terms of formation of drug 
nanocomposites vs. ASD via nanoextrusion process as well as their dissolution 
performance at both non-supersaturating and supersaturating conditions. In addition, 
for a given drug–polymer pair, the dissolution performance of the extrudates obtained 
from nanoextrusion must be compared to that of traditional hot melt extrusion (HME) 
process to assess whether nanoextrusion offers any significant advantages. 
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9.2.2  Production of Nanocomposites and ASDs via Spray Drying 
Although the nanoextrusion process could produce both forms of the same drug, i.e., 
nanocomposites vs. ASDs, the production of each form of the drug largely depends 
on the selection of polymer and the drug‒polymer miscibility. Thus, it is very 
difficult, if not impossible, for the nanoextrusion process to produce both 
nanocomposite and ASDs using the same polymer. Alternatively, spray drying is also 
a well-established process for the preparation of ASDs and nanocomposites. For 
example, when water-based drug nanosuspensions were fed to the spray dryer, as 
shown in Chapter 6, drug nanocomposites were produced, and as demonstrated in 
literature, when a drug–polymer solution is fed, ASDs can be produced. Thus, it 
would be promising to use spray dryer to produce both nanocomposites and ASDs of 
the same drug with identical formulation by changing the precursor material, i.e., 
drug nanosuspension vs. drug solution. 
 
9.2.3  Develop an Understanding of the Drug‒Polymer Interaction on the 
Formation of Drug Nanocomposites and ASDs 
Both nanoextrusion and spray drier can be used to produce drug nanocomposites as 
well as ASDs. However, the mechanisms for these two processes are quite different. 
It would be of fundamental importance to understand the role of drug‒polymer 
interaction on the formation of drug nanocomposites and ASDs; and how these 
interactions affect the formation of drug nanocomposites and ASDs via each process. 
Multiple characterization techniques, such as DSC, XRD, Raman spectroscopy, and 
FTIR analysis, can be used to gain insight into the thermodynamic properties of 
different physical forms of the drug, transformation of physical forms of the drug 
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upon processing, and drug–polymer interactions. This understanding can help the 
formulation scientist on the selection of polymer and processing on drug development.  
 
9.2.4  Understanding of the Impact of Physico-chemical/mechanical Properties 
and Outlook in Wet stirred media Milling  
Considering the lack of correlation between the physical stability and physico-
chemical drug properties, future research on the stabilization of drug nanosuspensions 
will probably continue to evolve along two major directions: first is further 
fundamental research on elucidating the impact of physico-chemical drug properties 
(Choi et al., 2005; Lee et al., 2008; Lee et al., 2005) and second is development of 
complementary characterization methods that help to screen stabilizer(s) and 
determine their optimal concentrations in a streamlined fashion (Knieke et al., 2013; 
Verma et al., 2009).  
To generalize the findings in Chapters 3 and 4 and develop an understanding 
of the impact of various drug properties such as mechanical strength, elastic 
properties, etc., multiple drugs should be studied, and the impact of bead size and 
type at different bead loading levels should be investigated. Moreover, a mixture of 
different bead sizes, which entails a modification of the microhydrodynamic model 
for analysis, and staged use of different bead sizes (coarser beads during initial 
milling followed by their replacement with smaller beads) could offer further process 
optimization potential and warrant future investigation. 
Regarding the intensified WSMM process, one can fine-tune or optimize the 
parameters of the process so as to minimize any one or all of the following response 
variables: desired fineness for a given application, production cycle time, specific 
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energy consumption, and bead wear/product contamination. When such a full-fledged, 
multi-objective optimization study is carried out for a specific industrial application, 
either a high weighting for bead wear can be used to ensure low media contamination 
or a constraint on bead wear can be imposed per strict health authority requirements.  
 286 
 
APPENDIX A 
CALCULATIONS OF MICROHYDRODYNAMIC PARAMETERS 
 
The mathematical expressions for the effective drag (dissipation) coefficient Rdiss and 
the microhydrodynamic parameters can be found in Eskin et al. (2005b). They are 
reported here for the sake of completeness. Wylie et al. (2003) gives Rdiss as  
L
21
Lb0dissdiss )()( dcKcRR   (A.1) 
where L is the density of the equivalent liquid and K is a coefficient given by an 
empirical correlation of bead concentration c  
  454.4212.0 )1(142.0096.0)( cccK   (A.2) 
Rdiss0 in Eq. (A.1) is the dissipation coefficient taking into account squeezing in the 
equivalent liquid film between two approaching beads and is expressed as follows: 
m210diss ln)()()( ckckcR   (A.3) 
In Eq. (A.3), εm is the non-dimensional bead–bead gap thickness at which the 
lubrication force stops increasing and becomes a constant. According to Sangani et al. 
(1996), εm can be taken as 0.003. k1 and k2 in Eq. (A.3) are computed using 
  )77.2157.161.51(26.11ln64135231)( 321 cccccccck   (A.4) 
  32 )1(5.01)( cccck   (A.5) 
Eqs. (A.1)–(A.5) were used in Eq. (3.4) of the main text to calculate the granular 
temperature. With  known, all other microhydrodynamic parameters were 
calculated, as discussed in the main text and below, using the expressions derived by 
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Eskin et. al (2005b). The average maximum normal force Fb
n 
and the radius of the 
contact circle αb during collision of two identical elastic beads were calculated from 
5/32
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where Yb, and ɳb are the Young modulus and Poisson’s ratio of the bead material, i.e., 
yttrium stabilized zirconia, and were taken from the literature as 200 GPa and 0.2, 
respectively (Ashby and Cebon, 1993; Srikar et al., 2004); Rb is the bead radius and 
was taken as half of the measured median size db. The probability p of a single drug 
particle with radius Rp being caught between beads was estimated as the ratio of the 
volume containing the caught particles to the volume of milled drug suspension 
falling on a pair of the milling beads and is expressed as 
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APPENDIX B 
A MICROHYDRODYNAMIC RATIONALE FOR SELECTION OF BEAD SIZE 
IN PREPARATION OF DRUG NANOSUSPENSIONS VIA WET STIRRED 
MEDIA MILLING 
 
 
The supplementary materials of Chapter 3 are shown in this section.
  
Table B.1  The Time It Takes Drug Median Size d50 to Reach 0.5 µm (td50) and d90 to Reach 1 µm (td90) and Characteristic Time 
Constant (τp) Fitted by the Empirical Model (Eq. (1)) to the Evolution of the Median Particle Size  
Run 
No. 
Stirrer 
Speed 
(rpm, m/s) 
Bead 
Size 
(µm) 
Characteristic Milling Times
a
 
Parameters of the Empirical 
Model Fit 
td50 (min) td90 (min) dlim (µm) 
τp 
(min) 
R
2
 
1 1000, 3.67 200 129.1 242.8 0.256 33.4 0.970 
2 1000, 3.67 400 60.2 100.3 0.324 12.7 0.955 
3 1000, 3.67 800 107.1 185.8 0.465 16.9 0.904 
4 1000, 3.67 1500 237.4 –b 0.878 20.1 0.870 
5 1600, 5.86 100 41.9 105.9 0.220 11.0 0.986 
6 1600, 5.86 200 21.0 27.3 0.187 5.9 0.990 
7 1600, 5.86 400 23.5 42.3 0.214 8.0 0.945 
8 1600, 5.86 800 43.6 60.2 0.278 11.5 0.945 
9 1600, 5.86 1500 92.8 166.5 0.391 18.4 0.926 
10 2800, 10.3 100 3.9 7.2 0.151 1.0 0.961 
11 2800, 10.3 200 6.0 9.4 0.173 1.5 0.982 
12 2800, 10.3 400 7.1 10.3 0.171 3.7 0.985 
13 2800, 10.3 800 19.4 27.9 0.213 6.8 0.958 
14 4000, 14.7 50 1.5 3.0 0.144 0.4 0.886 
15 4000, 14.7 100 1.7 3.5 0.142 0.9 0.949 
16 4000, 14.7 200 2.7 4.2 0.150 1.4 0.987 
17 4000, 14.7 400 4.0 7.7 0.163 2.1 0.986 
18 4000, 14.7 800 13.4 22.2 0.173 5.7 0.979 
a
Calculated by Hermite interpolation. 
b
d90 = 1 µm was not reached during 256 min milling in Run 4. 
2
8
9
 
  
Table B.2  Power Applied per Unit Volume of Slurry Pw, Apparent Shear Viscosity L and Density L of the Milled Drug 
Suspensions, and All Microhydrodynamic Parameters (, ub, , b
max
, a, and F) Calculated for Runs 1–18 
Run 
No. 
Stirrer Speed 
(rpm, m/s) 
Bead Size 
(µm) 
Pw 
(W/m
3
) 
µL 
(mPa·s) 
ρL 
(kg/m
3
) 
 (m2/s2) ub (m/s) ν (KHz) 
b
max
 
(GPa) 
a (mHz) F(m
0.6
/s
2.6
) 
1 1000, 3.67 200 6.25104 13.3 1020 7.7010–4 4.4310–2 2.73 1.12 7.47 1.43105 
2 1000, 3.67 400 8.33104 13.3 1020 3.1810–3 8.9910–2 2.77 1.48 6.69 2.26105 
3 1000, 3.67 800 9.38104 13.6 1020 7.7510–3 1.4010–1 2.33 1.77 4.33 2.09105 
4 1000, 3.67 1500 1.15105 13.6 1030 1.6410–2 2.0510–1 1.86 2.06 2.55 1.66105 
5 1600, 5.86 100 8.33104 10.5 1030 4.7010–4 3.4610–2 3.62 1.01 13.8 2.17105 
6 1600, 5.86 200 1.00105 7.00 1030 1.9610–3 7.0610–2 4.35 1.34 17.3 4.82105 
7 1600, 5.86 400 1.04105 8.9 1030 4.7310–3 1.1010–1 3.39 1.60 9.58 3.80105 
8 1600, 5.86 800 1.15105 10.7 1020 9.7510–3 1.5810–1 2.62 1.85 5.33 2.82105 
9 1600, 5.86 1500 1.25105 11.2 1020 1.8110–2 2.1510–1 1.95 2.10 2.78 1.89105 
10 2800, 10.3 100 1.46105 5.3 1030 1.4210–3 6.0210–2 6.31 1.26 37.5 9.19105 
11 2800, 10.3 200 1.56105 5.6 1020 3.3210–3 9.1910–2 5.67 1.49 27.8 9.58105 
12 2800, 10.3 400 2.13105 6.1 1030 9.5610–3 1.5610–1 4.81 1.85 18.0 9.47105 
13 2800, 10.3 800 2.19105 6.6 1020 1.7410–2 2.1010–1 3.49 2.08 8.95 5.97105 
14 4000, 14.7 50 4.79105 4.9 1030 9.1010–4 4.8110–2 11.8 1.15 136 2.79106 
15 4000, 14.7 100 5.83105 4.5 1030 5.4510–3 1.1810–1 12.3 1.65 125 5.26106 
16 4000, 14.7 200 6.15105 4.5 1030 1.1210–2 1.6910–1 10.4 1.91 83.3 4.67106 
17 4000, 14.7 400 6.56105 4.7 1030 2.3410–2 2.4410–1 7.52 2.21 40.3 3.03106 
18 4000, 14.7 800 6.77105 5.3 1030 3.9310–2 3.1610–1 5.26 2.45 18.7 1.73106 
 
2
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Figure B.1  Time-wise evolution of particle size distribution of griseofulvin during 
wet stirred media milling with various bead sizes–stirrer speeds (Runs 1‒18). Each 
particle size distribution corresponds to an average of four (n = 4) laser diffraction 
measurements. (Continued) 
 
 292 
 
Particle size (m)
0.01 0.1 1 10 100
C
u
m
u
la
ti
v
e
 v
o
lu
m
e
 (
%
)
0
20
40
60
80
100
0 min
1 min
2 min
4 min
8 min
16 min
24 min
32 min
48 min
64 min
96 min
128 min
256 min
Run 4
 
Particle size (m)
0.01 0.1 1 10 100
C
u
m
u
la
ti
v
e
 v
o
lu
m
e
 (
%
)
0
20
40
60
80
100
0 min
1 min
2 min
4 min
8 min
16 min
24 min
32 min
48 min
64 min
96 min
128 min
256 min
Run 5
 
Particle size (m)
0.01 0.1 1 10 100
C
u
m
u
la
ti
v
e
 v
o
lu
m
e
 (
%
)
0
20
40
60
80
100
0 min
1 min
2 min
4 min
8 min
16 min
24 min
32 min
48 min
64 min
96 min
128 min
256 min
Run 6
 
Figure B.1  Time-wise evolution of particle size distribution of griseofulvin during 
wet stirred media milling with various bead sizes–stirrer speeds (Runs 1‒18). Each 
particle size distribution corresponds to an average of four (n = 4) laser diffraction 
measurements. (Continued) 
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Figure B.1  Time-wise evolution of particle size distribution of griseofulvin during 
wet stirred media milling with various bead sizes–stirrer speeds (Runs 1‒18). Each 
particle size distribution corresponds to an average of four (n = 4) laser diffraction 
measurements. (Continued) 
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Figure B.1  Time-wise evolution of particle size distribution of griseofulvin during 
wet stirred media milling with various bead sizes–stirrer speeds (Runs 1‒18). Each 
particle size distribution corresponds to an average of four (n = 4) laser diffraction 
measurements. (Continued) 
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Figure B.1  Time-wise evolution of particle size distribution of griseofulvin during 
wet stirred media milling with various bead sizes–stirrer speeds (Runs 1‒18). Each 
particle size distribution corresponds to an average of four (n = 4) laser diffraction 
measurements. (Continued) 
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Figure B.1  (Continued) Time-wise evolution of particle size distribution of 
griseofulvin during wet stirred media milling with various bead sizes–stirrer speeds 
(Runs 1‒18). Each particle size distribution corresponds to an average of four (n = 4) 
laser diffraction measurements.  
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Figure B.2  Time-wise evolution of particle size distribution of griseofulvin during 
wet stirred media milling in Run 4 (the slowest, least intense breakage among all runs) 
and Run 14 (fastest, most intense breakage among all runs). Markers represent the 
experimental data in the original runs, while solid lines represent the experimental 
data in the repeated runs. Each particle size distribution corresponds to an average of 
four (n = 4) laser diffraction measurements.  
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APPENDIX C 
ENHANCED DISSOLUTION OF ITRACONAZOLE FROM HIGH DRUG-
LOADED SURFACTANT-FREE NANOCOMPOSITE MICROPARTICLES 
 
C.1  Details of the Characterization Methods used for Liquid Penetration Study 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Hołownia et al., 2008; Washburn, 1921). In this study, liquids and powder 
are deionized water/stabilizer solutions (HPC, SDS, HPC‒SDS/Mannitol/Sucrose) 
and itraconazole (ITZ), respectively. These formulations were selected corresponding 
to the precursor suspension formulations of F1‒3, F6, F9, F10, and F17 in the 
absence of drug. The apparent shear viscosity and surface tension of the solutions 
were measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA), 
respectively; then, the drug wettability was quantified via a wetting effectiveness 
factor using the modified Washburn equation.  
 
C.1.1  Surface Tension of the Solutions 
The surface tension of deionized water and the aforementioned stabilizer solutions 
was measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) 
and reported in Table C2. The Attention software calculates surface tension from 
force measurements of the interaction of a probe (Wilhelmy plate) at the boundary 
between air and a liquid, i.e., the deionized water or the stabilizer solutions.  
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C.1.2  Liquid Penetration Study 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of water/aforementioned stabilizer solutions into a packed 
powder bed of drug (ITZ) particles inside a cylindrical column and determine the 
drug powder wettability, based on the Washburn method. The assembly consists of a 
sample holder in the form of a cylindrical metallic tube with small holes at the bottom 
as well as a hook at the top of the cover equipped with screw threads. About 0.8 g of 
ITZ powder was packed uniformly into the tube before each measurement. A filter 
paper was placed at the perforated end of the sample holder to support the drug 
powder sample. A petri dish containing deionized water/stabilizer solution was 
placed below the perforated end of the holder on the mechanical platform.  
Upon contact of the sample holder with deionized water/stabilizer solution, 
the liquid penetrated into the drug powder bed, while Attension Sigma 700 recorded 
the mass of liquid penetrated into the drug powder bed as a function of time. The 
contact angle for the deionized water/stabilizer solution and the drug can be 
determined using the modified Washburn equation, which provides a relationship 
between liquid penetration rate and contact angle θ, i.e., , where T, 
M, η, ρ, and γ are time after contact, mass of the liquid penetrated into the drug 
powder bed, viscosity of the liquid, density of the liquid, and surface tension of the 
liquid, respectively. C is a characteristic parameter of the powder sample (ITZ 
powder in the current study), which could have been determined independently using 
a completely wetting liquid such as hexane, heptane, etc. Since the same drug powder 
(ITZ) was used as the powder sample and C depends only on powder packing, C 
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remained invariant for different stabilizer solutions and deionized water studied. This 
allows us to calculate the ratio of cosθss/cosθw as a wetting effectiveness factor, in 
which θss is the contact angle between ITZ and the stabilizer solution and θw is the 
contact angle between ITZ and deionized water. The wettability enhancement upon 
the use of different stabilizers (polymers/surfactant) on the wetting of drug particles 
can be assessed by using this ratio, taking the wettability by water as a basis for 
comparison. The slope of the modified Washburn equation, i.e.,  , was 
obtained by fitting the linear region of liquid penetration curve (i.e., from T = 120 to 
600 s). All the values of R
2
 are above 0.99. Using the slope for different stabilizer 
solutions and water, cosθss/cosθw was calculated. The viscosity, surface tension, and 
the calculated wetting effectiveness factor are reported in Table C2.  
 
C.2  Dissolution Profile Comparison 
Dissolution profiles of F2, F4‒F17 were compared to F1 and F3, respectively, and 
those with 4.5% total dispersants (F5, F8, F12, F14, and F16) were compared to F17, 
using difference (ƒ1) and similarity (ƒ2)  factors (Boateng et al., 2009; Costa and 
Lobo, 2001). Generally, ƒ1 values up to 15 (0‒15) and ƒ2 values greater than 50 
(50‒100) ensure similarity/sameness/equivalence of the two profiles. When ƒ1 is 
greater than 15 or ƒ2 is smaller than 50, the dissolution profiles were regarded as 
statistically different. 
  
 
Table C.1  Volume-based Particle Sizes of the ITZ Precursor Suspensions (after Milling/Addition of Dispersants) and after 7-day 
Storage 
Formula 
ID 
Formulation (% w/w)
a
 After Milling/Addition of Dispersants (µm) After 7-day Storage (µm) 
 
d10 SD d50 SD d90 SD d10 SD d50 SD d90 SD 
F1 2.5% HPC 0.171 0.003 0.289 0.003 1.543 0.003 0.195 0.008 4.134 3.072 61.62 11.23 
F2 0.2% SDS 4.322 0.212 10.09 0.712 21.97 0.581 4.887 0.193 11.69 0.858 24.22 1.665 
F3 2.5% HPC, 0.2% SDS 0.116 0.001 0.168 0.001 0.242 0.000 0.119 0.003 0.169 0.002 0.242 0.001 
F4 2.5% HPC, 1% Mannitol
b 
0.155 0.004 0.300 0.010 1.346 0.167 0.294 0.019 0.788 0.615 2.345 1.064 
F5 2.5% HPC, 2% Mannitol
b 
0.195 0.005 0.331 0.006 1.628 0.055 0.188 0.005 0.679 0.077 2.190 0.032 
F6 2.5% HPC, 4% Mannitol
b 
0.160 0.002 0.304 0.007 1.494 0.164 0.159 0.005 0.294 0.004 1.267 0.049 
F7 2.5% HPC, 1% Sucrose
b 
0.187 0.002 0.311 0.003 1.544 0.008 0.161 0.013 0.275 0.003 1.711 0.001 
F8 2.5% HPC, 2% Sucrose
b 
0.148 0.004 0.290 0.006 1.256 0.014 0.164 0.013 0.288 0.009 0.968 0.272 
F9 2.5% HPC, 4% Sucrose
b 
0.180 0.004 0.307 0.004 1.585 1.555 0.173 0.003 0.325 0.037 2.457 0.402 
F10 6.5% HPC 0.127 0.004 0.194 0.008 0.305 0.024 0.127 0.004 0.183 0.037 0.316 0.016 
F11 2.5% HPC, 1% SSG
c 
0.189 0.001 0.342 0.004 28.26 0.361 0.195 0.007 1.082 0.868 23.00 6.121 
F12 2.5% HPC, 2% SSG
c 
0.211 0.005 0.430 0.015 42.40 1.913 0.206 0.003 1.607 1.267 59.50 13.91 
F13 2.5% HPC, 1% CP
c 
0.227 0.006 0.840 0.088 34.61 1.917 0.264 0.014 4.810 1.107 88.60 4.095 
F14 2.5% HPC, 2% CP
c 
0.169 0.003 0.353 0.009 36.94 0.171 0.195 0.004 2.527 0.226 80.87 4.522 
F15 2.5% HPC, 1% CCS
c 
0.177 0.002 0.477 0.042 44.38 4.651 0.192 0.003 0.511 0.055 58.63 4.375 
F16 2.5% HPC, 2% CCS
c 
0.229 0.013 0.840 1.364 61.23 4.084 0.148 7.637 0.400 3.827 79.98 7.483 
F17 4.5% HPC 0.130 0.001 0.210 0.002 0.346 0.006 0.111 0.040 0.236 0.003 0.421 0.008 
a
Drug loading in all suspensions is 10%. % w/w is with respect to the weight of deionized water, 200 g.  
b
Added to the suspension after milling. 
c
Co-milled along with ITZ for 15 min. 
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Table C.2  Area-based Particle Size of the ITZ Precursor Suspensions (after Milling/Addition of Dispersants) and after 7-day 
Storage 
Formula 
ID 
Formulation  
(% w/w)
a
 
After Milling/Addition of Dispersants 
(µm) 
After 7-day Storage (µm) 
d10 SD d50 SD d90 SD d10 SD d50 SD d90 SD 
F1 2.5% HPC 0.151 0.004 0.232 0.003 0.420 0.008 0.137 0.003 0.225 0.002 0.431 0.003 
F2 0.2% SDS 3.044 0.059 6.640 0.379 21.97 0.581 3.341 0.020 7.580 0.336 17.51 1.240 
F3 2.5% HPC, 0.2% SDS 0.109 0.001 0.154 0.001 0.226 0.000 0.112 0.004 0.156 0.002 0.227 0.001 
F4 2.5% HPC, 1% Mannitol
b 
0.126 0.004 0.216 0.004 0.454 0.022 0.139 0.008 0.246 0.009 1.058 0.559 
F5 2.5% HPC, 2% Mannitol
b 
0.154 0.004 0.230 0.002 0.414 0.009 0.140 0.005 0.227 0.004 0.407 0.003 
F6 2.5% HPC, 4% Mannitol
b 
0.131 0.003 0.220 0.003 0.452 0.024 0.132 0.006 0.222 0.006 0.436 0.005 
F7 2.5% HPC, 1% Sucrose
b 
0.153 0.011 0.232 0.010 0.395 0.027 0.134 0.005 0.221 0.006 0.398 0.011 
F8 2.5% HPC, 2% Sucrose
b 
0.128 0.021 0.214 0.015 0.433 0.012 0.141 0.017 0.225 0.012 0.438 0.033 
F9 2.5% HPC, 4% Sucrose
b 
0.140 0.001 0.229 0.001 0.422 0.002 0.144 0.014 0.231 0.007 0.420 0.010 
F10 6.5% HPC 0.117 0.004 0.172 0.006 0.271 0.015 0.117 0.004 0.174 0.005 0.282 0.011 
F11 2.5% HPC, 1% SSG
c 
0.155 0.002 0.242 0.002 0.418 0.003 0.195 0.007 0.244 0.001 0.407 0.001 
F12 2.5% HPC, 2% SSG
c 
0.171 0.002 0.257 0.002 0.421 0.005 0.156 0.009 0.242 0.007 0.388 0.014 
F13 2.5% HPC, 1% CP
c 
0.105 0.004 0.183 0.052 0.470 0.015 0.140 0.006 0.237 0.007 0.453 0.013 
F14 2.5% HPC, 2% CP
c 
0.133 0.004 0.222 0.002 0.409 0.004 0.140 0.006 0.237 0.007 0.453 0.013 
F15 2.5% HPC, 1% CCS
c 
0.133 0.002 0.221 0.001 0.413 0.002 0.079 0.002 0.161 0.004 0.426 0.019 
F16 2.5% HPC, 2% CCS
c 
0.133 0.005 0.231 0.004 0.454 0.008 0.106 0.015 0.211 0.013 0.449 0.012 
F17 4.5% HPC 0.118 0.001 0.181 0.001 0.299 0.002 0.092 0.040 0.190 0.015 0.328 0.017 
a
Drug loading in all suspensions is 10%. % w/w is with respect to the weight of deionized water, 200 g.  
b
Added to the suspension after milling. 
c
 Co-milled along with ITZ for 15 min. 
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Table C.3  Difference (f1) and Similarity (f2) Factors for Dissolution Profiles of ITZ Nanocomposites with Various Dispersants 
(F4‒F17) as Compared with that of F1. F1 Formulation Has 10% ITZ‒2.5% HPC in the Precursor Suspension 
Difference and 
Similarity 
factors 
Formula ID 
F2* F3 F4* F5 F6 F7* F8* F9 F10 F11 F12 F13 F14 F15 F16 F17 
f1 11.7 412.6 5.1 49.0 183.7 7.7 15.0 161.7 247.0 215.9 345.4 100.9 158.5 165.7 211.0 247.0 
f2 58.4 13.2 68.0 44.8 18.3 64.1 59.5 20.7 16.1 17.1 13.7 29.7 20.9 20.1 17.8 16.1 
*These formulations have a statistical similarity comparing to F1. 
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Table C.4  Difference (f1) and Similarity (f2) Factors for Dissolution Profiles of ITZ Nanocomposites with Various Dispersants 
(F4‒F17) as Compared with that of F3. F3 Formulation has 10% ITZ‒2.5% HPC‒0.2% SDS in the Precursor Suspension 
Difference and 
Similarity Factors 
Formula ID 
F1 F2 F4 F5 F6 F7 F8 F9 F10 F11 F12* F13 F14 F15 F16 F17* 
f1 80.5 87.0 84.7 73.5 34.9 84.8 81.9 43.7 37.8 37.3 7.2 63.3 47.2 44.6 37.2 6.0 
f2 13.2 11.7 12.3 15.4 31.4 12.3 12.8 26.9 29.9 30.7 62.3 18.8 25.2 26.1 30.6 63.0 
*These formulations have a statistical similarity comparing to F3. 
 
 
3
0
4
 
  
 
Table C.5  Difference (f1) and Similarity (f2) Factors for Dissolution Profiles of ITZ Nanocomposites with 2% Various 
Dispersants (F5, F8, F12, F14, F16) as Compared with That of F17. F17 Formulation Has 10% ITZ‒4.5% HPC in the Precursor 
Suspension 
Difference and 
Similarity Factors 
Formula ID 
F5 F8 F12* F14 F16 
f1 68.0 78.2 7.2 28.3 37.0 
f2 16.6 13.4 61.0 36.0 30.0 
*This formulation has a statistical similarity comparing to F17. 
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APPENDIX D 
A COMPARATIVE ASSESSMENT OF NANOCOMPOSITES VS. AMORPHOUS 
SOLID DISPERSIONS PREPARED VIA NANOEXTRUSION FOR DRUG 
DISSOLUTION ENHANCEMENT 
 
D.1  Details of the Characterization Methods used for Drug Wettability 
Measurements 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Wahsburn, 1921; Hołownia et al. 2008). In the current study, liquids and 
powder are aqueous stabilizer solutions of HPC/Soluplus® with SDS and GF, 
respectively. Both solutions had 10% polymer and 0.002% SDS. All percentages are 
w/w with respective to deionized water. These concentrations were selected so that 
the viscosity can be accurately measured in our viscometer set-up, and the polymer-
to-surfactant concentration ratio was kept the same as in F2/F4 extrudate 
formulations. The apparent shear viscosity and surface tension of the solutions were 
measured using R/S Plus Rheometer (Brookfield Engineering, Middleboro, MA, 
USA) and Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) 
respectively, as described below; then, the drug wettability was quantified via a 
wetting effectiveness factor using the modified Washburn equation.  
 
D.1.1  Apparent Shear Viscosity of the Polymeric Solutions 
The apparent shear viscosity of the above solutions was measured using an R/S Plus 
Rheometer (Brookfield Engineering, Middleboro, MA, USA) with a water jacket 
assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A coaxial cylinder 
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(CC40) was used to provide a controlled shear rate on the samples from 0 to 1000 1/s 
for 60 s. The temperature of the jacket was kept constant at 25 ± 0.5 °C. The raw data 
were analyzed using the Rheo 3000 software (Brookfield Engineering, Middleboro, 
MA, USA) of the equipment to obtain the apparent shear viscosity as a function of 
the shear rate. The viscosities at the lowest shear rate that are representative of the 
low shear rates in the liquid penetration experiments below were reported in Table 
D.1. 
 
D.1.2  Surface Tension of the Solutions 
The surface tension of deionized water and the aforementioned solutions was 
measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) and 
reported in Table D.1. The Attention software calculates surface tension from force 
measurements of the interaction of a probe (Wilhelmy plate) at the boundary between 
air and a liquid, i.e., the deionized water or the solution.  
 
D.1.3  Drug Wettability with the Solutions 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of water/aforementioned polymeric solutions into a packed 
powder bed of drug (griseofulvin, GF) particles inside a cylindrical column and 
determine the drug powder wettability, based on the Washburn method. The 
assembly consists of a sample holder in the form of a cylindrical metallic tube with 
small holes at the bottom as well as a hook at the top of the cover equipped with 
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before 
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each measurement. A filter paper was placed at the perforated end of the sample 
holder to support the drug powder sample. A petri dish containing deionized 
water/polymeric solution was placed below the perforated end of the holder on the 
mechanical platform.  
Upon contact of the sample holder with deionized water/polymeric solution, 
the liquid penetrated into the drug powder bed, while Attension Sigma 700 recorded 
the mass of liquid penetrated into the drug powder bed as a function of time. The 
contact angle for the deionized water/solution and drug can be determined using the 
modified Washburn equation, which provides a relationship between liquid 
penetration rate and contact angle θ, i.e., , where T, M, η, ρ, and γ 
are time after contact, mass of the liquid penetrated into the drug powder bed, 
viscosity of the liquid, density of the liquid, and surface tension of the liquid, 
respectively. C is a characteristic parameter of the powder sample (GF powder in the 
current study), which could have been determined independently using a completely 
wetting liquid such as hexane, heptane, etc. Since the same drug powder (GF) was 
used as the powder sample and C depends only on powder packing, C remained 
invariant for different polymer–SDS solutions and deionized water studied. This 
allows us to calculate the ratio of cosθss/cosθw as a wetting effectiveness factor, in 
which θss is the contact angle between GF and the polymer–SDS stabilizer solution 
and θw is the contact angle between GF and deionized water. The wettability 
enhancement upon the use of different stabilizers (polymers/surfactant) on the 
wetting of drug particles can be assessed by using this ratio, taking the wettability by 
water as a basis for comparison. The slope of the modified Washburn equation, i.e.,  
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, was obtained by fitting the linear region of liquid penetration curve (i.e., 
from T = 200 to 450 s). Using the slope for different stabilizer solutions and water, 
cosθss/cosθw was calculated. The viscosity, surface tension, and calculated wetting 
effectiveness factor are reported in Table D.1. 
 
Table D.1  Wetting Effectiveness Factor Calculated for Various Stabilizer Solutions 
using the Modified Washburn Method 
Formulation 
 
(s/g
2
) 
R
2 η (cP) ρ (g/ml) γ (mN/m) cosθss/cosθw 
Water 1078 0.997 0.89 1 70.8 1 
HPC SL–SDS 1281 1.000 93.1 1.1 40.4 127 
Soluplus®–SDS 487 0.997 5.15 1.1 41.9 20 
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APPENDIX E 
IMPACT OF PARTICLE (MATRIX) SIZE ON DISSOLUTION ENHANCEMENT 
FROM GRISEOFULVIN-LADEN EXTRUDATES PREPARED VIA 
NANOEXTRUSION 
 
E.1  Details of the Characterization Methods used for Drug Wettability 
Measurements 
Penetration of a liquid into a packed powder bed of a drug inside a cylindrical column 
allows for measurement of the drug powder wettability, based on the Washburn 
method (Wahsburn, 1921; Hołownia et al. 2008). In the current study, liquids and 
powder are aqueous stabilizer solutions of Soluplus®/Kolliphor®/HPC with SDS and 
GF, respectively. All solutions had 10% polymer. All percentages are w/w with 
respective to deionized water. These concentrations were selected so that the 
viscosity can be accurately measured in our viscometer set-up. The apparent shear 
viscosity and surface tension of the solutions were measured using R/S Plus 
Rheometer (Brookfield Engineering, Middleboro, MA, USA) and Attension Sigma 
700 (Biolin Scientific, Linthicum, MD, USA) respectively, as described below; then, 
the drug wettability was quantified via a wetting effectiveness factor using the 
modified Washburn equation.  
 
E.1.1  Apparent Shear Viscosity of the Polymeric Solutions 
The apparent shear viscosity of the above solutions was measured using an R/S Plus 
Rheometer (Brookfield Engineering, Middleboro, MA, USA) with a water jacket 
assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A coaxial cylinder 
(CC40) was used to provide a controlled shear rate on the samples from 0 to 1000 1/s 
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for 60 s. The temperature of the jacket was kept constant at 25 ± 0.5 °C. The raw data 
were analyzed using the Rheo 3000 software (Brookfield Engineering, Middleboro, 
MA, USA) of the equipment to obtain the apparent shear viscosity as a function of 
the shear rate. The viscosities at the lowest shear rate that are representative of the 
low shear rates in the liquid penetration experiments below were reported in Table 
S1. 
 
E.1.2  Surface Tension of the Solutions 
The surface tension of deionized water and the aforementioned solutions was 
measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD, USA) and 
reported in Table S1. The Attention software calculates surface tension from force 
measurements of the interaction of a probe (Wilhelmy plate) at the boundary between 
air and a liquid, i.e., the deionized water or the solution.  
 
E.1.3  Drug Wettability with the Solutions 
Attension Sigma 700 set-up (Biolin Scientific, Linthicum, MD, USA) was used to 
study the penetration of water/aforementioned polymeric solutions into a packed 
powder bed of drug (griseofulvin, GF) particles inside a cylindrical column and 
determine the drug powder wettability, based on the Washburn method. The 
assembly consists of a sample holder in the form of a cylindrical metallic tube with 
small holes at the bottom as well as a hook at the top of the cover equipped with 
screw threads. About 0.8 g of GF powder was packed uniformly into the tube before 
each measurement. A filter paper was placed at the perforated end of the sample 
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holder to support the drug powder sample. A petri dish containing deionized 
water/polymeric solution was placed below the perforated end of the holder on the 
mechanical platform.  
Upon contact of the sample holder with deionized water/polymeric solution, 
the liquid penetrated into the drug powder bed, while Attension Sigma 700 recorded 
the mass of liquid penetrated into the drug powder bed as a function of time. The 
contact angle for the deionized water/solution and drug can be determined using the 
modified Washburn equation, which provides a relationship between liquid 
penetration rate and contact angle θ, i.e., , where T, M, η, ρ, and γ 
are time after contact, mass of the liquid penetrated into the drug powder bed, 
viscosity of the liquid, density of the liquid, and surface tension of the liquid, 
respectively. C is a characteristic parameter of the powder sample (GF powder in the 
current study), which could have been determined independently using a completely 
wetting liquid such as hexane, heptane, etc. Since the same drug powder (GF) was 
used as the powder sample and C depends only on powder packing, C remained 
invariant for different polymer solutions and deionized water studied. This allows us 
to calculate the ratio of cosθss/cosθw as a wetting effectiveness factor, in which θss is 
the contact angle between GF and the polymer–SDS stabilizer solution and θw is the 
contact angle between GF and deionized water. The wettability enhancement upon 
the use of different stabilizers (polymers/surfactant) on the wetting of drug particles 
can be assessed by using this ratio, taking the wettability by water as a basis for 
comparison. The slope of the modified Washburn equation, i.e.,  , was 
obtained by fitting the linear region of liquid penetration curve (i.e., from T = 100 to 
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300 s). Using the slope for different stabilizer solutions and water, cosθss/cosθw was 
calculated. The viscosity, surface tension, and calculated wetting effectiveness factor 
are reported in Table E1. 
 
Table E.1  Wetting Effectiveness Factor Calculated for Various Stabilizer Solutions 
Using the Modified Washburn Method 
Formulation 
  
(s/g
2
) 
R
2
 η (cP) 
ρ 
(g/ml) 
γ 
(mN/m) 
cosθss/cosθw 
Water 1331 0.967 0.89 1 70.8 1 
Soluplus® 2315 0.991 5.10 1.1 41.6 5 
Kolliphor® 470 1.000 7.42 1.1 36.2 38 
HPC 7150 0.979 93.9 1.1 41.9 27 
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